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Abstract	  The	  aim	  of	   this	  project	  was	   to	   explore	   the	   role	  of	   the	   tyrosine	  kinases	   JAK1	  and	  JAK3	  in	  cytokine	  signalling,	  focusing	  on	  interleukin-­‐2	  signalling	  in	  CD8+	  effector	  T	  lymphocytes.	   Initial	   experiments	   compared	   the	   effects	   of	   the	   pan	   JAK1/JAK3	  inhibitor	   tofacitinib,	   the	   selective	   JAK1	   inhibitor	   GSK186,	   and	   the	   selective	   JAK3	  inhibitor	  GSK192	  on	   IL-­‐2	   control	  of	   effector	  CD8+	   cytotoxic	  T	   cells	   (CTL).	  On	   the	  basis	   of	   these	   preliminary	   data,	   a	   detailed	   analysis	   of	   the	   effect	   of	   tofacitinib	   on	  effector	  CD8+	  T	  lymphocytes	  was	  performed.	  	  	  Phosphorylation	   events	   regulated	   by	   tofacitinib	   were	   identified	   using	   mass	  spectrometry	   analysis	   of	   SILAC	   (stable	   isotope	   labelling	  with	   amino	   acids	   in	   cell	  culture)	  labelled	  CTL.	  Tofacitinib	  regulated	  a	  selective	  number	  of	  phosphorylation	  sites,	  with	  less	  than	  1.2%	  of	  the	  CTL	  phosphoproteome	  significantly	  regulated	  by	  tofacitinib	   treatment	   following	   4hrs	   tofacitinib	   treatment.	   Proteins	   with	  downregulated	   phosphorylation	   sites	   were	   enriched	   in	   functions	   related	   to	   the	  Jak-­‐STAT	  signalling,	  regulation	  of	  gene	  expression,	  and	  MAPK	  signalling	  cascades.	  Proteins	   with	   upregulated	   phosphorylations	   were	   also	   enriched	   in	   functions	  related	  to	  	  regulation	  of	  gene	  transcription.	  	  	  The	   proteome	   of	   tofacitinib	   treated	   CTL	   was	   defined	   by	   label	   free	   mass	  spectrometry.	   Approximately	   4.5%	   of	   the	   CTL	   proteome	   was	   significantly	  regulated	  following	  24	  hours	  tofacitinib	  treatment,	  suggesting	  tofacitinib	  regulates	  the	  expression	  of	  a	  selective	  subset	  of	  proteins.	  Tofacitinib	   treatment	  resulted	   in	  the	   downregulation	   of	   proteins	   involved	   in	   ribosome	   biosynthesis,	   steroid	  biosynthesis,	  regulation	  of	  transcription	  and	  the	  cell	  cycle;	  and	  the	  upregulation	  of	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proteins	  with	  hydrolase	  activity,	  and	  with	  roles	  in	  the	  lysosome	  and	  extracellular	  exosomes.	   The	   phosphoproteomic	   and	   proteomic	   data	   demonstrates	   that	   JAK	  kinase	   dependent	   IL-­‐2	   signalling	   regulates	   essential	   processes	   in	   CTL	   by	  controlling	  a	  selective	  number	  of	  phosphorylation	  events	  and	  proteins.	  Validation	  of	   proteins	   identified	   as	   regulated	   following	   tofacitinib	   treatment	   identified	   new	  targets	   of	   IL-­‐2	   signalling	   in	   CTL,	   including	   the	   transcription	   factor	  NFIL3.	  NFIL3	  was	  shown	  to	  be	  upregulated	  in	  CD8+	  T	  lymphocytes	  following	  stimulation	  with	  IL-­‐2	  and	  regulated	  perforin	  and	  CD62L	  expression,	  suggesting	  a	  role	  in	  the	  regulation	  of	  CTL	  effector	  function.	  	  
Papers	  	  	  	  Ross,	  S.	  H.,	  Rollings,	  C.,	  Anderson,	  K.	  E.,	  Hawkins,	  P.	  T.,	  Stephens,	  L.	  R.,	  &	  Cantrell,	  D.	  A.	  (2016).	  Phosphoproteomic	  Analyses	  of	  Interleukin	  2	  Signaling	  Reveal	  Integrated	  JAK	  Kinase-­‐Dependent	  and	  -­‐Independent	  Networks	  in	  CD8.	  Immunity,	  1–17.	  	  	  	  JAK	  kinase	  regulation	  of	  the	  CTL	  proteome	  (in	  preparation)	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Chapter	  1.	  Introduction	  This	  project	   focused	  on	   the	   roles	  of	   JAK1	  and	   JAK3	   in	   signalling	  by	   the	   common	  gamma	  chain	   (γc)	   cytokine	   IL-­‐2.	   IL-­‐2	  dependent	  murine	   cytotoxic	  T	   lymphocytes	  (CTL)	   were	   used	   as	   a	   model	   system	   in	   which	   to	   study	   IL-­‐2	   signalling.	   The	   JAK	  kinases	   are	   tyrosine	   kinases	   that	   associate	   with	   cytokine	   receptors	   and	   are	  involved	  in	  the	  initiation	  of	  downstream	  signalling.	  Due	  to	  their	  role	  in	  signalling	  by	  the	  γc	  cytokine	  family,	  which	  includes	  key	  cytokines	  such	  as	  IL-­‐2,	  IL-­‐7,	  IL-­‐15	  and	  IL-­‐21,	   JAK1	   and	   JAK3	   are	   involved	   in	   lymphoid	   cell	   development,	   differentiation	  and	   survival.	   Mutations	   in	   JAK3	   are	   associated	   with	   severe	   combined	  immunodeficiency	   syndrome	   (SCID),	  which	  presents	   in	  humans	  as	  T	   cell	   and	  NK	  cell	  deficiency	  with	  B	  cell	  dysfunction.	  	  The	   importance	   of	   the	   γc	   cytokine	   family	   in	   regulating	   immunity	   has	   led	   to	   the	  development	  of	  JAK	  kinase	  inhibitors	  such	  as	  tofacitinib	  for	  use	  in	  the	  treatment	  of	  inflammatory	   conditions	   such	   as	   rheumatoid	   arthritis	   (van	   Vollenhoven	   et	   al.,	  2012).	  However,	  questions	   remain	  concerning	   the	  best	   strategy	   for	   targeting	   the	  JAK	   kinases.	   This	   introduction	  will	   discuss	   innate	   and	   adaptive	   immunity,	   B	   cell	  and	   T	   cell	   development,	   cytotoxic	   T	   lymphocytes,	   type	   I/II	   cytokines,	   γc	   chain	  cytokines	  and	  IL-­‐2,	  the	  JAK	  kinases	  and	  JAK	  kinase	  inhibitors.	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1.1	  Immunity	  Immunity	  requires	  the	  coordinated	  actions	  of	  a	  number	  of	  different	  cell	  types	  that	  can	  be	  broadly	  divided	   into	   the	   innate	   and	  adaptive	   immune	   system.	   Innate	   and	  adaptive	  immune	  cells	  respond	  to	  various	  signals,	  including	  reacting	  to	  pathogens	  and	  damaged	  self-­‐cells.	  As	  reacting	  to	  any	  pathogenic	  challenge	  requires	  the	  action	  of	   multiple	   different	   immune	   cells,	   they	   also	   respond	   to	   direct	   signals	   such	   as	  costimulation	  and	  indirect	  signals	  such	  as	  cytokines	  produced	  by	  other	  cells.	  
1.1.1	  Innate	  immune	  system	  Innate	   immune	   cells	   can	   be	   divided	   into	   myeloid	   and	   lymphoid	   derived	   cells.	  Myeloid	   derived	   cells	   include	   monocytes/macrophages,	   neutrophils,	   basophils,	  eosinophils	  and	  mast	  cells	  (Riera	  Romo	  et	  al.,	  2016;	  Voehringer,	  2013);	  while	  cells	  such	   as	   	   the	   ILC	   (innate	   lymphoid	   cells)	   have	   a	   lymphoid	   origin	   (Artis	   &	   Spits,	  2015).	   The	   origin	   of	   dendritic	   cells	   is	   disputed,	   and	   dendritic	   cells	   derived	   from	  myleloid	   and	   lymphoid	   lineages	   have	   been	   reported	   (Mildner	   &	   Jung,	   2014).	  Dendritic	   cells	   are	   part	   of	   the	   innate	   immune	   system,	   but	   play	   a	   key	   role	   in	  directing	  adaptive	  immunity	  by	  presenting	  antigen	  to	  T	  cells.	  Innate	  cells	  respond	  to	  generalised	  non-­‐self/damaged	  self	  signals	  such	  as	  PAMPs	  (pathogen	  associated	  molecular	   patterns)	   and	   DAMPs	   (damage	   associated	   molecular	   patterns)	   via	  germline	   encoded	   receptors	   such	   as	   PRR	   (pattern	   recognition	   receptors)	   that	  recognise	   molecular	   structures	   shared	   by	   multiple	   pathogens	   (Brubaker	   et	   al.,	  2015;	   D.	   Tang	   et	   al.,	   2012).	   Innate	   immune	   cells	   also	   respond	   to	   and	   produce	  cytokines.	   Innate	   cells	   do	   not	   demonstrate	   a	   classical	   memory	   response	   to	  repeated	   infection.	   However,	   there	   is	   evidence	   that	   previous	   infections	   may	  ‘imprint’	   innate	   cells	   such	   as	   macrophages	   and	   NK	   cells	   via	   epigenetic	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reprogramming,	  producing	  a	   response	   referred	   to	  as	   trained	   immunity	  or	   innate	  immune	  memory	  (Netea	  et	  al.,	  2016).	  	  	  Dendritic	  cells,	  macrophages	  and	  neutrophils	  are	  phagocytes.	  Neutrophils	  are	  the	  most	   abundant	   population	   of	   phagocytes	   and	   respond	   rapidly	   to	   infection.	  Dendritic	   cells	   phagocytose	   invading	   bacteria	   and	   are	   professional	   antigen	  presenting	  cells	  (APCs,	  Mildner	  &	  Jung,	  2014).	  Macrophages	  phagocytose	  invading	  bacteria	   and	   damaged	   self	   tissue	   such	   as	   damaged	   red	   blood	   cells,	   and	   are	   also	  involved	   in	  the	  regulation	  of	  wound	  repair	  (Murray	  &	  Wynn,	  2011;	  van	  Bruggen,	  2014).	   Monocytes/macrophages	   and	   neutrophils	   also	   produce	   antimicrobial	  compounds	   (Riera	   Romo	   et	   al.,	   2016).	   Basophils,	   eosinophils	   and	  mast	   cells	   are	  involved	   in	   the	   response	   to	   large	   extracellular	   parasites	   such	   as	   helminths,	   and	  mediate	  the	  allergic	  response	  (Anthony	  et	  al.,	  2007;	  K.	  D.	  Stone	  et	  al.,	  2010).	  	  	  The	  ILC	  are	  grouped	  into	  the	  NK	  (natural	  killer)	  cells,	  ILC1,	  ILC2	  and	  ILC3;	  and	  are	  activated	   by	   cytokine	   signalling.	   NK	   cells	   are	   cytotoxic,	   targeting	   virally	   infected	  cells;	  ILC1	  are	  involved	  in	  the	  killing	  of	  cells	  infected	  by	  intracellular	  bacteria	  and	  the	   response	   to	   parasitic	   infection.	   ILC2	   are	   the	   innate	   counterpart	   to	   Th2	   (T	  helper	  2)	  cells,	  and	  are	  involved	  in	  regulating	  mucosal	  immunity	  and	  the	  response	  to	   extracellular	   parasites	   such	   as	   helminths.	   ILC3	   include	   Lti	   (lymphoid	   tissue	  inducer	  cells)	  and	  are	  involved	  in	  maintaining	  barrier	  function	  and	  the	  response	  to	  extracellular	  bacteria	  (Artis	  &	  Spits,	  2015).	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1.2	  Adaptive	  immune	  system	  The	  adaptive	   immune	  system	  is	  comprised	  of	  B	   lymphocytes	  and	  T	   lymphocytes,	  which	  respond	  to	  a	  specific	  antigenic	  stimulus	  (usually	  a	  peptide)	  using	  the	  BCR	  (B	  cell	  receptor)	  or	  TCR	  (T	  cell	  receptor).	  The	  loci	  encoding	  the	  BCR	  and	  TCR	  chains	  have	  multiple	   copies	  of	   the	  different	   segments	  which	  make	  up	   the	  TCR	  and	  BCR	  chains,	  the	  V	  (variability),	  D	  (diversity)	  and	  J	  (joining)	  segments:	  during	  T	  cell	  and	  B	   cell	   development,	   these	   loci	   undergo	   somatic	   recombination,	   forming	   chains	  with	  a	  single	  copy	  of	  either	  the	  VDJ	  or	  VJ	  segments.	  This	  results	  in	  the	  generation	  of	  cells	  with	  a	  huge	  range	  of	  potential	  antigen	  specificities	  (Bassing	  et	  al.,	  2002).	  	  	  T	  and	  B	   lymphocytes	  also	  demonstrate	  a	  classical	  memory	  response	   to	   infection.	  During	   the	   response	   to	   a	   novel	   infection,	   the	   loci	   encoding	   the	   B	   cell	   receptor	  chains	   undergo	   somatic	   hypermutation,	   resulting	   in	   the	   selection	   of	   a	   receptor	  with	  higher	  affinity	  for	  an	  antigen.	  Some	  of	  the	  responding	  B	  cells	  differentiate	  into	  long	   lived	   plasma	   cells	   that	   are	   capable	   of	   rapidly	   producing	   high	   affinity	  antibodies	  rapidly	  in	  response	  to	  re-­‐infection	  (Kurosaki	  et	  al.,	  2015).	  A	  subset	  of	  T	  cells	   reacting	   to	   the	   novel	   infection	   will	   differentiate	   into	   memory	   T	   cells,	   both	  tissue	   resident	   and	   central	   memory	   cells,	   which	   have	   already	   undergone	   clonal	  selection.	  In	  the	  event	  of	  reinfection,	  these	  cells	  are	  able	  to	  perform	  their	  effector	  functions	  more	  rapidly	  than	  naïve	  T	  cells	  (Mueller	  &	  Mackay,	  2015).	  	  In	   addition	   to	   the	   classically	   adaptive	   lymphocytes	  described	  above,	   both	   sets	  of	  lymphoid	   cells	   have	   subsets	  with	   a	   restricted	  BCR/TCR	   repertoire	   that	   could	   be	  described	  as	  innate-­‐like.	  B1	  and	  marginal	  zone	  B	  cells	  have	  polyreactive	  BCRs,	  and	  respond	  strongly	  to	  TLR	  (Toll-­‐like	  receptor,	  a	  PRR	  receptor)	  stimulation.	  B-­‐1	  cells	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produce	   IgM	   and	   IgA	   in	   the	   absence	   of	   an	   inflammatory	   response,	   and	   are	  phagocytic	  (Baumgarth,	  2010;	  Cerutti	  et	  al.,	  2013).	  NKT	  cells	  (natural	  killer	  T	  cells)	  have	   a	   restricted	   TCR	   repertoire	   and	   recognize	   glycolipids	   presented	   by	   CD1d	  (Anderson	  et	  al.,	  2013).	  	  
1.2.1	  B	  cells	  and	  B	  cell	  development	  B	  cells	  use	   a	  BCR	  composed	  of	  membrane	  bound	   immunoglobulin,	   either	   IgM	  or	  IgD;	   and	   Igα	   and	   Igβ	   chains	   required	   for	   signalling	   (Treanor,	   2012).	   B	   cells	  expressing	  a	  mature	  BCR	  recognize	  antigen	  in	  solution	  and	  produce	  antibodies.	  B	  cells	   are	   capable	   of	   producing	   multiple	   different	   classes	   of	   antibodies,	   with	   the	  class	  produced	  reflecting	  the	  maturity	  of	  the	  B	  cell	  and	  the	  signals	  received	  when	  first	   activated.	   IgM	   is	   expressed	   on	   maturing	   B	   cells,	   and	   is	   involved	   in	  opsonization	  when	  secreted.	  IgD	  is	  co-­‐expressed	  with	  IgM	  on	  mature	  B	  cells	  and	  is	  predominantly	   membrane	   bound.	   IgG	   is	   also	   involved	   in	   opsonization,	   IgA	   in	  mucosal	   defense	   and	   IgE	   in	   allergy	   (Schroeder	   &	   Cavacini,	   2010).	   B	   cells	   also	  produce	  cytokines	  with	  various	   functions	   including	  coordinating	   lymphoid	   tissue	  development	  and	  polarizing	  T	  helper	  cell	  differentiation	  (Shen	  &	  Fillatreau,	  2015).	  	  	  B	   cell	   development	   is	   discussed	  below.	  Both	  myeloid	   and	   lymphoid	   lineage	   cells	  develop	  from	  haematopoetic	  stem	  cells	  (HSC),	  the	  majority	  of	  which	  are	  found	  in	  the	   bone	   marrow.	   During	   differentiation,	   HSCs	   differentiate	   into	   multipotent	  progenitor	   cells	   (MPP),	   which	   further	   differentiate	   into	   the	   common	   myeloid	  progenitor	  (CMP)	  and	  the	   lymphoid	  primed	  multipotent	  progenitor	  (LMPP).	  CMP	  potential	   is	   limited	   to	   myeloid	   lineage	   cells.	   LMPP	   differentiate	   into	   common	  lymphoid	   progenitor	   (CLP)	   cells.	   CLP	   have	   the	   potential	   to	   differentiate	   into	   all	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lymphoid	   lineages	   (Mehta	   &	   Baltimore,	   2016).	   A	   diagram	   of	   lymphoid	   cell	  development	  is	  shown	  in	  figure	  1.1.	  	  B	  cells	  develop	   in	   the	   fetal	   liver	  during	  embryogenesis	  and	  otherwise	  develop	   in	  the	  bone	  marrow.	  Commitment	  to	  the	  B	  cell	  lineage	  over	  other	  lymphoid	  lineages	  is	  marked	  by	  the	  expression	  of	  the	  transcription	  factors	  EBF,	  E2A	  and	  Pax5,	  which	  are	  required	  for	  the	  expression	  of	  B	  cell	  specific	  genes	  (Sigvardsson	  et	  al.,	  2002).	  B	  cell	  receptors	  are	  formed	  from	  a	  heavy	  and	  a	  light	  chain	  immunoglobulin	  proteins.	  The	   genes	   encoding	   the	   heavy	   and	   light	   chain	   immunoglobulins	   are	   arranged	   in	  segments.	   The	   heavy	   chain	   has	  multiple	   copies	   of	   V,	   D	   and	   J	   segments	  with	   a	   C	  (constant)	  segment,	  and	  the	  light	  chain	  has	  multiple	  copies	  of	  the	  V	  and	  J	  segments	  and	  the	  C	  segment.	  	  	  To	   form	   a	   functional	   BCR,	   developing	   B	   cells	   rearrange	   the	   IgH	   and	   IgL	   loci	   to	  splice	   out	   the	   multiple	   V(D)J	   segments.	   Developing	   B	   cells	   upregulate	   the	  expression	  of	  the	  RAG1	  and	  RAG2	  recombinases,	  allowing	  rearrangement	  to	  occur.	  	  Rearrangement	  of	  the	  IgH	  locus	  begins	  by	  joining	  a	  V	  segment	  to	  the	  D	  region,	  then	  the	   combined	   VD	   segment	   to	   the	   J	   region.	   The	   RAG	   recombinases	   bind	   to	   RSS	  (recombination	  signal	  sequences)	  flanking	  the	  copies	  of	  the	  various	  segments,	  and	  induce	   double	   strand	   breaks.	   These	   breaks	   are	   then	   repaired	   in	   an	   error	   prone	  manner,	   increasing	   the	   potential	   diversity	   of	   the	   rearranged	   chain.	   Joining	   of	  different	  segments	  is	  enforced	  by	  the	  requirement	  to	  join	  a	  12	  base	  pair	  RSS	  to	  a	  23	  base	  pair	  RSS	  (Sadofsky,	  2001).	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The	   rearranged	   heavy	   chain	   is	   then	   expressed	  with	   a	   surrogate	   light	   chain	   as	   a	  preBCR,	   allowing	   the	   developing	   B	   cells	   to	   receive	   a	   proliferative	   signal.	   If	   a	  functional	   heavy	   chain	   has	   been	   formed	   by	   this	   process,	   the	   developing	   cell	   can	  then	   proceed	   to	   rearrangement	   of	   the	   light	   chain	   (Melchers,	   2015).	   Once	   this	   is	  completed,	  the	  developing	  cell	  expresses	  a	  BCR,	  and	  can	  exit	  the	  bone	  marrow	  and	  enter	   secondary	   lymphoid	   tissue.	   Following	   antigen	   encounter	   and	   germinal	  centre	  formation,	  B	  cells	  can	  differentiate	  further	  by	  class	  switching	  in	  response	  to	  cytokine	   and	   coreceptor	   signals	   received	   from	   CD4+	   T	   cells.	   Activated	   B	   cells	  undergo	  somatic	  hypermutation	  following	  upregulation	  of	  AID	  (activation	  induced	  cytidine	  deanimase)	  expression	  (Stavnezer	  et	  al.,	  2008).	  This	  introduces	  mutations	  into	  the	  BCR	  chain	  loci,	  creating	  a	  pool	  of	  antigen	  reactive	  B	  cells	  with	  a	  range	  of	  antibody	  affinities	  for	  antigen,	  allowing	  selection	  of	  B	  cells	  producing	  high	  affinity	  antibodies.	  	  	  
1.2.2	  T	  cells	  and	  T	  cell	  development	  T	   cells	   recognize	   a	   peptide	   antigen	   presented	   in	   association	   with	   MHC	   (major	  histocompatability)	   proteins	   by	   an	   antigen	   presenting	   cell	   (APC)	   such	   as	   a	  dendritic	   cell.	   The	   antigens	   recognized	   by	   T	   cells	   are	   produced	   following	  proteolytic	  degradation	  of	  proteins	  by	  APCs.	  T	  cells	  are	  divided	  into	  the	  αβ	  and	  γδ	  T	  cells	  based	  on	  their	  expression	  of	  different	  chains	  of	  the	  T	  cell	  receptor	  (TCR).	  In	  addition	  to	  the	  αβ	  or	  γδ	  chains,	   the	  TCR	  includes	  the	  CD3	  complex	  (composed	  of	  the	  γ,δ	  and	  ε	  chains)	  and	  the	  ζ	  chain.	  The	  αβ	  T	  cells	  can	  be	  divided	  into	  two	  groups	  based	  on	  their	  coreceptor	  expression.	  CD4+	  T	  cells	  recognize	  antigen	  presented	  by	  APCs	  in	  association	  with	  MHC	  class	  II,	  expression	  of	  which	  is	  mostly	  restricted	  to	  professional	   APCs	   (Kambayashi	   &	   Laufer,	   2014).	   CD4+	   T	   cells	   undergo	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differentiation	   based	   on	   the	   cytokine	   and	   other	   signals	   received	   during	   TCR	  activation	  into	  different	  T	  helper	  cell	  populations	  such	  as	  Th1,	  Th2,	  Th9,	  Th17,	  Tfh	  and	   peripheral	   Tregs	   (induced	   in	   the	   periphery).	   T	   helper	   cell	   identify	   within	   a	  subset	   is	   enforced	   by	   expression	   of	   a	   master	   transcription	   factor,	   as	   described	  below.	  	  	  Th1	  cells	  require	  IFNγ	  and	  IL-­‐12	  stimulation	  during	  activation	  and	  express	  T	  bet.	  Th1	  cells	  produce	  IFNγ	  and	  are	  involved	  in	  the	  response	  to	  intracellular	  bacteria.	  Th2	  cells	  differentiate	   in	  response	   to	   IL-­‐2	  and	   IL-­‐4	  stimulation	  during	  activation,	  and	  express	  the	  transcription	  factor	  GATA3.	  Th2	  cells	  are	   involved	  in	  allergy	  and	  the	  response	  to	  extracellular	  parasites	  such	  as	  helminths.	  Th9	  cells	  differentiate	  in	  response	  to	  TGFβ	  and	  IL-­‐4	  stimultion	  during	  activation.	  Th9	  cells	  produce	  IL-­‐9	  and	  are	   involved	   in	   allergy.	   Th17	   cells	   differentiate	   in	   response	   to	   IL-­‐6	   and	   TGFβ	  during	  activation	  and	  express	   the	   transcription	   factor	  RORγt.	  Th17	  cells	  produce	  IL-­‐17	   and	   are	   involved	   in	   the	   response	   to	   extracellular	   bacteria	   and	   fungal	  infection.	  Tfh	  (T	  follicular	  helper	  cells)	  differentiate	  in	  response	  to	  IL-­‐6	  and	  IL-­‐21	  during	  activation	  and	  express	  the	  transcription	  factor	  Bcl6.	  Tfh	  produce	  IL-­‐21	  and	  provide	  B	  cell	  help;	  driving	  germinal	  centre	   formation,	  B	  cell	  class	  switching	  and	  affinity	  maturation.	  Tregs	  induced	  in	  the	  periphery	  differentiate	  in	  response	  to	  IL-­‐2	   and	   TGFβ	   stimulation	   during	   activation	   and	   express	   the	   transcription	   factor	  FoxP3.	  Tregs	  produce	  IL-­‐10	  and	  suppress	  the	  activity	  of	  other	  immune	  cells	  (Li	  et	  al.,	  2014).	  T	  helper	  cell	  identify	  is	  not	  always	  absolute	  and	  may	  change	  in	  response	  to	  an	  inflammatory	  stimulus.	  	  
	   24	  
CD8+	  T	  cells	  recognize	  antigen	  presented	  in	  association	  with	  MHC	  class	  I,	  which	  is	  expressed	  by	  all	  nucleated	  cells.	  After	  a	  naïve	  CD8+	  T	  cell	  is	  activated	  by	  presented	  antigen,	  it	  can	  differentiate	  into	  a	  cytotoxic	  T	  lymphocyte	  (CTL).	  CTL	  can	  recognize	  antigens	  presented	  by	  non-­‐professional	  antigen	  presenting	  cells	  and	  will	  directly	  kill	  virally	  infected	  cells.	  CTL	  also	  produce	  effector	  cytokines	  such	  as	  IFNγ	  (Zhang	  &	  Bevan,	  2011).	  	  	  γδ	  T	  cells	  differ	  from	  αβ	  T	  cells.	  While	  some	  γδ	  T	  cells	  are	  localized	  to	  the	  lymph	  nodes,	   most	   are	   tissue	   residents.	   Tissue	   resident	   γδ	   T	   cells	   have	   a	   lower	   TCR	  diversity	  than	  lymph	  node	  resident	  γδ	  T	  cells,	  and	  act	  in	  an	  innate-­‐like	  manner	  by	  rapidly	   producing	   cytokines	   to	   an	   antigen	   rather	   than	   going	   through	   rounds	   of	  clonal	  proliferation.	  The	  antigens	   they	  respond	   to	  are	  also	   less	  well	  defined	   than	  the	  antigens	  recognized	  by	  αβ	  T	  cells.	  γδ	  T	  cells	  have	  been	  reported	  to	  respond	  to	  antigens	  presented	  by	  MHC	   class	   I,	  MHC	   class	   II,	   CD1d,	   as	  well	   as	   responding	   to	  antigen	   independently	  of	   an	  antigen	  presenting	  molecule	   (Vantourout	  &	  Hayday,	  2013).	  	  T	   cells	   undergo	   a	   similar	   developmental	   process	   to	   developing	   B	   cells,	   and	  rearrange	  their	  antigen	  receptors	  (figure	  1.1).	  T	  cell	  development	  begins	  following	  entry	   of	   precursor	   cells	   such	   as	   CLP	   to	   the	   thymus.	   Commitment	   to	   the	   T	   cell	  lineage	   is	   specified	  when	  precursor	   cells	   encounter	   thymic	   epithelial	   cells	   (TEC)	  expressing	  Delta	  ligands,	  resulting	  in	  Notch	  signalling	  in	  the	  T	  cell	  precursor	  cells	  that	  actively	  represses	  differentiation	  to	  other	  lineages	  such	  as	  B	  cells.	  Expression	  of	   a	   functional	   TCR	   requires	   the	   productive	   V(D)J	   recombination	   of	   either	   the	   α	  and	  β	   chain	   loci	  or	   the	  γ	  and	  δ	   loci.	  Rearrangement	  of	   the	  β,	   γ	   and	  δ	   loci	  begins	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simultaneously	   at	   the	  DN2b	   (double	   negative,	   CD4-­‐	   CD8-­‐)	   stage.	   Commitment	   to	  the	   αβ	   T	   cell	   lineage	   requires	   the	   formation	   of	   a	   productive	   rearranged	   β	   chain	  before	   the	   γ	   and	   δ	   chains	   are	   successfully	   rearranged.	   If	   a	   functional	   β	   chain	   is	  formed,	   TCRβ	   protein	   will	   be	   produced	   and	   paired	   with	   a	   surrogate	   α	   chain,	  forming	  a	  preTCR	  complex.	  Signalling	  through	  the	  preTCR	  will	  prevent	  further	  γδ	  recombinations	   and	   recombination	   at	   the	   α	   locus	   will	   begin.	   However,	   if	   no	  functional	  β	  chain	  is	  formed	  before	  the	  γ	  and	  δ	  loci	  have	  undergone	  recombination	  successfully,	   the	   T	   cell	   will	   commit	   to	   the	   γδ	   lineage.	   The	   preTCR/TCR	   signal	  induces	  proliferation,	  and	  at	  this	  stage	  developing	  T	  cells	  begin	  to	  express	  the	  both	  CD4	   and	  CD8	   coreceptor	   proteins,	   becoming	   double	   positive	   (Yui	  &	  Rothenberg,	  2014).	  CD4	  and	  CD8	  bind	  MHC	  class	  II	  and	  MHC	  class	  I	  respectively	  (Artyomov	  et	  al.,	  2010).	  	  At	   this	   stage,	   developing	  T	   cells	   undergo	   β	   selection,	   during	  which	   they	   interact	  with	   thymic	   epithelial	   cells	   (TECs)	   expressing	   MHC	   class	   I	   and	   II	   molecules	   in	  association	  with	  self-­‐peptides.	  T	  cells	   that	   fail	   to	   respond	  die	   from	  neglect,	  while	  responding	   T	   cells	   differentiate	   into	   either	   naïve	   T	   cells	   or	   Tregs	   (Hsieh	   et	   al.,	  2012).	  Cells	   that	   respond	   to	   antigen	   in	   complex	  with	  MHC	  class	   I	  will	   ultimately	  differentiate	  into	  CD8	  single	  positive	  T	  cells,	  while	  cells	  that	  responded	  to	  antigen	  in	   complex	   with	   MHC	   class	   II	   will	   differentiate	   into	   CD4	   single	   positive	   T	   cells.	  Commitment	   to	   the	   CD4+	   T	   cell	   lineage	   is	   reinforced	   by	   expression	   of	   the	  transcription	   factor	   THPOK	   and	   other	   transcription	   factors	   including	   E2A	   and	  GATA3.	  Commitment	  to	  the	  CD8+	  T	  cell	   lineage	  is	  reinforced	  by	  expression	  of	  the	  transcription	   factors	   RUNX1	   and	   RUNX3,	   which	   inhibit	   THPOK	   expression	   and	  bind	  the	  cd4	  and	  cd8	  loci.	  Alternatively,	  cells	  that	  respond	  to	  antigen	  presented	  by	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CD1d	   (expressed	   by	   DP	   thymocytes),	  will	   develop	   as	   NKT	   (natural	   killer	   T	   cells	  (Carpenter	  &	  Bosselut,	   2010).	   Following	   exit	   from	   the	   thymus,	   CD4+	   and	  CD8+	  T	  cells	  undergo	  further	  development	  when	  they	  encounter	  antigen	  in	  the	  secondary	  lymphoid	  tissue.	  CD4+	  T	  cells	  will	  differentiate	  into	  different	  T	  helper	  cell	  subsets	  as	  outlined	  in	  the	  previous	  section	  in	  response	  to	  cytokine	  cues	  and	  other	  signals	  received	  during	  TCR	  activation.	  CD8+	  T	  cells	  encountering	  antigen	  will	  differentiate	  into	   cytotoxic	   T	   lymphocytes.	   A	   proportion	   of	   the	   responding	   cells	   will	  differentiate	  into	  a	  memory	  phenotype	  (Mueller	  &	  Mackay,	  2015).	  	  
1.3	  Regulatory	  immune	  cells	  Numerous	  immune	  cells	  are	  involved	  in	  restraining	  inflammation,	  many	  of	  which	  produce	  the	  anti-­‐inflammatory	  cytokine	  IL-­‐10.	  The	  best	  characterized	  of	  these	  are	  the	  CD4+	  Tregs	  (T	  regulatory	  cells),	  which	  express	  FoxP3	  and	  are	  dependent	  on	  IL-­‐2	  signalling	  for	  their	  survival	  and	  which	  can	  develop	  either	  in	  the	  thymus	  or	  in	  the	  periphery	  (Ohkura	  et	  al.,	  2013).	  In	  addition	  to	  these	  Tregs,	  some	  CD8+	  subsets	  have	  been	   demonstrated	   to	   have	   regulatory	   function	   (Wang	   &	   Alexander,	   2009).	  Regulatory	  B	  cells	  have	  been	  identified	  that	  produce	  IL-­‐10	  (Yoshizaki	  et	  al.,	  2013).	  Cells	  with	  a	  regulatory	  function	  such	  as	  alternatively	  activated	  macrophages	  have	  also	  been	  identified	  in	  the	  myeloid	  lineage	  (Manjili	  et	  al.,	  2014).	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1.4	  Cytotoxic	  T	  lymphocytes	  
1.4.1	  Activation	  of	  naïve	  CD8+	  T	  lymphocytes	  Naïve	   CD8+	   T	   lymphocytes	   are	   small,	   quiescent	   cells	   that	   undergo	   homeostatic	  proliferation.	  Naïve	  T	  cells	  circulate	  through	  the	  secondary	   lymphoid	  system	  and	  the	   blood.	   Professional	   APCs,	   such	   as	   dendritic	   cells,	   activate	   naïve	   CD8+	   T	  lymphocytes	   encountered	   in	   secondary	   lymphoid	   tissue	   by	   cross-­‐presenting	  antigen	  acquired	   from	  other	  cells	   (i.e.	   virally	   infected	  or	  cancerous	  cells).	  During	  cross-­‐presentation,	   externally	   acquired	   antigen	   is	   loaded	   onto	   MHC	   class	   I	  molecules	  rather	  than	  MHC	  class	  II	  molecules	  (Joffre	  et	  al.,	  2012).	  	  	  Naïve	   CD8+	   T	   lymphocytes	   contact	   APCs	   transiently	   while	   crawling	   through	  secondary	   lymphoid	  tissue.	  Binding	  of	   the	  cognate	  antigen	  presented	  with	  class	  I	  MHC	   triggers	  TCR	  activation	   and	  prolonged	   contact	  with	   the	   activated	  APC.	  TCR	  activation	  will	  be	  discussed	  further	  in	  section	  1.4.3	  of	  the	  introduction.	  In	  addition	  to	  presentation	  of	   antigen,	  APCs	  also	  produce	  other	   signals	   that	   regulate	  CD8+	  T	  cell	   activation,	   for	   example	   producing	   IL-­‐12.	   Following	   T	   cell	   activation	   and	  expression	   of	   a	   high	   affinity	   IL-­‐12	   receptor	   (Valenzuela	   et	   al.,	   2002),	   IL-­‐12	  increases	   expression	   of	   the	   key	   CD8+	   T	   cell	   effector	   cytokine	   IFNγ	   (Henry	   et	   al.,	  2008).	   APCs	   also	   express	   costimulatory	   receptors	   such	   as	   B7-­‐1	   and	   -­‐2.	   B7-­‐1/2	  positively	   regulate	   T	   cell	   activation	  when	   they	   bind	   T	   cell	   CD28,	   and	   negatively	  regulate	  it	  when	  bound	  to	  T	  cell	  CTLA-­‐4.	  APCs	  also	  express	  the	  TNF	  superfamily	  of	  receptors	  such	  as	  4-­‐1BBL,	  which	  binds	  T	  cell	  4-­‐1BB	  and	  can	  regulate	  T	  cell	  survival	  and	   proliferation	   (Chen	  &	   Flies,	   2013).	   Activating	   CD8+	   T	   cells	  may	   also	   receive	  CD4+	   T	   cell	   help	   in	   the	   form	   of	   CD40/CD40L	   costimulation	   and	   IL-­‐2	   (Kaech	   &	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Wherry,	  2007).	  TCR	  activation	  stimulates	  the	  production	  of	  effector	  proteins	  such	  as	  perforin	  and	  granzymes,	  as	  well	  as	  the	  production	  of	  cytokines	   including	  IFNγ	  and	  TNFα	  (Cox	  et	  al.,	  2011).	  Most	  of	  the	  cells	  produced	  by	  clonal	  activation	  have	  a	  SLEC	   (short	   lived	   effector	   cell,	   KLRGhi	   CD127lo)	   phenotype,	   and	  will	   not	   survive	  past	   the	   resolution	  of	   the	   initiating	   challenge.	  Other	   cells	  have	  a	  MPEC	   (memory	  precursor	  effector	  cell,	  KLRGlo	  CD127hi)	  phenotype	  and	  will	  contribute	  to	  the	  CD8+	  T	  cell	  memory	  pool	  following	  resolution	  (Cox	  et	  al.,	  2013).	  	  	  
1.4.2	  Effector	  function	  of	  CD8+	  T	  lymphocytes	  Exit	  from	  the	  secondary	  lymphoid	  tissue	  and	  entry	  into	  tissue	  is	  mediated	  by	  TCR	  induced	  changes	  in	  chemokine	  and	  chemokine	  receptor	  expression.	  TCR	  activated	  cells	   downregulate	   secondary	   lymphoid	   tissue	   homing	  molecules	   such	   as	   CD62L	  and	  CCR7	  and	  upregulate	   the	   expression	  of	   chemokine	   receptors	   such	   as	  CXCR3	  and	  CCR5	  (Griffith	  et	  al.,	  2014).	  CTL	  become	  polarized	  when	  they	   interact	  with	  a	  cell	   presenting	   their	   cognate	   antigen	   plus	   class	   I	   MHC.	   TCRs	   and	   associated	  signalling	  molecules	  are	  redistribute	  within	  the	  plasma	  membrane	  to	  form	  SMACs	  (supramolecular	   activation	   clusters),	   with	   TCRs	   in	   the	   cSMAC	   (central	  supramolecular	   activation	   cluster).	   The	   CTL	  microtubule	   and	   actin	   cytoskeleton	  also	   undergoes	   extensive	   reorganization;	   and	   CTL	   form	   tight	   contacts	   with	   the	  target	  cell,	  forming	  a	  cytolytic	  synapse.	  Cytolytic	  granules	  containing	  perforin	  and	  granzymes	   are	   directed	   along	   the	   reoriented	   cytoskeleton,	   released	   into	   the	  synaptic	  cleft	  and	  so	  directed	  towards	  the	  target	  cell	  (la	  Roche	  et	  al.,	  2016,	  figure	  1.2).	   Perforin	   inserts	   into	   the	  membrane	   of	   the	   target	   cell,	   allowing	   entry	   of	   the	  granzymes	  that	  induce	  cell	  death	  pathways	  including	  caspase	  activation,	  resulting	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in	  death	  of	   the	   target	   cell	   (Voskoboinik	   et	   al.,	   2015).	   In	   addition	   to	  perforin	   and	  granzyme	  mediated	  cytotoxicity,	  CTL	  express	  FasL	  (Fas	  ligand)	  and	  can	  kill	  target	  cells	  via	  Fas/FasL	  interactions	  (Meiraz	  et	  al.,	  2009),	  and	  produce	  effector	  cytokines	  such	  as	  IFNγ	  and	  TNFα	  (Zhang	  &	  Bevan,	  2011).	  	  	  
Figure	   1.2:	   Cytotoxic	   T	   cells	   directionally	  
release	   cytotoxic	   granules	   and	   effector	  




1.4.3	  TCR	  activation	  The	  effector	  function	  of	  CD8+	  T	  lymphocytes	  is	  dependent	  on	  TCR	  signalling,	  both	  during	   priming	   by	   an	   APC	   and	   during	   killing	   of	   target	   cells.	   A	   diagram	   of	   TCR	  signalling	   is	   shown	   below	   in	   figure	   1.3.	   Antigen	   specificity	   is	   provided	   by	   the	  rearranged	  α	  and	  β,	  or	  γ	  and	  δ,	  chains	  of	  the	  TCR	  (Arstilla	  et	  al.,	  1999);	  while	  the	  initation	  of	  downstream	  signalling	  following	  antigen	  recognition	  is	  facilitated	  by	  a	  pair	  of	  ζ	  chains	  and	  CD3,	  a	  multi-­‐subunit	  complex	  consisting	  of	  a	  γ	  chain,	  a	  δ	  chain	  and	   two	   ε	   chains	   (Punt	   et	   al.,	   1994).	   The	   CD3γ,	   δ,	   ε	   and	   ζ	   chains	   propagate	  downstream	   signalling	   via	   ITAM	   (immunoreceptor	   tyrosine-­‐based	   activation	  motifs)	   intracellular	   signalling	   domains.:	   these	   domains	   have	   two	   tyrosine	  residues	  (Romeo	  et	  al.,	  1992;	  Johnson	  et	  al.,	  1995)	  which	  form	  tandem	  SH2	  ligands	  when	  phosphorylated.	  The	  CD3γ,	  δ	  and	  ε	  chains	  contain	  a	  single	  ITAM	  each	  while	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the	  ζ	  chains	  have	  three	  ITAM	  domains	  per	  chain.	  In	  addition	  to	  binding	  MHC	  class	  I,	  the	   CD8	   coreceptor	   binds	   the	   kinase	   LCK	   (Veillette	   et	   al.,	   1988).	   CD8	   has	   been	  suggested	   to	   regulate	   the	   sensitivity	   to	   peptide	   ligands	   via	   its	   interactions	   with	  class	  I	  MHC	  and	  by	  localizing	  LCK	  to	  the	  TCR	  (Artyomov	  et	  al.,	  2010),	  although	  free	  cytoplasmic	  LCK	  has	  also	  been	  suggested	  to	  be	  involved	  in	  TCR	  signalling	  (Casas	  et	  al.,	  2014).	  	  Following	  binding	  of	  the	  TCR	  to	  the	  appropriate	  antigen/MHC	  class	  I	  complex,	  LCK	  phosphorylates	  the	  tyrosine	  motifs	  of	  the	  ITAM	  motifs,	  allowing	  recruitment	  of	  the	  SH2	   domain	   containing	   kinase	   ZAP-­‐70	   (Iwashima	   et	   al.,	   1994).	   ZAP-­‐70	   then	  phosphorylates	  the	  adaptor	  proteins	  LAT	  (linker	  for	  activation	  of	  T	  cells;	  Zhang	  et	  al,	   1998)	   and	   SLP76	   (Wardenburg	   et	   al.,	   1996),	   facilitating	   the	   recruitment	   of	  further	   signalling	   proteins	   to	   the	   T	   cell	   receptor.	   TCR	   activation	   results	   in	   an	  increase	   in	   the	   activity	   of	   the	   PI3K	   lipid	   kinases,	   increasing	   PtdIns(3,4,5)P3	  generation	   (Costello	   et	   al.,	   2002);	   allowing	   the	   recruitment	   of	   PH	   domain	  containing	   proteins	   such	   as	   the	   serine/threonine	   kinase	   PDK1,	   the	  serine/threonine	   kinase	   PKB	   and	   the	   Tec	   tyrosine	   kinases	   such	   as	   ITK.	  Colocalization	   of	   PDK1	   and	   PKB	   allows	   PDK1	   phosphorylation	   and	   activation	   of	  PKB	   (Waugh,	   2009).	   ITK	   is	   recruited	   to	   the	   TCR	   following	   PtdIns(3,4,5)P3	  generation	   and	   interacts	   with	   SLP76	   (Bunnel	   et	   al.,	   2000).	   ITK	   then	   tyrosine	  phosphorylates	  and	  activates	  phospholipase	  Cγ	  (PLCγ,	  Lui	  et	  al.,	  1998).	  	  	  Activation	  of	  PLCγ	  results	  in	  hydrolysis	  of	  PIP2,	  generating	  IP3	  and	  DAG	  (Kim	  et	  al.,	  2000;	   Malissen	   et	   al.,	   2014).	   IP3	   binds	   and	   opens	   calcium	   channels	   in	   the	  endoplasmic	   reticulum	   (ER;	   Jayaraman	   et	   al.,	   1995),	   releasing	   calcium	   into	   the	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cytoplasm.	  Depletion	  of	  ER	  calcium	  triggers	  activation	  of	  the	  endoplasmic	  calcium	  sensors	   STIM1	   and	   STIM2	   (Oh-­‐hora	   et	   al.,	   2008),	   which	   induce	   the	   opening	   of	  calcium	   release	   activated	   channels	   (CRAC)	   in	   the	   plasma	   membrane	   following	  binding	  to	  the	  CRAC	  pore	  forming	  subunit	  ORAI1	  (Gwack	  et	  al.,	  2008).	  Opening	  of	  CRAC	  channels	   results	   in	   further	  calcium	  release	  and	  ultimately	   the	  activation	  of	  the	  NFAT	  transcription	  factor	  (Joseph	  et	  al.,	  2014).	  	  	  The	   formation	   of	   a	   DAG	   gradient	   around	   the	   TCR	   signalling	   complex	   results	   in	  polarized	   recruitment	   of	   the	   C1	   domain	   containing	   PKC	   (protein	   kinase	   C),	  particularly	   PKCθ	   (Monks	   et	   al.,	   1997);	   transient	   recruitment	   of	   PKD	   (protein	  kinase	   D,	   Spitaler	   et	   al.,	   2006);	   and	   the	   recruitment	   of	   the	   Ras	   GEF	   (guanine	  exchange	   factor)	   RASGRP	   (Ebinu	   et	   al.,	   2000,	   Malissen	   et	   al.,	   2014,	   Navarro	   &	  Cantrell,	  2014).	  PKCθ	  phosphorylates	  the	  scaffold	  protein	  CARMA1	  (Matsumoto	  et	  al.,	  2005),	  allowing	  CARMA1	  to	  form	  a	  complex	  with	  the	  scaffold	  protein	  Bcl10	  and	  the	  paracaspase	  MALT1	  (Che	  et	  al.,	  2004)	  and	  ultimately	  resulting	  in	  the	  activation	  of	  NFκB	   (Navarro	  &	   Cantrell,	   2014).	   PKCθ	   is	   also	   involved	   in	   T	   cell	   polarization	  following	  TCR	  activation:	  PKCθ	  regulates	  centrosome	  reorganization	  by	  regulating	  non	  muscle	  myosin	  II	  and	  dynein	  (Liu	  et	  al.,	  2013).	  PKCζ	  has	  also	  been	  reported	  to	  be	  involved	  in	  regulation	  of	  polarity	  (Bertrand	  et	  al.,	  2010;	  la	  Roche	  et	  al.,	  2016).	  	  PKDs	   recruited	   to	   the	   immune	   synapse	   following	   TCR	   activation	   are	  phosphorylated	   by	   PKCs	   at	   sites	   in	   the	   catalytic	   domain,	   contributing	   to	   PKD	  activation	   (Wood	  et	   al.,	   2005).	  PDK2,	   the	  PKD	   isoform	  most	   abundant	   in	  murine	  lymphocytes,	   is	   involved	   in	   the	   regulation	   of	   cytokine	   production	   in	   mature	   T	  lymphocytes	   in	   response	   to	  TCR	  activation	   (Matthews	  et	   al.,	   2010),	   and	   controls	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the	  phosphorylation	  of	  proteins	  involved	  in	  intracellular	  trafficking	  and	  regulation	  of	   gene	   expression	   (Navarro	   et	   al.,	   2014),	   suggesting	   that	  PKD2	  may	   involved	   in	  multiple	  processes	  downstream	  of	  TCR	  activation.	  Recruitment	  of	  RASGRP	  triggers	  activation	  of	  RAS,	  and	  subsequently	   the	  activation	  of	  an	  MAPK	  cascade	  (Ebinu	  et	  al.,	   2000).	   RAS	   activation	   is	   also	   increased	   by	   Vav	   dependent	   recruitment	   of	   the	  Ras	   GEF	   SOS	   to	   the	   LAT	   adaptor	   protein	   (Reynolds	   et	   al.,	   2004;	  Malissen	   et	   al.,	  2014).	  	  	  TCR	   activation	   also	   stimulates	   mTOR	   signalling	   (Finlay	   et	   al.,	   2012).	   The	   exact	  mechanism	   by	   which	   mTORC1	   is	   activated	   in	   response	   to	   TCR	   signalling	   is	   not	  known:	  however,	  it	  has	  been	  reported	  that	  mTORC1	  signalling	  in	  response	  to	  TCR	  signalling	   requires	   the	   adaptor	   protein	   CARMA1	   and	   the	   paracaspase	   MALT1	  (Hamilton	  et	  al.,	  2014).	  The	  TCR	  induced	  upregulation	  of	  amino	  acid	  transporters	  such	  as	  the	  system	  L	  amino	  acid	  transporter	  light	  chain	  SLC7A5	  also	  maintains	  the	  influx	  of	  amino	  acids	  such	  as	  leucine	  and	  so	  supports	  mTORC1	  activation	  (Sinclair	  et	   al.,	   2013).	   Hedgehog	   signalling	   has	   also	   been	   reported	   to	   stimulated	   by	   TCR	  activation	   and	   to	   be	   required	   for	   centrosome	  polarization,	   actin	   remodeling	   and	  CTL	   killing,	   with	   Hedgehog	   signalling	   regulating	   the	   transcription	   of	   Rac1	   (la	  Roche	  et	  al.,	  2013;	  la	  Roche	  et	  al.,	  2016).	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Figure	  1.3:	  T	  cell	  receptor	  (TCR)	  signalling.	  Calcium	  concentrations	  from	  Srikanth	  and	  Gwack	  (2013).	  mTOR	  signalling:	  Laplante	  and	  Sabatini	  (2009).	  	  HIF	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1.5	  Type	  I/II	  cytokines	  Cytokines	  are	  small	  hormone-­‐like	  proteins	  produced	  by	  immune	  and	  non-­‐immune	  system	  cells.	  Cytokines	  are	  used	   for	   local	  autocrine	  and	  paracrine	  signalling,	  and	  longer	  distance	  signalling	  via	  distribution	  in	  the	  circulatory	  system.	  The	  cytokines	  are	   divided	   into	   various	   structurally	   distinct	   families	   of	  molecules	   including	   the	  type	  I/II	  cytokines,	  the	  IL-­‐1	  family,	  the	  TNF	  family	  and	  chemokines	  (Turner	  et	  al.,	  2014).	  The	  type	  I/II	  cytokines	  include	  over	  50	  cytokines	  that	  signal	  using	  cytokine	  receptor	   associated	   JAK	   kinases,	   as	   shown	   in	   table	   1.1.	   The	   type	   I/II	   cytokine	  family	   includes	  members	   with	   diverse	   functions	   including	   regulation	   of	   growth,	  haematopoesis	   and	   immunity	   (Schwartz	   et	   al.,	   2015).	   JAK	  kinases	   associate	  with	  type	   I/II	   cytokines	   receptors	   via	   the	  membrane	   proximal	   region	   of	   the	   cytokine	  receptor,	  which	  contains	   the	  conserved	  box1/box2	  motif	   (Usacheva	  et	  al.,	  2002).	  Type	   I	   cytokines	  have	  a	   four	  α	  helical	  bundle	   structure	  and	  a	   cytokine	   receptors	  featuring	  common	  domains	  such	  as	  a	  WSXWS	  motif.	  Type	  II	  cytokines	  have	  more	  diverse	  cytokine	  structure	  but	  retain	  the	  common	  features	  of	  the	  cytokine	  receptor	  subunits	   (Gadina	   et	   al.,	   2001).	   Type	   I/II	   cytokines	   use	   multi-­‐subunit	   cytokine	  receptors	  to	  signal,	  and	  are	  subdivided	  into	  cytokine	  families	  based	  on	  the	  usage	  of	  common	  cytokine	  receptor	  subunits.	  	  	  The	   type	   I	   cytokines	   include	   the	   γc	   family,	   the	   βc	   family	   the	   gp130	   family,	   the	  homodimeric	   receptor	   family	   and	   the	   IL-­‐12	   family.	   The	   γc	   family	   uses	   the	   γc	  receptor	  subunit	  and	  includes	  IL-­‐2,	  IL-­‐4,	  IL-­‐7,	  IL-­‐9,	  IL-­‐15,	  IL-­‐21.	  The	  βc	  family	  uses	  the	  βc	  receptor	  subunit	  and	  includes	  GM-­‐CSF,	  IL-­‐3	  and	  IL-­‐5.	  The	  gp130	  family	  uses	  the	   gp130	   receptor	   subunit	   and	   includes	   IL-­‐6,	   IL-­‐11,	   IL-­‐27,	   LIF	   (leukaemia	  inhibitory	   factor),	   OSM	   (oncostatin	   M),	   CNTF	   (ciliary	   neurotrophic	   factor),	   CT-­‐1	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(cardiotrophin-­‐1)	   and	   CLC	   (cardiotrophin-­‐like	   cytokine	   1).	   The	   homodimeric	  family	  of	   type	   I	   cytokines,	   comprising	  prolactin,	   growth	  hormone,	  erythropoietin	  and	   thrombopoietin,	   do	   not	   use	   a	   common	   receptor	   subunit.	   However,	   they	   all	  form	  a	  receptor	  formed	  of	  a	  homodimer	  of	  their	  receptor	  subunits	  (Schwartz	  et	  al.,	  2015).	  IL-­‐13	  uses	  IL4Rα	  and	  IL-­‐13Rα1,	  forming	  a	  receptor	  which	  can	  also	  bind	  IL-­‐4	  (LaPorte	  et	  al.,	  2008).	  The	   IL-­‐12	   family	  are	  grouped	   together	  as	   the	   IL-­‐12	   family	  cytokines	  are	  formed	  of	  shared	  heterodimer	  cytokine	  subunits,	  rather	  than	  based	  on	   cytokine	   receptor	   use	   alone,	   although	   there	   is	   some	   overlap	   of	   cytokine	  receptor	   usage	   between	   different	   IL-­‐12	   family	   cytokines.	   IL-­‐12	   (p35/p40	  heterodimer)	  uses	   IL-­‐12Rβ1	  and	  IL-­‐12Rβ2.	   IL-­‐23	  (p19/p40	  heterodimer)	  uses	   IL-­‐23R	   and	   IL-­‐12Rβ1.	   IL-­‐27	   (p28/Ebi3	   heterodimer)	   uses	   IL-­‐27R	   and	   gp130.	   IL-­‐35	  (p35/Ebi3	   heterodimer)	   uses	   IL-­‐12Rβ2	   and	   gp130,	   a	   gp130	   homodimer	   or	   a	   IL-­‐12Rβ2	  homodimer	  (Vignali	  &	  Kuchroo,	  2012).	  
	  The	   type	   II	   cytokines	   includes	   type	   I,	   type	   II	   and	   type	   III	   interferons	   and	   IL-­‐10	  family	   cytokines.	   The	   type	   I	   interferons,	   which	   include	  multiple	   IFNα	   cytokines,	  IFNβ,	   IFNε,	   IFNζ	   (limitin)	  and	   IFNκ,	   signal	  via	  an	   IFNAR1/IFNAR2	  heterodimeric	  receptor	   complex.	   The	   type	   II	   interferon	   IFNγ	   signals	   via	   an	   IFNGR1/IFNGR2	  heterodimeric	  receptor.	  The	  type	  III	  interferons,	  which	  in	  mice	  include	  IFNλ2	  and	  IFNλ3	   (humans	   have	   IFNλ1-­‐4),	   signal	   via	   a	   IFNλR1/IL-­‐10Rβ	   heterodimeric	  receptor	   (Oritani	   &	   Kanakura,	   2005;	   Pestka	   et	   al.,	   2004;	   van	   Pesch	   et	   al.,	   2004;	  Wack	  et	  al.,	  2015).	  The	  IL-­‐10	  family	  of	  cytokines	  includes	  IL-­‐10,	  IL-­‐19,	  IL-­‐20,	  IL-­‐24	  and	  IL-­‐22.	  	  IL-­‐10	  signals	  via	  an	  IL-­‐10R1/IL-­‐10R2	  heterodimer.	  IL-­‐19,	  IL20	  and	  IL-­‐24	  can	  signal	   through	  an	  IL-­‐20R1/IL-­‐20R2	  heterodimer,	  and	  IL-­‐20	  and	  IL-­‐24	  can	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also	   signal	   via	   an	   IL-­‐20R2/IL-­‐22R	   heterodimer.	   IL-­‐22	   signals	   via	   an	   IL-­‐22R/IL-­‐10R2	  heterodimer	  (Ouyang	  et	  al.,	  2011a).	  	  
	  
	  
Table	  1.1:	  JAK	  kinase	  use	  by	  type	  I/type	  II	  cytokine	  receptors	  Made	  using	  information	  from	  Ouyang	   et	   al.,	   2011a;	   Pestka	   et	   al.,	   2004;	   Schwartz	   et	   al.,	   2015;	   van	   Pesch	   et	   al.,	   2004;	   Vignali	  &	  Kuchroo,	  2012;	  Wack	  et	  al.,	  2015.	  	  
1.5.1	  Common	  gamma	  chain	  cytokines	  As	  previously	  stated,	  the	  γc	  chain	  cytokine	  family	  includes	  IL-­‐2,	  IL-­‐4,	  IL-­‐7,	  IL-­‐9,	  IL-­‐15	  and	  IL-­‐21.	  The	  γc	  chain	  cytokine	  receptors	  use	  additional	  receptor	  subunits	  as	  listed	  below	  in	  table	  1.4,	  and	  use	  JAK1	  and	  JAK3	  to	  signal.	  JAK3	  associates	  with	  the	  γc	   chain,	   while	   JAK1	   associates	   with	   the	   other	   receptor	   chain	   in	   the	   receptor	  complex.	  In	  the	  trimeric	  IL-­‐2	  and	  IL-­‐15	  receptors,	  JAK1	  associates	  with	  the	  IL-­‐2Rβ	  subunit.	   The	   IL-­‐13	   receptor	   and	   the	   TSLP	   receptor	   both	   use	   receptor	   subunits	  from	  the	  γc	  chain	  cytokine	  receptor	  family	  (the	  IL-­‐4R	  and	  IL-­‐7Rα	  respectively)	  but	  do	  not	  use	  the	  γc	  chain,	  and	  so	  are	  not	  considered	  to	  be	  γc	  chain	  cytokines.	  The	  IL-­‐15	   receptor	   can	   signal	   in	   trans:	   IL-­‐15Rα/IL-­‐15	   can	   be	   trans-­‐presented	   to	   a	  responder	   cell	   expressing	   the	   IL-­‐2Rβ	   receptor	   and	   γc	   chain.	   The	   IL-­‐15Rα/IL-­‐15	  
Receptor family cytokines Jak1 Jak2 Jak3 Tyk2
type I βc family GM-CSF, IL-3, IL-5 +
γc family IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 + +
IL-13 IL-13 + + + +
gp130 family IL-6, IL-11, IL-27, LIF, OSM, CNTF, CT-1, CLC + + +
homodimeric family Prolactin, growth hormone, erythropoietin, thrombopoietin +
IL-12 family IL-12, IL-23 + +
IL27, IL-35 + +
type II type I IFN IFNα (1-14), IFNβ, IFNε, IFNζ (limitin), IFNκ + +
type II IFN IFNγ + +
type III IFN IFNλ2, IFNλ3 + +
IL-10 family IL-10, IL-19, IL-20, IL-22, IL-24 + +
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may	   be	   cleaved	   from	   the	   presenting	   cell	   and	   internalized	   by	   the	   responder	   cell	  (Tamzalit	  et	  al.,	  2014).	  	  The	  γc	  chain	  cytokine	  family	  has	  important	  functions	  in	  regulating	  immune	  system	  functioning	  (table	  1.4).	  IL-­‐2	  functions	  as	  a	  T	  cell	  growth	  factor	  in	  vitro.	  In	  vivo	  IL-­‐2	  is	  essential	  for	  function	  of	  regulatory	  T	  cells,	  with	  IL-­‐2-­‐/-­‐	  mice	  developing	  various	  autoimmune	  conditions	  such	  as	  haemolytic	  anaemia	  and	  bowel	  inflammation	  (Ma	  et	  al.,	  1995).	  The	  functions	  of	  IL-­‐2	  in	  vivo	  will	  be	  discussed	  further	  later	  in	  section	  1.6.2.	   IL-­‐4	   is	  a	  Th2	  type	  cytokine	  and	   is	   involved	   in	  coordinating	  the	  response	  to	  specific	  infectious	  agents	  such	  as	  helminth	  infection	  (Pelly	  et	  al.,	  2016).	  IL-­‐4	  is	  also	  involved	   in	   the	   development	   of	   allergic	   responses	   (Zhu	   et	   al.,	   2015).	   IL-­‐7	   is	  essential	  for	  T	  cell	  development	  and	  B	  cell	  maturation	  (Alves	  et	  al.,	  2007).	  IL-­‐9	  has	  been	  reported	   to	  be	   involved	   in	  allergy	  and	  regulates	  mast	   cell	  proliferation	  and	  goblet	  cell	   function	  (Goswami	  &	  Kaplan,	  2011).	   IL-­‐15	   is	   involved	   in	  NK,	  NKT	  and	  IEL	  development	  and	   the	  maintenance	  of	  CD8+	  T	   cell	  memory:	  however,	   tertiary	  memory	   cells	   may	   be	   IL-­‐15	   independent	   (Lodolce	   et	   al.,	   1998;	   Schenkel	   et	   al.,	  2016).	  	  	  IL-­‐21	   regulates	   various	   aspects	   of	   B	   cell	   and	   T	   cell	   differentiation	   and	   function	  (Spolski	   and	   Leonard,	   2014;	   Tian	   and	   Zajac,	   2016).	   In	   B	   cells,	   IL-­‐21	   regulates	  plasma	   cell	   survival	   (Rasheed	   et	   al.,	   2013),	   regulates	   antibody	   production	  (Rasheed	   et	   al.,	   2013)	   and	   both	   the	   number	   of	   germinal	   centre	   B	   cells	   formed	  (Linterman	   et	   al.,	   2010)	   and	   the	   amount	   of	   time	   they	   endure	   in	   response	   to	  immune	   challenge	   (Rasheed	   et	   al.,	   2013).	   IL-­‐21	   signalling	   during	   TCR	   activation	  inhibits	   the	   development	   of	   highly	   cytolytic	   CD8+	   effector	   cells	   (Hinrichs	   et	   al.	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2008),	   prevents	   T	   cell	   exhaustion	   (Yi,	   Du	   and	   Zajac,	   2009),	   and	   promotes	   T	  follicular	   helper	   cell	   development	   (Vogelzang	   et	   al.,	   2008).	   IL-­‐21	   can	   also	  substitute	  for	  IL-­‐6	  during	  in	  vitro	  Th17	  cell	  polarization	  (Wei	  et	  al.,	  2007;	  Nurieva	  et	   al.,	   2007),	   although	   Th17	   cell	   differentiation	   is	   retained	   in	   IL-­‐21	   and	   IL-­‐21R	  deficient	   mice	   (Coquet	   et	   al.,	   2008),	   suggesting	   that	   IL-­‐21	   is	   not	   absolutely	  required	  for	  Th17	  development.	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1.6	  IL-­‐2	  
1.6.1	  IL-­‐2	  production	  in	  vivo	  Figure	  1.4	   shows	   a	   summary	  of	   the	  main	   IL-­‐2	  producing	   and	   consuming	   cells	   in	  
vivo.	  During	  an	  active	  inflammatory	  response,	  activated	  T	  cells	  (particularly	  CD4+	  T	  cells)	  produce	  large	  amounts	  of	  IL-­‐2	  (Boyman	  &	  Sprent,	  2012).	  In	  the	  absence	  of	  an	  inflammatory	   response,	   Setoguchi	   et	   al.	   (2005)	   reported	   that	   CD4	   T	   cells	   other	  than	  regulatory	  T	  cells	  (i.e.	  CD4+	  T	  cells	  expressing	  low	  levels	  of	  CD25)	  produce	  the	  majority	   of	   IL-­‐2	   in	   the	   spleen	   (Setoguchi	   et	   al.,	   2005).	   CD25	   low	   T	   cells	   could	  include	  naive	  or	  memory	  CD4+	  T	  cells.	  	  Yamamoto	  et	  al.	  (2013)	  identified	  IL-­‐2	  producing	  cells	  using	  an	  IL-­‐2	  fate	  reporter	  mouse	  model,	  which	  was	  produced	  by	  crossing	  mice	  in	  which	  Cre	  recombinase	  had	  been	   inserted	   into	   the	   IL-­‐2	   locus	   (resulting	   in	   co-­‐expression	   of	   IL-­‐2	   and	   Cre	  recombinase),	   with	   the	   eGFP	   (enhanced	   green	   fluorescent	   protein)	   Z/EG	   mice.	  .(Yamamoto	   et	   al.,	   2013).	   Z/EG	   mice	   have	   been	   engineered	   with	   a	   reporter	  construct	  containing	  a	  floxed	  LacZ	  gene	  and	  the	  eGFP	  (enhanced	  green	  fluorescent	  protein)	  gene.	  Expression	  of	  Cre	  recombinase	  (and	   in	   this	  case	   IL-­‐2)	   initiates	   the	  removal	   of	   the	   LacZ	   gene,	   allowing	   the	   transcription	   of	   the	   eGFP	   gene	   and	   so	  production	  of	  eGFP	  in	  IL-­‐2	  expressing	  cells	  (Novak	  et	  al.,	  2000).	   	  Tracking	  of	  IL-­‐2	  producing	  cells	  with	  this	  eGFP	  il2	  fate	  reporter	  mouse	  found	  that	  in	  the	  absence	  of	  inflammation,	   only	   CD4+	   T	   cells	   expressed	   GFP.	   Fate	   reporters	   are	   not	   always	  completely	   sensitive	   and	   so	  may	   not	   in	   this	   experiment	   be	   identifying	   cells	   that	  produce	  low	  levels	  of	  IL-­‐2:	  however,	  this	  result	  does	  support	  the	  idea	  that	  CD4+	  T	  cells	   are	   the	   main	   IL-­‐2	   source	   in	   the	   absence	   of	   inflammation.	   CD4+eGFP+	   cells	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were	  found	  in	  the	  thymus	  (single	  positive	  CD4+	  cells	  only),	  spleen,	  bone	  marrow,	  mesenteric	   lymph	  nodes,	   lung	  and	   lamina	  propria.	  The	  percentage	  of	  CD4+eGFP+	  cells	  was	  highest	  in	  the	  CD4+	  IEL.	  In	  all	  tissues	  eGFP+	  cells	  formed	  the	  minority	  of	  CD4+	   T	   cells,	   suggesting	   a	   limited	   number	   of	   CD4+	   T	   cells	   actually	   produce	   IL-­‐2	  without	   an	   inflammatory	   stimulus.	   	   CD4+eGFP+	   cells	   had	   an	   activated	  phenotype	  (CD44hiCD62Llow)	   and	   crossing	   of	   the	   eGFP	   il2	   fate	   reporter	   mice	   to	   mice	  expressing	   the	  OTII	  TCR	   transgene	   reduced	   the	  number	  of	  CD4+eGFP+	   cells.	  This	  suggested	  that	  the	  IL-­‐2	  production	  was	  limited	  to	  CD4+	  T	  cells	  that	  had	  previously	  been	   activated,	   as	   the	  mice	   expressing	   the	   OTII	   transgene	   were	   not	   exposed	   to	  ovalbumin	   derived	   peptides	   and	   so	  were	   not	   activated.(Yamamoto	   et	   al.,	   2013).	  However,	   as	   these	   experiments	   used	   a	   fate	   reporter,	   it	   is	   unclear	   if	   the	   IL-­‐2	  expression	  detected	  in	  this	  assay	  was	  limited	  to	  immediately	  after	  TCR	  activation	  or	  if	  previously	  activated	  T	  cells	  continued	  to	  produce	  IL-­‐2	  after	  the	  removal	  of	  the	  antigenic	  stimulus.	  	  Other	   cell	   types	   have	   also	   have	   been	   reported	   to	   produce	   IL-­‐2.	   	   Setoguchi	   et	   al.	  (2005)	  reported	  that,	   in	  addition	  to	  non-­‐regulatory	  CD4+	  T	  cells,	  CD25high	  CD4+	  T	  cells	   (regulatory	   T	   cells),	   NK	   cells,	   NKT	   cells	   and	   CD8+	   T	   cells	   produced	   varying	  levels	  of	  IL-­‐2	  mRNA	  (Setoguchi	  et	  al.,	  2005),	  suggesting	  that	  they	  could	  contribute	  to	   splenic	   IL-­‐2	   production	   to	   some	   extent.	   Granucci	   et	   al.	   (2001)	   performed	  microarray	  analyisis	  of	  dendritic	  cells	  and	  demonstrated	  dendritic	  cell	  expression	  of	   IL-­‐2	   following	   stimulation	  with	   bacteria.	   Subsequent	  RT-­‐PCR	   analysis	   showed	  that	  stimulation	  of	  dendritic	  cells	  with	  a	  bacterial	  stimulus	  induced	  a	  transient	  (4-­‐6hrs)	  upregulation	  of	  IL-­‐2	  expression,	  while	  an	  ELISA	  assay	  showed	  that	  dendritic	  cells	   produced	   IL-­‐2	   protein	   in	   response	   to	   a	   bacterial	   stimulus	   (Granucci	   et	   al.,	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2001).	  IgE	  activated	  mast	  cells	  have	  also	  been	  reported	  to	  produce	  IL-­‐2,	  suggesting	  mast	  cells	  can	  act	  as	  a	  source	  of	  IL-­‐2	  during	  allergic	  type	  responses	  (Hershko	  et	  al.,	  2011).	   Experiments	   using	   an	   IL-­‐2	   YFP	   fate	   reporter	   have	   suggested	   that	   lung	  derived	   ILC	   (particularly	   ILC1/3)	   can	   also	   produce	   IL-­‐2.	   These	   experiments	  showed	   that,	   in	   the	   lung,	   YFP	   expression	   (indicating	   IL-­‐2	   expression)	   could	   be	  detected	   in	   various	   cells:	   between	   1-­‐2%	   of	   CD4+	   T	   cells	   and	   CD2+ILC1/3	   were	  YFP+,	  while	  others,	   including	   ILC2,	  CD8+	  T	  cells,	  dendritic	   cells	  and	  macrophages	  were	  less	  than	  1%	  YFP+	  (Roediger	  et	  al.,	  2015).	  	  
1.6.2	  Role	  of	  IL-­‐2	  in	  vivo	  An	   important	   role	   of	   IL-­‐2	   in	  vivo	   is	   supporting	   the	   function	  of	  Tregs,	  with	   IL-­‐2-­‐/-­‐	  mice	  succumbing	  rapidly	  to	  autoimmune	  disease	  (Ma	  et	  al.,	  1995).	  IL-­‐2	  is	  required	  for	  maintenance	  of	  Tregs	  rather	  than	  inducing	  Treg	  differentiation.	  Setoguchi	  et	  al.	  (2005)	  reported	  that	  acute	  neutralization	  of	  IL-­‐2	  with	  α-­‐IL-­‐2	  reduced	  the	  number	  of	   CD25high	   and	   FoxP3+	   CD4+	   T	   cells	   in	   the	   thymus,	   spleen	   and	   lymph	   nodes,	  demonstrating	  a	  constant	  need	  for	  IL-­‐2	  to	  maintain	  Treg	  cell	  numbers.	  The	  number	  of	   Tregs	  was	   also	   reduced	   following	   administration	   of	   α-­‐IL-­‐2	   after	   thymectomy,	  demonstrating	  that	  IL-­‐2	  is	  required	  to	  maintain	  Tregs	  in	  the	  periphery	  as	  well	  as	  thymic	  Tregs	  (Setoguchi	  et	  al.,	  2005).	  	  	  Fortenot	  et	  al.	  (2005)	  reported	  that	  in	  the	  absence	  of	  IL-­‐2	  signalling,	  FoxP3+	  CD4+	  cells	   were	   present	   in	   the	   thymus	   and	   lymph	   nodes	   and	   were	   capable	   of	  suppressing	   the	   proliferation	   of	   CD4+	   T	   cells	   in	   vitro.	   However,	   in	   a	   CD25+/+:	  	  	  CD25-­‐/-­‐	  bone	  marrow	  chimera,	  CD25-­‐/-­‐	  FoxP3+	  CD4+	  cells	  were	  reduced	  compared	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to	  CD25+/+	  FoxP3+	  CD4+,	   suggesting	   that	   the	  absence	  of	   functional	   IL-­‐2	  signalling	  reduced	   Treg	   survival	   or	   proliferation.	   Expression	   analysis	   of	   FoxP3+	   CD4+	   cells	  from	   IL-­‐2-­‐/-­‐	  mice	   also	   indicated	   reduced	   expression	   of	   genes	   involved	   in	   the	   cell	  cycle	   and	   cell	   growth	   in	   the	   absence	   of	   IL-­‐2	   signalling	   (Fontenot	   et	   al.,	   2005).	  D’Cruz	   and	   Klein	   (2005)	   also	   reported	   that	   IL-­‐2	   was	   required	   for	   Treg	  maintenance	  in	  the	  periphery	  but	  not	  Treg	  development	  (D'Cruz	  &	  Klein,	  2005).	  	  	  In	   addition	   to	   maintaining	   Treg	   cells,	   IL-­‐2	   has	   another	   role	   in	   CD4+	   T	   cells:	  regulating	  polarization	  of	  naïve	  CD4+	   cells	   to	  different	  T	  helper	   subsets.	   IL-­‐2	  has	  been	   reported	   to	   increase	   polarization	   of	   naïve	   CD4+	   T	   cells	   to	   a	   Th1	   and	   Th2	  phenotype;	  and	  to	  inhibit	  polarization	  to	  a	  Tfh	  and	  Th17	  phenotype	  (Ballesteros-­‐Tato	  et	  al.,	  2012;	  Cote-­‐Sierra	  et	  al.,	  2004;	  Liao	  et	  al.,	  2011).	  	  There	  have	  been	  some	  reports	  of	  a	  reduction	  in	  the	  size	  of	  the	  primary	  CD8+	  T	  cell	  response	   to	   infection	   in	   the	   absence	   of	   IL-­‐2	   signalling.	   Cousens	   et	   al.	   (1995)	  reported	  that	  the	  expansion	  of	  CD8+	  T	  cells	  7-­‐9	  days	  after	  infection	  with	  LCMV	  was	  reduced	  in	  IL-­‐2-­‐/-­‐	  mice,	  but	  was	  rescued	  following	  administration	  of	  IL-­‐2	  (Cousens	  et	  al.,	  1995).	  Bachmann	  et	  al.	  (2007)	  reported	  reduced	  expansion	  of	  CD25-­‐/-­‐	  CD8+	  T	  cells	   in	  mixed	  CD25+/+:	  CD25-­‐/-­‐	  bone	  marrow	  chimera	  mice	  8	  days	  after	   infection	  with	   LCMV	   compared	   to	   that	   of	   CD25+/+	   CD8+	   T	   cells.	   However,	   an	   equal	  percentage	   of	   CD8+	   cells	   in	   the	   CD25+/+	   and	   CD25-­‐/-­‐	   cells	   were	   specific	   for	   the	  LCMV	  peptide	  gp33	  and	  produced	  IFNγ	  and	  TNFα,	  suggesting	  that	  the	  CD25-­‐/-­‐	  CD8+	  cells	   that	  were	   present	   responded	   normally	   to	   antigen	   (Bachmann	   et	   al.,	   2007).	  Other	  reports	  have	  suggested	  that	  the	  primary	  CD8+	  T	  cell	  response	  remains	  intact	  in	  the	  absence	  of	  IL-­‐2	  signalling	  (Kündig	  et	  al.,	  1993).	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IL-­‐2	   signalling	   can	   contribute	   to	   the	   formation	  of	   an	  effector	  CD8+	  T	   lymphocyte	  phenotype.	  In	  vitro,	  IL-­‐2	  signalling	  and	  activation	  of	  CD8+	  T	  cells	  in	  the	  presence	  of	  IL-­‐2	   has	   been	   shown	   to	   increase	   granzyme	   B	   expression	   and	   to	   increase	  cytotoxicity	   towards	  a	   target	  cells	  (Hinrichs	  et	  al.,	  2008).	  Lai	  et	  al.	   (2009)	  used	  a	  tumour	  model	  in	  which	  melanoma	  cells	  expressing	  gp33	  peptide	  were	  transferred	  to	  mice.	   P14	   CD8+	  T	   cells	   primed	   in	   the	   presence	   or	   absence	   of	   IL-­‐2	   were	   then	  transferred	   into	   the	   mice	   to	   assess	   the	   role	   of	   IL-­‐2	   in	   regulating	   CD8+	   effector	  function.	   Tumour	   clearance	   was	   better	   in	   the	   mice	   receiving	   IL-­‐2	   primed	   CD8+	  cells,	  suggesting	  that	  CD8+	  T	  cells	  receiving	  IL-­‐2	  signalling	  during	  activation	  were	  more	  cytotoxic	  (Lai	  et	  al.,	  2009).	  	  	  In	  addition	  to	  altered	  effector	  function,	  there	  have	  been	  reports	  of	  a	  defect	  in	  the	  CD8+	  memory	   in	   the	   absence	   of	   IL-­‐2	   signalling.	   In	  mixed	   CD25+/+:	   CD25-­‐/-­‐	   bone	  marrow	   chimera	   LCMV	   infection	   studies,	   the	   number	   of	   CD25-­‐/-­‐	   antigen	   specific	  CD8+	  T	  cells	  recovered	  after	  a	  secondary	  challenge	  is	  substantially	  fewer	  than	  the	  number	  of	  CD25+/+	  antigen	  specific	  CD8+	  T	  cells	  (Bachmann	  et	  al.,	  2007;	  Williams	  et	   al.,	   2006),	   suggesting	   that	   IL-­‐2	   signalling	   is	   required	   for	   the	   expansion	   of	  memory	   CD8+	   T	   cells	   on	   rechallenge	   .	   However,	   CFSE	   dilution	   experiments	   by	  Williams	   et	   al.	   (2006)	   showed	   that	   CD25-­‐/-­‐	   CD8+	   T	   cells	   divided	   on	   rechallenge,	  suggesting	   that	   the	   reduction	   in	  CD25-­‐/-­‐	   numbers	  may	  be	   a	   failure	   of	   survival	   of	  memory	   cells	   in	   the	   absence	   of	   IL-­‐2	   signalling	   rather	   than	   failure	   to	   proliferate:	  however,	   it	   is	   possible	   that	   proliferation	  was	   also	   slowed	   in	   the	   CD25-­‐/-­‐	   CD8+	   T	  cells.	   Formation	   of	   a	   CD8+	   memory	   response	   seems	   to	   require	   IL-­‐2	   signalling	  during	  the	  primary	  response,	  as	  Williams	  et	  al.	  (2006)	  found	  that	  administration	  of	  IL-­‐2/anti-­‐IL-­‐2	   during	   the	   primary	   response	   but	   not	   the	   secondary	   response	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rescues	   the	   number	   of	   CD25-­‐/-­‐	   CD8+	   T	   cells	   recovered	   after	   secondary	   challenge	  (Williams	  et	  al.,	  2006).	  	  	  Obar	  et	  al.	  (2010)	  studied	  the	  CD8+	  primary	  and	  secondary	  response	  to	  ovalbumin	  expressing	  viruses	  in	  CD25+/+:	  CD25-­‐/-­‐	  bone	  marrow	  chimeras.	  In	  contrast	  with	  the	  results	   outlined	   above,	   they	   found	   that	   the	   primary	   response	   by	   CD25-­‐/-­‐	   CD8+	   T	  cells	  was	  reduced	  compared	  to	  CD25+/+	  CD8+	  lymphocytes	  but	  that	  the	  secondary	  response	  was	  largely	  intact,	  if	  slightly	  reduced.	  This	  argues	  that	  IL-­‐2	  is	  required	  for	  CD8+	   short	   lived	   effector	   cells	   (SLECs)	  but	   is	   not	   essential	   for	  CD8+	  memory	   cell	  differentiation	   (Obar	   et	   al.,	   2010).	   It	   is	   possible	   that	   the	   requirement	   for	   IL-­‐2	   in	  CD8+	  T	  cell	  response	  in	  vivo	  differs	  with	  the	  stimulus.	  	  	  Pipkin	   et	   al.	   (2010)	   posited	   a	   model	   in	   which	   the	   dose	   of	   IL-­‐2	   received	   by	   a	  responding	   CD8+	   T	   cell	   dictates	   differentiation	   into	   an	   effector	   or	   memory	  phenotype.	  In	  experiments	  examining	  the	  effect	  of	  different	  doses	  of	  IL-­‐2	  on	  CD8+	  effector	  and	  memory	  function,	  in	  vitro	  CD8+	  T	  cells	  cultured	  in	  high	  dose	  IL-­‐2	  had	  an	  effector	  phenotype	  (CD25hi	  CD127-­‐	  CD62Llo),	  expressed	  Blimp-­‐1	  and	  high	  levels	  of	  perforin	  and	  granzymes.	  Cells	  cultured	  in	   low	  dose	  IL-­‐2	  had	  a	  central	  memory	  phenotype	   (CD25loCD127hiCD62Llo),	   expressed	  BCL6	   and	   expressed	   less	   perforin	  and	   granzymes	   than	   cells	   cultured	   in	   the	   presence	   of	   a	   high	   dose	   of	   IL-­‐2.	  Cytotoxicity	   against	   target	   cells	  was	   also	   higher	   in	   CD8+	   T	   cells	   cultured	   in	   high	  dose	  IL-­‐2	  than	  cells	  cultured	  in	  low	  dose	  IL-­‐2.	  	  	  CD8+	   T	   cells	   differentiated	   in	   the	   presence	   of	   high	   dose	   IL-­‐2	   did	   not	  survive/proliferate	   as	   efficiently	   as	   CD8+	   T	   cells	   differentiated	   in	   low	   dose	   IL-­‐2	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when	  transferred	  to	  a	  new	  host,	  suggesting	  that	  the	  effector	  phenotype	  produced	  by	   a	   high	   level	   of	   IL-­‐2	   signalling	   had	   a	   cost	   in	   proliferative	   potential.	   However,	  differentiation	  in	  the	  presence	  of	  high	  or	  low	  dose	  IL-­‐2	  did	  not	  affect	  the	  ability	  of	  transferred	   cells	   to	   proliferate	   in	   response	   to	   LCMV	   infection,	   suggesting	   that	  although	   IL-­‐2	   signalling	   promoted	   an	   effector	   CD8+	   T	   cell	   phenotype,	   it	   did	   not	  prevent	  the	  formation	  of	  longer	  lived	  CD8+	  T	  cells	  (Pipkin	  et	  al.,	  2010).	  	  	  In	   addition	   to	   regulating	   tolerance	   and	   CD8+	   effector	   function	   in	   the	   adaptive	  immune	   system,	   IL-­‐2	   may	   also	   have	   a	   role	   in	   regulating	   innate	   immune	   cells,	  particularly	   ILC2.	   ILC2	  express	  CD25,	  and	  administration	  of	   IL-­‐2	  and	   IL-­‐2/α-­‐IL-­‐2	  has	   been	   reported	   to	   expand	   populations	   of	   ILC	   in	   the	   lung	   and	   dermis	  respectively	   (Roediger	   et	   al.,	   2015;	   2013).	   In	   addition	   to	   regulating	   ILC2	  proliferation,	   in	   vitro	   experiments	   have	   suggested	   that	   IL-­‐2	   can	   regulate	   ILC2	  cytokine	   expression.	   IL-­‐2	   has	   been	   reported	   to	   induce	   ILC2	   expression	   of	   IL-­‐9	  (Wilhelm	  et	  al.,	  2011),	  and	  expression	  of	  IL-­‐5	  and	  IL-­‐15	  (Mirchandani	  et	  al.,	  2014).	  It	  has	  not	  been	  determined	   if	   ILC2	   require	  a	   constant	   source	  of	   IL-­‐2	   to	  maintain	  their	  population	  in	  the	  steady	  state,	  or	  if	  ILC2	  respond	  to	  IL-­‐2	  produced	  as	  part	  of	  an	   inflammatory	   response.	   The	   source	   of	   IL-­‐2	   that	   ILC2	   respond	   to	   has	   also	   not	  been	  determined	  conclusively.	  It	  has	  been	  suggested	  that	  ILC2	  respond	  to	  CD4+	  T	  cell	   derived	   IL-­‐2	   (Mirchandani	   et	   al.,	   2014),	   and	   that	   ILC2	  may	   respond	   to	   IL-­‐2	  production	  by	  ILC3	  (Roediger	  et	  al.,	  2015).	  	  The	  different	  roles	  of	   IL-­‐2	   in	  vivo	  have	   led	  to	  the	  use	  of	   IL-­‐2	  therapeutically	   for	  a	  number	  of	  diseases.	  Low	  dose	  IL-­‐2	  has	  been	  used	  for	  the	  treatment	  of	  HCV	  induced	  vasculitis	  and	  chronic	  GVHD	  (graft	  vs.	  host	  disease),	  while	  high	  dose	  IL-­‐2	  has	  been	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used	   in	   cancer	   treatment,	   particularly	   renal	   cell	   carcinoma	   and	  melanoma.	   This	  reflects	   the	   multiple	   roles	   of	   IL-­‐2,	   with	   a	   constant	   basal	   amount	   required	   to	  maintain	   an	   adequate	   Treg	   population	   and	   a	   higher	   amount	   induced	   during	  activation	  involved	  in	  the	  proinflammatory	  response	  (Klatzmann	  &	  Abbas,	  2015).	  
	  
Figure	  1.4:	  Role	  of	   IL-­‐2	   in	  vivo	  Figure	  shows	  reported	  producers	  of	  and	  functions	  of	   IL-­‐2	   in	  
vivo	  Treg:	  regulatory	  T	  cell;	  NKT:	  natural	  killer	  T	  cell;	  NK	  cell:	  natural	  killer	  cell;	  SLEC:	  short	  lived	  effector	   cell;	   MPEC:	   memory	   precursor	   effector	   cells;	   Tfh:	   T	   follicular	   helper	   cell;	   ILC:	   innate	  lymphoid	  cell.	  	  
1.6.3	  Signalling	  downstream	  of	  the	  IL-­‐2	  receptor	  IL-­‐2	   can	   signal	   via	   a	   dimeric	   IL-­‐2	   receptor	   consisting	   of	   IL-­‐2Rβ	   (CD122)	   and	   γc	  (CD132),	   or	   a	   trimeric	   IL-­‐2	   receptor	   consisting	   of	   IL-­‐2Rα	   (CD25),	   IL-­‐2Rβ	   and	   γc	  (Cho	  et	  al.,	  2013).	  The	  dimeric	  IL-­‐2	  receptor	  has	  a	  lower	  affinity	  for	  IL-­‐2	  than	  the	  trimeric	   receptor	   (dimeric	   receptor:	  Kd	  ≈	  10-­‐9M;	   trimeric	   receptor	  Kd	  ≈	  10-­‐11M).	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The	  IL-­‐2Rα	  subunit	  of	  the	  receptor	  binds	  IL-­‐2	  independently	  with	  a	  Kd	  ≈	  10-­‐8M	  and	  lacks	  extensive	  intracellular	  signalling	  domains.	  The	  IL-­‐2Rβ	  subunit	  binds	  IL-­‐2	  but	  with	   a	   lower	   affinity,	   and	   possesses	   intracellular	   domains	   that	   participate	   in	  signalling,	   including	  the	  binding	  site	   for	   JAK1.	  The	  γc	  chain	  demonstrates	   little	   to	  no	   independent	   binding	   to	   free	   IL-­‐2	   but	   like	   IL-­‐2Rβ	   has	   intracellular	   signalling	  domains,	  and	  associates	  with	  JAK3.	  Crystallographic	  analysis	  of	  the	  human	  IL-­‐2/IL-­‐2	  receptor	  complex	  suggests	  that	  the	  IL-­‐2Rα	  subunit	  does	  not	  directly	  contact	  the	  other	  IL-­‐2	  receptor	  subunits,	  and	  the	  trimeric	  holoreceptor	  is	  assembled	  following	  IL-­‐2	  binding	   to	   IL-­‐2Rα,	   binding	  of	   IL-­‐2/IL-­‐2Rα	   to	   IL-­‐2Rβ	  and	  binding	  of	   IL-­‐2/IL-­‐2Rα/IL-­‐2Rβ	  to	  γc	  (Boyman	  &	  Sprent,	  2012;	  Wang	  et	  al.,	  2005).	  	  IL-­‐2	  binding	  to	  the	  trimeric	  IL-­‐2	  receptor	  triggers	  the	  activation	  of	  JAK1	  and	  JAK3	  (Miyazaki	  et	  al.,	  1994),	  which	  phosphorylate	  IL-­‐2Rβ	  at	  tyrosine	  residues	  including	  Y341,	  Y395	  and	  Y498	  (Liao	  et	  al.,	  2013).	  In	  addition	  to	  the	  JAK	  kinases,	  SRC	  family	  kinases	   including	   p56	   LCK	   have	   been	   reported	   to	   interact	   with	   the	   IL-­‐2Rβ	  (Delespine-­‐Carmagnat	  et	  al.,	  1999;	  Hatakeyama	  et	  al.,	  1991):	  however,	  reports	  of	  SRC	  family	  kinase	  interaction	  with	  the	  IL-­‐2	  receptor	  have	  been	  infrequent.	  In	  CTL	  the	  SRC	  kinases	  are	  active	  independently	  of	  IL-­‐2	  signalling	  (Ross	  et	  al.,	  2016).	  	  	  Phosphorylation	  of	  IL-­‐2Rβ	  at	  Y395	  and	  Y498	  (sites	  in	  mouse,	  equivalent	  Y392	  and	  Y510	  in	  humans)	  allow	  the	  recruitment	  of	  STAT	  (signal	  transducer	  and	  activator	  of	  transcription)	   transcription	   factors	   to	   the	   IL-­‐2Rβ	   receptor	   via	   the	   STAT	   SH2	  domain.	   Following	   recruitment	   to	   the	   IL-­‐2Rβ,	   STAT	   transcription	   factors	   are	  tyrosine	  phosphorylated	  by	  the	  JAK	  kinases	  near	  the	  c-­‐terminal	  of	  the	  protein.	  The	  IL-­‐2	  receptor	  predominantly	   induces	  phosphorylation	  of	   the	  STAT5	  transcription	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factors,	  STAT5A	  and	  STAT5B	  (phosphorylated	  at	  Y694	  and	  Y699	  respectively).	  In	  addition	  to	  STAT5,	  STAT3	  is	  phosphorylated	  at	  Y705	  and	  STAT1	  is	  phosphorylated	  at	  Y701	  (Liao	  et	  al.,	  2013).	  When	  the	  STATs	  disassociate	   from	  IL-­‐2Rβ,	  STATs	  can	  form	  dimers	   by	   head-­‐to-­‐tail	   interaction	   of	   the	   tyrosine	   phosphorylated	   site	  with	  the	  SH2	  domain	  located	  near	  the	  c-­‐terminus	  of	  the	  protein,	  which	  can	  then	  bind	  to	  DNA	   and	   regulate	   transcription.	   STAT5a	   and	   STAT5b	   can	   also	   form	   tetramers	  through	   interactions	   at	   the	   N-­‐terminal	   of	   the	   protein.	   The	   STAT	   transcription	  factor	   dimers	   bind	   to	   the	   GAS	   (γ	   interferon	   activated	   sequence)	   TTCN3GAA	  (TTCN4GAA	   for	   STAT6),	  with	   STAT5	   tetramers	   binding	   pairs	   of	   GAS	  motifs	  with	  looser	  stringency	  and	  a	  linker	  of	  6-­‐22	  nucleotides	  between	  motifs	  (Lin	  et	  al.,	  2012).	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activation	   of	   other	   signalling	   pathways	   are	   adaptor	   molecules	   such	   as	   SHC.	  Experiments	  with	  the	  CTLL-­‐20	  cell	  line	  demonstrated	  that,	  following	  binding	  of	  IL-­‐2	   to	   its	   receptor,	   SHC	   is	   tyrosine	   phosphorylated	   and	   interacts	   with	   the	   IL-­‐2Rβ	  chain.	   SHC	   also	   associates	   with	   the	   adaptor	   GRB2	   and	   the	   guanine	   nucleotide	  exchange	   factor	   SOS,	   suggesting	   that	   following	   IL-­‐2	   signalling	   SHC	   activates	  Ras/MAPK	   signalling	   by	   recruiting	   mSOS	   to	   the	   membrane	   in	   association	   with	  GRB2.	   SOS	   then	   facilitates	   GTP	   loading	   of	   Ras	   (Ravichandran	  &	  Burakoff,	   1994).	  Further	  experiments	  suggested	  that	  the	  interaction	  required	  the	  SHC	  PTB	  domain,	  and	   determined	   that	   SHC	   was	   likely	   to	   be	   interacting	   with	   pY338	   (human,	  equivalent	  Y341	  in	  mouse,	  Ravichandran	  et	  al.,	  1996).	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PtdIns(3,4)P2	   and	   PtdIns(3,4,5)P3.	   PKB	   can	   bind	   these	   phosphorylated	   inositol	  lipids	   by	   a	   PH	   (pleckstrin	   homology	   domain),	   concentrating	   PKB	   at	   the	   cell	  membrane	   where	   it	   can	   be	   phosphorylated	   by	   PDK1	   at	   the	   T-­‐loop	   T308	   site	  (Pearce	   et	   al.,	   2010).	   Various	   adaptor	   proteins	   have	   been	   suggested	   to	   bind	   the	  regulatory	  p85	   subunit	   of	   PI3K	   in	   in	   response	   to	   IL-­‐2	   signalling,	   including	  GAB2	  (Gadina	   et	   al.,	   2000)	   and	   CBL	   (Gesbert	   et	   al.,	   1998b).	   GAB2	   is	   tyrosine	  phosphorylated	   following	   IL-­‐2	   signalling,	   reportedly	   by	   JAK3,	   suggesting	   it	   is	  localized	  to	  the	  IL-­‐2	  receptor.	  However,	  GAB2	  does	  not	  bind	  the	  receptor	  directly	  and	  probably	  interacts	  with	  an	  adaptor	  protein	  such	  as	  SHC	  (Gadina	  et	  al.,	  2000).	  	  	  Recently	  both	  the	  regulatory	  and	  catalytic	  subunits	  of	  PI3K	  have	  been	  identified	  as	  increasing	  their	  interaction	  with	  GAB2	  following	  IL-­‐2	  stimulation,	  as	  well	  as	  other	  GAB2	  interacting	  proteins	  such	  as	  SHP-­‐2	  in	  the	  KIT225	  T	  cell	  line	  (Osinalde	  et	  al.,	  2016).	   It	   seems	   reasonable	   to	   link	   the	   IL-­‐2	   induced	   binding	   of	   PI3K	   subunits	   to	  GAB2	   to	   IL-­‐2	   induced	   changes	   in	   PI3K	   activity	   and	   so	   changes	   in	   PKB	   activity.	  	  However,	  the	  loss	  of	  IL-­‐2	  signalling	  does	  not	  reduce	  the	  ratio	  of	  PIP3	  to	  PIP2	  or	  PKB	  T308	  phosphorylation	  in	  primary	  CTL	  cultures,	  suggesting	  that	  in	  these	  cells	  IL-­‐2	  does	   not	   regulate	   PI3K	   activity	   (Ross	   et	   al.,	   2016).	   Alternatively,	   IL-­‐2	   may	   also	  increase	   the	  expression	  or	  activity	  of	  a	   lipid	  phosphatase,	  negating	   the	  results	  of	  increased	  PI3K	  activity.	  
	  IL-­‐2	   signalling	   also	   activates	   mTORC1	   signalling,	   with	   subsequent	   activation	   of	  downstream	   mTORC1	   effectors	   such	   as	   4-­‐EPB1	   and	   S6K	   and	   regulation	   of	   the	  amount	  of	  the	  transcription	  factor	  HIF1α.	  Following	  phosphorylation	  by	  mTORC1,	  S6K	  phosphorylates	  the	  ribosomal	  protein	  S6	  (Pullen	  &	  Thomas,	  1997).	  Activation	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of	  mTORC1	  by	  IL-­‐2	  has	  been	  proposed	  to	  be	  a	  result	  of	  activation	  of	  PKB	  signalling:	  in	   some	   cells,	   active	   PKB	   can	   phosphorylate	   and	   inactivate	   PRAS40	   and	   TSC2,	  which	  negatively	  regulate	  mTORC1	  activity	  (Laplante	  &	  Sabatini,	  2009).	  However,	  treatment	  of	   IL-­‐2	  maintained	  CTL	  with	  a	  PKB	   inhibitor	   (Akti)	  does	  not	  affect	   the	  phosphorylation	  of	  mTORC1	  pathway	  components	  such	  as	  S6	  (Finlay	  et	  al.,	  2012),	  suggesting	  that	  PKB	  activity	  is	  not	  important	  for	  regulating	  mTOR	  activity	  in	  CTL.	  However,	   S6	   phosphorylation	   is	   lower	   in	   response	   to	   IL-­‐2	   in	   T	   cells	   bearing	  phenylalanine	   residues	   in	   the	   IL-­‐2Rβ	   at	   the	   putative	   SHC	   binding	   site	   (Y341,	  mouse)	  and	  in	  T	  cells	  bearing	  phenylalanine	  residues	  in	  the	  IL-­‐2Rβ	  at	  the	  putative	  STAT5	  binding	  sites	  (Y395	  and	  Y498,	  SHC	  phosphorylation	  lost	  in	  T	  cells	  with	  this	  mutation,	  mouse),	   suggesting	   that	  a	  SHC	  dependent	  pathway	  could	  contribute	   to	  mTORC1	   signalling	   in	   response	   to	   IL-­‐2	   (Yu	   et	   al.,	   2009).	   In	   addition	   to	   these	  pathways,	  IL-­‐2	  signalling	  regulates	  the	  activity	  of	  various	  other	  proteins,	  including	  maintaining	   protein	   production	   of	   the	   MYC	   transcription	   factor	   (Preston	   et	   al.,	  2015)	   and	   maintaining	   the	   expression	   of	   PIM1	   through	   STAT5	   dependent	  transcriptional	  regulation	  (Basham	  et	  al.,	  2008).	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1.6.4	  IL-­‐2	  signalling	  in	  CTL	  One	  of	  the	  aims	  of	  this	  project	  was	  to	  use	  techniques	  such	  as	  phosphoproteomics	  and	  proteomics	   to	  explore	   the	  contribution	  of	   JAK	  kinases	   to	   IL-­‐2	  signalling,	  and	  how	  IL-­‐2	  signalling	  in	  CTL	  is	  perturbed	  by	  the	  JAK	  kinase	  inhibitor	  tofacitinib.	  One	  of	  the	  advantages	  of	  techniques	  such	  as	  phosphoproteomics	  and	  proteomics	  is	  that	  they	   allow	   observation	   of	   changes	   in	   protein	   phosphorylation	   and	   protein	  abundance	   without	   making	   prior	   assumptions	   as	   to	   which	   phosphorylation	  sites/proteins	   are	   most	   likely	   to	   be	   regulated,	   as	   is	   required	   for	   more	   directed	  techniques	   such	   as	   Western	   blotting	   or	   RT-­‐PCR	   analysis.	   Various	   studies	   have	  previously	  been	  published	  that	  focus	  on	  different	  aspects	  of	  IL-­‐2	  signalling	  using	  in	  
vitro	  models	  of	  CTL,	  using	  both	  directed	  and	  non-­‐directed	  techniques,	  and	  will	  be	  reviewed	  briefly	  below.	  
	  Lin	  et	  al.	  (2012)	  examined	  the	  role	  of	  STAT5	  tetramers	  in	  IL-­‐2	  signalling	  in	  T	  cells	  using	   a	   double	   knock-­‐in	   STAT5A/B	   mouse	   in	   which	   the	   residues	   required	   for	  tetramer	   formation	   (I28,	   F81	   and	   L82)	   were	   mutated	   to	   alanine.	   The	   resulting	  STAT5	  proteins	  could	  be	  tyrosine	  phosphorylated	  and	  dimerize,	  but	  were	  unable	  to	   form	   tetramers.	  Microarray	  analysis	  of	  T	   cells	   (CD4+	   and	  CD8+)	  demonstrated	  that	   a	   tenth	   of	   genes	   whose	   expression	   was	   induced	   by	   IL-­‐2	   stimulation	   of	  previously	   TCR	   activated	   T	   cells	   was	   differently	   regulated	   (by	   at	   least	   1.5	   fold	  change	  to	  IL-­‐2	  stimulated	  wild	  type)	  in	  the	  T	  cells	  expressing	  the	  tetramerization	  deficient	  STAT5A/B.	  	  	  Differently	   regulated	   genes	   included	   CD25,	   IFNγ,	   IL-­‐24,	   TNF,	   lymphotoxin	   α	   and	  IRF8,	   suggesting	   that	   STAT5	   tetramerization	   was	   required	   for	   their	   expression;	  
	   55	  
and	   pathway	   analysis	   suggested	   regulation	   of	   various	   pathways	   including	   the	  JAK/STAT	  pathway,	  cytokine	  cytokine	  receptor	  interaction	  and	  the	  T	  cell	  receptor	  signalling	  pathway.	  CD8+	  T	  cells	  failed	  to	  proliferate	  in	  response	  to	  IL-­‐2	  in	  the	  cells	  expressing	  the	  double	  knock-­‐in	  STAT5A/B,	  which	  could	  be	  attributed	  to	  either	  the	  requirement	  for	  STAT5	  tetramers	   in	  regulating	  cell	  cycle	  components	  or	  reduced	  expression	   of	   CD25	   in	   the	   knock-­‐in	   cells.	   CD8+	   T	   cells	   expressing	   the	   knock-­‐in	  STAT5A/B	   also	   had	   reduced	   upregulation	   of	   genes	   including	   granzyme	   B(G,H),	  SOCS1	  and	  NFAT	  in	  response	  to	  IL-­‐2	  (Lin	  et	  al.,	  2012).	  	  In	  CD8+	  T	  cells	  that	  are	  TCR	  activated	  and	  then	  maintained	  in	  IL-­‐2,	  IL-­‐2	  signalling	  is	  required	  to	  maintain	  expression	  of	  the	  system	  L	  amino	  acid	  transporter	  light	  chain	  SLC7A5	  and	  to	  maintain	  the	  uptake	  of	  phenylalanine	  and	  other	  large	  neutral	  amino	  acids	   (Sinclair	   et	   al.,	   2013).	   IL-­‐2	   is	   also	   required	   to	  maintain	  CTL	   leucine	  uptake	  and	  maintains	  the	  abundance	  of	  the	  transcription	  factor	  Myc	  (Preston	  et	  al.,	  2015).	  Myc	  is	  phosphorylated	  by	  GSK3	  at	  T58	  and	  targeted	  for	  proteosomal	  degradation,	  and	  IL-­‐2	  signalling	  maintains	  a	  high	  enough	  amino	  acid	  uptake	  to	  maintain	  a	  high	  level	  of	  Myc	  protein	  production	  (Preston	  et	  al.,	  2015).	  	  The	  availability	  of	  leucine	  and	  glutamine	  positively	  regulate	  mTORC1	  signalling	  in	  IL-­‐2	  maintained	  CTL	  (Sinclair	  et	  al.,	  2013).	  In	  CTL,	  proteomic	  analysis	  of	  rapamycin	  treated	   CTL	   has	   demonstrated	   that	   mTORC1	   signalling	   positively	   regulates	   the	  abundance	  of	  glucose	   transporters,	  proteins	   involved	   in	   the	  glycolysis	  and	  sterol	  biosynthesis	   pathway	   and	   the	   abundance	   of	   cytoplasmic	   ribosome	   subunits.	  Inhibition	   of	   mTORC1	   signalling	   by	   rapamycin	   treatment	   also	   increases	   the	  abundance	   of	   proteins	   involved	   in	   oxidative	   phosphorylation	   and	  mitochondrial	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ribosomal	  subunits.	  Rapamycin	  treatment	  reduced	  the	  abundance	  of	  CTL	  perforin,	  granzymes	   and	   IFNγ,	   suggesting	   that	   mTORC1	   signalling	   is	   required	   for	   CTL	  effector	   function	   (Hukelmann	   et	   al.,	   2015).	   This	   suggests	   that	   IL-­‐2	   induced	  mTORC1	  signalling	  can	  maintain	  the	  glycolytic	  phenotype	  of	  CTL.	  	  	  HIF1,	   a	   transcription	   factor	   complex	   composed	   of	   the	  HIF1α	   and	  HIF1β	   (ARNT)	  subunits,	   is	  a	  downstream	  effector	  of	  mTORC1	  signalling	   in	   IL-­‐2	  maintained	  CTL.	  HIF1α	   protein	   is	   reduced	   following	   rapamycin	   treated	   CTL,	   suggesting	   HIF1α	  protein	   is	   stabilized	   downstream	   of	   mTORC1	   signalling.	   Similarly	   to	   rapamycin	  treated	   CTL,	   CTL	   deficient	   in	   HIF1β	   have	   reduced	   expression	   of	   the	   glucose	  transporter	   GLUT1,	   perforin	   and	   multiple	   granzymes.	   HIF1	   also	   negatively	  regulates	   CTL	   expression	   of	   cell	   membrane	   proteins	   involved	   in	   cell	   trafficking	  including	  CD62L,	  CCR7	  and	  SP1,	  suggesting	  that	  mTORC1	  signalling	  is	  involved	  in	  CTL	  localization	  (Finlay	  et	  al.,	  2012).	  	  	  	  	  	  	  	  	  HIF	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1.7	  JAK	  kinases	  The	  JAK	  kinases	  are	  a	  small	  family	  of	  non-­‐receptor	  tyrosine	  kinases,	  consisting	  of	  a	  single	   JAK	   kinase	   in	   invertebrates	   (e.g.	   hopscotch	   in	   Drosophila)	   and	   four	   JAK	  kinases	  in	  vertebrates:	  JAK1,	  JAK2,	  JAK3	  and	  TYK2	  (Liongue	  et	  al.,	  2012).	  The	  name	  of	  the	  JAK	  kinase	  family	  is	  an	  acronym	  (standing	  for	  Just	  Another	  Kinase):	  a	  legacy	  of	   the	   discovery	   of	   JAK1	   and	   JAK2	   in	   a	   PCR	   screen	   with	   a	   degenerate	   tyrosine	  kinase	   domain	   primers	   intended	   to	   identify	   receptor	   tyrosine	   kinases.	   However,	  the	  authors	  of	  the	  paper	  identifying	  JAK1	  and	  JAK2	  modified	  the	  derivation	  of	  JAK	  kinases	   on	   publication	   to	   refer	   instead	   to	   the	   double	   headed	   Roman	   god	   Janus	  (Wilks,	   2008;	   Wilks	   et	   al.,	   1991).	   TYK2,	   was	   identified	   in	   another	   screen	   for	  tyrosine	   kinases,	   and	   a	   similar	   cloning	   strategy	   was	   later	   used	   to	   identify	   JAK3	  (Kawamura	   et	   al.,	   1994;	   Takahashi	   &	   Shirasawa,	   1994).	   JAK3	   was	   described	   as	  having	   a	   much	   more	   limited	   expression	   than	   JAK1,	   JAK2	   and	   TYK2,	   with	  expression	  limited	  to	  lymphocytes	  and	  NK	  cells	  (Kawamura	  et	  al.,	  1994).	  	  	  While	   the	   JAK	  kinases	   are	  not	   receptor	   tyrosine	   kinases,	   they	   associate	  with	   the	  cytokine	  receptor	  subunits	  of	   type	  I	  and	  type	  II	  cytokines	  as	  discussed	   in	  section	  1.4.	  JAK	  kinases	  function	  in	  a	  manner	  analogous	  to	  the	  kinase	  domain	  of	  receptor	  tyrosine	  kinases	  by	  phosphorylating	   tyrosine	   residues	  of	   the	  associated	  cytokine	  receptor,	  allowing	  the	  recruitment	  of	  SH2	  domain	  signalling	  proteins	  and	  adaptors	  (Babon	   et	   al.,	   2014).	   The	   JAK	   kinases	   have	   been	   reported	   to	   be	   involved	   in	  signalling	   pathways	   outwith	   binding	   to	   type	   I/type	   II	   cytokine	   receptors,	   for	  example	   in	  signalling	  downstream	  of	   chemokines	   (Montresor	  et	  al.,	  2013)	  or	   the	  reported	  localization	  and	  activity	  of	  JAK2	  in	  the	  nucleus	  (Dawson	  et	  al.,	  2009),	  but	  the	  function	  of	  JAK	  kinases	  in	  cytokine	  signalling	  will	  be	  the	  focus	  of	  this	  thesis.	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The	   JAK	  kinases	  are	   involved	   in	  signalling	  pathways	  vital	   to	   life.	   JAK1-­‐/-­‐	  mice	  are	  small	  at	  birth,	  fail	  to	  suckle	  and	  die	  within	  24	  hours	  of	  birth.	  Thymocyte	  numbers	  and	  B	  cell	  numbers	  are	  reduced	  in	  the	  thymus	  and	  spleen	  respectively,	  likely	  due	  to	   failure	   to	   respond	   to	   IL-­‐7	   signalling.	   In	   vitro	   experiments	   demonstrated	   a	  reduced	  survival	  of	  JAK1-­‐/-­‐	  neuronal	  cells	  in	  response	  to	  cytokines	  such	  as	  LIF	  that	  use	   the	   gp130	   receptor.	   The	   exact	   cause	   of	   death	   was	   not	   defined	   but	   was	  suggested	  to	  be	  a	  result	  of	  a	  neuronal	  defect	  (Rodig	  et	  al.,	  1998).	  The	  generation	  of	  JAK2-­‐/-­‐	  mice	  demonstrated	  that	  JAK2	  deficiency	  is	  embryonic	  lethal,	  due	  to	  a	  failure	  of	  erythropoiesis	  (Neubauer	  et	  al.,	  1998;	  Parganas	  et	  al,	  1998).	  	  	  Both	  humans	  and	  mice	  deficient	  in	  JAK3	  have	  severe	  combined	  immunodeficiency	  (SCID).	  JAK3-­‐/-­‐	  mice	  have	  hypoplastic	  thymi,	  lymph	  nodes	  and	  spleens	  and	  reduced	  T	  cell	  and	  B	  cells	  numbers.	  The	  T	  cells	   that	  are	  present	  are	  unresponsive	   to	  TCR	  stimulation	  and	  have	  an	  activated	  phenotype	  (Baird	  et	  al.,	  1998;	  Park	  et	  al.,	  1995).	  Patients	  with	  JAK3	  mutations	  typically	  lack	  T	  cell	  and	  NK	  cell	  populations.	  B	  cells	  are	  present	  (T-­‐	  B+	  NK-­‐),	  but	  lack	  T	  cell	  help	  and	  are	  dysfunctional	  (Casanova	  et	  al.,	  2012).	  	  	  In	  mice,	  TYK2	  deficiency	  has	  been	  reported	  to	  reduce	  the	  response	  to	  type	  I	  and	  II	  interferons	   and	   IL-­‐12;	   reduce	   survival	   in	   response	   to	   VSV	   (vesicular	   stomatitis	  virus);	  reduce	  the	  CTL	  response	  to	  lymphocytic	  choriomeningitis	  virus	  (LCMV)	  and	  reduce	   clearance	   of	   vaccinia	   virus	   (VV).	   This	   suggests	   a	   role	   for	   TYK2	   in	   the	  response	   to	  viral	   infection	   (Karaghiosoff	   et	   al.,	   2000).	  A	  human	  patient	  has	  been	  identified	  with	   a	   homozygous	  mutation	   in	   tyk2	   leading	   to	   a	   predicted	   truncated	  TYK2	  protein	  and	  with	  no	  detectable	  TYK2	  expression	  in	  T	  cells.	  This	  patient	  had	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hyper	   IgE	   syndrome;	   skewed	   CD4+	   differentiation	   to	   a	   Th2	   phenotype;	   and	  increased	  susceptibility	  to	  various	  viral,	  fungal	  and	  mycobacterial	  (BCG)	  infections.	  Patient	  T	  cells	  failed	  to	  respond	  to	  type	  I	   interferons,	  IL-­‐6,	  IL-­‐10,	  IL-­‐12	  and	  IL-­‐23	  (Minegishi	   et	   al.,	   2006),	   suggesting	   a	   role	   for	   TYK2	   in	   signalling	   pathways	  coordinating	  response	  to	  infection.	  	  
1.7.1	  JAK	  kinase	  structure	  A	  diagram	  of	  the	  basic	  JAK	  kinase	  domain	  structure	  is	  shown	  below	  in	  figure	  1.4.	  JAK	   kinases	   share	   regions	   of	   homology	   termed	   JH1-­‐JH7.	   JAKs	   can	   also	   be	  functionally	  divided	  into	  a	  kinase	  domain,	  a	  psuedokinase	  domain,	  an	  SH2	  domain	  and	  a	  FERM	  domain	  (figure	  1.3).	  The	  JH1	  domain	  is	  a	  typical	  kinase	  domain,	  with	  expression	   of	   a	   truncated	   protein	   expressing	   only	   the	   JH1	   domain	   sufficient	   to	  phosphorylate	   target	   peptides	   in	   an	   in	   vitro	   kinase	   assay	   (Saharinen	   &	  Silvennoinen,	  2002).	  	  	  The	   JAK	   kinases	   are	   somewhat	   unusual	   in	   that,	   in	   addition	   to	   a	   tyrosine	   kinase	  domain	   at	   the	   carboxyl-­‐terminus	   of	   the	   polypeptide	   (JH1),	   the	   JAK	   kinases	   have	  another	   kinase-­‐like	  domain	   (JH2).	  The	   JH2	  domain	   forms	  a	   kinase	   fold	  but	   lacks	  typical	   catalytic	   residues,	   and	   so	   is	   designated	   a	   psuedokinase	   (Lupardus	   et	   al.,	  2014).	  The	  JH2	  domain	  plays	  an	  important	  role	  in	  regulating	  JAK	  kinase	  activity:	  in	  
vitro	   kinase	   assays	   using	   JAK2	   and	   JAK3	   lacking	   the	   JH2	   domain	   demonstrate	  increased	  basal	  activity	  against	  target	  peptides,	  but	  a	  failure	  to	  increase	  activity	  in	  response	  to	  a	  cytokine	  stimulus,	  suggesting	  that	  the	  JH2	  domain	  is	  required	  both	  to	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restrain	   JAK	   kinase	   activity	   in	   the	   absence	   of	   stimulation	   and	   to	   maintain	  responsiveness	  to	  cytokine	  signalling	  (Saharinen	  &	  Silvennoinen,	  2002).	  	  	  The	   importance	   of	   the	   JH2	   domain	   in	   regulating	   JAK	   kinase	   activity	   is	  demonstrated	  by	  the	  pathology	  that	  occurs	  when	  the	  JH2	  domain	  is	  compromised.	  Mutations	   in	   the	   JH2	   domain	   of	   JAK2	   (V617F	   mutations)	   are	   often	   present	   in	  patients	  with	   the	  myeloproliferative	   disorder	   polycythemia	   vera	   (Vainchenker	  &	  Constantinescu,	   2005);	   while	   mutations	   in	   the	   JH2	   domain	   of	   JAK3	   have	   been	  identified	  in	  patients	  with	  acute	  megakaryoplastic	  leukaemia	  (Walters	  et	  al.,	  2006).	  Mutations	   in	   the	   JH2	   domain	   of	   JAK3,	   which	  when	   expressed	   in	   cell	   lines	   show	  increased	  basal	  activity	  and	  loss	  of	  cytokine	  responsiveness,	  have	  also	  been	  linked	  to	  non	  X-­‐linked	  SCID	  (Chen	  et	  al.,	  2000).	  	  Several	   models	   have	   been	   proposed	   to	   explain	   the	   role	   of	   the	   JH2	   domain	   in	  regulating	   JAK	   kinase	   activity.	   Toms	   et	   al.	   (2013)	   have	   suggested	   that	  rearrangement	   of	   F-­‐V-­‐V	   triad	   of	   residues	   in	   the	   SH2-­‐JH2	   linker	   and	   JH2	   domain	  (F575,	  F636	  and	  V658	  in	  human	  JAK1)	  destabilizes	  autoinhibitory	  interactions	  of	  the	   JH2	   domain	   with	   the	   JH1	   domain.	   This	   model	   was	   developed	   based	   on	   the	  observation	  that	  JAK1	  expressing	  a	  V658F	  mutant	  adopts	  a	  configuration	  in	  which	  F575	  is	   ‘flipped	  out’	  relative	  to	   its	  position	  in	  wild	  type	  JAK1	  (Toms	  et	  al.,	  2013).	  Shan	   et	   al.	   (2014)	   proposed	   an	   alternative	  model	   based	   on	  molecular	   dynamics	  simulations	   of	   human	   JAK2,	   in	   which	   JH2	   forms	   multiple	   interfaces	   with	   JH1,	  stabilizing	  the	  inactive	  conformation	  (Shan	  et	  al.,	  2014).	  The	  JH2	  domain	  of	  TYK2	  has	  also	  been	  reported	  to	  form	  an	  interaction	  interface	  with	  the	  JH1	  domain,	  and	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many	   TYK2	   mutations	   linked	   to	   TYK2	   hyperactivity	   are	   within	   this	   interface	  (Lupardus	  et	  al.,	  2014).	  	  	  As	  noted	  by	  Toms	  et	  al.	  (2013),	  while	  JAK1	  and	  TYK2	  have	  equivalents	  of	  the	  JAK2	  V617	  site	  (V658),	  JAK3	  has	  a	  methionine	  at	  the	  equivalent	  residue	  (M592):	  unlike	  JAK1,	   JAK2	   and	  TYK2	  mutation	   of	   this	   residue	   to	   a	   phenylalanine	   residue	   is	   not	  associated	  with	   hyperactivity	   (Staerk	   et	   al.,	   2005;	   Toms	   et	   al.,	   2013),	   suggesting	  that	  JAK3	  uses	  a	  different	  mechanism	  of	  autoinhibition	  by	  the	  JH2	  domain.	  	  ATP	   binding	   by	   the	   psuedokinase	   domain	   (JH2)	   in	   an	   atypical	   binding	   site	   (one	  metal	  ion	  only)	  has	  been	  demonstrated	  in	  JAK1,	  JAK2	  and	  TYK2	  (Hammarén	  et	  al.,	  2015;	  Min	   et	   al.,	   2015).	   In	   JAK2	   the	   JH2	  domain	  has	  been	  demonstrated	   to	  have	  
bona	  fide	  phosphotransfer	  activity,	  catalyzing	  the	  phosphorylation	  of	  the	  inhibitory	  sites	  S532	  and	  Y570	  and	  so	  participating	  in	  the	  regulation	  of	  JAK2	  kinase	  activity	  (Ungureanu	  et	  al.,	  2011).	  Conversely,	  the	  ATP	  binding	  activity	  of	  the	  JAK1	  and	  JAK2	  JH2	  domains	  have	  been	  reported	  to	  be	  required	  for	  the	  hyperactive	  phenotype	  of	  the	   JAK1	   V658F	   and	   JAK2	   V617F	  mutation	   (Hammarén	   et	   al.,	   2015),	   suggesting	  that	   JH2	   ATP-­‐binding	   has	   multiple	   roles	   in	   JAK2.	   	   ATP	   binding	   has	   not	   been	  demonstrated	  for	  the	  JH2	  domain	  of	  JAK3.	  	  Despite	   its	   similarity	   to	   functional	   SH2	   domains,	   the	   function	   of	   the	   JAK	   kinase	  SH2-­‐like	  domain	  is	  not	  well	  defined.	   JAK1,	  JAK2	  and	  JAK3,	  but	  not	  TYK2,	  retain	  a	  key	  arginine	  residue	  in	  the	  SH2	  domain	  which,	  in	  a	  functional	  SH2	  domain	  would	  contact	   phosphotyrosine	   residues	   (Radtke	   et	   al.,	   2005).	   However,	   Radtke	   et	   al.	  (2005)	  reported	  that	  mutation	  of	  this	  arginine	  to	  a	  lysine	  (R446K),	  a	  substitution	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which	   in	   Abl	   has	   been	   shown	   to	   abolish	   phosphotyrosine	   binding	   (Mayer	   et	   al.,	  1992),	  did	  not	   affect	   surface	  expression	  of	   JAK1	  or	   the	  oncostatin	  M	   receptor	  or	  signalling	  through	  this	  receptor,	  suggesting	  phosphotyrosine	  binding	  by	  Jak	  kinase	  SH2	   domains	   may	   not	   be	   essential	   for	   Jak	   kinase	   dependent	   localisation	   or	  signalling.	   In	   contrast,	   deletion	   of	   the	   SH2	   domain	   did	   disrupt	   localisation,	  suggesting	  that	  while	  the	  phosphotyrosine	  binding	  function	  of	  the	  SH2	  domain	  is	  dispensible,	  the	  domain	  itself	  is	  required	  (Radtke	  et	  al.,	  2005).	  	  The	  FERM	  domain	   identified	   in	   JAK	  kinases	  diverges	   from	  that	   found	   in	  classical	  FERM	  domain	  containing	  proteins	  such	  as	  moesin	  (S.	  Haan	  et	  al.,	  2008).	  The	   JAK	  kinase	   FERM	   (four	   point	   one,	   ezrin,	   radixin	   and	  moesin)	   domain	   is	   involved	   for	  interaction	  of	  JAK	  kinases	  with	  the	  membrane	  proximal/box	  1	  and	  box	  2	  motifs	  of	  type	  I/II	  cytokine	  receptors,	  and	  so	  mediating	  JAK	  kinase	  interaction	  with	  cytokine	  receptors	   (Hilkens	   et	   al.,	   2001).	   Recently	   a	   PxxLxF	   motif	   in	   type	   II	   cytokine	  receptors	  that	  mediates	   interaction	  with	  human	  JAK1	  has	  been	  defined,	  although	  this	  motif	  is	  absent	  in	  type	  I	  receptors	  (Ferrao	  et	  al.,	  2016).	  	  Experiments	   examining	   the	   effect	   of	   JAK3	   FERM	   mutations	   identified	   in	   non-­‐x	  linked	  SCID	  patients	  demonstrated	  that	  FERM	  domain	  mutations	  affected	  catalytic	  activity	   in	   addition	   to	   reducing	   JAK3	   binding	   to	   γc.	   This	   suggests	   that	   the	   FERM	  domain	  has	  a	   function	  beyond	  cytokine	  receptor	  binding	  and	  may	  be	  required	  to	  maintain	  JAK	  kinases	  in	  an	  conformation	  that	  allows	  activation	  (Zhou	  et	  al.,	  2001).	  The	   activation/conformation	   of	   the	   kinase	   domain	   may	   also	   contribute	   to	   JAK	  kinase	  binding	  to	   the	  receptor,	  as	   inhibition	  of	   JAK3	  with	  staurosporine	  (Zhou	  et	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al.,	   2001)	  and	   JAK1	  with	  kinase	  domain	  mutations	   (Haan	  et	   al.,	   2008)	  have	  both	  been	  reported	  to	  alter	  binding	  to	  cytokine	  receptors.	  	  
	  
Figure	  1.8:	  Functional	  domains	  of	  the	  JAK	  kinases	  Figure	  adapted	  from	  Yamaoka	  et	  al.,	  2004.	  	  
1.7.2	  Regulation	  of	  JAK	  kinase	  activity	  JAK	  kinases	  contain	   tandem	  tyrosine	  residues	  within	   the	  activation	   loop	   that	  are	  analagous	  to	  regulatory	  sites	  in	  other	  kinases,	  and	  these	  sites	  have	  been	  reported	  to	  regulate	  JAK	  kinase	  activity.	  In	  JAK2,	  the	  Y1007F	  mutation	  but	  not	  the	  Y1008F	  mutation	   abolishes	   autophosphorylation	   and	   downstream	   signalling	   (Feng	   et	   al.,	  1997).	   Mutation	   of	   the	   TYK2	   Y1054/Y1055	   sites	   to	   phenylalanine	   abolishes	  activation	   in	   response	   to	   IFNα	   (single	   site	   mutants	   were	   not	   examined,	   sites	   in	  human,	  mouse	  equivalent	  Y1047	  and	  Y1048)	  (Gauzzi	  et	  al.,	  1996).	  The	  Y1033	  site,	  but	  not	  Y1034,	  of	  JAK1	  (mouse	  sites,	  Y1034	  and	  Y1035	  in	  humans)	  and	  Y975	  but	  not	  Y976	  (mouse	  sites,	  Y980	  and	  Y981	  in	  humans)	  of	  JAK3	  has	  been	  reported	  to	  be	  required	   for	  STAT5	  activation,	  as	  measured	  by	  DNA	  binding,	   in	  response	   to	   IL-­‐2,	  suggesting	  that	  the	  first	  of	  the	  tyrosine	  sites	  is	  required	  for	  JAK	  kinase	  activity	  and	  the	  other	  is	  dispensible	  (Liu	  et	  al.,	  1997).	  However,	  there	  has	  been	  a	  report	  that	  the	  JAK3	  Y980F	  abolishes	  JAK3	  activity	  while	  the	  Y981F	  mutation	  increases	  it	  (human	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sites),	  suggesting	  that	  the	  first	  tyrosine	  site	  has	  a	  positive	  regulatory	  role	  and	  the	  second	  a	  negative	  regulatory	  function	  (Zhou	  et	  al.,	  1997).	  	  In	   addition	   to	   regulation	   of	   JAK	   kinase	   activity	   by	   tyrosine	   phosphorylation,	   the	  JAK	  kinases	  are	  regulated	  by	  the	  tyrosine	  phosphatases	  SHP1,	  SHP2,	  CD45,	  PTP1B	  and	  TC-­‐PTP.	  SHP-­‐1	  has	  been	  reported	  to	  bind	  JAK1,	  JAK2	  and	  TYK2	  (Babon	  et	  al.,	  2014),	  and	  in	  vitro	  incubation	  of	  JAK1	  and	  TYK2	  with	  SHP-­‐1	  results	  in	  loss	  of	  JAK1	  and	  TYK2	  phosphorylation	   (Yetter	  et	  al,	  1995).	  SHP-­‐2	  has	  been	  reported	   to	  bind	  JAK1	  and	  JAK2	  (Babon	  et	  al.,	  2014),	  and	  SHP-­‐2	  deficient	  fibroblasts	  were	  reported	  to	  have	  increased	  STAT1	  and	  STAT2	  tyrosine	  phosphorylation	  in	  response	  to	  IFNα,	  and	  increased	  STAT1	  and	  JAK1	  tyrosine	  phosphorylation	  in	  response	  to	  IFNγ	  (You	  et	  al.,	  1999).	  CD45	  has	  been	  reported	  to	  dephosphorylate	  all	  JAK	  kinases	  (Babon	  et	  al,	   2014):	   CD45	   deficient	   mast	   cells	   have	   increased	   JAK2	   phosphorylation	   in	  response	   to	   IL-­‐3;	   CD45	   deficient	   jurkat	   cells	   have	   increased	   JAK1	   and	   JAK3	  phosphorylation	   in	   response	   to	   IL-­‐4;	   and	   CD45	   can	   dephosphorylate	   JAK1,	   JAK2	  and	   TYK2	   in	   vitro	   (Irie-­‐Sasaki	   et	   al.,	   2000).	   PTP1B	   has	   been	   reported	   to	  dephosphorylate	   TYK2	   and	   JAK2	   (Babon	   et	   al.,	   2014):	   Meyers	   et	   al.	   (2001)	  reported	   that	   TYK2	   and	   JAK2	   were	   coimmunoprecipitated	   using	   a	   substrate	  trapping	   PTP1B	   mutant	   following	   stimulation	   with	   IFNα	   and	   IFNγ	   stimulation	  respectively;	  and	  that	  MEFs	  deficient	  in	  PTP1B	  had	  hyperphosphorylated	  JAK2	  in	  response	  to	   insulin,	   IFNα	  and	  IFNγ	  stimulation	  (Meyers	  et	  al.,	  2001).	  TC-­‐PTP	  has	  been	  reported	  to	  dephosphorylate	  JAK1	  and	  JAK3	  (Babon	  et	  al.,	  2014):	  Simoncic	  et	  al.	   (2002)	   reported	   that	   JAK1	  and	   JAK3	  can	  be	  pulled	  down	  with	  TC-­‐PTP	   in	   IL-­‐2	  stimulated	   CTLL	   transfected	   with	   a	   substrate	   trapping	   TC-­‐PTP	   mutant,	   and	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stimulation	   of	   TC-­‐PTP	   deficient	   thymocytes	   with	   IFNα	   resulted	   in	  hyperphosphorylation	  of	  STAT1	  (Simoncic	  et	  al.,	  2002).	  	  The	  JAKs	  are	  also	  regulated	  by	  SH2	  domain	  containing	  proteins	  such	  as	  the	  SOCS	  protein	   family	   and	   LNK	   (SH2B3).	   The	   SOCS	   proteins	   bind	   to	   JAK/receptor	  complexes	  in	  association	  with	  the	  E3	  ligase	  cullin	  5	  and	  elongin	  B	  and	  C,	  resulting	  in	   JAK/receptor	   ubiquitination	   and	   triggering	   their	   degradation.	   Additionally,	  SOCS1	  and	  SOCS3	  can	  directly	  inhibit	  JAK	  kinase	  activity	  by	  inserting	  a	  KIR	  (kinase	  inhibitory	   region)	   domain	   into	   the	   active	   site	   of	   the	   JAK	   kinase,	   occluding	   the	  active	   site	   and	   preventing	   substrate	   access.	   SOCS3	   can	   inhibit	   JAK1,	   JAK2	   and	  TYK2,	  but	  is	  unable	  to	  inhibit	  JAK3	  as	  JAK3	  lacks	  a	  GQM	  motif	  required	  for	  SOCS3	  binding	  (Babon	  et	  al.,	  2012).	  The	  adaptor	  protein	  LNK	  (SH2B3)	  has	  been	  reported	  to	   bind	   tyrosine	   phosphorylated	   JAK2	   and	   JAK3	   and	   to	   inhibit	   JAK2	   dependent	  erythropoietin	   signalling	   and	   JAK3	   dependent	   IL-­‐7	   signalling,	   although	   the	  mechanism	  for	  this	  is	  not	  yet	  understood	  (Bersenev	  et	  al.,	  2008;	  Cheng	  et	  al.,	  2016;	  Tong,	  2005).	  
1.7.3	  JAK	  kinase	  inhibitors	  JAK	   kinase	   inhibitors	   have	   been	   developed	   as	   potential	   treatments	   for	  inflammatory	  disorders	   such	   as	   rheumatoid	   arthritis	   and	   to	   inhibit	   aberrant	   cell	  proliferation	  driven	  by	  mutated	  JAK	  kinases.	  The	  first	  JAK	  inhibitor	  to	  be	  approved	  was	  ruxolitinib.	  Ruxolitonib	  is	  a	  JAK1/2	  inhibitor	  used	  to	  treat	  myeloproliferative	  neoplasms	   such	   as	   polycythemia	   vera	   that	   are	   driven	   by	   signal	   independent	  haematopoeisis	   resulting	   from	   the	   V617F	   mutation	   of	   JAK2	   in	   the	   JH2	   domain	  (Vannucchi	  et	  al.,	  2015).	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Tofacitinib	   was	   developed	   as	   a	   JAK3	   inhibitor,	   but	   in	   vitro	   assays	   suggest	   that	  tofacitinib	   also	   inhibits	   JAK1	   with	   a	   similar	   potency	   (Kulagowski	   et	   al.,	   2012).	  Tofacitinib	   has	   been	   through	   clinical	   trials	   and	   demonstrated	   efficacy	   in	   the	  treatment	  of	  rheumatoid	  arthritis	  (Lee	  et	  al.,	  2014;	  van	  Vollenhoven	  et	  al.,	  2012),	  colitis	   (Sandborn	   et	   al.,	   2012)	   and	   maintaining	   kidney	   transplantation	   in	   the	  absence	  of	  cyclosporine	  A	  (Vincenti	  et	  al.,	  2012).	  Tofacitinib	  is	  approved	  for	  sale	  in	  the	   US	   but	   not	   in	   the	   EU.	   Tofacitinib	   treatment	   is	   linked	   to	   some	   side	   effects	  directly	   linked	   to	   its	  mechanism	   of	   action,	   namely	   an	   increase	   in	   the	   number	   of	  infections	   such	   as	   upper	   respiratory	   tract	   infections	   and	   herpes	   zoster	   and	   an	  increase	   in	   some	   malignancies	   (Hodge	   et	   al.,	   2016;	   Sandborn	   et	   al.,	   2012;	   van	  Vollenhoven	   et	   al.,	   2012).	   Anaemia	   has	   also	   been	   reported,	   presumably	   due	   to	  JAK2	  inhibition	  (Vincenti	  et	  al.,	  2012).	  Tofacitinib	  treatment	  is	  also	  linked	  to	  some	  side	  effects	   less	  clearly	  related	  to	   its	  mechanism	  of	  action:	  namely	  an	   increase	   in	  blood	  lipids	  and	  serum	  creatinine	  levels	  (Hodge	  et	  al.,	  2016;	  Sandborn	  et	  al.,	  2012;	  van	  Vollenhoven	  et	  al.,	  2012).	  	  	  Most	   JAK	  kinases	  used	   currently	   such	   as	   ruxolitonib	  or	   tofacitinib	   are	   reversible	  ATP	  competitors.	  Due	  to	  the	  similarity	  of	  active	  sites	  within	  the	  JAK	  kinase	  family	  this	   limits	   selectivity	   for	   individual	   JAK	   kinases.	   More	   selective	   JAK	   kinase	  inhibitors	   are	   in	   development,	   including	   JAK1	   inhibitors	   based	   on	   a	   imidazo-­‐pyrrolopyridine	  scaffold	  that	  seems	  to	  afford	  selectivity	  to	  JAK1	  (Kulagowski	  et	  al.,	  2012).	   JAK3	   inhibitors	   have	   also	   been	   developed	   that	   form	   a	   non-­‐reversible	  covalent	  bond	  via	  the	  thiol	  group	  in	  a	  cysteine	  found	  in	  the	  JAK3	  active	  site	  but	  not	  other	  JAK	  kinases.	  However,	  it	  is	  found	  in	  other	  kinases	  such	  as	  BTK	  (Goedken	  et	  al.,	  2014).	  	  
	   67	  
1.8	  Models	  of	  JAK	  kinase	  activation	  As	  discussed	  previously,	  on	  binding	  of	  ligand	  to	  a	  type	  I/type	  II	  cytokine	  receptor,	  the	   associated	   JAK	   kinases	   are	   activated	   and	   phosphorylate	   the	   receptor,	  recruiting	   further	   signalling	   proteins.	   This	   explanation	   of	   the	   activation	   of	   JAK	  kinase	  activity	  is	  sufficient	  for	  understanding	  many	  aspects	  of	  cytokine	  signalling,	  including	   downstream	   signalling	   events	   that	   depend	   primarily	   on	   the	  phosphorylation	   of	   the	   cytokine	   receptor	   and	   the	   phosphorylation	   of	   other	  signalling	  components.	  	  	  Given	  the	  shared	  use	  of	  the	  JAK	  kinases	  by	  a	  large	  number	  of	  cytokines,	  producing	  JAK	  kinase	  inhibitors	  that	  target	  a	  single	  JAK	  kinase	  could	  be	  useful	  in	  limiting	  the	  number	   of	   cytokine	   families	   targeted.	   As	   previously	   described,	   only	   the	   γc	  chain	  family	  cytokine	  receptors	  associate	  with	  JAK3.	  Given	  the	  role	  of	  γc	  chain	  cytokines	  in	   regulating	   immune	   function,	   inhibition	   of	   signalling	   by	   this	   cytokine	   family	  alone	  may	  be	  sufficient	  to	  provide	  therapeutic	  benefit	  in	  inflammatory	  conditions.	  However,	   the	  model	   of	   JAK	  kinase	   activity	  discussed	  previously	   is	   insufficient	   to	  predict	   if	   targeting	   a	   specific	   JAK	   kinase	   family	   member	   with	   high	   selectivity	  compared	  to	  other	  JAK	  kinases	  would	  be	  an	  efficient	  method	  of	  blocking	  signalling	  through	  a	  receptor	  using	  two	  different	  JAK	  kinases.	  For	  example,	  this	  model	  cannot	  be	   used	   to	   predict	   if	   a	   specific	   and	   potent	   JAK3	   inhibitor	  would	   block	   signalling	  downstream	  of	  a	  γc	  cytokine	  receptor,	  which	  associates	  with	  both	  JAK1	  and	  JAK3,	  as	  it	  is	  unclear	  if	  the	  kinase	  activity	  of	  both	  JAK	  kinases	  is	  required	  for	  downstream	  signalling.	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1.8.1	  JAK3	  protein	  expression	  is	  required	  for	  γc	  signalling	  Models	   of	   the	   activation	   of	   JAK	   kinases	   during	   γc	   cytokine	   signalling	   differ	   on	  whether	   the	   kinase	   activity	   of	   JAK3	   is	   essential	   or	   if	   JAK3	   fulfils	   a	   mostly	  scaffolding	  function.	  Studies	  have	  shown	  that	  JAK3	  protein	  expression	  is	  essential	  for	   γc	   signal	   transduction,	   with	   loss	   of	   JAK3	   associated	   with	   non	   X-­‐linked	   SCID.	  Russell	  et	  al.	  (1995)	  reported	  a	  patient	  with	  a	  non-­‐X	  linked	  SCID	  recapitulating	  the	  clinical	  features	  seen	  in	  X-­‐linked	  SCID,	  which	  is	  associated	  with	  mutation	  in	  the	  γc	  chain	  gene	  il2rg.	  The	  patient	  had	  multiple	  infections	  and	  a	  failure	  to	  thrive,	  and	  on	  further	   investigation	   was	   found	   to	   have	   low	   lymphocyte	   counts	   (including	   low	  CD4+	   and	   CD8+	   counts).	   Serum	   IgG,	   IgA	   and	   IgE	   were	   low	   but	   IgM	   levels	   were	  normal,	   indicating	   a	   lack	   of	   B	   cell	   maturation.	   Lymphocyte	   proliferation	   in	  response	   to	   mitogenic	   stimuli	   including	   phytohaemagglutinin	   (PHA)	   and	  concanavalin	  A	  (Con	  A)	  was	  also	  reduced.	  Some	  JAK3	  RNA	  was	  identified,	  but	  JAK3	  protein	   was	   absent,	   while	   other	   components	   of	   the	   common	   gamma	   chain	  signalling	   pathway,	   including	   JAK1	   and	   the	   γc	   chain,	   were	   expressed	   normally	  (Russell	   et	   al.,	   1995).	   Given	   the	   similarity	   of	   the	   presentation	   to	   that	   of	   patients	  with	  mutations	  in	  il2rg,	  this	  suggested	  that	  JAK3	  protein	  is	  absolutely	  required	  for	  γc	  cytokine	  signalling.	  
	  The	   requirement	   for	   JAK3	   protein	   was	   also	   demonstrated	   by	   the	   generation	   of	  mice	  with	  JAK3	  deficiency	  (Nosaka	  et	  al.,	  1995;	  Thomis	  et	  al.,	  1995).	  Nosaka	  et	  al.	  (1995)	   reported	  a	   lack	  of	  mature	  and	   immature	  B	   cells	   in	   the	  bone	  marrow	  and	  spleens	  of	  JAK3-­‐/-­‐	  mice,	  and	  reduction	  in	  the	  cellularity	  of	  the	  thymus	  but	  relatively	  normal	  proportions	  of	  CD4+	  and	  CD8+	  T	  cells.	  The	  number	  of	  cells	  present	   in	   the	  spleens	   of	   JAK3-­‐/-­‐	   were	   not	   obviously	   less	   than	   JAK+/+	   mice.	   However,	   T	   cells	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isolated	  from	  the	  spleens	  of	   JAK3-­‐/-­‐	  had	  an	  activated	  phenotype	  (increased	  CD44,	  CD25	  and	  CD69)	  and	  a	  reduced	  proliferative	  response	  to	  mitogenic	  stimulus	  even	  when	  exogenous	  IL-­‐2	  was	  supplied	  (Nosaka	  et	  al.,	  1995).	  	  	  Thomis	   et	   al.	   (1995)	   reported	   a	   similar	   phenotype,	   noting	   a	   reduction	   in	  mesenteric	   and	   peripheral	   lymphocytes	   and	   GALT	   (gut	   associated	   lymphoid	  tissue)	   in	   addition	   to	   reduced	   cellularity	   of	   the	   thymus;	   reduced	   numbers	   of	  lymphoid	   cells	   but	   normal	   numbers	   of	   other	   haematopoetic	   cell	   types	   including	  granulocytes	  in	  the	  blood.	  In	  contrast	  to	  Nosaka	  et	  al.	  (1995),	  Thomis	  et	  al.	  (1995)	  reported	  reduced	  cellularity	  of	  the	  spleen,	  and	  an	  increase	  in	  CD4+	  cells	  relative	  to	  CD8+	   cells	   in	   the	   thymus,	   which	   they	   speculated	   indicated	   an	   increased	  dependence	   of	   CD8+	   cells	   for	   γc	   signalling	   during	  maturation	   compared	   to	   CD4+	  cells	  (Thomis	  et	  al.,	  1995).	  	  	  While	  the	  phenotypes	  produced	  by	  naturally	  occurring	  JAK3	  mutations	  and	  JAK3-­‐/-­‐	  mice	  suggest	  an	  absolute	  requirement	   for	   JAK3	  protein,	  experiments	   in	  cell	   lines	  have	   suggested	   a	   model	   in	   which	   JAK3	   is	   dispensable	   for	   short	   term	   γc	   chain	  signalling	  but	   is	   required	   for	  more	  sustained	  signalling.	  Fujii	   (2007)	   investigated	  the	   respective	   roles	   of	   JAK1	   and	   JAK3	   in	   IL-­‐2	   signalling	   transduction	   using	   a	  fibroblast	   cell	   line	   reconstituted	   with	   the	   human	   IL-­‐2	   receptor	   subunits,	   which	  expressed	   JAK1	   but	   not	   JAK3	   (3T3αβγ)	   and	   a	   modified	   cell	   line	   (J3)	   that,	   in	  addition	   to	   expressing	   the	   human	   IL-­‐2	   receptor	   and	   human	   JAK1,	   expressed	  murine	   JAK3.	   Stimulation	   of	   the	   3T3αβγ	   cell	   line	   with	   IL-­‐2	   resulted	   in	   some	  tyrosine	   phosphorylation	   of	   JAK1,	   suggesting	   that	   JAK1	   kinase	   activity	   can	   be	  activated	   in	   the	   absence	   of	   JAK3.	   However,	   JAK1	   tyrosine	   phosphorylation	   was	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higher	  in	  response	  to	  IL-­‐2	  stimulation	  in	  the	  JAK3	  expressing	  J3	  cells,	  which	  would	  suggest	   that	   maximum	   JAK1	   phosphorylation	   requires	   JAK3	   expression.	   IL-­‐2	  stimulation	  of	  the	  3T3αβγ	  cell	  line	  also	  resulted	  in	  some	  STAT	  activation,	  but	  this	  was	  higher	  in	  J3	  cells.	  IL-­‐2	  stimulation	  of	  3T3αβγ	  cells	  also	  resulted	  in	  a	  transient	  induction	  of	  fos	  and	  c-­‐myc	  expression:	  however,	  in	  the	  JAK3	  expressing	  J3	  cells	  this	  induction	  was	  greater	  and	  more	  sustained	  (Fujii,	  2007).	  	  	  The	  transient	  JAK1	  and	  STAT	  phosphorylation	  in	  the	  absence	  of	  JAK3	  seen	  by	  Fuji	  et	   al.	   (2014)	   suggested	   that	   in	   the	   absence	   of	   JAK3,	   JAK1	   can	   be	   activated	   in	  response	  to	  IL-­‐2,	  but	  cannot	  support	  sustained	  signalling.	  It	  is	  possible	  that,	  in	  the	  absence	   of	   JAK3,	   another	   JAK	   kinase	   is	   able	   to	   bind	   to	   the	   vacant	   γc	   chain	  (presumably	  with	  a	  lower	  affinity)	  and	  form	  an	  ersatz	  IL-­‐2	  receptor	  that	  is	  able	  to	  replicate	  some,	  but	  not	  all,	  of	  IL-­‐2	  receptor	  function.	  Alternatively,	  in	  the	  absence	  of	   a	   JAK	   kinase	   on	   the	   γc,	   multiple	   IL-­‐2	   receptors	   may	   be	   able	   to	   cluster	   close	  enough	  to	  transphosphorylate	  and	  activate	  JAK1.	  
	  
1.8.2.	  The	  importance	  of	  JAK3	  kinase	  activity	  in	  IL-­‐2	  signalling	  The	  importance	  of	  JAK3	  kinase	  activity	  in	  γc	  cytokine	  signalling	  has	  been	  analysed	  by	  various	  methods,	  including	  the	  expression	  of	  kinase	  dead	  JAK1	  and	  JAK3	  or	  use	  of	   selective	   JAK3	   inhibitors.	   These	   will	   be	   reviewed	   here	   briefly.	   	   Thoma	   et	   al.	  (2011)	  produced	  a	   selective	   JAK3	   inhibitor	  with	  an	   IC50	   for	   JAK3	  of	  8nM.	  Kinase	  assays	  demonstrated	   the	  compound	  was	  100	   times	  more	  selective	   for	   JAK3	   than	  JAK1,	   and	   not	   selective	   for	   any	   other	   JAK	   kinase.	   Despite	   this,	   the	   compound	  inhibited	   IL-­‐2	   induced	   STAT5	   phosphorylation	   with	   an	   IC50	   of	   ≈1.3μM,	   while	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tofacitinib	  (which	  in	  their	  kinase	  assays	  had	  an	  IC50	  for	  JAK3	  activity	  of	  8nM	  and	  an	  IC50	  for	  JAK1	  of	  6.1nM)	  inhibited	  STAT5	  phosphorylation	  with	  an	  IC50	  of	  48nM.	  The	  concentration	  of	  the	  JAK3	  selective	  compound	  in	  treated	  Jurkat	  and	  CTLL	  cell	  lines	  was	  not	  less	  than	  the	  concentration	  of	  tofacitinib	  following	  incubation	  of	  cells	  with	  equal	   concentrations	   of	   the	   JAK3	   selective	   compound	   and	   tofacitinib	   suggesting	  that	  the	  poor	  inhibition	  of	  STAT5	  phosphorylation	  was	  not	  due	  to	  poor	  uptake	  into	  cells.	   This	   data	   would	   support	   the	   hypothesis	   that	   JAK3	   kinase	   inhibition	   is	  insufficient	  to	  inhibit	  IL-­‐2	  signalling	  (Thoma	  et	  al.,	  2011).	  	  A	  model	  in	  which	  JAK1	  activity	  is	  most	  important,	  but	  in	  which	  maximal	  signalling	  also	   requires	   the	   kinase	   activity	   of	   JAK3	   is	   supported	   by	   work	   by	   Haan	   et	   al.	  (2011).	   Knockdown	   of	   either	   JAK1	   or	   JAK3	   expression	   in	   cell	   lines	   abolished	  STAT5	  phosphorylation	  in	  response	  to	  IL-­‐2,	  indicating	  that	  expression	  of	  both	  JAKs	  was	   required	   for	   IL-­‐2	   signalling.	  However,	  while	   expression	  of	  kinase	  dead	   JAK1	  (K908A,	   human	   sites)	   with	  wild	   type	   JAK3	   abolished	   STAT5	   phosphorylation	   in	  response	   to	   IL-­‐2,	   expression	   of	   kinase	   JAK3	   (K855A)	   with	   wild	   type	   JAK1	   only	  reduced	   STAT5	   phosphorylation.	   IL-­‐2	   induced	   phosphorylation	   of	   JAK1	   but	   not	  phosphorylation	   of	   JAK3	  was	   lost	   in	   cells	   expressing	   kinase	   dead	   JAK3	   and	  wild	  type	  JAK1;	  conversely	  IL-­‐2	  induced	  phosphorylation	  of	  JAK3	  but	  not	  JAK1	  was	  lost	  in	  cells	  expressing	  kinase	  dead	  JAK1	  and	  wild	  type	  JAK3.	  This	  suggested	  that	  JAK1	  and	   JAK3	   were	   phosphorylating	   each	   other	   following	   ligand	   binding	   to	   the	  receptor	  (Haan	  et	  al.,	  2011).	  	  Recently,	  JAK3	  inhibitors	  that	  form	  a	  covalent	  bond	  with	  a	  cysteine	  residue	  absent	  from	   JAK1,	   JAK2	   and	   TYK2	   (but	   present	   in	   other	   kinases	   including	   TEC	   family	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kinases)	  have	  been	  developed,	  bypassing	  the	  problems	  of	  selectivity	  within	  the	  JAK	  kinase	  family	  inherent	  in	  the	  production	  of	  an	  ATP	  competitive	  inhibitor.	  One	  such	  compound,	   JAK3i,	  was	  used	  by	  Smith	  et	  al.	   (2016)	  to	   investigate	  the	  role	  of	   JAK3	  versus	  JAK1	  in	  IL-­‐2	  signalling.	  Tofacitinib,	  which	  has	  low	  selectivity	  within	  the	  JAK	  kinase	  family,	  had	  a	   lower	  IC50	   for	   inhibition	  of	  STAT5	  phosphorylation	  after	  1hr	  IL-­‐2	  stimulation	  than	  the	  more	  selective	  JAK3i,	  suggesting	  tofacitnib	  inhibited	  IL-­‐2	  signalling	   more	   potently	   than	   JAK3i.	   However,	   JAK3i	   had	   a	   lower	   IC50	   than	  tofacitinib	  for	  inhibition	  of	  IL-­‐2	  induced	  proliferation	  of	  CD4+	  T	  cells,	  which	  would	  seem	  to	  suggest	  that	  JAK3i	  was	  the	  more	  potent	  inhibitor.	  	  	  Additional	   experiments	   demonstrated	   that	   IL-­‐2	   stimulation	   of	   CD4+	   T	   cells	  produced	   two	   waves	   of	   STAT5	   phosphorylation:	   an	   immediate	   high	   level	   of	  phosphorylation	   that	   dipped	   at	   approximately	   one	   hour	   and	   a	   later	   phase.	   The	  JAK3i	   inhibitor	   did	   not	   affect	   the	   first	   wave	   of	   STAT5	   phosphorylation,	   but	  inhibited	  the	  second.	  Tofacitinib	   inhibited	  both	  waves	  of	  STAT5	  phosphorylation.	  The	  authors	  speculated	  that	  the	  first	  wave	  of	  signalling	  is	  dependent	  on	  JAK1,	  but	  that	   IL-­‐2	   stimulated	   SOCS1	   and	   SOCS3	   inhibit	   JAK1	   at	   later	   timepoints	   and,	  following	   inhibition	   of	   JAK1,	   JAK3	   activity	   becomes	   necessary	   to	   initiate	   further	  downstream	  signalling	  events	  (Smith	  et	  al.,	  2016).	  This	  would	  explain	  the	   lack	  of	  sustained	  signalling	  seen	  in	  cells	  with	  JAK1	  but	  not	  JAK3	  seen	  by	  Fujii	  (Fujii,	  2007).	  
HIF	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1.9	  Thesis	  aims	  The	   aims	   of	   this	   thesis	   were	   to	   compare	   the	   effect	   of	   JAK1	   and/or	   JAK3	   kinase	  inhibition	  on	   signalling	  by	   the	  γc	   cytokine	   IL-­‐2	   in	   cytotoxic	  T	   lymphocytes	   (CTL)	  and	  to	  define	  the	  effect	  of	  the	  JAK1/3	  inhibitor	  tofacitinib	  on	  the	  phosphoproteome	  and	  proteome	  of	  IL-­‐2	  maintained	  CTL.	  Due	  to	  the	  more	  limited	  use	  of	  JAK3	  by	  type	  I/II	   cytokine	   receptors,	   there	   is	   interest	   in	   using	   JAK3	   kinase	   inhibitors	   in	  inflammatory	  conditions	  to	  inhibit	  a	  smaller	  subset	  of	  cytokine	  signalling	  than	  pan	  JAK	  inhibitors.	  However,	  there	  have	  been	  conflicting	  reports	  as	  to	  the	  role	  of	  JAK3	  during	  signalling	  through	  γc	  cytokine	  receptors.	  The	  inhibition	  of	  IL-­‐2	  signalling	  by	  tofacitinib,	  a	  pan	  JAK1/JAK3	  inhibitor,	  was	  compared	  with	  selective	  JAK1	  and	  JAK3	  inhibitors	   to	   evaluate	   if	   selective	   inhibition	   of	   JAK3	   is	   a	   viable	   option	   for	   the	  treatment	   of	   inflammatory	   disorders.	   Phosphoproteomic	   and	   proteomic	   analysis	  was	   used	   to	   identify	   novel	   JAK	   kinase	   dependent	   phosphorylation	   events	   and	  proteins	  regulated	  downstream	  of	  IL-­‐2	  signalling.	  	  	  Experiments	  using	   the	   selective	   JAK	  kinase	   inhibitors	  GSK186	  and	  GSK192	  were	  done	  as	  part	  of	  a	  collaboration	  with	  GSK:	  all	  data	  pertaining	  to	  these	  inhibitors	  are	  confidential.	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Chapter	  2:	  Methods	  and	  materials	  	  
2.1.	  Transgenic	  mice	  
2.1.1	  P14	  mice	  
	  P14	  mice	  express	  a	  Vα2Vβ8.1	  TCR	  (P14	  TCRα	  chain)	  that	  recognises	  the	  gp33-­‐41	  peptide,	   which	   is	   derived	   from	   the	   LCMV	   (Lymphocytic	   Choriomeningitis	   Virus)	  glycoprotein	  P14,	  when	  presented	  by	  the	  H-­‐2Db	  MHC	  class	  I	  molecule	  (Brändle	  et	  al.,	  1995).	  	  
2.1.2	  FoxO1-­‐GFP	  
	  FOXO1-­‐GFP	  mice	  express	  a	  fusion	  FOXO-­‐GFP	  protein	  as	  a	  result	  of	  insertion	  of	  the	  sequence	  coding	  for	  GFP	  between	  the	  final	  protein	  coding	  and	  termination	  codons	  of	  the	  foxo1	  gene	  (Stone	  et	  al.,	  2015).	  This	  allows	  study	  of	  FOXO1	  localisation	  and	  activity	  at	  endogenous	  levels	  of	  expression.	  
2.1.3	  Vav-­‐cre	  HIF1αfl/fl	  
	  Mice	  expressing	  Cre	  recombinase	  under	  the	  Vav	  promoter	  sequence	  were	  crossed	  to	  mice	  with	  loxP	  sites	  flanking	  exon	  2	  of	  the	  hif1a	  gene	  (purchased	  from	  Jackson).	  The	  guanine	  nucleotide	  exchange	  factor	  Vav	  is	  highly	  expressed	  in	  haematopoetic	  cells	   and	   mice	   expressing	   Vav-­‐Cre	   express	   Cre	   in	   haematopoetic	   lineage	   cells,	  endothelial	   cells	   and	   germ	   cells	   (Georgiades	   et	   al.,	   2002).	   CTL	   generated	   from	  these	  mice	  referred	  to	  in	  text	  as	  HIF1α	  deficient	  or	  HIF1α-­‐/-­‐	  CTL.	  	  All	  mice	  were	  bred	  and	  maintained	  in	  the	  Transgenic	  Unit	  at	  the	  Wellcome	  Trust	  Biocentre,	   University	   of	   Dundee,	   in	   compliance	   with	   UK	   Home	   Office	   Animals	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(Scientific	   Proceedures)	   Act	   1986	   guidelines.	   Spleens	   from	   NFIL3-­‐/-­‐	   mice	   were	  kindly	  provided	  by	  Dr	  Hugh	  Brady	  (Gascoyne	  et	  al.,	  2009).	  	  HIF	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2.2.	  Cell	  culture	  
2.2.1	  Buffers	  
RPMI	   media:	   Complete	   RPMI	   -­‐	   RPMI	   1640	   with	   glutamine	   and	   D-­‐glucose	  (Invitrogen)	   supplemented	   with	   10%	   FCS	   (fetal	   calf	   serum,	   Life	   Technologies),	  50μM	  β	  mercaptoethanol	   (Sigma),	  10U/mL	  penicillin	  and	  10μg/mL	  streptomycin	  (Gibco).	  	  
ACK	  buffer:	  150mM	  NH4Cl,	  10mM	  KHCO3,	  100μM	  Na2EDTA	   in	  500mL	  deionized	  water,	  adjusted	  to	  pH	  7.8	  and	  sterilized.	  
2.2.2	  Generation	  of	  CTL	  Spleens	  were	  mashed	  through	  a	  70μM	  filter	  into	  ACK	  buffer	  and	  resuspended	  into	  complete	  RPMI	  media.	  Splenocytes	  from	  P14	  mice	  were	  activated	  for	  2	  days	  with	  100ng/mL	  gp33-­‐41.	  Splenocytes	  from	  non-­‐TCR	  transgenic	  mice	  were	  activated	  for	  2	   days	   with	   0.5μg/mL	   α-­‐CD3,	   0.5μg/mL	   α-­‐CD28,	   20ng/mL	   IL-­‐2	   (Proleukin,	  Novartis)	  and	  2ng/mL	  IL-­‐12	  (R	  and	  D	  Systems).	  Cells	  were	  expanded	  for	  3-­‐5	  days	  in	  the	  presence	  of	  20ng/mL	  IL-­‐2,	  with	  cultures	  kept	  at	  a	  density	  of	  between	  0.3-­‐0.5	  x	  106	  cells/mL.	  Where	  cytokine	  starvation	  of	  cells	  is	  indicated,	  cells	  were	  washed	  in	  an	  excess	  of	  prewarmed	  RPMI	  1640	  media	  to	  remove	  IL-­‐2	  and	  resuspended	  in	  complete	   RPMI	   1640	  media	   without	   cytokine.	   Naïve	   T	   cells	   were	  maintained	   in	  5ng/mL	  IL-­‐7	  (R	  and	  D	  Systems)	  
2.2.3	  Isolation	  of	  CD8+	  splenocytes	  CD8+	  T	  lymphocytes	  were	  isolated	  from	  mixed	  splenocytes	  cultures	  as	  indicated	  in	  the	   text	   using	   the	   EasySep™	   Mouse	   CD8+	   isolation	   kit	   as	   directed	   by	   the	  maufacturers	   instructions.	  Following	   isolation	  of	  CD8+	  T	   lymphocytes,	   cells	  were	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resuspended	   in	  RPMI	  1640	  media	  and	  put	   in	   incubator	  at	  37°C	   in	  5%	  CO2	   for	  at	  least	  one	  hour	  before	  RNA	  isolation/lysis.	  
2.2.4	  Inhibitors	  Inhibitors	  used	  at	  concentations	  indicated	  below	  in	  table	  2.1	  and	  for	  the	  duration	  indicated	  in	  the	  text.	  
	  
Table	  2.1	  Inhibitors	  used	  in	  cell	  culture	  	  
HIF	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Inhibitor Target Stock concentration Final concentration used at Source
Tofacitinib Jak1/Jak3 10mM 100nM GSK
GSK186 Jak1 10mM 100nM GSK
GSK192 Jak3 10mM 1-2µM GSK
Rapamycin mTORC1 1mM 20nM Calbiochem
KU0063794 mTORC1/2 10mM 1µM R and D systems
Akti Akt 10mM 1µM Merk Chemicals
IC87114 P13K 10mM 10µM In house
PDK1i (GSK2334470) PDK1 10mM 10µM In house
PP2 Src kinases 10mM 10µM R and D systems
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2.3.	  Flow	  cytometry	  
2.3.1	  Cell	  surface	  staining	  Cells	  were	   centrifuged	   at	   335xg	   (1200	   rpm	   using	   Allegra	   X-­‐12R	   centrifuge	  with	  SX4750A	   rotor	   with	   radius	   of	   207.8mm)	   for	   5	   minutes,	   then	   resuspended	   in	  staining	  solution	  (antibodies	  diluted	  in	  1%	  (w/v)	  BSA/PBS)	  for	  twenty	  minutes	  at	  4°C.	  Antibodies	  used	  for	  cell	  staining	  shown	  in	  table	  2.2.	  After	  staining,	  cells	  were	  washed	   with	   1%	   (w/v)	   BSA/PBS	   and	   centrifuged	   at	   335xg	   for	   5	   minutes,	  resuspended	  in	  1%	  (w/v)	  BSA/PBS	  with	  DAPI	  (Molecular	  Probes)	  and	  analysed	  on	  either	   a	   FACSVerse	   or	   LSR	   Fortessa	   flow	   cytometer.	   Data	   was	   analysed	   using	  FlowJo	  (Treestar)	  software.	  
2.3.2	  pS6	  S235/236	  staining	  CTL	   treated	   with	   20nM	   rapamycin	   for	   30	   minutes	   were	   included	   as	   a	   negative	  control	  and	  CTL	  treated	  with	  50μg/mL	  PdBu	  for	  30	  minutes	  as	  a	  positive	  control	  for	   pS6	   S235/236	   staining.	   Following	   treatment,	   cells	  were	   immediately	   fixed	   in	  0.5%	  (w/v)	  paraformaldehyde	  without	  centrifugation	  of	  the	  cells	  for	  15	  minutes	  at	  37°C.	  Following	  fixation,	  cells	  were	  washed	  with	  PBS	  and	  permeablized	  using	  90%	  (v/v)	   ice	  cold	  methanol	  at	   -­‐20°C	  for	  15	  minutes.	  Following	  permeablization,	  cells	  were	   washed	   twice	   with	   PBS	   and	   then	   incubated	   with	   pS6	   S235/235	   primary	  antibody	   (CST,	  #2211)	  diluted	  1	   in	  100	   in	  1%	  (w/v)	  BSA/PBS	   for	  30	  minutes	  at	  room	   temperature.	   Cells	   were	   then	   washed	   twice	   with	   1%	   (w/v)	   BSA/PBS	   and	  resuspended	   in	   PE-­‐conjugated	   donkey	   α	   rabbit	   IgG	   (H+L)	   (Jackson	  ImmunoResearch,	  #	  711-­‐116-­‐152)	  diluted	  1	  in	  100	  in	  1%	  (w/v)	  BSA/PBS	  and	  cell	  surface	  marker	   stains	   for	   30	  minutes	   at	   room	   temperature.	   After	   staining,	   cells	  were	  washed	  twice	  with	  1%	  (w/v)	  BSA/PBS,	  resuspended	  in	  1%	  (w/v)	  BSA/PBS	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and	  analysed	  on	   the	  FACSVerse	   flow	  cytometer.	  Data	  was	  analysed	  using	  FlowJo	  (Treestar)	  software.	  
	  
2.3.3	  FOXO1-­‐GFP	  cell	  nuclei	  isolation	  FOXO1-­‐GFP-­‐/-­‐	   CTL	   were	   included	   as	   a	   negative	   control	   and	   FOXO1-­‐GFP+/+	   CTL	  treated	  with	   1μM	  Akti	   as	   a	   positive	   control	   for	   FOXO1	   GFP	   nuclear	   localisation.	  Following	  treatment,	  cells	  were	  washed	  in	  1%	  (w/v)	  BSA/PBS	  and	  centrifuged	  at	  4°C.	  After	  washing,	   cells	  were	   lysed	  by	   adding	  300μL	  of	   a	   hypotonic	   lysis	   buffer	  (3.8mM	   Na₃C₆H₅O₇,	   9.6mM	   NaCl,	   0.05%	   NP40)	   and	   fixed	   by	   adding	   300μL	   IC	  fixation	  buffer	  (eBioSciences)	  for	  15	  minutes	  at	  4°C.	  Cells	  were	  then	  washed	  with	  1%	  (w/v)	  BSA/PBS	  and	  stained	  with	  DAPI	  diluted	  in	  1%	  (w/v)	  BSA/PBS.	  Samples	  were	   analysed	   on	   either	   a	   FACSVerse	   or	   LSR	   Fortessa	   flow	   cytometer.	  Data	  was	  analysed	  using	  FlowJo	  (Treestar)	  software.	  
	  
2.3.4	  LAMP1	  (CD107a)	  staining	  The	  LAMP1	  assay	  has	  been	  described	  by	  Alter	  et	  al.	  (2004).	  CTL	  generated	  from	  a	  P14	  mouse	  were	  used	  as	  the	  effector	  cells	  and	  B	  cells	  from	  a	  non-­‐TCR	  transgenic	  mouse	  were	  used	  as	  target	  cells.	  The	  day	  before	  LAMP1	  staining,	  splenocytes	  were	  isolated	  from	  a	  non-­‐TCR	  transgenic	  mouse	  and	  resuspended	  to	  a	  concentration	  of	  20x106	  cells/mL	  in	  pre-­‐warmed	  serum-­‐free	  RPMI	  media.	  Cell	  Tracker	  Orange	  dye	  (Molecular	   Probes,	   CMTMR)	   was	   added	   to	   the	   cells	   to	   a	   final	   concentration	   of	  20μM	  and	  cells	  stained	  at	  37°C	   for	  10	  minutes.	  After	  staining,	  cells	  were	  washed	  three	  times	  with	  complete	  RPMI	  with	  10%	  FCS	  to	  quench	  staining.	  Cells	  were	  left	  in	  complete	  RPMI	  at	  37°C	  for	  10	  minutes	  on	  the	  final	  wash	  to	  ensure	  staining	  had	  been	  quenched.	  Some	  splenocytes	  were	  left	  unstained	  as	  a	  negative	  control	  for	  Cell	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Tracker	   Orange	   staining.	   Target	   cells	   were	   divided	   into	   three	   conditions:	   an	  unstimulated	   control	   condition,	   a	   10μg/mL	   LPS	   activated	   condition	   and	   a	  10μg/mL	  LPS	  activated	  and	  1μg/mL	  gp33-­‐41	  peptide	  loaded	  condition.	  Target	  cells	  were	   treated	   overnight.	   Effector	   cells	   were	  maintained	   in	   IL-­‐2	   and	   treated	  with	  100nM	  tofacitinib	  or	  deprived	  of	  IL-­‐2	  overnight	  as	  indicated	  in	  the	  text.	  	  On	   the	   day	   of	   LAMP1	   staining,	   target	   cell	   cultures	   were	   resuspended	   to	   a	  concentration	  of	  10x106	  live	  B220+	  cells/mL.	  Effector	  P14	  cell	  cultures	  were	  set	  to	  a	   concentration	   of	   10x106	   live	   CD8+	   cells/mL.	   Golgiplug	   (BD	   Biosciences)	   and	  monensin	  (Biolegend)	  were	  added	  to	  target	  and	  effector	  cells	  at	  a	  dilution	  of	  1	  in	  1000.	  Monensin	  prevents	  endosomal	  acidification,	   and	  can	   therefore	  prevent	   the	  degradation	   of	   LAMP1	   labelled	   at	   the	   cell	   membrane	   (which	   is	   what	   is	   being	  measured	   in	   this	   assay)	   that	   has	   subsequently	   been	   internalized	   (Alter	   et	   al.,	  2004).	  Golgiplug	  contains	  the	  exocytosis	  inhibitor	  brefeldin	  A	  and	  is	  used	  to	  inhibit	  the	   exocytosis	   of	   cytokine	   containing	   vesicles	   (Alter	   et	   al.,	   2004),	   allowing	   the	  measurement	   of	   IFNγ	   production.	   In	   NK	   cells,	   exocytosis	   of	   cytokine	   containing	  vesicles	   and	   cytolytic	   vesicles	   containing	   perforin	   have	   been	   shown	   to	   proceed	  through	   different	   routes	   (Reefman	   et	   al.,	   2010),	   allowing	   exocytosis	   of	   cytolytic	  vesicles	  to	  be	  measured	  in	  brefeldin	  A	  treated	  cells.	  	  Target	  and	  effector	  cells	  were	  aliquoted	   into	  a	  96	  well	  plate,	  with	  0.5x106	   target	   cells	  and	  0.5x106	  P14	  effector	  cells	  in	  each	  well	  in	  combinations	  as	  indicated	  in	  the	  text.	  Cells	  were	  aliquoted	  for	  single	  stain	  controls	  and	  CD107a	  and	  IFNγ	  fluorescence	  minus	  one	  controls	  (FMO)	  as	  appropriate.	  FMO	  controls	  are	  stained	  with	  the	  full	  antibody	  panel	  to	  be	  used	  in	  a	   stain	  with	   the	   exception	   of	   a	   single	   antibody,	   and	   can	   be	   used	   to	   differentiate	  between	   a	   positive	   signal	   in	   the	   channel	   in	   which	   the	   dye	   conjugated	   to	   that	  
	   81	  
antibody	   fluoresces,	  and	  bleed-­‐through	  from	  dyes	  conjugated	  to	  other	  antibodies	  in	  the	  staining	  panel	   in	  a	  fully	  stained	  sample.	  After	  aliquoting,	  5μL	  CD107a-­‐FITC	  antibody	  was	  added	  to	  each	  test	  well	  and	  cells	  incubated	  at	  37°C	  at	  5%CO2	  for	  four	  hours.	  	  	  After	   incubation,	   the	   96	   well	   plate	   was	   centrifuged	   at	   552xg	   (1500rpm	   using	  Allegra	   X-­‐12R	   centrifuge	   with	   SX4750A	   rotor	   with	   radius	   of	   207.8mm)	   for	   3	  minutes,	   the	   supernatant	   discarded	   and	  50	  μL	  Fc	   block	  diluted	  1	   in	   70	  with	  1%	  (w/v)	   BSA/PBS	   added	   to	   each	  well.	   The	   plate	  was	   then	   incubated	   on	   ice	   for	   10	  minutes.	   After	   10	  minutes,	   50	   μL	   of	   staining	   solution	   (1	   in	   100	  dilutions	   of	   CD8	  Alexa780,	   CD25	  PeCy7,	   B220	  PerCpCy5.5	   and	   live/dead	   aqua	   in	   PBS)	   and	   single	  stains/FMO	   control	   stains	   was	   added	   to	   the	   appropriate	   wells	   and	   the	   plate	  incubated	  on	   ice	   in	   the	  dark	   for	  30	  minutes.	  After	   incubation,	   cells	  were	  washed	  with	  200	  μL	  1%	  (w/v)	  BSA/PBS	  per	  well	  and	  centrifuged	  at	  552xg	  for	  5	  minutes	  at	  4°C.	  Cells	  were	   then	   fixed	  with	  100	  μL	   IC	   fixation	  buffer	   for	  15	  minutes	  at	   room	  temperature	  in	  the	  dark,	  and	  then	  washed	  with	  200	  μL	  1xPermeablization	  buffer	  (eBioScience).	   Cells	   were	   then	   resuspended	   in	   200	   μL	   1xPermeablization	   buffer	  and	   centrifuged	   at	   552xg	   for	   five	   minutes.	   After	   centrifugation,	   cells	   were	  resuspended	  in	  a	  1	  in	  100	  dilution	  of	  IFNγ-­‐APC	  and	  stained	  for	  20	  minutes	  at	  room	  temperature	  in	  the	  dark.	  After	  staining,	  cells	  were	  washed	  with	  200	  μL	  1%	  (w/v)	  BSA/PBS,	   then	   resuspended	   in	   1	   mL	   1%	   (w/v)	   BSA/PBS	   and	   analysed	   on	   the	  FACSVerse	  flow	  cytometer.	  Data	  was	  analysed	  using	  FlowJo	  (Treestar)	  software.	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Table	  2.2:	  Antibodies	  used	  for	  flow	  cytometry	  	  HIF	  	  	  	  	  	  	  	  	  
Antibody Clone Source Catalogue number Dilution
4-1BB PE 17B5 eBioscience 12-1371-81 1 in 200
B220 FITC RA3-6B2 BD Bioscience 553087 1 in 200
B220 PeCy5.5 RA3-6B2 eBioscience 45-0452-82 1 in 200
CD107a FITC 1D4B BD Bioscience 553793 1 in 100
CD25 PE PC61 BD Pharmingen 553866 1 in 200
CD25 PE-Cy7 PC61 BD Bioscience 552880 1 in 200
CD25 FITC 7D4 BD Pharmingen 553072 1 in 200
CD4 Alexa 780 RM4-5 eBioscience 47-0042-82 1 in 200
CD4 APC 700 RM4-5 eBioscience 56-0042-80 1 in 200
CD4 PE GK1.5 BD Bioscience 557308 1 in 200
CD4 PeCy7 RM4-5 BD Bioscience 552775 1 in 200
CD44 FITC IM7 BD Pharmingen 553133 1 in 200
CD62L APC MEL-14 BD Pharmingen 553152 1 in 200
CD69 PerCpCy5.5 H1.2F3 eBioscience 45-0691-82 1 in 200
CD71 APC R17217 eBioscience 17-0711-82 1 in 200
CD8 PeCy7 53-6.7 BioLegend 100722 1 in 200
CD8 V450 53-6.7 BD Bioscience 560469 1 in 200
CD8 V500 53-6.7 BD Bioscience 560776 1 in 200
CD8 PerCPCy5.5 53-6.7 BD Bioscience 551162 1 in 200
CD98 PE RL388 BioLegend 128208 1 in 200
IFNγ-APC  XMG1.2 BD Bioscience 554413 1 in 100
TCRβ FITC H57-597 BD Pharmingen 553171 1 in 200
TCRβ PerCpCy5.5 H57-597 eBioscience 45-5961-82 1 in 200
Donkey α-rabbit IgG (H+L) PE Jackson ImmunoResearch 711-116-152 1 in 100
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2.4.	  Western	  blotting	  
2.4.1	  Lysis	  and	  lysis	  buffers	  
Lysis	  with	  F	  buffer	  and	  RIPA	  buffer:	  cells	  were	  lysed	  at	  between	  20-­‐30	  million	  cells/mL	  buffer	   for	  10	  minutes	  on	   ice,	   centrifuged	   for	  10	  minutes	  at	  4°C	  and	   the	  lysate	  boiled	  for	  10	  minutes	  at	  70°C	  with	  NuPAGE®	  LDS	  sample	  buffer	  (4X).	  	  	  
Modification	   of	   lysis	   protocol	   for	   HIF-­‐1α:	   for	   blotting	   of	   HIF-­‐1α	   in	   CTL,	   IL-­‐2	  maintained	  CTL	  treated	  with	  20nM	  rapamycin	  were	  used	  as	  a	  negative	  control	  and	  IL-­‐2	  maintained	  CTL	  incubated	  in	  hypoxic	  conditions	  (1%	  O2)	  for	  four	  hours	  were	  used	  as	  a	  positive	  control.	  Following	  treatment,	  CTL	  were	  centrifuged	  at	  1450.7xg	  (2500	   rpm	   using	   Allegra	   X-­‐12R	   centrifuge	   with	   SX4750A	   rotor	   with	   radius	   of	  207.8mm)	  for	  1	  minute	  and	  the	  supernatant	  aspirated.	  Cells	  were	  then	  lysed	  in	  F	  buffer	  with	  20mM	  TCEP	  and	  protease	   inhibitors	  (Roche,	   cOmplete™	   	  mini	  EDTA-­‐free	   protease	   inhibitor	   tablets)	   at	   4oC	   for	   10	   minutes	   at	   10-­‐30x106	   cells/mL	   F	  buffer.	  
	  
F	  buffer:	  10mM	  Tris	  pH	  7.05,	  50mM	  NaCl,	  30mM	  Na	  pyrophosphate,	  50mM	  NaF,	  5μM	   ZnCl2,	   10%	   (v/v)	   glycerol,	   0.5%	   (v/v)	   Triton	   X100,	   20mM	   TCEP	   and	  cOmplete™	  mini	  EDTA	  free	  protease	  inhibitor	  tablet	  (Roche).	  	  
RIPA	   buffer:	   50mM	   Tris	   pH	   7.4,	   1%	   (v/v)	   NP-­‐40,	   0.5%	   (w/v)	   Na	   doxycholate,	  0.1%	  (w/v)	  SDS,	  150mM	  NaCl,	  2mM	  EDTA,	  50mM	  NaF,	  20mM	  TCEP,	   cOmplete™	  	  mini	  EDTA	  free	  protease	  inhibitor	  tablet	  (Roche).	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2.4.2	  Electrophoresis	  	  Following	  boiling	  of	  samples	  with	  LDS	  buffer,	  samples	  were	  separated	  using	  a	  4%	  stacking/10%	   resolving	   SDS-­‐PAGE	   gel,	  with	   the	   equivalent	   of	   150,000	   cells/well	  used	  in	  most	  gels	  (300,000	  cells/well	  used	  for	  HIF1α	  blots,	  75,000	  cells/well	  used	  for	   NFIL3	   blots	   ±	   hypoxia)	   at	   150V	   for	   1	   hour	   (100V	   through	   the	   stacking	   gel)	  using	   the	   Mini-­‐PROTEAN	   Tetra	   Cell	   system.	   Where	   loading	   by	   protein	  concentration	   is	   indicated,	   protein	   concentration	  was	   determined	   using	   the	  BCA	  assay	  (Thermo)	  as	  directed.	  	  
	  
Resolving	  gel	  buffer:	  1.5M	  Tris-­‐HCl,	  pH8.8	  
Stacking	  gel	  buffer:	  0.5M	  Tris-­‐HCl,	  pH	  6.8	  
Electrophoresis	  running	  buffer:	  25mM	  Tris,	  192mM	  glycine,	  0.1%	  (w/v)	  SDS	  
2.4.3	  Transfer	  to	  nitrocellulose	  membranes	  Following	   separation,	   proteins	   were	   transferred	   to	   nitrocellulose	   membranes	  (Hybond-­‐C	  Extra,	  Amersham	  or	  Protran	  membranes)	  for	  90	  minutes	  at	  350mA	  or	  30V	   overnight	   at	   4	   oC.	   Following	   transfer,	   membranes	   were	   briefly	   stained	   in	  Ponceau	   solution,	  washed	   and	   the	  membranes	   blocked	   in	   either	   5%	   (w/v)	  milk	  (Marvel)/PBS-­‐tween	  or	  5%	  (w/v)	  BSA/PBS-­‐tween	  (for	  phosphotyrosine	  sites)	  for	  one	  hour	  at	  room	  temperature.	  	  
	  
Transfer	  buffer:	  48mM	  Tris,	  39mM	  glycine,	  10%	  (v/v)	  methanol	  
2.4.4	  Immunoblotting	  Following	  blocking,	  membranes	  were	  washed	   three	   times	   in	  PBS-­‐tween,	  with	  10	  minutes	  per	  wash,	   then	   incubated	  with	  primary	  antibody	  overnight	   at	  4oC.	  After	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incubation	  with	  primary	  antibody,	  membranes	  were	  washed	   three	   times	   in	  PBS-­‐tween,	  with	  10	  minutes	  per	  wash,	  then	  incubated	  with	  HRP	  conjugated	  secondary	  anti	   rabbit	  or	   anti	  mouse	   IgG	   (Pierce)	   antibody	   for	  1	  hour	  at	   room	   temperature.	  After	  incubation	  with	  secondary	  antibody,	  membranes	  were	  washed	  three	  times	  in	  PBS-­‐tween,	   with	   10	   minutes	   per	   wash.	   Membranes	   were	   then	   exposed	   to	   ECL	  solution	   (Thermo	  Scientific	  Pierce	  ECL	  Western	  Blotting	  Substrate,	   SuperSignal™	  West	   Pico	   Chemiluminescent	   Substrate)	   and	   either	   exposed	   to	   film	   (Konica)	   or	  recorded	   using	   the	   Licor	   Odyssey	   system.	   Antibodies	   were	   used	   as	   indicated	   in	  table	  2.3	  
	  
Table	  2.3:	  Antibodies	  used	  for	  Western	  blotting	  	  
Phosphospecific antibodies




pErk1/2 (p44/42) T202/Y204 E10 CST 9106 - 1 in 1000 42, 44
pFoxO1/3 T32/24 - CST 9464 - 1 in 1000 78-82, 95
pPKB S473 193H12 CST 4058 - 1 in 1000 60
pPKB T308 244F9 CST 4056 - 1 in 1000 60
pS6 S236/236 - CST 2211 - 1 in 5000 32
pS6 S240/244 - CST 2215 - 1 in 5000 32
pS6K T389 - CST 9205 - 1 in 1000 70, 85
pSTAT4 Y693 D2E4 CST 4134 - 1 in 1000 81
pSTAT5 Y694 C11C5 CST 9359 - 1 in 1000 90
Total protein specific 
antibodies




STAT5 - CST 9363 - 1 in 1000 90
STAT4 C46B10 CST 2653 - 1 in 1000 81
S6K - CST 9202 - 1 in 1000 70-85
S6 5G10 CST 2217 - 1 in 1000 32
PKB - CST 9272 - 1 in 1000 60
FoxO1 L27 CST 9454 - 1 in 1000 78-82
Erk1/2 3A7 CST 9107 - 1 in 1000 42, 44
c-myc - CST 9402 - 1 in 1000 57-70
PIM1 12H8 Santa Cruz sc-13513 1µg/mL 1 in 200 36, 45
E4BP4/NFIL3 D5K8O CST 14312 - 1 in 1000 60
granzyme B(G,H) - CST 4275 - 1 in 1000 30-37
perforin-1 - CST 3693 - 1 in 1000 70-75
SMC1 - Bethyl labs A300-005A 200ng/mL 1 in 5000 145
GSK3α/β 0011-A Santa Cruz sc-7291 1µg/mL 1 in 200 51, 46
Hif1α 241809 R and D Systems MAB1536 1µg/mL 1 in 500 120
Secondary antibodies
Antibody Clone Source Catalouge number Concentration used at Dilution
HRP-conjugated goat α rabbit 
IgG (H+L) - Pierce 31460 160ng/mL 1 in 5000
HRP-conjugated goat α mouse 
IgG (H+L) - Pierce 31431 200ng/mL 1 in 5000
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2.5.	  Real-­‐time	  PCR	  
2.5.1	  RT-­‐PCR	  reactions	  RNA	  was	  isolated	  using	  the	  Qiagen	  RNeasy	  kit	  as	  indicated	  by	  the	  manufacturer’s	  instructions.	   Following	   isolation,	   RNA	   was	   quantified	   using	   the	   NanoDrop	  spectrophotometer.	   After	   quantification	   of	   RNA,	   reverse	   transcriptase	   reactions	  were	   set	   up	   using	   500ng	   of	   RNA	   and	   the	   Quantas	   cDNA	   synthesis	   kit	   in	   a	   total	  reaction	  mix	  of	  20μL.	  Once	  reverse	  transcriptase	  reactions	  were	  completed,	  cDNA	  was	  diluted	  by	  adding	  100μL	  DEPC	  (Diethylpyrocarbonate	  treated)	  water.	  	  Reaction	  mixes	  for	  PCR	  were	  made	  up	  to	  7.5μL	  2x	  Syber	  Green	  mastermix	  (Roche),	  4μM	  each	  of	   the	   forward	  and	  reverse	  primers,	  3.5μL	  DEPC	  water	  and	  3μL	  of	   the	  diluted	  cDNA.	  Primers	  used	  are	  listed	  in	  table	  2.4).	  PCR	  reactions	  were	  set	  up	  in	  96	  well	   plates	   (BioRad,	   Hard-­‐Shell®	   semi	   skirted	   96	   well	   PCR	   plate),	   with	   each	  reaction	  in	  triplicate.	  Plates	  were	  sealed	  with	  Microseal®	  Adhesive	  seals	  (BioRad)	  and	   analysed	   using	   the	   iCycler	   iQ™	   PCR	  machine.	   The	   real-­‐time	   PCR	   conditions	  were	   as	   follows:	   95°C	   held	   for	   3	   minutes;	   then	   40	   cycles	   of	   95°C	   held	   for	   10	  seconds	   followed	   by	   57°C	   held	   for	   25	   seconds.	   A	   melting	   curve	   for	   the	   cDNA	  product	  was	   generated	  by	   increasing	   the	   temperature	   of	   the	   reaction	   from	  60°C	  and	  to	  90°C	  over	  61	  cycles	  of	  8	  secinds	  each,	  increasing	  0.5°C	  per	  cycle.	  This	  gives	  an	  indication	  of	  if	  a	  single	  product	  has	  been	  formed	  by	  the	  real-­‐time	  PCR	  reaction.	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Table	  2.4:	  Primers	  used	  for	  RT-­‐PCR	  analysis	  	  











CD25 5'-TTT CCT TCT GAT CCC TGG GTT TC-3' 5'-GAT AGA GTT GCT GTT ATG TCC TGT G-3'
CD62L 5'-CCT GTA GCC GTC ATG GTC AC-3' 5'-GAA TCA GTA TGG ATC ATC CAT C-3'
CD8 5'-GAT ATA AAT CTC CTG TCT GCC CAT C-3' 5'-ATT CAT ACC ACT TGC TTC CTT GC-3'
Glut-1 5'-CCA GCA GCA AGA AGG TGA-3' 5'-ATG TTT GAT TGT AGA ACT CCT C-3'
Hexokinae II 5'-AGG ACA CCA CAG GCT ACC-3' 5'-TCA CTA AGG CTC AAC TTC GG-3'
HPRT 5'-TGA TCA GTC AAC GGG GGA CA-3' 5'-TTC GAG AGG TCC TTT TCA CCA-3'
IFNγ 5'-TTA CTG CCA CGG CAC AG T C-3' 5'-AGA TAA TCT GGC TCT GGC TCT GCA GG-3'
LAT1 5'-CTG GAT CGA GCT GCT CAT C-3' 5'-GTT CAC AGC TGT GAG GAG C-3'
NFIL3 coding 5'-GCG ATG GTA GCC GGA AGT TGC-3' 5'-CCT GTG CGG GGC TTT CCT GAG-3'
NFIL3 UTR 5'-TCA CGG ACC AGG GAG CAG CAC-3' 5'-AGC CTC TCA TCC ATC AAT GGG TCC T-3'
perforin 5'-CGT CTT GGT GGG ACT TCA G-3' 5'-GCA TTC TGA CCG AGT GGC AG-3'
TBP 5'-GGG GAG CTG TGA TGT GAA GT-3' 5'-CCA GGA AAT AAT TCT GGC TCA T-3'
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2.6.	  Glucose	  uptake	  IL-­‐2	  maintained	  CTL	  were	  treated	  with	  100nM	  tofacitinib	  or	  20nM	  rapamycin	  for	  the	   indicated	   times.	  Eppendorfs	  were	  prepared	  with	  a	  500μL	  of	  a	  1:1	  mixture	  of	  silicone	  oil	  (Sigma	  Aldrich)	  and	  dibutyl	  phthalate	  (Sigma	  Aldrich).	  Radiolabelled	  2-­‐deoxy-­‐d-­‐[1-­‐3H]glucose	  (Perkin	  Elmer)	  was	  added	  to	  glucose	  free	  RPMI	  media	  to	  a	  final	  concentration	  of	  0.5	  μCi/ml,	  and	  200	  μL	  of	  radiolabelled	  media	  layered	  over	  the	  oil	  mixture.	  Cells	   to	  be	  used	   for	  glucose	  uptake	  were	  resuspended	   in	  glucose	  free	  media	  (Gibco)	  to	  a	  concentration	  of	  5x106	  cells/mL,	  and	  200μL	  of	  cells	  added	  to	  each	  eppendorf,	  so	  that	  each	  uptake	  consisted	  of	  1x106	  cells.	  Cells	  were	  allowed	  to	   take	   up	   the	   radiolabelled	   glucose	   analogue	   for	   4	   minutes,	   and	   were	   then	  centrifuged	  at	  5900xg	  (8000rpm	  in	  Eppendorf	  Centriguge	  5415D)	  for	  3	  minutes	  to	  stop	  the	  uptake.	  The	  radiolabelled	  media	  at	  the	  top	  of	  the	  eppendorf	  was	  aspirated	  and	  the	  tube	  washed	  with	  MilliQ	  water,	  then	  the	  oil	  mixture	  removed	  and	  the	  cells	  lysed	  in	  200μL	  100mM	  NaOH.	  Lysates	  were	  transferred	  to	  scintillation	  vials,	  3mL	  of	   scintillation	   fluid	  was	   added	   and	   the	   samples	   analysed	   using	   the	  Beckman	  LS	  6500	  Multi-­‐Purpose	  Scintillation	  Counter	  (Beckman	  Coulter).	  	  HIF	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2.7.	  Lactate	  output	  CTL	  were	  maintained	  in	  IL-­‐2	  and	  treated	  with	  100nM	  tofacitinib,	  maintained	  in	  IL-­‐2	   and	   treated	  with	  20nM	  rapamycin	  or	  deprived	  of	   IL-­‐2	   as	   indicated	   in	   the	   text.	  Following	  treatment,	  CTL	  were	  resuspended	  to	  a	  concentration	  of	  2x106	  cells/mL	  in	  RPMI	  with	  10%	  (v/v)	  dialysed	  serum	  and	  incubated	  at	  37°C	  at	  5%CO2	   in	  a	  12	  well	   plate	   for	   four	  hours.	  After	   incubation,	   cells	  were	   centrifuged	   at	   335xg	   for	  5	  minutes,	   the	   supernatants	   collected	   and	   flash	   frozen	   in	   liquid	   nitrogen.	   Lactate	  concentration	  was	  determined	  using	  an	  enzymatic	  assay	  in	  which	  the	  oxidation	  of	  lactate	   by	   lactate	   dehydrogenase	   (LDH)	   was	   monitored	   by	   the	   change	   in	  absorption	  at	  340nM	  caused	  by	  the	  reduction	  of	  NAD+	  to	  NADH.	  
Reaction:	  	  
	  Lactate	   standards	  were	  made	  by	  dissolving	   sodium	  L-­‐lactate	   in	  RPMI	  1640	  with	  10%(v/v)	  dialysed	  FCS.	  	  Standards	  started	  at	  250mM	  lactate	  and	  were	  diluted	  1	  in	  5	  to	  a	  final	  concentration	  of	  3.2μM.	  For	  the	  assay,	  100μL	  of	  sample/standard	  was	  added	   to	   a	   96	   well	   flat	   bottomed	   plate,	   then	   an	   equal	   volume	   of	   mastermix	  (320mM	  glycine,	  320mM	  hydrazine,	  2U	  lactate	  dehydrogenase,	  2.4mM	  NAD+)	  was	  added	   and	   samples	   incubated	   for	   10	   minutes	   at	   room	   temperature.	   Mastermix	  without	  LDH	  used	   for	  blank	  wells.	  Absorbance	  of	   the	   reactions	  was	   then	   read	  at	  340nM	   using	   a	   cytofluor	   II	   Fluorescence	   Multi-­‐Well	   Plate	   Reader	   (Perceptive	  BioSystems).	   A	   standard	   curve	   was	   generated	   from	   the	   samples	   and	   the	  concentration	  of	  lactate	  in	  the	  test	  samples	  inferred	  (data	  analysed	  in	  Prism).	  
Lactate&+&NAD+&&&&&&&&&&&&&&&&&&&&&&&&&&&Pyruvate&+&NADH&
LDH&
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2.8.	  Phosphoproteomics	  
2.8.1	  Cell	  culture	  and	  SILAC	  labelling	  Splenocytes	   from	   P14	   mice	   were	   isolated	   as	   previously	   indicated	   and	   activated	  with	   100ng/mL	   gp33-­‐41	   peptide	   for	   2	   days	   in	   complete	   RPMI	   media.	   Three	  biological	   replicates	   were	   used	   for	   each	   experiment.	   Following	   activation,	   cells	  were	  washed	  out	  of	  activation	  and	  for	  each	  biological	  replicate	  half	  the	  cells	  were	  switched	  into	  media	  supplemented	  with	  lysine	  and	  arginine	  labelled	  with	  13C	  and	  
15N	   (heavy	   media)	   and	   half	   into	   media	   supplemented	   with	   arginine	   and	   lysine	  labelled	  with	  12C	  and	  14N	  (light	  media).	  	  	  SILAC	  RPMI	  1640	  media	  (Thermo	  Scientific)	  was	  supplemented	  with	  10%	  dialysed	  FCS	  (Life	  Technologies),	  50μM	  β	  mercaptoethanol,	  penicillin/streptomycin,	  1x	  ITS	  (insulin,	  transferrin	  and	  selenium,	  Life	  Technologies),	  1x	  MEM	  vitamins	  (minimum	  essential	  medium,	  Life	  Technologies),	  1mM	  sodium	  pyruvate	  (Life	  Technologies),	  200mg/L	   L-­‐proline,	   84mg/L	   L-­‐arginine	   and	   300mg/L	   L-­‐glutamate.	   Light	   media	  was	  also	  supplemented	  with	  L-­‐[12C6,	  14N4]	  arginine	  (referred	  to	  as	  RO)	  and	  L-­‐[12C6,	  
14N2]	  lysine	  (referred	  to	  as	  K0);	  while	  heavy	  media	  was	  supplemented	  with	  L-­‐[13C6,	  
15N4]	  arginine	  (referred	  to	  as	  R10)	  and	  l-­‐[13C6,	  15N2]	  lysine	  (referred	  to	  as	  K8)	  (Ross	  et	  al.,	  2016).	  After	  RPMI	  media	  was	  supplemented,	   it	  was	  filtered	  using	  Stericups	  (Millipore).	   Cells	  were	  maintained	   in	   IL-­‐2	   (Proleukin)	   for	   5	   days	   and	  were	   split	  daily	   to	   a	   cell	   density	   of	   0.5x106	   cells/mL.	   The	   day	   that	   the	   CTL	   were	   to	   be	  collected,	   cells	  were	   first	   split	   and	   the	   IL-­‐2	   refreshed.	   After	   at	   least	   1	   hour,	   CTL	  were	  treated	  as	  indicated.	  Heavy	  labelled	  cells	  were	  treated	  with	  tofacitinib	  while	  light	  labelled	  cells	  were	  maintained	  in	  IL-­‐2	  only.	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2.8.2	  Lysis	  and	  protein	  digest	  Following	   treatment,	   the	   light	   IL-­‐2	   maintained	   and	   heavy	   labelled	   IL-­‐2	   and	  tofacitinib	  treated	  cells	  were	  mixed	  in	  a	  1:1	  ratio	  (120x106	  cells	  each)	  within	  their	  biological	  replicates.	  Cells	  were	  then	  centrifuged	  at	  335xg	  for	  five	  minutes	  at	  4°C	  to	  pellet,	  and	  lysed	  in	  8M	  urea	  buffer	  (8M	  urea,	  50mM	  Tris	  pH	  8.0,	  1mM	  TCEP)	  with	  protease	   (cOmplete™	   	   mini	   EDTA	   free,	   Roche)	   and	   phosphatase	   inhibitors	  (PhosStop,	  Roche)	  at	   room	   temperature	   for	  30	  minutes.	   Samples	  were	   sonicated	  briefly	  to	  shear	  DNA.	  	  	  Proteins	  were	  then	  precipitated	  by	  adding	  10%	  TCA	  (trichloroacetic	  acid)	  at	  room	  temperature.	   Following	   precipitation,	   lystates	   were	   centrifuged	   at	   4539.5xg	  (4000rpm	  in	  Beckman	  J6HC	  centrifuge	  with	  a	  JS-­‐4.2	  rotor)	  for	  15	  minutes	  at	  room	  temperature.	   The	   pellet	   was	   washed	   three	   times	   with	   90%	   (v/v)	   acetone,	   with	  samples	  centrifuged	  at	  4539.5xg	  	  for	  15	  minutes	  at	  4°C	  between	  washes.	  After	  the	  final	  wash,	   the	   acetone	  was	   removed	   and	   the	   sample	   resuspended	   in	   900μL	   8M	  urea	   buffer,	   transferred	   to	   a	   low	   bind	   eppendorf	   tube	   (Eppendorf)	   and	  mashed	  with	  a	  dounce	  homogenizer	  to	  aid	  resuspension.	  Samples	  were	  adjusted	  to	  pH	  8.5	  with	  NH4OH	  if	  necessary	  and	  mixed	  on	  an	  IP	  shaker	  for	  2	  hours.	  	  	  Following	   mixing,	   carbamindomethylation	   of	   cysteine	   thiol	   residues	   was	  performed	  to	  prevent	  cysteine	  oxidation	  and	  cysteine	  bridge	  formation	  by	  adding	  freshly	  prepared	  iodoacetemide	  (final	  concentration	  50mM)	  to	  samples	  for	  1	  hour	  in	   the	   dark.	   During	   the	   reaction,	   samples	   were	   mixed	   in	   the	   IP	   shaker.	   The	  carbamindomethylation	   reaction	   was	   quenched	   by	   adding	   5mM	   DTT.	   Samples	  were	  then	  diluted	  to	  1M	  urea	  with	  Tris	  pH	  8.0,	  and	  digested	  with	  trypsin.	  Trypsin	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(Promega)	   was	   reconstituted	   to	   a	   concentration	   of	   1μg/μL	   in	   50mM	   Tris/1mM	  CaCl2	  pH	  8.0,	  and	  33μL	  added	  to	  each	  sample	  every	  four	  hours,	  so	  that	  in	  total	  each	  sample	  received	  approximately	  100μg	  trypsin.	  Trypsin	  digests	  were	  carried	  out	  at	  30°C	  on	  the	  IP	  shaker.	  	  
	  
2.8.3	  Desalting	  Before	  desalting,	  trypsin	  was	  inactivated	  by	  the	  addition	  of	  1μL	  formic	  acid	  per	  mL	  sample.	   Peptides	   were	   quantified	   using	   the	   CBQCA	   protein	   quantification	   kit	   as	  directed	   by	   the	   manufacturer's	   instructions.	   Samples	   were	   centrifuged	   for	   five	  minutes	   at	   335xg	   and	   the	   supernatant	   desalted	   using	   Sep-­‐Pack	   C18	   columns	  (Waters).	   Samples	   were	   divided	   so	   that	   <	   1mg	   of	   peptide	   was	   loaded	   on	   each	  column.	   Columns	   were	   primed	   twice	   with	   2.5mL	   50%	   acetonitrile	   0.1%	   formic	  acid,	  then	  equilibrated	  with	  two	  washes	  of	  2.5mL	  0.1%	  formic	  acid.	  Samples	  were	  applied,	   then	   reapplied	   to	   the	   columns,	   the	   columns	   washed	   twice	   with	   2.5mL	  0.1%	  formic	  acid	  and	  peptides	  eluted	  into	  low	  bind	  eppendorf	  tubes	  (Eppendorf)	  with	   600μL	   50%	   acetonitrile	   0.1%	   formic	   acid.	   Following	   elution,	   samples	  were	  dried	  down	  in	  a	  SpeediVac	  and	  stored	  at	  -­‐20°C	  until	  further	  processing.	  	  
2.8.4	  Fractionation	  Samples	   were	   fractionated	   using	   HILIC	   (hydrophilic	   interaction	   liquid	  chromatography)	  on	  the	  Ultimate	  3000	  HPLC	  using	  a	  4.6x250mm	  TSK	  gel	  Amide-­‐80	   5μM	   particle	   column	   (Tosoh	   Biosciences),	   with	   16	   fractions	   collected	   per	  sample.	  Buffer	  A	  was	  0.1%	  TFA,	   and	  buffer	  B	  was	  99.9%	  acetonitrile/0.1%	  TFA:	  buffers	   were	   made	   with	   HPLC	   grade	   acetonitrile	   and	   water.	   Prior	   to	   injection,	  samples	  were	  resuspended	  in	  800μL	  80%	  acetonitrile	  0.1%	  TFA	  and	  mixed	  on	  the	  IP	  shaker	  for	  30	  minutes.	  Multiple	  injections	  of	  200μL	  were	  used	  for	  each	  sample.	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Loading	  buffer:	  250nM	  lactic	  acid,	  in	  3%	  TFA/70%	  acetonitrile.	  
Washing	  solvent	  1:	  80%	  acetonitrile,	  1%	  TFA.	  	  
Washing	  solvent	  2:	  	  20%	  acetonitrile,	  0.5%	  TFA.	  
Elution	  solvent	  1:	  28%	  ammonia,	  pH	  11.3.	  
Elution	  solvent	  2:	  50%	  elution	  solvent	  1,	  50%	  acetonitrile	  Phosphopeptides	  were	  enriched	  using	  TiO2	  beads.	  Equivalent	  fractions	  of	  different	  injections	   of	   the	   same	   sample	   were	   combined	   in	   200μL	   of	   loading	   solvent	   and	  transferred	   to	   low-­‐bind	   eppendorf	   tubes	   (Eppendorf).	   Acidity	   of	   samples	   was	  checked	   with	   pH	   strips	   (should	   be	   approximately	   pH	   2	   to	   maximize	   specific	  binding	   of	   phosphopeptides	   to	   TiO2	   beads).	   A	   50mg/mL	   slurry	   of	   TiO2	   beads	   in	  loading	   buffer	  was	  made	   up,	   then	   25μL	   of	   TiO2	  slurry	  was	   added	   per	   eppendorf	  tube.	  Tubes	  were	  vortexed	  briefly	  and	  mixed	  on	   the	   IP	   shaker	   for	  10	  minutes	  at	  room	  temperature,	  then	  centrifuged	  at	  5900xg	  for	  5	  minutes.	  The	  supernatant	  was	  removed	   and	   the	   beads	  washed	  with	   200μL	   of	   loading	   solvent,	   vortexed	   briefy,	  mixed	  on	  the	  IP	  shaker	  for	  5	  minutes	  and	  centrifuged	  at	  5900xg	  for	  five	  minutes.	  The	  supernatant	  was	  discarded	  and	  the	  beads	  washed	  with	  200μL	  washing	  buffer	  1,	   vortexed	  briefly	   and	  mixed	  on	   the	   IP	   shaker	   for	   5	  minutes	   and	   centrifuged	   at	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5900xg	   for	   five	  minutes.	   The	   supernatant	  was	   discarded	   and	   the	   beads	  washed	  with	  200μL	  washing	  buffer	  2,	   vortexed	  briefly	   and	  mixed	  on	   the	   IP	   shaker	   for	  5	  minutes	   and	   centrifuged	   at	   5900xg	   for	   five	   minutes.	   The	   supernatant	   was	  discarded,	  and	  200μL	  elution	  buffer	  1	  was	  added	   to	  beads,	  which	  were	  vortexed	  then	  mixed	  on	  IP	  shaker	  for	  1	  hour	  at	  room	  temperature.	  	  	  After	   1	   hour,	   the	   eppendorfs	   were	   centrifuged	   and	   the	   supernatant	   filtered	  through	  C8	  material	  to	  remove	  remaining	  beads	  as	  follows.	  A	  small	  amount	  of	  C8	  material	  was	   pushed	   into	   a	   pipette	   tip	   that	   had	   been	   cut	   at	   the	   tip.	   Pipette	   tips	  were	   then	   inserted	   into	   the	   lids	   of	   a	   fresh	   low	   bind	   eppendorf	   tubes	   and	   the	  supernatant	  loaded	  into	  the	  tips,	  100μL	  at	  a	  time.	  Following	  loading	  of	  the	  tips,	  the	  eppendorfs	  were	   centrifuged	   at	   5900xg	   for	   5	  minutes.	   After	   all	   the	   supernatant	  had	   been	   filtered,	   samples	  were	   dried	   down	   in	   the	   SpeediVac	   overnight.	   Elutant	  buffer	   2	   (200	   μL)	   was	   added	   to	   the	   remaining	   TiO2	   beads,	   which	   were	   then	  vortexed	  briefly	  and	  mixed	  on	  the	  IP	  shaker	  for	  1	  hour	  at	  room	  temperature.	  After	  one	   hour,	   the	   resulting	   supernatents	   were	   filtered	   as	   previously	   described,	  combined	  with	  the	  equivalent	  elution	  buffer	  1	  filtrate	  and	  dried	  down	  overnight	  in	  the	  SpeediVac.	  
2.8.6	  Mass	  spectrometry	  analysis	  Samples	   were	   submitted	   as	   dried	   down	   phosphopeptides	   to	   the	   FingerPrints	  Proteomics	   and	   Mass	   Spectrometry	   facility	   at	   the	   University	   of	   Dundee,	   who	  analysed	  samples	  as	  described	  in	  Ross	  et	  al.	  (2016):	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“Phosphopeptide	  samples	  were	  resuspended	   in	  1%	  formic	  acid	  and	  separated	  by	  
nanoscale	  C18	  reverse-­‐	  phase	   liquid	  chromatography	  (Ultimate	  3000	  RSLC	  nano	  
system,	   Thermo	   Scientific).	   The	   buffers	   used	   for	   chromatography	   were:	   HPLC	  
Buffer	   A	   (2%	   acetonitrile,	   0.1%	   formic	   acid),	   HPLC	   Buffer	   B	   (80%	   acetonitrile,	  
0.08%	  formic	  acid)	  and	  HPLC	  Buffer	  C	  (0.1%	  formic	  acid).	  Samples	  were	  washed	  
onto	  the	  column	  with	  HPLC	  Buffer	  C	  and	  eluted	  with	  the	  following	  buffer	  gradient:	  
2%	  B	  (0-­‐3	  minutes),	  2-­‐	  40%	  B	  (3-­‐128	  minutes),	  40-­‐98%	  B	  (128-­‐130	  minutes),	  98%	  
B	  (130-­‐150	  minutes),	  98-­‐2%	  B	  (150-­‐151	  minutes),	  and	  equilibrated	  in	  2%	  B	  (151-­‐
180	  minutes)	   at	   a	   flow	   rate	   of	   0.3	   μl/minute.	   The	   eluting	   peptide	   solution	   was	  
automatically	   electrosprayed	   into	   the	   coupled	   Linear	   Trap	   Quadrupole	   (LTQ)-­‐	  
Orbitrap	  mass	  spectrometer	  (LTQ-­‐Orbitrap	  Velos	  Pro;	  Thermo	  Scientific)	  using	  an	  
Easy-­‐Spray	   nanoelectrospray	   ion	   source	   (Thermo	   Scientific).	   The	   mass	  
spectrometers	   were	   operated	   in	   positive	   ion	   mode	   and	   were	   used	   in	   data-­‐
dependent	  acquisition	  modes.	  A	  full	  scan	  (FT-­‐MS)	  was	  acquired	  at	  a	  target	  value	  
of	   1,000,000	   ions	   with	   resolution	   R	   =	   60,000	   over	   a	   mass	   range	   of	   335-­‐1800	  
atomic	   mass	   unit	   (amu).	   The	   fifteen	   most	   intense	   ions	   were	   selected	   for	  
fragmentation	  in	  the	  LTQ	  Orbitrap	  Velos.	  Fragmentation	  in	  the	  LTQ	  was	  induced	  
by	   collision-­‐induced	   dissociation	   (CID)	   with	   a	   target	   value	   of	   10,000	   ions.	   For	  
accurate	  mass	  measurement,	   the	   "lock	  mass"	   function	   (lock	  mass	   =	   445.120024	  
Da)	   was	   enabled	   for	   MS	   scan	   modes.	   To	   improve	   the	   fragmentation	   of	  
phosphopeptides,	   the	   multistage	   activation	   algorithm	   in	   the	   Xcalibur	   software	  
was	   enabled	   for	   each	   MS/MS	   spectrum	   using	   the	   neutral	   loss	   values	   of	   97.98,	  
48.99,	   32.66	   and	   24.49	  m/z	   units.	   Former	   target	   ions	   selected	   for	  MS/MS	  were	  
dynamically	  excluded	  for	  45	  seconds.	  General	  mass	  spectrometric	  conditions	  were	  
as	  follows:	  spray	  voltage,	  1.8-­‐2.5	  kV;	  no	  sheath	  and	  auxiliary	  gas	  flow;	  ion	  transfer	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tube	   temperature,	   250	   °C;	   normalised	   collision	   energy	   (35%)	   using	   wide	   band	  
activation	  mode	  for	  MS2.	  The	  isolation	  width	  was	  set	  to	  2	  amu	  for	  IT-­‐MS/MS.	  Ion	  
selection	   thresholds	   were	   5000	   counts	   for	   MS2.	   An	   activation	   of	   q	   =	   0.25	   and	  
activation	  time	  of	  10	  ms	  were	  applied	  in	  MS2	  acquisitions.	  The	  fill	  time	  for	  FTMS	  
was	  set	  to	  500	  ms	  and	  for	  ITMS	  to	  100	  ms.”	  
2.8.7	  Data	  analysis	  RAW	  files	  were	  loaded	  into	  the	  MaxQuant	  program	  version	  1.5.0.	  with	  the	  settings	  as	  follows:	  SILAC	  with	  multiplicity	  of	  two	  (light	  R0K0,	  heavy	  R10K8);	  run	  against	  the	  mouse	   reviewed	  Uniprot	   FASTA	   file.	   Search	   parameters	  were	   set	   as	   follows:	  MS	   tolerance	   of	   20ppm	   and	   MS/MS	   tolerance	   of	   5Da;	   trypsin	   selected	   as	   the	  protease	  and	  up	  to	  two	  missed	  cleavages	  permitted;	  a	  minimum	  peptide	  length	  of	  6	  amino	  acids	  and	  an	  site	  and	  protein	  FDR	  of	  0.01	  as	  determined	  using	  a	  reverse	  library.	  The	  reverse	  library	  is	  generated	  by	  reversing	  the	  amino	  acid	  sequence	  of	  peptides,	   generating	   an	   additional	   peptide	   library	   containing	   peptide	   sequences	  that	  should	  not	  be	  identified	  in	  the	  actual	  dataset.	  This	  should	  eliminate	  peptides	  which	   are	   difficult	   to	   assign	   to	   a	   particular	   protein	   and	   allow	   calculation	   of	   the	  false	   discovery	   rate	   (FDR).	   Match	   between	   runs	   and	   was	   enabled.	   Protein	   N	  terminal	  acetylation,	  methionine	  oxidation,	  glutamine	  to	  pyroglutamate,	  glutamine	  and	   asparagine	   deamination	   and	   STY	   phosphorylation	  were	   selected	   as	   variable	  modifications;	  and	  carbamindolyation	  of	  cysteine	  residues	  as	  a	  fixed	  modification.	  	  	  Following	   processing	   of	   the	   files	   by	   MaxQuant,	   the	   phosphoSTY.txt	   file	   was	  imported	  into	  Excel	  and	  sites	  linked	  to	  phosphopeptides	  listed	  as	  contaminants	  or	  present	   in	   the	   reverse	   peptide	   library	   were	   removed.	   Sites	   were	   defined	   as	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regulated	  if	  they	  had	  a	  normalised	  SILAC	  ratio	  treated/untreated	  of	  ≥1.5	  or	  ≤	  0.67	  in	   2	   or	   more	   biological	   replicates	   and	   if	   the	   regulation	   was	   consistent	   across	  biological	   replicates.	   Statistical	   significance	   was	   assessed	   using	   a	   one-­‐sample	   T-­‐test	   performed	   using	   the	   Perseus	   software	   of	   the	   fold	   changes	   between	   the	  abundance	  of	  phosphosites	  in	  IL-­‐2	  maintained	  and	  tofacitinib	  treated	  samples,	  and	  sites	  were	  defined	  as	  significantly	  regulated	  if	  they	  had	  a	  ratio	  of	  ≥1.5	  or	  ≤	  0.67	  and	  a	   p-­‐value	   of	   ≤0.05.	   Lists	   of	   significantly	   regulated	   sites	   were	   submitted	   to	   the	  DAVID	  analysis	  tool	  for	  pathway	  analysis.	  	  HIF	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2.9.	  Proteomics	  
2.9.1	  Cell	  culture	  and	  inhibitor	  treatment	  	  
Label-­‐free	  proteomics:	  Splenocytes	  from	  P14	  mice	  were	  activated	  with	  gp33-­‐41	  peptide	  for	  two	  days,	  then	  washed	  out	  of	  activation	  and	  maintained	  for	  5	  days	  in	  the	  presence	  of	  20ng/mL	  IL-­‐2	  (Proleukin).	  Cells	  were	  cultured	   in	  complete	  RPMI	  supplemented	   with	   10%	   FCS,	   50mM	   β-­‐mercaptoethanol	   and	   penicillin	  streptomycin,	  and	  maintained	  at	  a	  concentration	  of	  0.5x106	  cells/mL.	  Treatment:	  CTL	  were	   either	  maintained	   in	   IL-­‐2	   only	   or	  maintained	   in	   IL-­‐2	   and	   treated	  with	  100nM	  tofacitinib	  for	  24	  hours.	  On	  the	  day	  of	  collection,	  cells	  were	  split	  and	  the	  IL-­‐2	  refreshed	  at	  least	  an	  hour	  before	  cells	  were	  collected.	  
	  
SILAC	  labelled	  4	  hours	  tofacitinib	  treated	  proteomics:	  cell	  culture	  as	  indicated	  in	  the	  phosphoproteomics	  section.	  
2.9.2	  Lysis	  and	  protein	  digest	  Twenty	   five	   million	   cells	   were	   taken	   from	   control	   and	   treated	   conditions	   for	  analysis	   by	   mass	   spectrometry.	   Cells	   were	   centrifuged	   at	   335xg	   at	   4°C	   for	   five	  minutes,	  washed	  twice	  with	  cold	  HBSS	  (Hanks’	  buffered	  salt	  solution),	  transferred	  to	  a	   low	  bind	  eppendorf	  tube	  (Eppendorf)	  and	  lysed	  in	  8M	  urea	  buffer	  (8M	  urea,	  50mM	  Tris	  pH	  8.0,	  1mM	  TCEP)	  with	  protease	  (cOmplete™	  	  mini	  EDTA	  free,	  Roche)	  and	   phosphatase	   inhibitors	   (PhosStop,	   Roche)	   at	   room	   temperature	   for	   30	  minutes.	  Samples	  were	  sonicated	  briefly	  to	  shear	  DNA.	  Protein	  concentration	  was	  determined	  using	  a	  BCA	  assay.	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After	  samples	  were	  taken	  for	  protein	  determination,	  10mM	  DTT	  was	  added	  to	  each	  sample	  and	  samples	  incubated	  for	  30	  minutes	  at	  30°C	  on	  an	  IP	  shaker.	  Following	  incubation	   with	   DTT,	   50mM	   freshly	   prepared	   iodoacetimide	   was	   added	   to	   each	  sample.	  Samples	  were	  then	  incubated	  for	  45	  minutes	  in	  the	  dark	  on	  an	  IP	  shaker.	  Samples	  were	   then	  diluted	   to	  4M	  urea	  with	  100mM	  Tris	  pH	  8.0/1mM	  CaCl2,	  and	  LysC	   (Wako)	   reconstituted	   in	  100mM	  Tris	  pH	  8.0/1mM	  CaCl2	  was	   then	  added	   to	  each	   sample	   at	   a	   ratio	   of	   50:1	   protein:LysC.	   Samples	   were	   incubated	  with	   LysC	  overnight	   at	   30°C.	   After	   incubation	   with	   LysC,	   samples	   transferred	   to	   low	   bind	  15mL	   falcon	   tubes	   (Eppendorf)	   and	   were	   further	   diluted	   with	   100mM	   Tris	   pH	  8.0/1mM	  CaCl2	  to	  0.8M	  urea.	  Trypsin	   (Promega),	   reconstituted	  with	  100mM	  Tris	  pH	  8.0/1mM	  CaCl2,	  was	   then	  added	  to	  samples	  at	  a	  ratio	  of	  50:1	  protein:trypsin,	  and	  incubated	  for	  8	  hours	  at	  30°C.	  
2.9.3	  Desalting	  Samples	   were	   desalted	   using	   the	   C18	   SepPack	   cartridges	   as	   indicated	   in	   the	  phosphoproteomics	   section,	  with	   the	   exception	   that	   formic	   acid	  was	   substituted	  for	   TFA	   (trifluroacetic	   acid).	   Samples	   were	   then	   dried	   down	   overnight	   in	   the	  SpeediVac.	  
2.9.4	  Fractionation	  Peptide	   samples	   were	   fractionated	   using	   SAX	   (strong	   anion	   exchange)	  chromatography	  with	  an	  Ultimate	  3000	  HPLC	  and	  an	  AS24	  strong	  anion	  exchange	  column	   as	   described	   by	   Hukelmann	   et	   al.,	   (2015).	   Dried	   down	   samples	   were	  resuspended	  in	  210μL	  10mM	  sodium	  borate	  20%	  (v/v)	  acetonitrile,	  pH9.3	  (buffer	  adjusted	  with	  NaOH)	  and	  separated	   into	   twelve	  750μL	   fractions	  using	  an	  elution	  gradient	  with	  increasing	  NaCl	  into	  a	  Deepwell	  96	  well	  low	  bind	  plate	  (Eppendorf).	  
	   100	  
Following	   elution,	   samples	   were	   desalted	   using	   Sep-­‐pack	   C18	   96	   well	   desalting	  plates	  (Waters)	  and	  dried	  down	  in	  the	  SpeediVac	  overnight.	  
2.9.5	  Mass	  spectrometry	  analysis	  Dried	  down	   samples	  were	   resuspended	   in	   40μL	  5%	   formic	   acid	   and	   adjusted	   to	  1.2μg/18μL	   (peptide	   concentration	   determined	   using	   CBQCA	   kit	   as	   directed).	  Samples	   were	   then	   submitted	   to	   the	   to	   the	   FingerPrints	   Proteomics	   and	   Mass	  Spectrometry	  facility	  at	  the	  University	  of	  Dundee,	  and	  analysed	  as	  follows:	  	  	  
“Trypsin-­‐digested	  peptides	  were	  separated	  using	  an	  Ultimate	  3000	  RSLC	  (Thermo	  
Scientific)	   nanoflow	   LC	   system.	   Protein	   was	   loaded	   with	   a	   constant	   flow	   of	   5	  
µl/min	  onto	  an	  Acclaim	  PepMap100	  nanoViper	  C18	  trap	  column	  (100	  µm	  inner-­‐
diameter,	   2cm;	   Thermo	   Scientific).	   After	   trap	   enrichment,	   peptides	   were	   eluted	  
onto	  an	  EASY-­‐Spray	  PepMap	  RSLC	  nanoViper,	  C18,	  2	  µm,	  100	  Å	  column	  (75	  µm,	  50	  
cm;	  ThermoScientific)	  with	  a	  linear	  gradient	  of	  2–40%	  solvent	  B	  (80%	  acetonitrile	  
with	   0.08%	   formic	   acid)	   over	   124	  min	  with	   a	   constant	   flow	   of	   300	   nl/min.	   The	  
HPLC	  system	  was	  coupled	  to	  a	  linear	  ion	  trap	  Orbitrap	  hybrid	  mass	  spectrometer	  
(LTQ-­‐Orbitrap	   Velos,	   Thermo	   Scientific)	   via	   a	   nano-­‐electrospray	   ion	   source	  
(Thermo	  Scientific).	  Full-­‐scan	  MS	  survey	  spectra	  (m/z	  335–1800)	  in	  profile	  mode	  
were	  acquired	  in	  the	  Orbitrap	  with	  a	  resolution	  of	  60,000.	  The	  fifteen	  most	  intense	  
peptide	  ions	  from	  the	  preview	  scan	  in	  the	  Orbitrap	  were	  fragmented	  by	  collision-­‐
induced	  dissociation	   (normalized	  collision	  energy,	  35%;	  activation	  Q,	  0.250;	  and	  
activation	  time,	  10	  ms)	  in	  the	  LTQ	  after	  the	  accumulation	  of	  5,000	  ions.	  Maximal	  
filling	   times	  were	   1,000	  ms	   for	   the	   full	   scans	   and	   150	  ms	   for	   the	  MS/MS	   scans.	  
Precursor	   ion	   charge	   state	   screening	   was	   enabled	   along	   with	   multistage	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activation	   for	   neutral	   loss	   ions	   for	   phosphorylated	   samples,	   and	   all	   unassigned	  
charge	  states	  as	  well	  as	  singly	  charged	  species	  were	  rejected.	  The	  lock	  mass	  option	  
was	   enabled	   for	   survey	   scans	   to	   improve	   mass	   accuracy.	   Samples	   were	   run	   in	  
triplicate.	   Data	   were	   acquired	   using	   the	   Xcalibur	   software.”	   FingerPrints	  Proteomics	  and	  Mass	  Spectrometry	  facility.	  
2.9.6	  Data	  analysis	  
Label	  free	  24	  hours	  tofacitinib	  treated	  proteomics:	  RAW	  files	  were	  loaded	  into	  the	   MaxQuant	   program	   version	   1.5.0.	   with	   the	   settings	   as	   follows:	   label	   free	  quantification;	   run	   against	   the	   mouse	   reviewed	   Uniprot	   2014	   FASTA	   file;	   MS	  tolerance	  of	  20ppm	  and	  MS/MS	  tolerance	  of	  5Da;	  trypsin	  and	  LysC	  selected	  as	  the	  proteases	  and	  up	  to	  two	  missed	  cleavages	  permitted;	  a	  minimum	  peptide	  length	  of	  6	  amino	  acids	  and	  an	  site	  and	  protein	  FDR	  of	  0.01	  as	  determined	  using	  a	  reverse	  library.	   Match	   between	   runs	   was	   enabled.	   Protein	   N	   terminal	   acetylation,	  methionine	   oxidation,	   glutamine	   to	   pyroglutamate,	   glutamine	   and	   asparagine	  deanimation	   and	   STY	   phosphorylation	   were	   selected	   as	   variable	   modifications;	  and	  carbamindolyation	  of	  cysteine	  residues	  as	  a	  fixed	  modification.	  	  Following	   processing	   of	   the	   files	   by	   MaxQuant,	   the	   proteingroups.txt	   file	   was	  imported	   into	   the	  Perseus	   software	  and	   the	  copy	  numbers	  of	  proteins	  estimated	  using	  the	  proteome	  ruler	  plug-­‐in.	  The	  proteomic	  ruler	  plug-­‐in	  uses	  the	  abundance	  of	   histones	   to	   calculate	   the	   copy	   number	   of	   proteins	   per	   cell	   (Wiśniewski	   et	   al.,	  2014).	   The	   resulting	   file	  was	   imported	   into	   Excel	   and	   to	   determine	   the	   effect	   of	  tofacitnib	   on	   the	   CTL	   proteome	   the	   ratio	   of	   copy	   numbers	   within	   biological	  replicates	   was	   calculated.	   Proteins	   were	   defined	   as	   reproducibly	   detected	   to	   be	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regulated	  if	  they	  had	  a	  copy	  numbers	  ratio	  treated/untreated	  of	  ≥1.5	  or	  ≤	  0.67	  in	  2	  or	  more	  biological	  replicates	  and	  if	  the	  regulation	  was	  consistent	  across	  biological	  replicates.	   Statistical	   significance	   was	   assessed	   using	   a	   one-­‐sample	   T-­‐test	  performed	  using	  the	  Perseus	  software	  of	  the	  fold	  changes	  between	  the	  abundance	  of	  proteins	  in	  IL-­‐2	  maintained	  and	  tofacitinib	  treated	  samples,	  and	  proteins	  were	  defined	  as	  significantly	  regulated	  if	  they	  had	  a	  ratio	  of	  ≥1.5	  or	  ≤	  0.67	  and	  a	  p-­‐value	  of	   ≤0.05.	   Lists	   of	   significantly	   regulated	   proteins	   were	   submitted	   to	   the	   DAVID	  analysis	  tool	  for	  pathway	  analysis.	  
	  
SILAC	   labelled	  4	  hours	   tofacitinib	  proteomics:	  RAW	  files	  were	  loaded	  into	  the	  MaxQuant	   program	   version	   1.5.0.	   with	   the	   settings	   as	   follows:	   SILAC	   with	  multiplicity	   of	   two	   (light	   R0K0,	   heavy	   R10K8);	   run	   against	   the	  mouse	   reviewed	  Uniprot	   2014	   FASTA	   file.	   Search	   parameters	   were	   as	   follows:	   MS	   tolerance	   of	  20ppm	  and	  MS/MS	   tolerance	  of	  5Da;	   trypsin	   and	  LysC	   selected	  as	   the	  proteases	  and	  up	  to	  two	  missed	  cleavages	  permitted;	  a	  minimum	  peptide	  length	  of	  6	  amino	  acids	  and	  an	  site	  and	  protein	  FDR	  of	  0.01	  as	  determined	  using	  a	   reverse	   library.	  Match	   between	   runs	   was	   enabled.	   Protein	   N	   terminal	   acetylation,	   methionine	  oxidation,	  glutamine	  to	  pyroglutamate,	  glutamine	  and	  asparagine	  deanimation	  and	  STY	   phosphorylation	   were	   selected	   as	   variable	   modifications;	   and	  carbamindolyation	  of	  cysteine	  residues	  as	  a	  fixed	  modification.	  	  	  Following	   processing	   of	   the	   files	   by	   MaxQuant,	   the	   proteingroups.txt	   file	   was	  imported	   into	   Excel	   and	   proteins	   linked	   to	   peptides	   listed	   as	   contaminants	   or	  present	   in	   the	   reverse	   peptide	   library	   were	   removed.	   Proteins	   were	   defined	   as	  reproducibly	   detected	   to	   be	   regulated	   if	   they	   had	   a	   normalised	   SILAC	   ratio	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treated/untreated	   of	   ≥1.5	   or	   ≤	   0.67	   in	   2	   or	  more	   biological	   replicates	   and	   if	   the	  regulation	  was	   consistent	   across	  biological	   replicates.	   Statistical	   significance	  was	  assessed	  using	  a	  one-­‐sample	  T-­‐test	  performed	  using	   the	  Perseus	   software	  of	   the	  fold	  changes	  between	  the	  abundance	  of	  proteins	  in	  IL-­‐2	  maintained	  and	  tofacitinib	  treated	  samples,	  and	  proteins	  were	  defined	  as	  significantly	  regulated	  if	  they	  had	  a	  ratio	  of	  ≥1.5	  or	  ≤	  0.67	  and	  a	  p-­‐value	  of	  ≤0.05.	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Chapter	  3:	  Optimisation	  and	  validation	  of	  JAK	  kinase	  inhibitors	  	  
3.1	  Introduction	  One	   of	   the	   aims	   of	   this	   project	   was	   to	   compare	   the	   efficacy	   of	   JAK1	   and	   JAK3	  selective	   inhibitors	   at	   inhibiting	   signalling	   through	   the	   γc	   cytokine	   receptors,	  which	  bind	  both	  JAK1	  and	  JAK3.	  As	  discussed	  in	  the	  introduction,	  the	  importance	  of	   the	   JAK	   kinases	   in	   transducing	   cytokine	   signalling	   makes	   them	   an	   attractive	  target	   for	  developing	   inhibitors	   to	  modulate	  various	  aspects	  of	   immune	   function,	  for	   example	   as	   second	   line	   treatments	   for	   autoinflammatory	   diseases	   such	   as	  rheumatoid	   arthritis.	   The	  benefit	   of	   JAK	  kinases	   inhibitors	   is	   that	   they	   are	   small	  molecules	  inhibitors	  rather	  than	  biologicals	  (Smolen	  et	  al.,	  2016).	  	  
	  The	   selectivity	   of	   JAK	   kinase	   inhibitors	   such	   as	   tofacitinib	   for	   JAK	   kinases	   over	  other	  kinase	   families	   is	   generally	   good	   (figure	  3.1).	   	  However,	   the	  difficulty	  with	  producing	   JAK	   kinase	   inhibitors	   is	   producing	   an	   inhibitor	   with	   selectivity	   for	   a	  specific	   JAK	   kinase.	   Multiple	   families	   of	   cytokines	   use	   JAK	   kinases	   to	   transduce	  signalling,	   therefore	   a	   JAK	   kinase	   inhibitor	   with	   low	   specificity	   within	   the	   JAK	  kinase	   family	   may	   increase	   the	   range	   of	   side	   effects	   associated	   with	   using	   the	  inhibitor.	   For	   example,	   unwanted	   inhibition	   of	   JAK2	   results	   in	   inhibition	   of	  erythropoietin	  signalling	  and	  ultimately	  anaemia	  (Mesa	  &	  Cortes,	  2013).	  	  
	  Selective	  targeting	  of	  JAK3	  within	  the	  JAK	  kinase	  family	  would	  reduce	  the	  number	  of	   cytokine	   families	   inhibited,	   as	   within	   the	   type	   I/type	   II	   cytokines	   only	   the	   γc	  chain	  cytokine	  family	  uses	  JAK3.	  Common	  gamma	  chain	  cytokines	  are	  important	  in	  the	   development,	   function	   and	   survival	   of	   various	   immune	   cells,	   therefore	  inhibition	   of	   the	   γc	   cytokine	   family	   alone	  may	   be	   sufficient	   for	   a	   therapeutically	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beneficial	  level	  of	  immunomodulation.	  However,	  for	  a	  JAK3	  inhibitor	  to	  be	  useful,	  it	  has	   to	   inhibit	   common	   gamma	   signalling	   effectively.	   Common	   gamma	   chain	  cytokines	  use	  both	  JAK1	  and	  JAK3	  to	  transduce	  signalling,	  and	  as	  discussed	  in	  the	  introduction	   the	   individual	   contribution	   of	   JAK1	   and	   JAK3	   to	   common	   gamma	  chain	  signalling	  has	  not	  been	  fully	  delineated.	  	  	  Three	   JAK	   kinase	   inhibitors,	   tofacitinib,	   GSK186	   and	   GSK192,	   were	   used	   in	   the	  present	   study	   to	   probe	   the	   effect	   of	   inhibiting	   JAK1	   and	   JAK3	   on	   γc	   cytokine	  signalling	   in	  CD8+	  effector	  cells.	  Tofacitinib	   (sold	  as	  Xeljanz®,	  also	  known	  as	  CP-­‐690,550	  and	  tasocitinib),	  is	  a	  commercially	  available	  JAK	  kinase	  inhibitor	  that	  was	  originally	  developed	   to	  be	  a	   specific	   JAK3	   inhibitor	  but	  which	   is	  also	   likely	   to	  be	  targeting	   JAK1	   (Thoma	   et	   al.,	   2011).	   GSK186	   is	   a	   specific	   JAK1	   inhibitor	   and	  GSK192	   is	   a	   specific	   JAK3	   inhibitor	   (table	   3.1,	   data	   from	   GSK).	   Validation	   of	  GSK186	  and	  GSK192,	  and	  published	  reports	  describing	  the	  effects	  of	  tofacitinib	  in	  lymphocytes,	  have	  focused	  on	  either	  cell	  lines,	  PHA	  activated	  human	  lymphocytes	  (Changelian	  et	  al.,	  2003)	  or	  other	  cell	  types	  such	  as	  CD4+	  T	  cells	  (Ghoreschi	  et	  al.,	  2011).	  Experiments	  focused	  on	  characterizing	  the	  effect	  of	  tofacitinib,	  GSK186	  and	  GSK192	  on	  CTL,	  which	  are	  dependent	  on	  IL-­‐2	  signalling	  for	  their	  proliferation	  and	  growth	  (Cornish	  et	  al.,	  2006).	   	  
Table	  3.1:	  IC50	  of	  JAK	  kinase	  
inhibitors	   Table	   shows	   the	  concentration	   (nM)	   of	  tofacitinib,	   GSK186	   and	  GSK192	   required	   for	   50%	  inhibition	   of	   kinase	   activity.	  Data	  from	  GSK.	  
JAK1 JAK2 JAK3 TYK2
Tofacitinib 6.31 19.95 6.31 5.01
GSK186 7.94 63.10 398.11 199.53
GSK192 794.33 1584.89 6.31 794.33
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3.2	  Results	  
3.2.1	  Effect	  of	  tofacitinib	  on	  JAK	  kinase	  dependent	  signalling	  Initial	   experiments	   focused	   on	   identifying	   appropriate	   doses	   at	   which	   to	   use	  tofacitinib,	  GSK186	  and	  GSK192	   in	  order	   to	  study	   their	  effects	  on	   IL-­‐2	  signalling.	  Previously,	   the	   IC50	   for	   tofacitinib	   inhibition	   of	   IL-­‐2	   inhibition	   of	   STAT5	  phosphorylation	  was	   reported	   as	  48nM	   (Thoma	  et	   al.,	   2011),	   and	   tofacitinib	  has	  been	   shown	   to	   efficiently	   inhibit	   IL-­‐2	   signalling	   at	   a	   concentration	   of	   100nM	  (Ghoreschi	  et	  al.,	  2011),	   suggesting	   that	  100nM	  would	  be	  an	  appropriate	  dose	  at	  which	  to	  use	  tofacitinib	  in	  further	  experiments.	  Tofacitinib	  is	  also	  selective	  for	  JAK	  family	  kinases	  over	  other	  kinases	  at	  this	  concentration	  (figure	  3.1).	  	  	  To	  determine	   if	   tofacitinib	  was	   inhibiting	   IL-­‐2	  signalling	   in	  CTL	  efficiently	  at	   this	  concentration,	   the	   effect	   of	   tofacitinib	   on	   various	   IL-­‐2	   induced	   signalling	   events	  was	   assessed	   by	   Western	   blotting.	   IL-­‐2	   signalling	   results	   in	   the	   activation	   of	  multiple	   signalling	   pathways,	   including	   phosphorylation	   of	   the	   STAT5	  transcription	  factors	  (Johnston	  et	  al.,	  1995),	  activation	  of	  MAPK	  signalling	  (Perkins	  et	  al.,	  1993),	  activation	  of	  mTORC1	  signalling	  (Calvo	  et	  al.,	  1992)	  and	  regulation	  of	  the	  abundance	  of	  c-­‐myc	  (Preston	  et	  al.,	  2015).	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Figure	   3.1:	   Tofacitinib	   selectively	   inhibits	   JAK	   family	   kinases	   at	   100nM	   Graph	   shows	   the	  percentage	  activity	  in	  the	  listed	  kinases	  after	  the	  addition	  of	  100nM	  tofacitinib.	  Results	  from	  an	  in	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site	   (Pearce	   et	   al.,	   2010;	   Roux	   et	   al.,	   2007).	   The	   abundance	   of	   c-­‐myc	   was	   also	  measured	  by	  Western	  blot	  analysis	  (Preston	  et	  al.,	  2015).	  	  	  Tofacitinib	   treatment	   resulted	   in	   a	   rapid	   loss	   of	   STAT5	   phosphorylation	   at	   the	  Y694	  site,	  as	  well	  as	  a	  reduction	  in	  the	  amount	  of	  the	  STAT5	  transcriptional	  target	  PIM1	   (Basham	   et	   al.,	   2008),	   suggesting	   tofacitinib	   treatment	   reduced	   STAT5-­‐induced	  transcription	  (figure	  3.2A).	  Tofacitinib	  treatment	  also	  resulted	  in	  a	  loss	  of	  ERK1	  T202/Y204	  and	  ERK2	  T185/Y187	  phosphorylation,	   indicating	  inhibition	  of	  MAPK	   signalling	   (figure	   3.2B).	   Phosphorylation	   of	   p70S6K1	   at	   the	   mTORC1	  substrate	   site	   T389	   and	   the	   S6K	   substrate	   S6	   (figure	  3.2C)	   at	   the	   S235/236	   site	  was	   also	   reduced,	   indicating	   inhibition	   of	   mTORC1	   dependent	   signalling.	  Tofacitinib	  treatment	  reduced	  the	  amount	  of	  c-­‐myc	  (figure	  3.2E).	  
	  
Figure	   3.2:	   Effect	   of	   tofacitinib	   on	   IL-­‐2	   signalling	   IL-­‐2-­‐maintained	  P14	  CTL	  were	   treated	  with	  100nM	   tofacitinib	   as	   indicated	   and	   the	   activation	   of	   various	   signalling	   pathways	   assessed	   by	  Western	   blotting.	   N=2;	   one	   independent	   experiment.	   Western	   blots	   show:	   phosphorylation	   of	  STAT5	  at	  Y694	  (A);	  phosphorylation	  of	  Erk1/2	  at	  T202/Y204	  (B);	  phosphorylation	  of	  p70S6K1	  at	  T389	   and	   S6	   at	   S236/236	   (C);	   amount	   of	   PIM1	   (D);	   amount	   of	   c-­‐myc	   (E).	   	  Molecular	  weights	   of	  blotted	   proteins	   (kDa)	   indicated	   on	   left	   of	   blots.	   SMC1,	   which	   forms	   the	   chromosome	   binding	  cohesion	  complex	  with	  SMC3	  and	  RAD21	  (Laugsch	  et	  al.,	  2013),	  was	  used	  as	  a	  loading	  control.	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3.2.2	  Time	  course	  of	  mTORC1	  inhibition	  by	  tofacitinib	  As	  shown	  in	  figure	  3.2C,	  inhibition	  of	  the	  JAK	  kinases	  inhibits	  mTORC1	  activity	  in	  IL-­‐2	   maintained	   CTL.	   The	   loss	   of	   mTORC1	   signalling	   following	   tofacitinib	  treatment	  was	   less	  rapid	  than	  the	   loss	  of	  STAT5	  phosphorylation	  (figure	  3.2).	  To	  determine	   at	   which	   point	   mTORC1	   activity	   was	   lost,	   pS6	   S235/235	  phosphorylation	   in	   CTL	   treated	   with	   the	   mTORC1	   inhibitor	   rapamycin,	   the	   JAK	  kinase	   inhibitor	   tofacitinib	   and	   CTL	   deprived	   of	   IL-­‐2	   was	   assessed	   by	   flow	  cytometric	   analysis	   using	   a	   phosphospecific	   pS6	   S235/236	   antibody.	   The	  phosphorylation	  of	  p70S6K1	  at	  the	  T389	  site,	  S6	  at	  the	  235/236	  site	  and	  4E-­‐BP1	  at	  the	  T37/46	  site	  was	  also	  assessed	  by	  Western	  blotting.	  	  For	   flow	   cytometric	   analysis,	   CTL	   stimulated	   with	   PdBu	   (phorbol	   12,13-­‐dibutyrate)	   were	   included	   as	   a	   positive	   control	   for	   S6	   phosphorylation.	   The	  mTORC1	  inhibitor	  rapamycin	  caused	  a	  rapid	  loss	  of	  pS6	  phosphorylation:	  maximal	  inhibition	  of	   pS6	  phosphorylation	  was	   achieved	  within	  30	  minutes	   of	   treatment.	  This	  also	  confirms	  that	  the	  IL-­‐2	  induced	  pS6	  phosphorylation	  seen	  is	  dependent	  on	  mTORC1	   activity	   and	   so	   is	  mediated	   by	   p70S6K1	   rather	   than	  RSK.	  RSK	   can	   also	  phosphorylate	   S6	  but	   is	   not	   rapamycin	   sensitive	   (Roux	   et	   al.,	   2007).	   In	   contrast,	  tofacitinib	  does	  decrease	  S6	  phosphorylation	  compared	  to	  the	  IL-­‐2	  control	  within	  30	  minutes,	  but	  the	  maximal	  level	  of	  inhibition	  is	  not	  achieved	  until	  after	  overnight	  treatment,	   at	   which	   point	   there	   may	   also	   be	   loss	   of	   S6	   protein.	   Similarly,	   IL-­‐2	  deprivation	   reduces	   pS6	   phosphorylation,	   but	   less	   rapidly	   than	   rapamycin	  treatment	  (figure	  3.3).	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3.2.3	   GSK192	   inhibits	   IL-­‐2	   signalling	   at	   higher	   doses	   than	   tofacitinib	   or	  
GSK186	  GSK192	   inhibited	   STAT5	   phosphorylation	   less	   efficiently	   than	   did	   tofacitinib	   or	  GSK186	   (figure	  3.5).	  However,	   higher	  doses	  of	  GSK192	   inhibit	   IL-­‐2	   signalling,	   as	  seen	   in	   figure	  3.6,	  which	  shows	  Western	  blot	  analysis	  of	  STAT5	  phosphorylation,	  PIM1	   abundance	   and	   cell	   surface	   CD25	   expression	   on	   IL-­‐2-­‐maintained	   and	   JAK	  kinase	   inhibitor-­‐treated	   CTL.	   Phosphorylation	   of	   STAT5	   at	   the	   Y694	   site	   was	  reduced	   after	   18	   hours	   of	   treatment	   of	   IL-­‐2-­‐maintained	   CTL	   with	   100nM	  tofacitinib	  and	  the	  JAK1	  selective	  inhibitor	  GSK186.	  The	  phosphorylation	  of	  STAT5	  Y694	   in	   IL-­‐2-­‐maintained	   CTL	   treated	   with	   1μM	   GSK192	   was	   also	   reduced.	  However	   the	   reduction	   is	   less	   than	   that	   seen	   in	  CTL	   treated	  with	   tofacitinib	   and	  GSK186	  (figure	  3.6A).	  	  	  The	  abundance	  of	  the	  STAT5	  transcriptional	  target	  PIM1	  (Basham	  et	  al.,	  2008)	  was	  reduced	   after	   CTL	   were	   deprived	   of	   IL-­‐2.	   Following	   18	   hours	   treatment	   with	  tofacitinib,	   GSK186	   and	   GSK192	   PIM1	   levels	   were	   also	   reduced,	   suggesting	   that	  STAT5	   transcriptional	  activity	  was	   inhibited	  (figure	  3.6A).	  Expression	  of	   the	   IL-­‐2	  receptor	  α	  subunit,	  CD25,	  is	  upregulated	  following	  TCR	  activation	  (Fu	  et	  al.,	  2013)	  and	  is	  maintained	  by	  IL-­‐2	  signalling	  post	  activation	  (Kim	  et	  al.,	  2001;	  Nakajima	  et	  al.,	  1997).	  Following	  overnight	  treatment	  with	  100nM	  tofacitinib,	  100nM	  GSK186	  and	   2μM	   GSK192,	   cell	   surface	   expression	   of	   CD25	   was	   reduced,	   indicating	   a	  reduction	  in	  STAT5	  transcriptional	  activity	  (figure	  3.6B).	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Figure	   3.5:	   STAT5	   phosphorylation	  
following	   treatment	   with	   tofacitinib,	  
GSK186	   and	   GSK192	   Western	   blots	  showing	   the	   phosphorylation	   of	   STAT5	   in	  P14	  CTL	  treated	  for	  one	  hour	  with	  different	  concentrations	   of	   tofacitinib	   (A),	   GSK186	  
(B)	   or	   GSK192	   (C).	   The	   highest	  concentration	   (far	   right	   on	   each	   blot)	   used	  for	  each	  inhibitor	  was	  3μM,	  and	  one	  in	  three	  dilutions	   of	   each	   inhibitor	   were	   used.	   N=1,	  one	   independent	   experiment.	   Molecular	  weights	   of	   blotted	   proteins	   (kDa)	   indicated	  on	  left	  of	  blots.	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Figure	  3.6:	  Effect	  of	  GSK192	  on	  IL-­‐2	  signalling	  A.	  Western	  blot	  showing	  the	  phosphorylation	  of	  STAT5	   at	   the	   Y694	   site	   and	   the	   abundance	   of	   PIM1	   kinase	   following	   18	   hours	   treatment	   of	   IL-­‐2	  maintained	  P14	  CTL	  with	  DMSO,	  100nM	  tofacitinib,	  100nM	  GSK186	  or	  1μM	  GSK192.	  B.	  Cell	  surface	  expression	   of	   CD25	   in	   IL-­‐2	   maintained	   CTL	   treated	   overnight	   with	   100nM	   tofacitinib,	   100nM	  GSK186	  or	  2μM	  GSK192.	  Gated	  on	  live	  (DAPI	  negative),	  single	  CD8+	  cells.	  N=3,	  three	  independent	  experiments.	  Molecular	  weights	  of	  blotted	  proteins	  (kDa)	  indicated	  on	  left	  of	  blots.	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After	  48	  hours	   treatment	  with	   the	   JAK	  kinase	   inhibitors,	   the	  sizes	  of	  CTL	  treated	  with	  doses	  of	  tofacitinib	  and	  GSK186	  ≥333nM	  were	  similar,	  and	  comparable	  to	  CTL	  that	   had	   been	   deprived	   of	   IL-­‐2	   for	   48	   hours.	   There	  was	   a	   clear	   dose	   dependent	  effect	   on	   CTL	   size	   following	   48	   hours	   treatment	   with	   GSK192.	   The	   size	   of	   CTL	  treated	  with	  10μM	  GSK192	  was	  reduced	  compared	  to	  CTL	  maintained	  in	  IL-­‐2	  only,	  but	  still	  larger	  than	  IL-­‐2	  deprived	  cells	  (figure	  3.7B,	  figure	  3.8).	  	  	  	  
	  
Figure	   3.7:	   	   Effect	   of	   tofacitinib,	   GSK186	   and	   GSK192	   on	   CTL	   size	   P14	   CTL	  were	   plated	   at	  0.3x106	  cells/mL	  in	  the	  presence	  or	  absence	  of	  various	  doses	  of	  tofacitinib,	  GSK186	  or	  GSK192	  and	  analysed	  using	  flow	  cytometry	  after	  24	  hours	  (A)	  and	  48	  hours	  (B).	  Forward	  scatter	  was	  used	  as	  an	  indicator	  of	  cell	  size;	  for	  each	  sample	  the	  geometric	  mean	  of	  the	  forward	  scatter	  was	  used.	  Gated	  on	  live	   single	   cells.	   Graphs	   represent	   the	   arithmetic	   mean	   of	   values	   from	   three	   cultures	   (n=3)	   and	  error	  bars	  represent	  the	  standard	  deviation.	  On	  graphs,	  lines	  labelled	  IL-­‐2	  and	  no	  IL-­‐2	  indicate	  the	  mean	   FSC	   of	   IL-­‐2	   maintained	   and	   IL-­‐2	   deprived	   CTL	   at	   the	   indicated	   timepoints.	   N=3,	   three	  	  independent	  experiments.	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Figure	   3.8:	   Treatment	   with	   JAK	   kinase	   inhibitors	   reduces	   CTL	   size	   P14	  CTL	  were	  plated	   at	  0.3x106	  cells/mL	  in	  the	  presence	  or	  absence	  of	  various	  doses	  of	  tofacitinib,	  GSK186	  or	  GSK192	  and	  analysed	   using	   flow	   cytometry.	   Histograms	   show	   FSC/SSC	   after	   48	   hours	   treatment.	   Forward	  scatter	  was	  used	  as	  an	  indicator	  of	  cell	  size.	  N=3,	  three	  independent	  experiments.	  	  









































































































































































































































	   117	  
3.2.5	  Tofacitinib,	  GSK186	  and	  GSK192	  reduce	  CTL	  proliferation	  in	  response	  
to	  IL-­‐2	  IL-­‐2	   signalling	   also	   supports	   CTL	   proliferation	   (Cornish	   et	   al.,	   2006).	   As	   100nM	  tofacitinib	   effectively	   blocked	   IL-­‐2	   signalling,	   the	   effect	   of	   tofacitinib	   on	   CTL	  proliferation	   was	   measured	   at	   100nM	   and	   1μM.	   When	   IL-­‐2	   is	   present,	   CTL	  proliferate	   over	   48	   hours,	   and	   proliferation	   is	   not	   affected	   in	   the	   DMSO	   solvent	  control.	   CTL	  deprived	  of	   IL-­‐2	  do	  not	   increase	   in	   cell	  number	  over	  48	  hours.	  CTL	  treated	  with	  100nM	  tofacitinib	  show	  reduced	  proliferation	  compared	  to	  untreated	  CTL	  maintained	  in	  IL-­‐2,	  whereas	  1μM	  tofacitinib	  reduced	  proliferation	  to	  an	  extent	  similar	  to	  IL-­‐2	  deprived	  CTL	  (figure	  3.9).	  
	  
Figure	  3.9:	   	   Effect	  of	   tofacitinib	  on	  proliferation	  of	   IL-­‐2	  maintained	  CTL	  The	  proliferation	  of	  P14	  CTL	  maintained	  in	  IL-­‐2,	  maintained	  in	  IL-­‐2	  and	  treated	  with	  DMSO	  or	  tofacitinib,	  or	  deprived	  of	  IL-­‐2	   was	   assessed	   using	   cell	   counts	   obtained	   using	   flow	   cytometry.	   N=2,	   two	   independent	  experiments.	  	  To	   determine	   the	   effect	   of	   GSK186	   and	   GSK192	   inhibitors	   on	   CTL	   proliferation,	  survival	  and	  growth,	  CTL	  that	  had	  been	  cultured	  in	  the	  presence	  of	  IL-­‐2	  for	  3	  days	  after	  TCR	  activation	  were	  treated	  with	  a	  threefold	  serial	  dilution	  of	  the	  JAK	  kinase	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inhibitors	  tofacitinib,	  GSK186	  and	  GSK192,	  with	  10μM	  used	  as	  the	  maximum	  dose.	  The	   change	   in	   live	   cell	   number,	   cell	   size,	   and	   the	   number	   of	   dead	   cells	   in	   each	  culture	  was	  determined	  using	  flow	  cytometry,	  using	  exclusion	  of	  the	  DNA-­‐binding	  dye	  DAPI	  to	  define	  live	  cells	  and	  forward	  scatter	  as	  an	  indicator	  of	  cell	  size.	  	  After	  24	  hours	  of	  treatment	  with	  <1μM	  of	  the	  JAK	  kinase	  inhibitors	  the	  number	  of	  treated	   CTL	   was	   comparable	   to	   that	   seen	   in	   control	   IL-­‐2	   maintained	   CTL.	  Treatment	   with	   ≥1μM	   tofacitinib	   and	   GSK186	   resulted	   in	   reduced	   cell	   numbers	  compared	  to	  control	   IL-­‐2	  maintained	  CTL	  and	  was	  closer	  to	  that	  seen	   in	  24	  hour	  IL-­‐2-­‐deprived	   CTL.	   Treatment	   with	   >1μM	   GSK192	   also	   reduced	   cell	   number	  compared	  to	  IL-­‐2	  maintained	  CTL,	  but	  the	  cell	  number	  was	  higher	  than	  tofacitinib	  or	  GSK186	  treated	  CTL	  (figure	  3.10A).	  	  	  A	  much	  clearer	  dose	  dependent	  effect	  of	  the	  JAK	  kinases	  on	  proliferation	  emerged	  only	  after	  48	  hours	  of	  treatment.	  Doses	  ≥1μM	  of	  tofacitinib	  and	  GSK186	  resulted	  in	  a	  reduction	  in	  cell	  number	  comparable	  to	  IL-­‐2	  deprivation,	  whereas	   	  doses	  <1μM	  resulted	  in	  a	  clear	  dose	  dependent	  reduction	  of	  cell	  number	  in	  response	  to	  IL-­‐2.	  At	  the	   lowest	   dose	   of	   tofacitinib	   and	  GSK186	  used,	   cell	   number	  was	   similar	   to	   that	  seen	  in	  CTL	  maintained	  in	  IL-­‐2	  only.	  Consistent	  with	  the	  greater	  concentration	  of	  GSK192	   required	   for	   inhibition	   of	   STAT5	   phosphorylation,	   a	   dose	   dependent	  reduction	   in	   proliferation	   in	   response	   to	   IL-­‐2	   was	   only	   seen	   in	   concentrations	  >333nM,	   a	   higher	   concentration	   than	   required	   to	   see	   an	   effect	   of	   tofacitinib	   or	  GSK186.	   However,	   the	   maximum	   dose	   of	   GSK192	   used,	   10μM,	   resulted	   in	   a	  reduction	   in	   cell	   number	   in	   response	   to	   IL-­‐2	   comparable	   to	   that	   seen	  with	   IL-­‐2	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deprivation	   (figure	   3.10B).	   This	   suggests	   that	   tofacitinib	   and	   GSK186	   potently	  inhibited	  IL-­‐2	  induced	  proliferation,	  while	  GSK192	  was	  less	  effective.	  
	  
Figure	  3.10:	  Effect	  of	  GSK186	  and	  GSK192	  on	   the	  proliferation	  of	   IL-­‐2	  maintained	  CTL	  P14	  CTL	  were	  plated	  at	  0.3x106	  cells/mL	  in	  the	  presence	  or	  absence	  of	  three-­‐fold	  dilutions	  of	  tofacitinib,	  GSK186	  and	  GSK192	  (maximum	  dose	  used:	  10μM).	  The	  number	  of	  live	  cells	  in	  each	  condition	  was	  counted	   at	   24	   hours	   (A)	   and	   48	   hours	   (B).	   IL-­‐2	   was	   present	   in	   all	   cultures	   except	   for	   IL-­‐2	  deprivation	   conditions.	   Live	   cells	   defined	   as	   DAPI	   excluding	   cells	   falling	   FSC/SSC	   gate.	   Circles	  represent	  the	  mean	  and	  error	  bars	  the	  standard	  deviation,	  n=3,	  three	  independent	  experiments.	  	  
3.2.6	  Tofacitinib,	  GSK186	  and	  GSK192	  reduce	  the	  survival	  of	  IL-­‐2	  maintained	  
CTL	  To	  determine	  if	  the	  JAK	  kinase	  inhibitors	  affected	  CTL	  survival,	  the	  percentage	  of	  DAPI+	  cells	  in	  IL-­‐2	  maintained,	  IL-­‐2	  deprived	  and	  JAK	  kinase	  inhibitor	  treated	  CTL	  cultures	  was	  compared.	  In	  cultures	  maintained	  in	  IL-­‐2	  alone	  less	  than	  10%	  of	  CTL	  were	  DAPI+.	  After	  24	  hours,	  approximately	  20%	  of	  IL-­‐2	  deprived	  CTL	  were	  DAPI+.	  Doses	  of	  tofacitinib	  and	  GSK186	  ≥1μM	  increased	  CTL	  death	  to	  a	  level	  comparable	  with	   IL-­‐2	  deprivation,	   but	   this	  was	  quite	   variable;	  while	   even	  10μM	  GSK192	  did	  not	  result	  in	  a	  large	  increase	  in	  CTL	  death	  (figure	  3.11A).	  	  	  There	   was	   a	   much	   clearer	   dose	   dependent	   effect	   of	   tofacitinib,	   GSK186	   and	  GSK192	   treatment	  on	  CTL	  death	  after	  48	  hours.	  After	  48	  hours	   IL-­‐2	  deprivation,	  approximately	   55%	   of	   CTL	   were	   DAPI+,	   suggesting	   widespread	   cell	   death	   after	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long-­‐term	   loss	   of	   IL-­‐2	   signalling.	   At	   this	   timepoint,	   tofacitinib	   and	   GSK186	   had	  similar	   effects	   on	   CTL	   death,	   although	   the	   percentage	   of	   dead	   CTL	   in	   tofacitinib	  treated	   cultures	   was	   slightly	   higher.	   At	   doses	   ≥	   1μM,	   tofacitinib	   and	   GSK186	  increased	  CTL	  cell	  death	  comparable	  to	  that	  seen	  in	  IL-­‐2	  deprived	  CTL.	  In	  GSK192	  treated	  CTL,	  no	  increase	  in	  CTL	  death	  (compared	  to	  CTL	  maintained	  in	  IL-­‐2	  only)	  was	   seen	  until	  dose	  exceeded	  3.33μM.	  This	   suggests	   that	   tofacitinib	  and	  GSK186	  potently	   inhibit	   CTL	   survival,	   while	   GSK192	   can	   inhibit	   CTL	   survival	   but	   is	   less	  potent	  (figure	  3.11B).	  
	  
Figure	  3.11:	   Effect	   of	  GSK186	  and	  GSK192	  on	   the	   survival	   of	   IL-­‐2	  maintained	  CTL	  P14	  CTL	  were	   plated	   at	   0.3x106	   cells/mL	   in	   the	   presence	   or	   absence	   of	   three-­‐fold	   dilutions	   of	   tofacitinib,	  GSK186	  and	  GSK192	  (maximum	  dose	  used:	  10μM).	  The	  percentage	  of	  dead	  cells	  in	  each	  condition	  was	   counted	   at	   24	   hours	   (A)	   and	   48	   hours	   (B).	   IL-­‐2	  was	   present	   in	   all	   cultures	   except	   for	   IL-­‐2	  deprivation	   conditions.	  Dead	   cells	   defined	   as	  DAPI	  positive	   cells.	   Circles	   represent	   the	  mean	  and	  error	  bars	  the	  standard	  deviation,	  n=3,	  three	  independent	  experiments.	  	  The	   reduction	   in	   proliferation,	   CTL	   survival	   and	   cell	   size,	   as	   well	   as	   the	   loss	   of	  STAT5	   phosphoryation,	   suggested	   that	   tofacitinib	   and	   GSK186	   (and	   to	   a	   lesser	  extent	   GSK192)	   inhibited	   IL-­‐2	   signalling.	   The	   data	   suggest	   that	   the	   JAK	   kinase	  inhibitors	  affect	  IL-­‐2	  signalling,	  but	  do	  not	  show	  that	  they	  are	  inhibitors	  selective,	  either	  for	  the	  JAK	  kinase	  family	  or	  within	  the	  JAK	  kinase	  family.	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3.2.7	  JAK	  kinase	  inhibitors	  do	  not	  prevent	  T	  cell	  activation	  	  To	  determine	  if	  the	  JAK	  kinase	  inhibitors	  altered	  the	  ability	  of	  T	  cells	  to	  respond	  to	  TCR	   stimulation,	   splenocytes	   from	   TCR	   transgenic	   P14	   mice	   were	   either	  maintained	  with	  IL-­‐7	  as	  naïve	  cells,	  activated	  with	  the	  cognate	  peptide	  gp33-­‐41	  or	  activated	   with	   gp33-­‐41	   in	   the	   presence	   of	   tofacitinib,	   GSK186	   or	   GSK192.	   The	  upregulation	  of	  the	  activation	  markers	  CD25,	  CD69,	  CD71	  and	  CD44	  was	  measured	  using	  flow	  cytometry.	  	  	  Cell	  surface	  expression	  of	  the	  activation	  markers	  CD25,	  CD69,	  CD71	  and	  CD44	  was	  low	   in	   naïve	   cells	   and	   was	   upregulated	   after	   24	   hours	   TCR	   stimulation.	  Upregulation	  of	  these	  markers	  was	  not	  markedly	  affected	  in	  cells	  activated	  in	  the	  presence	  of	  the	  JAK	  kinase	  inhibitors	  (figure	  3.12).	  After	  48	  hours	  TCR	  stimulation,	  cells	  activated	  in	  the	  presence	  of	  the	  JAK	  kinase	  inhibitors	  had	  reduced	  CD25	  cell	  surface	  expression	  compared	  to	  TCR	  activated	  cells,	  but	  the	  cell	  surface	  expression	  of	  CD69,	  CD71	  and	  CD44	  were	  not	  significantly	  affected	  (figure	  3.13).	  The	  size	  of	  cells	   activated	   in	   the	   presence	   of	   JAK	   kinase	   inhibitors	   was	   not	   significantly	  different	   from	   cells	   activated	   with	   peptide	   alone	   at	   either	   the	   24	   or	   48	   hour	  timepoints,	  suggesting	  that	  the	  presence	  of	  JAK	  kinase	  inhibitors	  during	  activation	  did	  not	  affect	  the	  ability	  of	  CD8+	  T	  cells	  to	  increase	  their	  cell	  mass	  in	  response	  to	  TCR	  stimulation.	  The	  reduction	  in	  CD25	  in	  inhibitor	  treated	  cells	  may	  be	  a	  result	  of	  the	  changing	  regulation	  of	  CD25	  during	  T	  cell	  activation:	  the	  initial	  upregulation	  is	  TCR	  dependent	  while	  in	  the	  later	  stages	  IL-­‐2	  produced	  following	  T	  cell	  activation	  begins	  to	  regulate	  CD25	  levels.	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Figure	  3.12:	  CD25,	  CD69,	  CD71	  and	  CD44	  upregulation	  after	  24	  hours	  TCR	  stimulation	  in	  the	  
presence	  of	  JAK	  kinase	  inhibitors	  Splenocytes	  from	  TCR	  transgenic	  P14	  mice	  were	  activated	  with	  100ng/mL	   of	   the	   cognate	   peptide	   gp33-­‐41.	   Naïve	   splenocytes	   were	   cultured	   in	   the	   presence	   of	  5ng/mL	   IL-­‐7.	  Cell	   size	  and	  cell	   surface	  expression	  of	  CD25,	  CD69,	  CD71	  and	  CD44	  after	  24	  hours	  TCR	  activation	   in	   the	  presence	  of	  100nM	   tofacitinib,	   100nM	  GSK186	  or	  2μM	  GSK192.	  N=3,	   three	  independent	  experiments.	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Figure	  3.13:	  CD25,	  CD69,	  CD71	  and	  CD44	  upregulation	  after	  48	  hours	  TCR	  stimulation	  in	  the	  
presence	  of	  JAK	  kinase	  inhibitors	  Splenocytes	  from	  TCR	  transgenic	  P14	  mice	  were	  activated	  with	  100ng/mL	   of	   the	   cognate	   peptide	   gp33-­‐41.	   Naïve	   splenocytes	   were	   cultured	   in	   the	   presence	   of	  5ng/mL	  IL-­‐7.	  FACS	  plots	  (A)	  show	  cell	  size	  and	  cell	  surface	  expression	  of	  CD25	  after	  48	  hours	  TCR	  activation	  in	  the	  presence	  of	  100nM	  tofacitinib,	  100nM	  GSK186	  or	  2μM	  GSK192.	  Graphs	  show	  the	  geometric	  mean	  of	  FSC	  (B),	  CD25	  (C),	  CD69	  (D),	  CD71	  (E)	  CD44	  (F)	  in	  JAK	  kinase	  inhibitor	  treated	  cells	   relative	   to	   TCR	   only.	   In	   all	   graphs,	   bars	   represent	   the	   mean	   and	   error	   bars	   the	   standard	  deviation.	   Differences	   analysed	   with	   one-­‐way	   ANOVA	   with	   Dunnet’s	   post	   hoc	   test.	   Asterisks	  indicate	  significant	  difference	   from	  TCR	  only.	  Significance:	   *:P	  ≤	  0.05,	   **:	  P	  ≤	  0.01,	   ***:	  P	  ≤	  0.001,	  ****:	  P	  ≤	  0.0001.	  N=3,	  3	  independent	  experiments.	  	  
3.7.8	  Effect	  of	  tofacitinib,	  GSK186	  and	  GSK192	  on	  IL-­‐12	  signalling	  As	  mentioned	  previously,	  achieving	  selectivity	  of	  a	  JAK	  kinase	  inhibitor	  within	  the	  JAK	  kinase	   family	   is	   far	  more	  difficult	   than	  producing	  a	   JAK	  kinase	   inhibitor	   that	  does	  not	  show	  high	  selectivity	   for	  other	  kinase	   families.	  One	  way	  to	  determine	   if	  tofacitinib,	   GSK186	   and	   GSK192	   are	   inhibiting	   specific	   JAKs	   is	   to	   compare	   how	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effectively	  the	  inhibitors	  inhibit	  signalling	  through	  cytokines	  that	  use	  different	  JAK	  kinases.	  To	  this	  end,	  their	  ability	  to	  inhibit	  IL-­‐2	  and	  IL-­‐12	  dependent	  signalling	  in	  CTL	  was	  compared.	  While	  the	  IL-­‐2	  receptor	  associates	  with	  JAK1	  and	  JAK3,	  the	  IL-­‐12	  receptor	  has	  been	  reported	  to	  associate	  with	  Tyk2	  and	  JAK2	  (Bacon	  et	  al.,	  1995,	  figure	  3.14).	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CTL	  and	  was	  further	  increased	  by	  combined	  IL-­‐2	  and	  IL-­‐12	  signalling.	  The	  increase	  was,	  however,	  far	  lower	  than	  that	  seen	  in	  the	  induction	  of	  IFNγ	  (figure	  3.16B).	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Figure	  3.17:	  Effect	  of	  JAK	  kinase	  inhibitors	  on	  IFNγ	  expression	  in	  IL-­‐2	  and	  IL-­‐12	  stimulated	  
CTL	  Graphs	  show	  IFNγ	  expression	  in	  P14	  CTL	  maintained	  in	  IL-­‐2	  (A),	  then	  switched	  into	  IL-­‐12	  for	  18	   hours	   (B)	   or	   maintained	   in	   IL-­‐2	   and	   stimulated	   with	   IL-­‐12	   for	   18	   hours	   (C).	   N=2,	   two	  independent	  experiments.	  PCR	  data	  normalised	  to	  HPRT	  and	  expressed	  relative	  to	  IL-­‐2-­‐maintained	  CTL.	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Figure	  3.18:	  Effect	  of	   tofacitinib,	  GSK186	  and	  GSK192	  on	  IL-­‐2	  and	  IL-­‐12	  regulation	  of	  CD25	  
expression	  Graphs	  show	  CD25	  expression	  in	  P14	  CTL	  maintained	  in	  IL-­‐2	  (A),	  switched	  into	  IL-­‐12	  for	   18	   hours	   (B)	   or	   maintained	   in	   IL-­‐2	   and	   stimulated	   with	   IL-­‐12	   for	   18	   hours	   (C)	   following	  treatment	  with	  100nM	  tofacitinib,	  100nM	  GSK186	  or	  2μM	  GSK192	  for	  18	  hours,	  as	  determined	  by	  RT-­‐PCR.	  N=2,	  two	  independent	  experiments.	  PCR	  data	  normalised	  to	  HPRT	  and	  expressed	  relative	  to	  IL-­‐2	  maintained	  CTL.	  	  
3.2.8	   GSK186	   and	   GSK192	   inhibit	   multiple	   IL-­‐2	   dependent	   signalling	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site	   and	   its	   substrate,	   the	   ribosomal	  protein	   S6	   at	   S240/244	   (figure	  3.19B).	  Myc	  protein	  was	  lost	  following	  withdrawal	  of	  IL-­‐2	  from	  IL-­‐2	  maintained	  CTL,	  and	  was	  reduced	   by	   treatment	   of	   IL-­‐2	   maintained	   CTL	   with	   tofacitinib,	   GSK186	   and	  GSK192.	   Treatment	   with	   GSK192	   was	   less	   effective	   at	   reducing	   c-­‐myc	   protein	  compared	  to	  tofacitinib	  and	  GSK186	  (figure	  3.19C).	  
	  	  
Figure	   3.19:	   Effect	   of	   GSK186	   and	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3.3	  Discussion	  These	  results	  demonstrate	  that	  tofacitinib	  and	  GSK186	  act	  as	  potent	  inhibitors	  of	  IL-­‐2	   signalling.	   Tofacitinib	   and	   GSK186	   inhibited	   IL-­‐2	   induced	   STAT5	  phosphorylation	   and	   other	   IL-­‐2-­‐induced	   signalling	   pathways	   including	   the	  mTORC1	   and	   MAPK	   signalling	   pathways.	   They	   also	   inhibited	   the	   proliferation,	  survival	   and	   maintenance	   of	   cell	   size	   by	   CTL	   in	   response	   to	   IL-­‐2.	   The	   dose	  response	   curves	   for	   the	  proliferative	  and	   survival	   responses	  of	  CTL	   treated	  with	  tofacitinib	  and	  GSK186	  were	  very	  similar,	  with	  similar	  doses	  of	  the	  two	  inhibitors	  producing	  almost	  equivalent	  responses.	  	  	  Tofacitinib	   has	   been	   reported	   to	   inhibit	   JAK1	   and	   JAK3	   with	   similar	   potency	   in	  kinase	   assays,	   and	   experiments	   examining	   the	   phosphorylation	   of	   STAT1	   and	  STAT3	   in	   response	   to	   IL-­‐6	   in	   CD4+	   cells	   (Ghoreschi	   et	   al.,	   2011)	   suggest	   that	  tofacitinib	  inhibits	  JAK1	  to	  some	  extent	  in	  intact	  cells.	  The	  IL-­‐6	  receptor	  uses	  JAK1	  and	  JAK2,	  but	  the	  selectivity	  of	  tofacitinib	  in	  kinase	  assays	  for	  JAK1	  is	  higher	  than	  for	   JAK2.	   This	   suggests	   tofacitinib	   is	   likely	   to	   be	   acting	   as	   a	   pan	   JAK1/JAK3	  inhibitor.	  If	  the	  dose	  that	  GSK186	  was	  used	  at	  in	  the	  experiments	  described	  in	  this	  chapter	  was	   selective	   for	   JAK1	   over	   JAK3,	   that	   a	   JAK1	   selective	   inhibitor	   shows	  equivalent	   effectiveness	  with	  what	   is	   essentially	   a	   JAK1/JAK3	   inhibitor	   suggests	  that	  inhibition	  of	  JAK1	  alone	  is	  sufficient	  to	  inhibit	  signalling	  through	  γc	  cytokines.	  It	   is	   difficult	   to	   prove	   conclusively	   that	   the	   dose	   of	   GSK186	   used	   is	   selective	   for	  JAK1	  over	   JAK3,	   as	   JAK3	   is	   not	   found	   in	   any	   cytokine	   receptors	   except	   as	   a	   pair	  with	  JAK1.	  However,	   the	  kinase	  assays	  performed	  by	  GSK,	  who	  provided	  GSK186	  and	  GSK192,	  suggest	  that	  GSK186	  is	  JAK1	  selective.	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The	   JAK3	   selective	   inhibitor	   GSK192	   also	   inhibited	   the	   pathways	   and	   the	  proliferation,	  survival	  and	  maintenance	  of	  cell	  size	   in	  response	  to	  IL-­‐2,	   indicating	  that	  treatment	  with	  GSK192	  inhibited	  signalling	  downstream	  of	  the	  IL-­‐2	  receptor.	  However,	   in	   each	   assay	   the	   dose	   of	   the	   JAK3	   inhibitor	   required	   to	   produce	   the	  responses	  was	  much	  higher	  than	  that	  required	  to	  produce	  an	  equivalent	  response	  with	  tofacitinib	  and	  GSK186,	  despite	  the	  equivalent	  IC50	  of	  tofacitinib	  and	  GSK192	  for	  JAK3	  in	  an	  in	  vitro	  kinase	  assay	  (table	  3.1).	  	  
	  There	   are	   several	   possible	   interpretations	   of	   the	   apparent	   lack	   of	   efficacy	   of	  GSK192	  at	   inhibiting	   IL-­‐2	  signalling	  compared	   to	   tofacitinib	  and	  GSK186.	   	  One	   is	  that	  inhibition	  of	  JAK3	  is	  ultimately	  insufficient	  to	  inhibit	  signalling	  through	  the	  γc	  cytokine	  receptors,	  and	  that	  as	   long	  as	   JAK1	  kinase	  activity	   is	   intact	  downstream	  signalling	  events	   can	  be	   initiated	   in	   response	   to	   ligand	  binding.	  A	   similar	   lack	  of	  efficacy	   of	   a	   specific	   JAK3	   inhibitor	   in	   inhibiting	   IL-­‐2	   dependent	   signalling	   was	  reported	  previously	  by	  Haan	  et	  al.	   (2011).	   In	  addition	  to	  the	  poor	  potency	  of	   the	  JAK3	  inhibitor,	  expression	  of	  kinase	  dead	  JAK3	  in	  a	  cell	  line	  reduced	  IL-­‐2	  induced	  STAT5	  phosphorylation	   to	  some	  extent,	  whereas	  expression	  of	  kinase	  dead	   JAK1	  abolished	  STAT5	  phosphorylation	  (Haan	  et	  al.,	  2011).	  This	  was	  interpreted	  by	  the	  authors	   as	   indicating	   that	   the	   kinase	   activity	   of	   JAK1	   in	   the	   JAK1/JAK3	  pair	  was	  vital	  for	  signalling,	  whereas	  the	  kinase	  activity	  of	  JAK3	  was	  largely	  dispensable	  and	  signalling	  could	  proceed	  when	  JAK3	  was	  inhibited.	  	  	  According	   to	   this	   interpretation,	   the	   inhibition	   of	   IL-­‐2	   signalling-­‐dependent	  functions	  such	  as	  CTL	  proliferation	  seen	  at	  higher	  doses	  of	  GSK192	  (figure	  3.2A)	  may	   be	   the	   result	   of	   loss	   of	   specificity	   at	   this	   dose.	   The	   inhibitor	   may	   begin	   to	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inhibit	   JAK1	   in	   addition	   to	   JAK3;	   loss	   of	   JAK3	   kinase	   activity	   alone	   should	   not	  completely	   inhibit	   IL-­‐2	   signalling.	   The	   specificity	   of	   GSK192	   at	   the	   higher	   doses	  could	   be	   clarified	   using	   the	   methods	   of	   Ghoreschi	   et	   al.	   (2011)	   as	   used	   to	  determine	  if	   tofacitinib	   inhibited	  JAK1	   in	  vitro.	  They	  stimulated	  CD4+	  T	  cells	  with	  IL-­‐6	  in	  the	  presence	  and	  absence	  of	  tofacitinib	  and	  monitored	  phosphorylation	  of	  STAT1	   and	   STAT3	   (Ghoreschi	   et	   al.,	   2011).	   As	   the	   IL-­‐6	   receptor	   uses	   JAK1	   and	  JAK2,	  loss	  of	  phosphorylation	  would	  indicate	  inhibition	  of	  either	  JAK1	  or	  JAK2,	  and	  the	  lack	  of	  GSK192	  inhibition	  of	  IL-­‐12	  dependent	  signalling	  suggests	  that	  it	  is	  not	  inhibiting	  JAK2	  at	  the	  doses	  used	  (figure	  3.17,	  figure	  3.18).	  	  ATP	  competitive	  JAK3	  inhibitors	  seem	  to	  inhibit	  γc	  signalling	  inefficiently,	  but	  JAK3	  inhibitors	   with	   alternative	   modes	   of	   action	   have	   been	   reported	   to	   be	   more	  effective.	  The	   lack	  of	  potency	  of	  GSK192	  may	   therefore	  be	  related	   to	   its	  mode	  of	  action.	  One	  model	  of	  JAK1/JAK3	  activation	  in	  IL-­‐2	  signalling	  suggested	  by	  Smith	  et	  al.	  (2016)	  and	  discussed	  in	  the	  introduction	  is	  that	  an	  initial	  wave	  of	  signalling	  on	  IL-­‐2	  ligation	  to	  the	  IL-­‐2	  receptor	  is	  driven	  predominantly	  by	  JAK1,	  with	  inhibition	  of	   JAK3	  at	   this	   stage	  having	   little	  effect	  on	  downstream	  signalling	  events.	  A	   later	  wave	  of	   signalling	  requires	   the	  kinase	  activity	  of	   JAK3.	   	  Requirement	   for	   JAK3	   in	  the	   second	   wave	   was	   suggested	   because	   IL-­‐2-­‐induced	   SOCS	   expression	   inhibits	  JAK1	  activity.	  The	   formulation	  of	   this	  model	  was	  prompted	   following	  testing	  of	  a	  JAK3	  inhibitor	  that	  forms	  a	  covalent	  bond	  with	  a	  cysteine	  residue	  present	  in	  JAK3	  but	   absent	   in	   other	   JAK	   kinases.	   This	   inhibitor	   (JAK3i)	   inhibited	   IL-­‐2	   signalling	  events	  two	  hours	  after	  treatment,	  including	  STAT5	  phosphorylation,	  less	  potently	  than	   tofacitinib,	   but	   inhibited	   IL-­‐2-­‐induced	   proliferation	   more	   potently	   than	  tofacitnib	  (Smith	  et	  al.,	  2016).	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According	   to	   this	  model,	   a	   JAK3	   inhibitor	  would	  not	   be	   expected	   to	   inhibit	   IL-­‐2-­‐dependent	   signalling	   pathways	   efficiently	   at	   early	   timepoints,	   but	   would	   show	  improved	  potency	  at	  later	  timepoints.	  This	  model	  does	  not	  seem	  to	  explain	  the	  lack	  of	   potency	   of	   GSK192	   compared	   to	   tofacitinib	   and	   GSK186,	   however.	   GSK192	  showed	   reduced	  potency	   compared	   to	   tofacitinib	   even	  on	  proliferation	  assays	   in	  which	   this	   model	   suggests	   a	   JAK3	   inhibitor	   should	   perform	   well.	   As	   the	   JAK3	  inhibitor	  used	  by	  Smith	  et	  al.	  (2016)	  was	  a	  covalent	  inhibitor	  of	  JAK3	  rather	  than	  an	  ATP	  competitor	  such	  as	  GSK192,	  it	  may	  be	  that	  inhibition	  of	  the	  second	  wave	  is	  dependent	  on	  the	  mode	  of	  action	  of	  the	  JAK3	  inhibitor.	  	  	  However,	   if	   this	   second	  wave	  of	   JAK3	  dependent	   IL-­‐2	   signalling	   is	  dependent	  on	  SOCS-­‐mediated	  inhibition	  of	  JAK1	  kinase	  activity,	  this	  might	  suggest	  that	  the	  JAK1	  inhibitor	  GSK186	  should	  demonstrate	  initial	  efficacy	  but	  a	  loss	  of	  inhibition	  of	  IL-­‐2	  signalling	  at	  later	  timepoints.	  This	  was	  not	  the	  case	  however,	  as	  GSK186	  inhibited	  IL-­‐2	  signalling	  (figure	  3.19)	  and	  proliferation	  (figure	  3.10)	  over	  prolonged	  periods.	  The	  expression	  of	  SOCS1	  and	  SOCS3	  is	  induced	  by	  cytokine	  signalling	  and	  SOCS-­‐3	  binds	   to	   tyrosine	   phosphorylated	   JAK1	   (Cohney	   et	   al.,	   1999;	   Yoshimura	   et	   al.,	  2007).	   Inhibition	   of	   JAK1	   may	   therefore	   reduce	   the	   abundance	   of	   SOCS1	   and	  SOCS3	  or	  reduce	  their	  association	  with	  JAK1.	  This	  would	  suggest	  that	  lack	  of	  JAK1	  kinase	  activity	   is	  not,	   in	   itself,	   sufficient	   for	  signalling	   through	   JAK3,	  and	  that	   the	  presence	  of	  the	  SOCS	  proteins	  is	  required.	  	  	  Inhibition	   of	   JAK	   kinase	   activity	   by	   SOCS1	   and	   SOCS3	   has	   been	   suggested	   to	   be	  non-­‐competitive,	  relying	  on	  altering	  the	  conformation	  of	   the	   JAK	  catalytic	  region,	  thereby	   increasing	   the	   distance	   between	   the	   phosphate	   donor	   and	   acceptor	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(Babon	   et	   al.,	   2012).	   SOCS	  proteins	   can	   also	   recruit	   other	   signalling	   components	  including	   components	   of	   the	   ubiquitination	   machinery	   (Babon	   et	   al.,	   2009;	  Kamizono,	  2001).	   It	   is	  possible	  that	   ‘activation’	  of	   JAK3	  may	  require	  one	  of	   these	  events	  rather	  than	  the	  lack	  of	  JAK1	  kinase	  activity.	  	  HIF	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   135	  
Chapter	  4:	  Phosphoproteomic	  analysis	  of	  tofacitinib	  treated	  CTL	  
4.1	  Introduction	  Tofacitinib	  effectively	   inhibited	   JAK	  kinase	  dependent	   IL-­‐2	  signalling	  (chapter	  3).	  To	   further	   explore	   the	   role	   of	   JAK	   kinases	   in	   IL-­‐2	   signalling	   by	   identifying	   JAK	  kinase	   dependent	   phosphorylation	   sites,	   the	   phosphoproteomes	   of	   IL-­‐2	  maintained	  CTL	  and	  IL-­‐2	  maintained	  CTL	  treated	  with	  tofacitinib	  were	  compared.	  The	  phosphoproteomes	  of	  IL-­‐2	  maintained	  CTL	  treated	  with	  tofacitinib	  discussed	  in	  this	  chapter	  have	  been	  published	  as	  part	  of	  a	  wider	  analysis	  of	  IL-­‐2	  signalling	  in	  CTL	  that	  includes	  the	  phosphoproteome	  of	  IL-­‐2	  deprived	  CTL	  restimulated	  with	  IL-­‐2	  and	  IL-­‐2	  maintained	  CTL	  treated	  with	  the	  SRC	  kinase	  inhibitor	  PP2	  (Ross	  et	  al.,	  2016).	   The	   total	   phosphoproteome	  was	   analysed	   rather	   than	   analysing	   samples	  specifically	   enriched	   for	   tyrosine	   phosphorylations,	   as	   the	   aim	   of	   these	  experiments	   was	   to	   identify	   changes	   in	   downstream	   signalling	   events	   beyond	  direct	   JAK	   kinase	   targets.	   Tyrosine	   phosphorylation	   events	   in	   response	   to	   IL-­‐2	  signalling	  have	  previously	  been	  analysed	  in	  human	  Kit225	  cells	  by	  (Osinalde	  et	  al.,	  2011).	  
4.2	  Results	  The	  phosphoproteome	  of	  IL-­‐2	  maintained	  CTL	  was	  analysed	  after	  30	  minutes	  and	  4	  hours	  tofacitinib	  treatment.	  Previous	  experiments	  had	  shown	  that,	  while	  the	  loss	  of	   some	   IL-­‐2	   dependent	   phosphorylations	   occurred	   by	   30	   minutes	   tofacitinib	  treatment,	   including	   loss	  of	   STAT5	   tyrosine	  phosphorylation	  and	   loss	  of	  ERK1/2	  phosphorylation	   at	   the	   activating	   sites,	   other	   IL-­‐2	   dependent	   phosphorylations	  were	  more	   stable.	   For	   example,	   substantial	   loss	   of	   phosphorylation	   of	   S6	   at	   the	  S235/236	  site	  was	  not	  seen	  until	  CTL	  had	  been	  treated	  with	  tofacitinib	  for	  4	  hours	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(figure	  3.2).	  As	  changes	  in	  the	  levels	  of	  some	  proteins	  had	  been	  observed	  to	  change	  within	  four	  hours	  of	  tofacitinib	  treatment	  (figure	  3.2),	  the	  proteome	  of	  CTL	  treated	  with	  tofacitinib	  for	  four	  hours	  was	  also	  analysed.	  	  	  While	  the	  loss	  of	  some	  proteins	  within	  30	  minutes	  of	  tofacitinib	  treatment	  cannot	  be	   ruled	   out,	   this	   is	   likely	   to	   be	  minimal.	   Data	   from	   the	   30	  minutes	   dataset	   has	  been	   analysed	  with	   the	   assumption	   that	   the	   total	   protein	   is	   not	   changing	   unless	  there	   was	   compelling	   reason	   to	   think	   otherwise:	   for	   example	   if	   multiple	  phosphorylation	  sites	  on	  a	  protein	  are	  identified	  and	  all	  identified	  phosphorylation	  sites	   are	   either	   increasing	   or	   decreasing	   to	   the	   same	   extent,	   suggesting	   that	   the	  total	  protein	  abundance	  was	  regulated	  rather	  than	  phosphorylation	  at	  those	  sites.	  Samples	   for	   30	   minutes	   and	   4	   hours	   treatment	   were	   obtained	   in	   separate	  experiments.	  The	  30	  minutes	  treatment	  phosphoproteomic	  samples	  were	  obtained	  in	   two	   independent	   experiments.	   Samples	   for	   the	   4	   hour	   tofacitinib	   treatment	  proteomic	   and	   phosphoprotomic	   samples	  were	   obtained	   in	   a	   single	   experiment.	  The	   30	   minutes	   and	   4	   hours	   samples	   therefore	   have	   not	   been	   treated	   as	   a	  timecourse	  and	  have	  been	  considered	  separately.	  	  To	  identify	  phosphorylation	  sites	  regulated	  by	  tofacitinib	  in	  IL-­‐2	  maintained	  CTL,	  splenocytes	  from	  P14	  mice	  were	  activated	  for	  2	  days	  with	  gp33-­‐41	  peptide.	  After	  activation,	   splenocytes	   from	   each	   replicate	   were	   cultured	   for	   five	   days	   in	   the	  presence	   of	   20ng/mL	   IL-­‐2	   in	   SILAC	   (stable	   isotope	   labelling	   by	   amino	   acids	   in	  culture)	  media.	  SILAC	  media	  was	  supplemented	  with	  either	  ‘light’	  or	  ‘heavy’	  lysine	  and	   arginine	   (K0	   R0	   or	   K8	   R10	   respectively).	   Heavy	   arginine	   and	   lysine	   are	  produced	   by	   labelling	  with	   the	   heavy	   carbon	   and	   nitrogen	   isotopes	   13C	   and	   15N	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(Navarro	  et	  al.,	  2011).	  As	  5	  cell	  doublings	  have	  been	  reported	  to	  be	  sufficient	   for	  full	   labelling	   of	   cells	   with	   heavy	   amino	   acids,	   and	   CTL	   are	   capable	   of	   multiple	  divisions	  per	  day	  (figure	  3.9),	  CTL	  cultured	  in	  SILAC	  media	  should	  be	  fully	  labelled	  before	  treatment	  (Ong	  &	  Mann,	  2007).	  	  	  SILAC	  was	   used	   for	   phosphoproteomics	   experiments	   to	   increase	   the	   accuracy	   of	  the	   relative	   quantification	   of	   phosphosites.	   The	   protocol	   for	   producing	  phosphoenriched	   peptides	   involves	   fractionation	   of	   peptides	   and	   the	  phosphoenrichment	   of	   fractions	   individually,	   which	   can	   introduce	   differences	  between	  samples.	  When	  SILAC	  labelled	  samples	  are	  used,	   labelled	  CTL	  are	  mixed	  immediately	   following	   treatment,	   so	   differences	   introduced	   from	   processing	   are	  minimized	   between	   the	   light	   and	   heavy	   samples	   for	   each	   biological	   replicate	  (Mann,	  2006).	  Throughout	  this	  chapter,	  the	  relative	  abundance	  of	  phosphorylation	  sites	   in	   tofacitinib	   treated	  CTL	  and	  control	  CTL	  maintained	   in	   IL-­‐2	  only	  has	  been	  reported	  as	  either	  the	  normalised	  ratio	  between	  the	  abundance	  of	   the	  heavy	  and	  light	  phosphopeptide	  in	  each	  sample,	  the	  mean	  of	  the	  normalised	  heavy	  and	  light	  ratio	  or	  the	  fold	  change	  in	  the	  relative	  abundance	  of	  the	  phosphorylation	  site	  (log2	  normalised	   heavy/light	   ratio)	   as	   indicated	   in	   the	   figures	   and	   associated	   figure	  legends.	  	  The	  phosphoproteomics	  data	   from	   four	  hours	   treatment	  with	   tofacitinib	  has	  not	  been	   normalised	   to	   the	   proteomics	   data,	   as	   the	   proteins	   identified	   within	   the	  phosphoproteomics	   dataset	   and	   the	   proteomics	   dataset	   were	   not	   identical.	   For	  example,	   c-­‐myc	   is	   identified	   in	   the	   phosphoproteomics	   data	   but	   not	   in	   the	  proteomics	  data,	   likely	  as	  c-­‐myc	  degrades	  rapidly	  following	  removal	  from	  culture	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while	  phosphorylated	  c-­‐myc	  is	  enriched	  during	  phosphoenrichment	  of	  samples.	  If	  an	   observed	   change	   in	   the	   phosphorylation	   of	   a	   protein	   can	   be	   satisfactorily	  explained	   by	   an	   observed	   change	   in	   the	   total	   protein,	   then	   it	   has	   been	   assumed	  that	  the	  change	  in	  phosphorylation	  reflects	  a	  change	  in	  protein	  abundance	  rather	  than	  regulation	  of	  the	  phosphorylation	  site.	  	  	  
4.2.1	  Regulation	  of	  the	  CTL	  phosphoproteome	  by	  tofacitinib	  Phosphorylation	  sites	  were	  considered	  to	  be	  upregulated	  if	  they	  had	  a	  normalised	  heavy/light	   ratio	   of	   ≥	   1.5	   and	   downregulated	   if	   they	   had	   a	   ratio	   ≤	   0.67,	   with	  regulation	   consistent	   across	   biological	   replicates,	   and	   significantly	   regulated	   if	  these	  sites	  had	  a	  p-­‐value	  of	  0.05	  or	   less	  following	  a	  one-­‐sample	  T-­‐test	  performed	  on	  the	  fold	  change.	  	  	  	  In	   total,	   8839	   phosphorylation	   sites	   on	   3086	   proteins	  were	   identified	   in	   the	   30	  minutes	  tofacitinib	  treatment	  experiment.	  Of	  these	  sites,	  5195	  sites	  were	  identified	  in	  two	  or	  more	  replicates.	  At	  this	  timepoint,	  tofacitinib	  treatment	  resulted	  in	  both	  upregulation	   and	   downregulation	   of	   a	   similar	   number	   of	   phosphorylation	   sites,	  with	   283	   downregulated	   sites	   and	   237	   upregulated	   sites.	   In	   total,	   tofacitinib	  caused	  significant	  downregulation	  of	  36	  phosphosites	  and	  significant	  upregulation	  of	   48	  phosphosites.	   This	   represents	   significant	   downregulation	  of	   approximately	  0.41%	  and	  upregulation	  of	  approximately	  0.54%	  of	  the	  phosphoproteome	  of	  an	  IL-­‐2	   maintained	   CTL,	   suggesting	   that	   short	   term	   tofacitinib	   treatment	   regulates	  approximately	  0.95%	  of	   the	  IL-­‐2	  maintained	  CTL	  phosphoproteome.	  Significantly	  regulated	  phosphorylation	  sites	  are	  listed	  in	  Appendix	  A3,	  tables	  A12	  and	  A13..	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  In	   the	   four	   hours	   tofacitinib	   treatment	   dataset,	   11,822	   phosphorylation	   sites	   on	  3499	  proteins	  were	  identified.	  Of	  these	  sites,	  8113	  were	  identified	  in	  two	  or	  more	  replicates.	  At	   this	   timepoint,	   tofacitinib	  treatment	  results	   in	  more	  downregulated	  phosphorylation	  sites	  than	  upregulated	  phosphorylation	  sites.	   In	  total,	   tofacitinib	  treatment	  resulted	  in	  the	  significant	  downregulation	  of	  124	  phosphosites	  and	  the	  significant	   upregulation	   of	   17	  phosphorylation	   sites	   (figure	  4.1).	   This	   represents	  downregulation	   of	   approximately	   1.04%	   and	   upregulation	   of	   0.14%	   of	   the	   total	  phosphoproteome	   of	   an	   IL-­‐2	  maintained	   CTL,	   suggesting	   that	   4	   hours	   tofacitnib	  treatment	   could	   regulate	   approximatley	   1.18%	   of	   the	   detected	   phosphorylation	  sites.	  Significantly	  regulated	  sites	  are	  listed	  in	  Appendix	  A4,	  tables	  A14	  and	  A15.	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C. 30 minutes 4hrs
identified phosphorylation sites 8,839 11,822
identified proteins 3,086 3,499
% sites significantly regulated 0.95% 1.18%
% identified sites significantly downregulated 0.41% 1.04%
% identified sites significantly upregulated 0.54% 0.14%
30 mins phospho
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4.2.2	  Regulation	  of	  the	  CTL	  proteome	  following	  4	  hours	  tofacitinib	  treatment	  Proteomic	   analysis	   of	   IL-­‐2	  maintained	   CTL	   and	   IL-­‐2	  maintained	   CTL	   treated	   for	  four	  hours	  with	  tofacitinib	  resulted	  in	  the	  identification	  of	  5336	  proteins.	  Of	  these,	  4083	  proteins	  were	  identified	  in	  two	  or	  more	  replicates.	  In	  total,	  17	  proteins	  were	  significantly	   downregulated	   and	   2	   proteins	   were	   significantly	   upregulated	  following	  tofacitinib	  treatment	  (figure	  4.2).	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Uniprot ID Protein Gene BR1 ratio BR2 ratio BR3 ratio mean ratio t-test Significant
P48025 Tyrosine-protein kinase SYK Syk 0.22 0.16 0.35 0.24 +
Q6A028 Switch-associated protein 70 Swap70 0.44 0.45 - 0.45 +
Q9JHK5 Pleckstrin Plek 0.46 0.45 0.51 0.48 +
Q9D379 Epoxide hydrolase 1 Ephx1 0.52 0.52 0.47 0.50 +
P14483 H-2 class II histocompatibility antigen, A beta chain H2-Ab1 0.48 0.44 0.62 0.51 +
Q99JW4 LIM and senescent cell antigen-like-containing domain protein 1 Lims1 0.44 0.60 0.60 0.55 +
P15307 Proto-oncogene c-Rel Rel 0.54 0.52 0.59 0.55 +
P47738 Aldehyde dehydrogenase, mitochondrial Aldh2 0.59 0.57 0.56 0.57 +
O08750 Nuclear factor interleukin-3-regulated protein Nfil3 0.54 0.69 0.60 0.61 +
Q8K482 EMILIN-2 Emilin2 0.59 0.65 0.59 0.61 +
Q8BMK4 Cytoskeleton-associated protein 4 Ckap4 0.57 0.60 0.69 0.62 +
Q01237 3-hydroxy-3-methylglutaryl-coenzyme A reductase Hmgcr 0.64 0.60 - 0.62 +
P23611 Interferon regulatory factor 8 Irf8 0.64 0.62 0.62 0.63 +
P01843 Ig lambda-1 chain C region - 0.65 0.61 - 0.63 +
Q9JKD9 Zinc finger and BTB domain-containing protein 32 Zbtb32 0.61 0.68 0.64 0.64 +
Q60710 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Samhd1 0.67 0.61 0.66 0.64 +
O55222 Integrin-linked protein kinase Ilk 0.57 0.74 0.68 0.67 +
Q80XK6 Autophagy-related protein 2 homolog B Atg2b 1.97 1.91 - 1.94 +
Q8BG60-2 Thioredoxin-interacting protein Txnip 1.52 1.61 1.47 1.53 +
A. 
B. 
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4.2.3	  STAT5	  and	  S6	  phosphorylation	  following	  tofacitinib	  treatment	  Phosphorylation	   of	   STAT5A	   Y694	   and	   STAT5B	   Y699,	   the	   activating	   tyrosine	  phosphorylation	   sites	   that	   are	   phosphorylated	   on	   dimerization	   and	   activation	   of	  JAK1	  and	  JAK3	  following	  binding	  of	  IL-­‐2	  to	  its	  receptor	  (Lin	  &	  Leonard,	  2000),	  was	  reduced	  after	  both	  30	  minutes	  and	  4	  hours	  tofacitnib	  treatment	  (figure	  4.3).	  This	  confirms	  that	  IL-­‐2	  signalling	  was	  inhibited	  in	  samples	  used	  for	  phosphoproteomic	  analysis.	  	  	  Other	   sites	   associated	   with	   IL-­‐2	   signalling	   were	   also	   identified	   in	   the	  phosphoproteomic	  dataset.	  For	  example,	  phosphorylation	  of	  ribosomal	  protein	  S6	  was	   identified	   at	   S235,	   S236	   and	   S240.	   The	   S235	   site	   was	   reduced,	   but	   not	  significantly	  following	  30	  minutes	  tofacitinib	  treatment	  (mean	  ratio	  0.57)	  but	  was	  not	   identified	   at	   4	   hours	   treatment;	   while	   the	   S236	   site	   was	   significantly	  downregulated	  at	  30	  minutes	  but	  identified	  in	  a	  single	  replicate	  and	  not	  regulated	  at	  4	  hours	  tofacitinib	  treatment	  (mean	  ratio	  0.49	  and	  0.72	  respectively).	  The	  S240	  site	  was	  identified	  in	  a	  single	  replicate	  and	  not	  regulated	  at	  30	  minutes	  or	  4	  hours	  tofacitinib	  treatment.	  	  In	  addition	  to	  the	  STAT5	  tyrosine	  sites,	  which	  are	  known	  to	  be	  regulated	  by	  IL-­‐2	  signalling,	  phosphorylation	  of	  STAT5A	  at	  serines	  127	  and	  128	  was	  regulated	  after	  4	   hours	   tofacitinib	   treatment,	   but	   not	   following	   30	   minutes	   treatment.	   Serine	  phosphorylation	  of	  STAT5B	  at	  the	  equivalent	  S127/S128	  sites	  was	  not	  detected	  in	  the	   30	  minutes	   tofacitinib	   treatment	   dataset,	   and	  was	   not	   regulated	   in	   the	   four	  hours	   tofacitnib	   treatment	   dataset.	   The	   S127/128	   sites	   have	   previously	   been	  reported	  to	  be	  phosphorylated	  in	  response	  to	  ERBB4	  signalling	  (Clark	  et	  al.,	  2005)	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and	  to	  contribute	  to	  STAT5	  DNA	  binding.	  The	  kinase	  that	  phosphorylates	  this	  site	  is	  unknown,	  but	  has	  been	  suggested	   to	  be	  PAK.	  The	  STAT5A	  S779	  has	  also	  been	  reported	   to	   be	   phosphorylated	   by	   PAK	   (Berger	   et	   al.,	   2014).	   Phosphorylation	   at	  this	  site	  was	  not	  regulated	  by	  tofacitinib	  treatment.	  	  	  
	  
Table	  4.1:	  Regulation	  of	  STAT5A/B	  and	  S6	  phosphorylation	  following	  tofacitinib	  treatment	  Table	   shows	   the	   ratios	   of	   phosphosites	   in	   CTL	   treated	   with	   tofacitinib	   as	   indicated	   versus	   IL-­‐2	  maintained	  CTL.	  	  	  
4.2.4	  JAK	  kinase	  phosphorylation	  following	  tofacitinib	  treatment	  Phosphorylation	   of	   JAK2,	   JAK3	   and	   TYK2	   was	   detected	   by	   mass	   spectrometry.	  Phosphorylation	  of	  JAK2	  was	  detected	  at	  S523;	  phosphorylation	  of	  JAK3	  at	  S5,	  S17,	  S19,	   S20,	   S21,	   T778	   and	   Y781	   and	   phosphorylation	   of	   TYK2	   at	   S521	   and	   S713.	  Phosphorylation	   of	   JAK3	   at	   the	   T778	   and	   S19	   was	   significantly	   downregulated,	  while	   phosphorylation	   at	   the	   Y781	   sites	  was	   reduced	   but	   only	   identified	   in	   one	  replicate.	   The	   T778	   site	   of	   JAK3	  was	   not	   identified	   following	   4	   hours	   tofacitinib	  treatment,	   and	   the	   ratio	   of	   the	   Y781	   site	   was	   higher	   at	   four	   hours	   tofacitinib	  treatment	  than	  30	  minutes	  (table	  4.2).	  Phosphorylation	  of	   JAK3	  at	  the	  regulatory	  
                               30 mins                                                       4hrs                  
Protein Site BR1 ratio BR2 ratio BR3 ratio T-test BR1 ratio BR2 ratio BR3 ratio T-test
STAT5A Y694 0.11 0.10 0.06 + 0.19 0.22 0.18 +
STAT5A S127 0.78 - - 0.72 0.57 0.61 +
STAT5A S128 0.77 - - 0.64 0.66 0.65 +
STAT5A S779 0.89 0.86 0.87 - - -
STAT5B Y699 0.10 0.50 0.07 0.21 0.21 0.22 +
STAT5B S127 - - - 0.84 0.73 0.84
STAT5B S128 - - - 0.82 0.80 0.88
S6 S235 0.75 0.51 0.46 - - -
S6 S236 0.50 0.51 0.46 + - 0.72 -
S6 S240 0.74 - - 0.74 - -
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sites	   Y976	   and	   Y977	   (Liu	   et	   al.,	   1997)	   was	   not	   identified	   following	   either	   30	  minutes	  or	  four	  hours	  tofacitinib	  treatment.	  The	  JAK	  kinase	  sites	  identified	  in	  these	  experiments	   therefore	   do	   not	   provide	  much	   information	   on	   the	   activity	   of	   JAK1	  and	  JAK3	  following	  tofacitinib	  inhibition.	  	  	  
	  
Table	  4.2:	  Regulation	  of	  JAK	  kinase	  phosphorylation	  following	  tofacitinib	  treatment	  	  
4.2.5	  Regulation	  of	  tyrosine	  phosphorylation	  following	  tofacitinib	  treatment	  As	  shown	  in	  table	  4.3,	  tofacitnib	  treatment	  of	  IL-­‐2	  maintained	  CTL	  resulted	  in	  the	  downregulation	   of	   various	   tyrosine	   phosphorylation	   sites.	   After	   30	   minutes	  tofacitinib	  treatment,	  11	  tyrosine	  sites	  had	  a	  ratio	  below	  0.67	  and	  3	  of	  these	  sites	  were	   significantly	   regulated.	   After	   4	   hours	   tofacitinib	   treatment	   9	   tyrosine	  phosphorylation	  sites	  had	  ratios	  below	  0.67	  and	  4	  of	  these	  sites	  were	  significantly	  downregulated.	  After	  both	  30	  minutes	  and	  4	  hours	  tofacitinib	  treatment	  only	  one	  site	   had	   a	   mean	   ratio	   over	   1.5,	   and	   neither	   of	   these	   sites	   were	   significantly	  regulated.	  The	  majority	  of	   these	  sites	  are	  directly	   involved	  in	  signalling	  events	  at	  the	   IL-­‐2	   receptor.	  These	   include	  STAT5A	  Y694	  and	  STAT5B	  Y699	  sites,	  which	  as	  previously	   discussed	   are	   phosphorylated	   following	   JAK	   kinase	   activation.	   The	  
30 mins 4hrs



















Tyrosine-protein kinase JAK2 S523 1.06 1.07 1.09 1.07 1.29 1.06 1.13 1.16
Tyrosine-protein kinase JAK3 T778 0.66 0.72 0.53 0.64 + - - - -
Tyrosine-protein kinase JAK3 S19 0.66 0.68 - 0.67 + 0.96 1.00 - 0.98
Tyrosine-protein kinase JAK3 S17 0.92 1.16 1.07 1.05 0.75 0.88 0.77 0.80
Tyrosine-protein kinase JAK3 S20 0.75 0.92 - 0.83 0.80 0.88 0.70 0.80
Tyrosine-protein kinase JAK3 S21 0.85 - - 0.85 0.75 0.85 - 0.80
Tyrosine-protein kinase JAK3 S5 0.82 - - 0.82 - - - -
Tyrosine-protein kinase JAK3 Y781 0.61 - - 0.61 0.85 0.76 0.77 0.79
Non-receptor tyrosine-protein 
kinase TYK2 S713 - - 3.85 3.85 - - - -
Non-receptor tyrosine-protein 
kinase TYK2 S521 - 1.11 - 1.11 - - - -
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equivalent	  STAT4	  site,	  Y694,	  was	  also	  reduced	  following	  tofacitinib	  treatment,	  and	  significantly	   regulated	   following	   30	   minutes	   tofacitinib	   treatment.	   However,	  phosphorylation	  of	  the	  STAT4	  Y694	  site	  is	  low	  in	  IL-­‐2	  maintained	  CTL	  compared	  to	  the	   level	   seen	   following	   treatment	  with	   STAT4	   activating	   cytokine	   such	   as	   IL-­‐12	  (figure	  3.15).	  In	  addition	  to	  STAT5,	  phosphorylation	  of	  the	  adaptor	  protein	  SHC1	  at	  Y313	  was	  significantly	  reduced	  by	  tofacitinib	  treatment.	  Both	  STAT5A/B	  and	  SHC1	  localise	   to	   the	   IL-­‐2	   receptor	   during	   IL-­‐2	   signalling,	   and	   have	   been	   reported	   to	  directly	  interact	  or	  be	  phosphorylated	  by	  JAK1/JAK3	  (Fujitani	  et	  al.,	  1997;	  Mishra	  &	  Kumar,	  2014),	  suggesting	  that	  these	  sites	  are	  direct	  JAK	  kinase	  targets.	  	  Phosphorylation	  of	  the	  adaptor	  protein	  GAB3	  at	  the	  Y569	  site	  was	  downregulated,	  but	  not	  significantly,	  following	  four	  hours	  tofacitinib	  treatment.	  The	  GAB	  proteins	  (Grb2	  associated	  binding	  proteins)	   are	   recruited	   to	   the	   cell	  membrane	   following	  phosphorylation	   and	   fulfill	   their	   adaptor	   function	   by	   binding	   various	   other	  proteins	   including	   the	   regulatory	   P13K	   subunit	   p85	   via	   their	   PH	   domains	  (Vaughan	   et	   al.,	   2011).	   While	   GAB2	   has	   a	   well	   described	   role	   in	   IL-­‐2	   signalling	  (Arnaud	   et	   al.,	   2004;	   Gadina	   et	   al.,	   2000;	   Gesbert	   et	   al.,	   1998b),	   the	   function	   of	  GAB3	  is	  less	  clear:	  GAB3	  has	  previously	  been	  reported	  to	  be	  phosphorylated	  after	  IL-­‐2	  signalling	  (Osinalde	  et	  al.,	  2011),	  but	  GAB3	  does	  not	  seem	  to	  be	  required	  for	  an	  adequate	   immune	  response	  (Seiffert	  et	  al.,	  2003).	   It	   is	  possible	   that	  GAB2	  can	  substitute	  for	  GAB3.	  No	  GAB2	  tyrosine	  phosphorylation	  sites	  were	  identified	  in	  the	  30	   minutes	   or	   four	   hours	   tofacitinib	   treatment	   datasets.	   Phosphorylation	   of	  Uncharacterized	  protein	  FLJ45252	  homolog	  at	  the	  Y291	  site	  was	  reduced,	  but	  not	  significantly,	   following	  4	  hours	   tofacitinib	   treatment.	  The	   function	  of	   this	  protein	  and	  phosphorylation	  site	  is	  not	  known.	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The	   mean	   ratio	   of	   the	   abundance	   of	   the	   activating	   ERK1	   Y185	   and	   ERK2	   Y205	  phosphorylation	   sites	   was	   below	   0.67	   after	   30	   minutes	   tofacitinib	   treatment,	  although	   it	   was	   not	   significantly	   regulated.	   These	   sites	   were	   not	   regulated	  following	  four	  hours	  tofacitinib	  treatment	  (table	  4.3).	  The	  phosphorylation	  of	  the	  threonine	  sites	  also	  involved	  in	  ERK1	  and	  ERK2	  activation	  were	  reduced,	  but	  not	  significantly,	  following	  30	  minutes	  of	  tofacitinib	  treatment,	  while	  these	  sites	  were	  not	   reduced	   at	   four	   hours:	   the	   ERK1	   T183	   site	   had	   a	   mean	   ratio	   of	   0.55	   at	   30	  minutes	  treatment	  and	  0.93	  at	  four	  hours	  treatment;	  and	  the	  ERK2	  T183	  site	  had	  a	  mean	   ratio	   of	   0.24	   at	   30	   minutes	   treatment	   and	   0.88	   at	   four	   hours	   tofacitinib	  treatment.	   Inhibition	   of	   the	   phosphorylation	   of	   these	   sites	   is	   expected	   following	  tofacitinib	   treatment,	   as	   signalling	   through	   the	   Ras/MAPK	   pathway	   is	   initiated	  following	   IL-­‐2	  binding	   to	   its	  receptor	  (Marks	  et	  al.,	  2003).	  The	   loss	  of	   these	  sites	  likely	  reflects	  a	  reduction	  in	  the	  activity	  of	  the	  upstream	  kinases,	  MEK1	  and	  MEK2	  (Arthur	   &	   Ley,	   2013;	   Kolch,	   2005).	   The	   lack	   of	   regulation	   of	   these	   sites	   at	   four	  hours	   tofacitinib	   treatment	   may	   suggest	   that	   these	   sites	   rapidly	   become	  rephosphorylated	   after	   an	   initial	   dephosphorylation	   following	   tofacitinib	  treatment,	  but	  a	  detailed	  kinetics	  would	  be	  required	  to	  determine	  this.	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Table	   4.3:	   Regulation	   of	   tyrosine	   phosphorylation	   sites	   following	   30	  minutes	   and	   4	   hours	  
tofacitinib	   treatment	  Table	   shows	   tyrosine	  phosphorylation	  sites	   that	  were	   identified	   in	   the	  30	  minutes	   or	   4	   hours	   tofacitinib	   treatment	   as	   having	   a	   ratio	   in	   tofacitinib	   treated	   CTL	   versus	   IL-­‐2	  maintained	  CTL	  below	  0.67	  or	  above	  1.5.	  	  
4.2.6	   Regulation	   of	   serine,	   threonine	   and	   tyrosine	   phosphorylation	   sites	  
following	  tofacitinib	  treatment	  Tofacitinib	   is	  a	   JAK	  kinase	   inhibitor,	  and	  so	  would	  be	  expected	  to	  directly	   inhibit	  tyrosine	  phosphorylation	  only.	  However,	   tofacitinib	  treatment	  of	   IL-­‐2	  maintained	  CTL	   resulted	   in	   the	   regulation	  of	   serine,	   threonine	  and	   tyrosine	  phosphorylation	  sites	  (table	  4.4).	  This	  confirmed	  that,	  as	  expected,	  inhibition	  of	  JAK	  kinase	  activity	  also	   affected	   signalling	   further	   downstream	   of	   IL-­‐2	   signalling	   than	   direct	   JAK	  kinase	  phosphorylation	  events.	  	  
30 mins 4hrs
Protein names Site Ratio BR1 Ratio BR2 Ratio BR3 mean ratio
t-test 





Signal transducer and activator of 
transcription 5A
Y694 0.11 0.10 0.06 0.09 + 0.19 0.22 0.18 0.20 +
Signal transducer and activator of 
transcription 5B
Y699 0.10 0.50 0.07 0.22 0.21 0.21 0.22 0.21 +
Signal transducer and activator of 
transcription 4
Y694 0.45 - 0.45 0.45 + 0.23 0.31 - 0.27
GRB2-associated-binding protein 3 Y569 - - - - 0.60 - 0.47 0.53
SHC-transforming protein 1 Y313 0.45 0.52 0.40 0.46 + 0.58 0.46 0.57 0.54 +
Uncharacterized protein FLJ45252 
homolog
Y291 - - - - 0.65 0.49 - 0.57
Phosphatidylinositol 3,4,5-
trisphosphate 5-phosphatase 2
Y987 - - - - 0.56 0.68 - 0.62
Transferrin receptor protein 1 Y20 - - - - 0.53 0.69 0.72 0.65 +
Mitogen-activated protein kinase 1 Y185 0.81 0.60 0.48 0.63 0.89 0.68 - 0.78
Mitogen-activated protein kinase 3 Y205 0.82 0.54 0.53 0.63 0.88 0.69 - 0.78
Tyrosine-protein kinase JAK3 Y781 0.61 - - 0.61 0.85 0.76 0.77 0.79 +
Plastin-2 Y28 0.70 - - 0.70 0.74 - 0.88 0.81
FYN-binding protein Y559 1.17 - - 1.17 0.84 1.00 3.46 1.76
Eukaryotic translation initiation factor 
5A-1
Y98 0.15 - - 0.15 - - - -
T-cell surface glycoprotein CD3 zeta 
chain
Y83 0.71 0.43 - 0.57 - - - -
Pumilio homolog 1 Y224 - 0.64 - 0.64 - - - -
Lck-interacting transmembrane 
adapter 1
Y175 0.73 4.48 0.82 2.01 - - - -
	   149	  
	  
Table	  4.4:	  Distribution	  of	  serine,	  threonine	  and	  tyrosine	  phosphorylation	  sites	  in	  identified	  
by	  mass	  spectrometry	  and	  regulated	  by	  tofacitinib	  treatment	  	  
4.2.7	  Pathway	  analysis	  of	  proteins	  with	  regulated	  phosphorylation	  sites	  To	   identify	   signalling	   pathways	   and	   processes	   that	   were	   affected	   by	   tofacitinib	  treatment,	   lists	   of	   proteins	   whose	   phosphorylation	   was	   significantly	   regulated	  following	   30	   minutes	   and	   four	   hours	   tofacitinib	   treatment	   were	   submitted	   for	  analysis	   using	   the	   DAVID	   functional	   annotation	   tool	   (Huang	   et	   al.,	   2008;	   2009).	  KEGG	  pathways	  were	  used	  to	  identify	  signalling	  pathways	  regulated	  by	  tofacitinib	  treatment;	  and	  GO	  terms	  related	  to	  biological	  processes,	  molecular	   functions	  and	  cellular	   compartments	   were	   used	   to	   identify	   which	   processes	   within	   CTL	   were	  likely	   to	   be	   affected	   following	   tofacitinib	   treatment	   and	  which	   types	   of	   proteins	  were	  regulated	  respectively.	  	  After	  30	  minutes	  tofacitinib	  treatment	  there	  was	  significant	  enrichment	  in	  proteins	  with	  downregulated	  phosphorylation	   sites	  with	  KEGG	  annotations	   linked	   to	  Wnt	  signalling	   and	   Jak-­‐STAT	   signalling.	   Proteins	   with	   phosphorylation	   sites	  downregulated	   after	   30	   minutes	   tofacitinib	   were	   also	   enriched	   in	   GO	   term	  biological	  process	  annotations	  linked	  to	  cellular	  signal	  transduction,	  regulation	  of	  transcription,	   regulation	   of	   apoptosis	   and	   cytokine	   signalling.	   Proteins	   with	  
serine threonine tyrosine
30 minutes
Number identified 7443 1308 86
Number significantly downregulated 31 2 3
Number significantly upregulated 48 0 0
4hrs
Number identified 9928 1783 110
Number significantly downregulated 109 11 4
Number significantly upregulated 16 1 0
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downregulated	   phosphorylation	   sites	   were	   also	   enriched	   in	   GO	   term	   molecular	  function	  annotations	  linked	  to	  signal	  transduction,	  transcription	  factor	  activity	  and	  DNA	   binding	   (Appendix	   A.1,	   table	   A.2;	   appendix	   A.2,	   table	   A.6).	   Transcription	  factors	   with	   phosphorylation	   sites	   downregulated	   after	   30	   minutes	   tofacitinib	  treatment	   included	   STAT5A,	   NFATC2,	   NFIL3	   and	   TSC22D4.	   While	   many	   of	   the	  functions	  of	  the	  regulated	  phosphorylation	  sites	  are	  not	  known,	  this	  does	  suggest	  that	   following	   tofacitinib	   treatment	   there	   are	   widespread	   changes	   in	   the	  phosphorylation	  of	  proteins	  involved	  in	  the	  regulation	  of	  gene	  expression.	  For	  the	  downregulated	   phosphorylation	   sites,	   this	   also	   implies	   that	   they	   are	  phosphorylated	  downstream	  of	  IL-­‐2	  signalling.	  	  	  No	   enrichment	   in	   KEGG	   pathways	   annotations	   or	   GO	   term	   biological	   process	  annotations	  was	  found	  in	  the	  set	  of	  protein	  with	  upregulated	  phosphorylation	  sites	  following	   30	  mins	   tofacitinib	   treatment.	   There	  was	   significant	   enrichment	   in	   GO	  term	  molecular	  function	  annotations	  linked	  to	  RNA	  binding,	  and	  GO	  term	  cellular	  compartment	   annotations	   linked	   to	   the	   nucleus	   and	   nuclear	   membrane,	   and	  perichromatin	  fibrils	  (Appendix	  A.1,	  table	  A.2;	  appendix	  A.2,	  table	  A.7).	  	  	  After	  4	  hours	  tofacitinib	  treatment,	  proteins	  with	  downregulated	  phosphorylation	  sites	  were	   significantly	   enriched	   in	  KEGG	  pathway	  annotations	   linked	   to	   various	  cancers	  and	  JAK-­‐STAT	  signalling.	  There	  was	  also	  significant	  enrichment	  of	  GO	  term	  biological	  process	  annotations	  linked	  to	  regulation	  of	  transcription	  and	  the	  MAPK	  cascade.	   Proteins	   with	   downregulated	   sites	   were	   also	   enriched	   in	   GO	   term	  molecular	  function	  annotations	  linked	  to	  transcription	  factor	  activity,	  and	  binding	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to	  mRNA,	  protein	  and	  14-­‐3-­‐3	  protein	  binding	   (Appendix	  A.1,	   table	  A.4;	  appendix	  A.2,	  tables	  A.9	  and	  A.10).	  	  	  	  Proteins	   with	   upregulated	   phosphorylation	   sites	   following	   4	   hours	   tofacitinib	  treatment	  were	   significantly	   enriched	   in	   GO	   term	  biological	   process	   annotations	  linked	   regulation	   of	   transcription	   and	   chemotaxis	   (Appendix	   A.1,	   table	   A.5;	  appendix	  A.2,	   table	  A.11).	   This	   suggests	   that	   tofacitinib	   treatment	   positively	   and	  negatively	   regulated	   the	   phosphorylation	   of	   transcription	   factors	   following	   four	  hours	  tofacitinib	  treatment.	  	  
4.2.8	  Effect	  of	  tofacitinib	  on	  PKB	  signalling	  Phosphoproteomic	   analysis	   demonstrated	   that	   various	   signalling	   pathways,	  including	   STAT5	   activation	   and	   MAPK	   signalling,	   were	   regulated	   following	  tofacitinib	  treatment	  of	  IL-­‐2	  maintained	  CTL.	  For	  some	  signalling	  pathways	  too	  few	  phosphorylation	   sites	   known	   to	   be	   involved	   in	   that	   pathway	   were	   identified	   to	  determine	  if	  the	  pathway	  was	  regulated	  by	  tofacitinib.	  For	  example,	  PKB	  signalling	  is	  active	   in	   IL-­‐2	  maintained	  CTL	  and	  regulates	   important	  aspects	  of	  CTL	   function	  such	  as	  homing	  capabilities	  (Macintyre	  et	  al.,	  2011),	  so	   it	  would	  be	  interesting	  to	  determine	  if	  PKB	  activity	  in	  CTL	  was	  regulated	  by	  tofacitinib	  treatment.	  However,	  the	   PKB	   phosphorylation	   sites	   involved	   in	   the	   regulation	   of	   PKB	   kinase	   activity,	  S473	   and	   T308,	   were	   not	   identified	   by	   mass	   spectrometry.	   The	   PKB	  phosphorylation	  sites	  of	  the	  FOXO	  transcription	  factors	  were	  also	  not	  identified.	  	  Active	   PKB	   phosphorylates	   the	   FOXO	   transcription	   factors,	   leading	   to	   their	  exclusion	   from	   the	   nucleus	   (Calnan	   &	   Brunet,	   2008):	   in	   the	   absence	   of	   PKB	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signalling,	  the	  FOXO	  transcription	  factors	  are	  not	  phosphorylated	  and	  are	  localised	  to	  the	  nucleus.	  CTL	  were	  generated	  from	  mice	  expressing	  GFP	  tagged	  FOXO1,	  and	  the	   nuclear	   localization	   of	   FOXO1	   following	   tofacitinib	   treatment	   or	   IL-­‐2	  deprivation	  measured	  by	   flow	  cytometric	  analysis	  of	   isolated	  nuclei.	  Akti	   treated	  CTL	   were	   used	   as	   a	   positive	   control	   for	   FOXO1	   nuclear	   localization.	   Western	  blotting	  was	  also	  used	  to	  determine	  if	  the	  phosphorylation	  of	  PKB	  or	  FOXO1/3	  was	  regulated	  following	  tofacitinib	  treatment.	  	  Akti	  treatment	  of	  CTL	  resulted	  in	  a	  rapid	  and	  sustained	  increase	  in	  the	  abundance	  of	  FOXO1-­‐GFP	  in	  CTL	  nuclei	  compared	  to	  CTL	  maintained	  in	  IL-­‐2	  only.	  Tofacitinib	  and	   IL-­‐2	   deprivation	   increased	   FOXO1-­‐GFP	   abundance	   in	   the	   nucleus	   slightly	  compared	  to	  IL-­‐2	  maintained	  CTL,	  but	  not	  to	  the	  same	  extent	  as	  Akti	  treated	  CTL	  (figure	   4.4A,	   figure	   4.4B).	   Western	   blotting	   showed	   that,	   while	   tofacitinib	  treatment	  reduced	  phosphorylation	  of	  PKB	  at	  the	  hydrophobic	  motif	  S473	  site	  to	  some	  extent,	  it	  did	  not	  reduce	  phosphorylation	  at	  the	  T308	  site.	  Phosphorylation	  at	  the	   PKB	   target	   sites	   T32/24	   on	   FOXO1	   and	   FOXO3	   were	   also	   not	   regulated	   by	  tofacitinib	   treatment	   (figure	   4.5).	   This	  would	   suggest	   that	   JAK	  kinase	   dependent	  IL-­‐2	   signalling	   has	   a	   limited	   role	   in	   the	   regulation	   of	   PKB	   signalling	   in	   IL-­‐2	  maintained	  CTL.	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Figure	  4.4:	  Effect	  of	  tofacitinib	  on	  PKB	  signalling	  in	  IL-­‐2	  maintained	  CTL	  A.	  Histograms	  show	  FOXO1-­‐GFP	   MFI	   in	   nuclei	   from	   IL-­‐2	   maintained	   CTL,	   IL-­‐2	   maintained	   CTL	   treated	   with	   Akti	   or	  tofacitinib	  or	  deprived	  of	  IL-­‐2.	  N=4,	  four	  independent	  experiments.	  B.	  Abundance	  of	  FOXO1-­‐GFP	  in	  treated	  nuclei	  relative	  to	  IL-­‐2	  maintained	  CTL.	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Figure	   4.5:	   Effect	   of	   tofacitinib	   on	   PKB	   signalling	   in	   IL-­‐2	   maintained	   CTL.	   Western	   blot	  showing	   phosphorylation	   of	   PKB	   and	   FOXO1/3	   in	   CTL	   following	   Akti	   treatment,	   tofacitinib	  treatment	  or	  IL-­‐2	  deprivation.	  Molecular	  weights	  of	  blotted	  proteins	  (kDa)	  indicated	  on	  left	  of	  blot.	  N=3,	  three	  independent	  experiments	  	  HIF	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4.2.9	   Phosphorylation	   sites	   most	   highly	   regulated	   following	   tofacitinib	  
treatment	  of	  IL-­‐2	  maintained	  CTL	  To	  further	  examine	  the	  effect	  of	  tofacitinib	  on	  IL-­‐2	  maintained	  CTL,	  information	  on	  the	  function	  of	  the	  protein	  and	  the	  phosphorylation	  sites	  that	  were	  found	  to	  be	  the	  most	   highly	   regulated	   by	   tofacitinib	   treatment	   were	   used	   to	   determine	   if	   these	  sites	   were	   known	   to	   be	   involved	   in	   IL-­‐2	   signalling	   or	   were	   novel	   targets.	   The	  phosphorylation	   sites	  most	  highly	  downregulated	   following	   tofacitinib	   treatment	  are	  shown	  below	   in	   table	  4.5;	   the	  most	  highly	  upregulated	  phosphorylation	  sites	  following	   30	   minutes	   tofacitinib	   treatment	   in	   table	   4.6;	   the	   most	   highly	  downregulated	   phosphorylation	   sites	   following	   4	   hours	   tofacitinib	   treatment	   in	  table	  4.7;	  and	  the	  most	  highly	  upregulated	  phosphorylation	  sites	  following	  4	  hours	  tofacitinib	  treatment	  in	  table	  4.8.	  	  	  	  	  	  	  	  	  	  




Table	  4.5:	  Phosphorylation	  sites	  most	  downregulated	  after	  30	  minutes	  tofacitinib	  treatment.	  Table	  made	  using	  information	  from	  Uniprot,	  PhosphoSite	  and	  other	  references	  as	  indicated.	  
Most downregulated - 30 minutes tofacitinib treatment







protein function phosphorylation site function
P42230
Signal transducer and 
activator of 
transcription 5A
Stat5a Y 694 0.09 0.20 Transcription factor (Lin and Leonard, 
2000).
Dimerisation, nuclear 




homolog Cic S 2275 0.32 0.74
Transcriptional repressor, repression of 
receptor tyrosine kinase related genes. 
Inhibited by Erk (Jimenez et al, 2012).






Chd8 S 2040 0.40 0.75 Chromatin remodelling (Ceballos-Chavez 
et al., 2015)
Site not listed in PhosphoSite 
database.
Q61233 Plastin-2 Lcp1 S 5 0.44 0.66 Actin bundling (Janji et al., 2006) Increases actin bundling activity 
(Janji et al. 2006)
A2ADY9 Protein DDI1 homolog 
2
Ddi2 S 194 0.45 - Unknown.
Unknown. Regulated by insulin, 
LPS, LY294002 (P13K inhibitor) 
and MK-2206 (Akt inhibitor) 
(PhosphoSite)
Q6PGL7 WASH complex 
subunit FAM21
Fam21 S 832 0.45 0.69
Regulates protein recycling to the 
membrane as part of the WASH complex 
(Lee et al., 2016)
Unknown. Regulated by LPS 
(PhosphoSite)
P42228
Signal transducer and 
activator of 
transcription 4
Stat4 Y 694 0.45 0.27 Transcription factor (Wurster et al., 2000)
Dimerization, nuclear 
translocation (Wurster et al., 
2000)
Q99LI2 Chloride channel CLIC-
like protein 1
Clcc1 S 433 0.46 0.64 Likely chloride channel, localised to 
endoplasmic reticulum (Jia et al., 2015)
Unknown. Regulated by FTL3, 
insulin and LPS (PhosphoSite)
P98083-2
SHC-transforming 
protein 1 Shc1 Y 313 0.46 0.54
Adaptor protein involved in activation of 
Ras/Mapk and P13K signalling (Zheng et 
al., 2014)
Phosphorylation creates Grb2 
binding site (Zheng et al., 2014)
B2RY04 Dedicator of 
cytokinesis protein 5
Dock5 T 1793 0.48 0.52 RAC GEF reported to be involved in mast 
cell degranulation (Ogawa et al., 2014)
Site not listed in PhosphoSite 
database.
P62754 40S ribosomal protein 
S6
Rps6 S 236 0.49 0.72 Part of 40S ribosomal subunit (Roux et 
al., 2007)
RSK and S6K substrate, 
regulation of cap-dependent 
translation (Roux et al., 2007)
Q9EQN3
TSC22 domain family 
protein 4 Tsc22d4 S 271 0.51 0.79
Leucine zipper transcription factor (Kester 
et al., 1999)
Unknown. Regulated by FLT3 
and insulin (PhosphoSite)
P18653
Ribosomal protein S6 
kinase alpha-1 Rps6ka1 S 352 0.52 0.80
Serine/threonine kinase downstream of 
MAPK kinases (Anjum and Blenis, 2008).
Possible role in activation. May 
be Erk substrate (Anjum and 
Blenis, 2008)
Q5HZG4 Transcription initiation 
factor TFIID subunit 3
Taf3 S 199 0.53 - Part of the basal transcription factor TFIID 




Dennd4c S 1221 0.53 0.77 Rab10 guanine exchange factor (GEF; 
Sano et al., 2011)
Unknown, putative Erk2 
substrate (PhosphoSite)
Q8VE88-2 Protein FAM114A2 Fam114a
2





subunit alpha, liver 
isoform
Phka2 S 735 0.54 -
Regulatory subunit of phosphorylase 
kinase, which regulates glycogenlysis by 
phosphorylating glycogen phosphorylase 
(Carrière et al., 2008)
Unknown , regulated by insulin 
(PhosphoSite)
Q8BJ34-6
Meiosis arrest female 
protein 1 Marf1 S 65 0.55 0.82
Required for ogenesis in mice, human 
homolog found to associate with the 
cytoplasmic mRNA processing body (P-
body, Bloch et al., 2014)
Not listed in PhosphoSite 
database.
Q8VI36 Paxillin Pxn S 83 0.55 0.95
Scaffold protein involved in regulation of 
cell adhesion and the cytoskeleton 
(Deakin and Turner, 2008)




Usp25 S 136 0.55 - Deubiquitinase (Zhong et al., 2013) Site not listed in PhosphoSite 
database.
Q9ESV0 ATP-dependent RNA 
helicase DDX24
Ddx24 S 67 0.57 0.87 RNA helicase (Ma et al., 2013) Unknown (PhosphoSite)




Table	   4.6:	   Phosphorylation	   sites	  most	   upregulated	   after	   30	  minutes	   tofacitinib	   treatment.	  Table	  made	  using	  information	  from	  Uniprot,	  PhosphoSite	  and	  other	  references	  as	  indicated.	  	  	  	  	  
Most upregulated - 30 minutes tofacitinib treatment







protein function phosphorylation site function
Q9WVM1 Rac GTPase-
activating protein 1





containing gene 6A 
protein
Tnrc6a S 1825 2.70 -
Involved in miRNA silencing via 
association with Argonaute proteins (Nishi 
et al., 2012)




Tgs1 S 92 2.22 -
Addition of methyl groups to TMG cap on 
snRNA and snoRNA (Hausmann and 
Schuman, 2005)




KIF20A Kif20a S 681 2.19 -
Kinesin involved in cytokinesis (Neef et 
al., 2003)




ligase RanBP2 Ranbp2 S 1446 2.10 0.49
Nucleoporin with SUMO E3 ligase activity 
(Ritterhoff et al., 2016)




protein 43 Tardbp S 292 2.09 0.43
Involved in the regulation of RNA splicing 
(Lukavsky et al., 2013)




cell-specific protein Hcls1 S 232 2.09 0.59
Tyrosine phosphorylated in response to 
TCR stimulation. Binds Lck, Fyn, PLCγ1, 
p85 and Vav. Involved in reorganization to 
actin cytoskeleton in response to TCR 
activation (Gomez et al., 2006).




demethylase PHF8 Phf8 S 686 2.02 -
Histone demethylase reported to regulate 
rRNA production and progression through 
the cell cycle (Feng et al., 2010; Lui et al., 
2010)
Unknown (PhosphoSite)
Q9DBT5 AMP deaminase 2 Ampd2 S 53 2.02 0.40
Deamination of AMP, purine metabolism 
(Akizu et al., 2013)
Unknown, regulated by Kras, 
PAK4, insulin and MK-2206 (Akt 
inhibitor)
P26041 Moesin Msn S 407 2.00 0.37
Cytoskeleton binding protein with multiple 
roles in T cells including migration (Hirata 
et al., 2012) 
Unknown, regulated by insulin 




14 Rbm14 S 620 1.99 0.34
RNA-binding protein involved in regulating 










S 200 1.98 0.45
Nuclear ribonucleoprotein reported to be 
involved in miRNA loading into exosomes 
(Villarroya-Beltri et al., 2013)
S212 in PhosphoSite database. 




containing protein 17 Ankrd17 S 152 1.97 1.18
Various reported roles including cell 
division and innate immune signalling 






Osbpl9 S 228 1.96 -
Sterol binding protein involved in Golgi 
organization. Short isoform may be inhibit 
the function of the full length isoform (Ngo 
and Ridgeway, 2009).




notch homolog 1 Sbno1 S 804 1.95 1.11
Unknown, possibly involved in 
transcription (Uniprot)










Hnrnpm S 593 1.95 0.48
Ribonuclear protein involved in regulation 





methyltransferase 1 Dnmt1 S 15 1.92 1.67 DNA methylase (Lei et al., 1996) Unknown (PhosphoSite)
Q7TMY8-3 E3 ubiquitin-protein 
ligase HUWE1
Huwe1 S 2593 1.91 - E3 ubiquitin ligase (Uniprot) Unknown (PhosphoSite)
Q8CES0
N-alpha-
acetyltransferase 30 Naa30 S 192 1.89 0.71
Catalytic subunit of the N-alpha-
acetlytransferase, a protein acetlylase 
(van Damme et al., 2016)
Unknown (PhosphoSite)
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Table	   4.7:	   Phosphorylation	   sites	  most	   downregulated	   after	   4	   hours	   tofacitinib	   treatment.	  Table	  made	  using	  information	  from	  Uniprot,	  PhosphoSite	  and	  other	  references	  as	  indicated.	  
Most downregulated - 4hrs tofacitinib treatment







protein function phosphorylation site function
Q5SUQ9-3
CST complex subunit 
CTC1 Ctc1 T 2 0.12 -
Component of telemore protecting CST 
complex (Miyake et al., 2009)




Eomes S 659 0.15 -
Transcription factor, regulates T cell 
differentiation and function (Pearce et al., 
2003; Banerjee et al. 2010)




protein 2-like 2 N4bp2l2 S 35 0.17 -
Not well characterized, reported to form 
part of a transcriptional repressor complex 




Signal transducer and 
activator of 
transcription 5A
Stat5a Y 694 0.20 0.09 Transcription factor (Lin and Leonard, 
2000).
Dimerisation, nuclear 
tranlocation (Lin and Leonard, 
2000)
P42232
Signal transducer and 
activator of 
transcription 5B
Stat5b Y 699 0.21 0.22
Transcription factor (Lin and Leonard, 
2000).
Dimerisation, nuclear 




protein 1 Limd1 S 308 0.37 -
Interacts with pRB, inhibits E2F induced 
transcription (Sharp et al., 2004)








Pprc1 S 1059 0.40 1.18 Transcriptional coactivator (Gleyzer and 




beta Eef1b S 90 0.45 -
Facilitates t-RNA amino acid transfer to 
the ribosome by acting as a GEF (guanine 
exchange factor) for the G-protein 
elongation factor 1A (Le Sourd et al., 
2006)




2 S 112 0.47 0.54 Unknown.
Not listed in PhosphoSite 
database.
P48678 Prelamin-A/C Lmna S 12 0.48 -
Intermediate filament proteins that 
associate with the nuclear envelope, with 
roles in nuclear structure and regulating 
chromatin organization (Gruenbaum and 
Foisner, 2015)
Unknown, regulated by LPS 
(PhosphoSite)
P23950 Zinc finger protein 36, 
C3H1 type-like 1
Zfp36l1 S 92 0.48 -
Binds RNA and induces its degradation, 
so regulating gene expression (Hodson et 
al., 2010)
Unknown. Regulated by insulin 




factor 8 Irf8 S 162 0.48 1.00
Transcription factor with various roles in 
immune cell function including dendritic 
cell development and Th17 differentiation 
(Tamura et al. 2015; Ouyang et al. 2011)
Unknown (PhosphoSite)
P23611 Interferon regulatory 
factor 8
Irf8 S 164 0.48 1.89
Transcription factor with various roles in 
immune cell function including dendritic 
cell development and Th17 differentiation 




nuclear protein 1 Csrnp1 S 535 0.49 -
Expression induced by IL-2 in T cells, 
putative transcription factor (Gingras et 
al., 2007)






Hmha1 S 875 0.49 0.58 Rho GAP (guanine activating protein, 
Spierings et al., 2004)






Nfil3 S 210 0.50 0.90
Transcription factor and circadian protein. 
Required for development of various 







Ier3 S 31 0.50 -
Seems to positively regulate ERK activity 
by inhibiting PP2A containing the B56β 
regulatory subunit (Rocher et al., 2007)






Nfil3 S 301 0.50 0.95
Transcription factor and circadian protein. 
Required for development of various 
immune cells including ILC (Geiger et al., 
2014)
Unknown. Regulated by FLT3, 
insulin and LPS (Phosphosite)
Q6ZQ58 La-related protein 1 Larp1 S 743 0.51 0.91
Represses the translation of mRNAs 
containing TOP (terminal 
oligopyramindine) motifs (Fonseca et al., 
2015)
Unknown, putative mTOR 
substrate, regulated by FLT3, 
insulin, LPS, LY294002 and MK-




initiation factor 3 
subunit A
Eif3a S 584 0.51 0.89
Subunit of the eIF3 initation factor: may 
regulate the translation of a selective set 
of mRNA (Saletta et al., 2010)
Unknown, reported to be 
regulated by Raptor, Rictor, 
insulin, LY294002, MK-2206 (Akt 
inhibitor) and refeeding 
(Phosphosite)




Table	  4.8:	  Phosphorylation	  sites	  most	  upregulated	  after	  4	  hours	  tofacitinib	  treatment.	  Table	  made	  using	  information	  from	  Uniprot,	  PhosphoSite	  and	  other	  references	  as	  indicated.	  	  
	  	  	  	  	  	  
	  
Most upregulated - 4hrs tofacitinib treatment






protein function phosphorylation site function
Q8BI84
Melanoma inhibitory activity 
protein 3 Mia3 S 1566 4.03 -
ER protein involved in export of bulky proteins 
(Santos et al., 2016)
Unknown, regulated by insulin and LY294002 
(PI3K inhibitor)(Phosphosite)
Q922J3-2 CAP-Gly domain-containing 
linker protein 1
Clip1 S 194 2.65 1.50
Microtubule interacting protein involved in 
endocytosis and tethering kinetochoresduring 
chromosome assembly (Amin et al., 2015; 
Kedashiro et al., 2015)
Unknown: however, equivalent site in humans 
(S195) has been reported to be a PLK 
substrate, and to be regulated by BI2536 
(PLK inhibitor), MLN8054 (Aurora A inhibitor), 
SB202190 (p38 inhibitor), nocodazole 
(microtubule polymerization), EGF, 
ischaemia, siRNA and UV  (Phosphosite)
P19973-2 Lymphocyte-specific protein 1 Lsp1 T 164 2.01 1.09
Immune cell migration (Jongstra-Bilen and 
Jongstra, 2006)
T166 in Phosphosite database (splice). 
Unknown function, regulated by IFNγ, insulin 
and LPS (Phosphosite)
P19973-2 Lymphocyte-specific protein 1 Lsp1 S 166 1.88 1.09 Immune cell migration (Jongstra-Bilen and 
Jongstra, 2006)
S168 in Phosphosite database (splice). 
Regulated by insulin and LPS (PhosphoSite).
Q9EQM6 Microprocessor complex 
subunit DGCR8
Dgcr8 S 373 1.76 - miRNA biogenesis; snoRNA degradation (Macias 
et al., 2015)
Unknown, regulated by insulin (PhosphoSite)
P26350 Prothymosin alpha Ptma S 9 1.73 1.06
Enhances immune responses (Romani et al., 
2012)
Not known, human equivalent site regulated 
by EGF, nocodozole, PLX4032 (B-raf 
inhibitor) and U0126 (MEK1/2 inhibitor)
Q6P1G2 Lysine-specific demethylase 2B Kdm2b S 447 1.73 1.01
Lysine demethylase that acts on H3K4me3 (Janzer 
et al, 2012) Unknown (PhosphoSite)
P13864 DNA (cytosine-5)-
methyltransferase 1
Dnmt1 S 15 1.67 1.92 DNA methylase (Lei et al., 1996) Unknown (PhosphoSite)
Q6NZJ6 Eukaryotic translation initiation 
factor 4 gamma 1
Eif4g1 S 1081 1.67 1.04
Facilitates translation by acting as a scaffold for 
other initiation factors, allowing the formation of 
preinitation complexes. Also reported to be 
involved in ribosome scanning (Prévôt et al, 2003)
Unknown, regulared by Raptor, Rictor, insulin, 
LY294002 and MK-2206 (Akt inhibitor, 
PhosphoSite)
P41971
ETS domain-containing protein 
Elk-3 Elk3 S 398 1.65 1.11
ETS-family transcription factor (Hollenhurst et al., 
2011) Unknown (PhosphoSite)
O54824-2 Pro-interleukin-16 Il16 S 296 1.61 1.17
Cytokine. Acts as chemoattractant for CD4+ 
immune cells, regulates T cell growth (Richmond 
et al., 2013)
Unknown (Phosphosite)
P70399 Tumor suppressor p53-binding 
protein 1
Tp53bp1 S 1663 1.61 1.03 p53 binding protein with potential role in DNA 




factor-related protein 2 Hdgfrp2 S 640 1.60 -
Reported to be involved DNA repair by 
homologous recombination (Baude et al., 2016) Unknown (PhosphoSite)
Q9R1C7 Pre-mRNA-processing factor 
40 homolog A
Prpf40a S 884 1.59 -
Potential role in regulated RNA splicing (Makarov 
et al., 2011); binds N-WASP and prevents 
translocation to the cytoplasm (Mizutani et al., 
2004)
Unknown (PhosphoSite)
P19973-2 Lymphocyte-specific protein 1 Lsp1 S 178 1.56 1.12
Immune cell migration (Jongstra-Bilen and 
Jongstra, 2006) Unknown, regulated by LPS (PhosphoSIte)
Q99K74-2
Mediator of RNA polymerase II 
transcription subunit 24 Med24 S 840 1.53 1.15
Also known as TRAP100. Involved in regulation of 





protein 8 Tmc8 S 663 1.50 1.03
Localised to the endoplasmic reticulum. Homology 
to TMEM16A Ca2+ activated Cl- channel protein. 
However, Tmc8 does not appear to mediate Cl- 
transport. Inhibitory effect on transport by 
TMEM16Aand other channel proteins (Sirianant et 
al., 2014) 
Uknown, regulated by FLT3 (PhosphoSite)
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4.3	  Discussion	  Phosphoproteomic	  analysis	  of	  IL-­‐2	  maintained	  CTL	  resulted	  in	  the	  identification	  of	  82	   significantly	   regulated	   phosphorylation	   sites	   following	   30	  minutes	   tofacitinib	  treatment	  and	  140	  significantly	  regulated	  phosphorylation	  sites	  following	  4	  hours	  tofacitinib	  treatment,	  representing	  regulation	  of	  approximately	  0.92%	  and	  1.18%	  of	  the	  total	  identified	  phosphoproteome	  respectively..	  After	  30	  minutes	  treatment,	  the	  number	  of	  significantly	  upregulated	  phosphorylation	  sites	  was	  slightly	  higher	  than	   the	   number	   of	   downregulated	   sites,	   suggesting	   that	   IL-­‐2	   regulated	   the	  phosphorylation	  and	  dephosphorylation	  of	  a	  number	  of	   sites.	   In	  contrast,	   after	  4	  hours	   tofacitinib	   treatment,	   considerably	   more	   phosphorylation	   sites	   were	  identified	   as	   downregulated	   following	   tofacitinib	   treatment	   than	   were	  upregulated:	   this	   suggests	   that	   at	   the	   later	   timepoint,	   inhibition	   of	   JAK	   kinase	  activity	   was	   not	   resulting	   in	   an	   increase	   in	   phosphorylation	   or	   reduced	  dephosphorylation	  of	  a	  large	  number	  of	  phosphorylation	  sites.	  	  	  Stimulation	  of	  CTL	  with	  IL-­‐2	  regulates	  the	  phosphorylation	  of	  proteins	  involved	  in	  various	   aspects	   of	   gene	   regulation,	   GTPase	   GAPs	   and	   GEFs,	   proteins	   involved	   in	  regulation	  of	   the	  cytoskeleton	  and	  vesicle	   transport	   (Ross	  et	  al.,	  2016).	   	  Proteins	  with	   downregulated	   phosphorylation	   sites	   following	   tofacitinib	   treatment	   were	  enriched	  with	  functions	  involved	  in	  signal	  transduction	  and	  the	  regulation	  of	  gene	  expression.	  Proteins	  with	  upregulated	  phosphorylation	  sites	  were	  also	  enriched	  in	  proteins	  with	  transcriptional	  regulation	  functions.	  This	  indicates	  that	  JAK	  kinases	  regulate	   a	   variety	   of	   processes	   within	   IL-­‐2	   maintained	   T	   cells.	   Regulated	   sites	  included	   components	   on	   well-­‐characterized	   signalling	   pathways	   known	   to	   be	  activated	   downstream	   of	   IL-­‐2	   receptor	   signalling,	   including	   the	   STAT5	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transcription	  factors	  and	  proteins	  in	  the	  RAS/MAPK	  signalling	  pathway,	  as	  well	  as	  phosphorylation	  sites	  that	  had	  not	  previously	  been	  linked	  to	  IL-­‐2	  signalling.	  	  	  IL-­‐2	  stimulation	  of	  CTL	  results	  in	  the	  phosphorylation	  of	  various	  proteins	  involved	  in	   transcriptional	   regulation	   such	   as	   the	   transcription	   factors	   STAT5	   and	  NFIL3,	  nuclear	  pore	  proteins,	  and	  mRNA	  binding	  proteins	  such	  as	  YBX1;	  suggesting	  that	  IL-­‐2	  signalling	  can	  regulate	  gene	  transcription	  at	  various	  points	  (Ross	  et	  al.,	  2016).	  Phosphoproteomic	   analysis	   of	   tofacitinib	   treated	   CTL	   demonstrated	   that	   also	  regulated	   various	   proteins	   involved	   in	   gene	   regulation.	   As	   well	   as	   regulating	  transcription	   factors	   such	   as	   STAT5,	   phosphorylation	   of	   the	   transcription	   factor	  Eomes	   at	   the	   S659	   site	   and	   S52	   site	   were	   significantly	   reduced	   following	   four	  hours	   tofacitinib	   treatment	   (Appendix	   A	   table	   A14).	   The	   transcription	   factor	  Eomes	  is	  expressed	  in	  various	  immune	  cells,	  including	  CD8+	  T	  lymphocytes	  and	  NK	  cells	  (McLane,	  2014),	  and	  has	  various	  functions,	  including	  regulating	  CTL	  effector	  functions	   such	   as	   perforin	   and	   granzyme	   expression	   (Pearce	   et	   al.,	   2003)	   and	  regulating	   CD8+	   T	   cell	   memory	   (Banerjee	   et	   al.,	   2010).	   Eomes	   protein	   has	   been	  reported	   previously	   to	   be	   upregulated	   following	   IL-­‐2	   stimulation	   of	   CD8+	   T	  lymphocytes	  (Pipkin	  et	  al.,	  2010),	  but	  the	  reduction	  in	  phosphorylation	  at	  this	  site	  does	  not	  seem	  to	  be	  a	  result	  of	  reduced	  protein	  abundance,	  as	  the	  ratio	  of	  Eomes	  protein	   in	   tofacitinib	   treated	   CTL	   compared	   to	   IL-­‐2	   maintained	   CTL	   after	   four	  hours	   treatment	   is	   0.84.	   The	   function	   of	   the	   S659	   site	   and	   the	   S52	   sites	   are	   not	  known.	  	  Phosphorylation	   of	   Protein	   capicua	   homolog	   (Cic)	   S2275	   was	   reproducibly	  downregulated	   following	   30	   minutes	   tofacitinib	   treatment	   (Appendix	   A.3,	   table	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14).	   Cic	   has	   been	   reported	   to	   be	   a	   transcriptional	   repressor	   that	   binds	   to	   and	  represses	   transcription	   from	  genes	  regulated	  by	  receptor	   tyrosine	  kinases	   (RTK)	  in	   the	   absence	   of	   RTK	   signalling.	   Following	   ligand	   binding	   to	   the	   RTK,	   MAPK	  signalling	   is	   activated.	   Protein	   capicua	   homolog	   is	   then	   phosphorylated	   by	   ERK,	  and	  this	  lifts	  transcriptional	  repression,	  possibly	  by	  altering	  Cic	  stability	  (Jimenez	  et	   al.,	   2012).	  Phosphorylation	  also	   regulates	  Cic	   interaction	  with	  14-­‐3-­‐3	  proteins	  (Dissanayake	   et	   al.,	   2011).	   The	   S2275	   site	   is	   not	   listed	   as	   an	   ERK	   substrate	   in	  Phosphosite	  database,	  but	  would	  fit	  as	  ERK	  activation	  is	  reduced	  at	  this	  timepoint.	  However,	  Cic	  protein	  abundance	  is	  not	  significantly	   increased	  following	  24	  hours	  tofacitinib	  treatment	  (proteomics,	  mean	  copy	  number	  ratio	  1.38),	  suggesting	  that	  Cic	  stability	  may	  not	  be	  altered	  following	  tofacitinib	  treatment.	  	  The	   regulation	   of	   these	   transcription	   factors	   following	   tofacitinib	   treatment,	   and	  the	   regulation	   of	   other	   transcription	   factors	   and	   other	   proteins	   involved	   in	  transcriptional	   and	   translational	   regulation	   of	   gene	   expression	   suggest	   that	   JAK	  kinase	   dependent	   IL-­‐2	   signalling	   in	   CTL	   controls	   gene	   expression	   beyond	   the	  known	  regulated	   transcription	   factors	   such	  as	  STAT5.	  This	   could	  be	   investigated	  further	  by	  validating	  the	  regulation	  of	  the	  phosphorylation	  sites,	  investigating	  the	  functions	   of	   individual	   proteins	   in	   CTL	   using	   knockout	   mice	   and	   determing	   the	  function	  of	  the	  regulated	  phosphorylation	  sites.	  	  
	  Phosphoproteomic	  analysis	  indicated	  that	  both	  IL-­‐2	  stimulation	  of	  CTL	  (Ross	  et	  al.,	  2016)	  and	  tofacitinib	   treatment	  regulate	   the	  phosphorylation	  of	  various	  proteins	  linked	  to	  actin	  binding	  and	  microtubule	  binding.	  T	  lymphocyte	  migration	  requires	  the	  actin	  cytoskeleton	  (Dupré	  et	  al.,	  2015)	  and	  potentially	  microtubules	  (Takesono	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et	   al.,	   2010)..Regulated	   sites	   included	   known	   IL-­‐2	   signalling	   targets	   such	   as	   the	  plastin-­‐2	   S5	   site,	   which	   was	   downregulated	   at	   both	   30	  minutes	   and	   four	   hours	  tofacitinib	  treatment	  (Appendix	  A.3	  table	  A12,	  table	  A14)	  and	  is	  also	  induced	  by	  IL-­‐2	  stimulation	  of	  CTL	  (Ross	  et	  al.,	  2016).	  Plastin-­‐2	  is	  an	  actin	  bundling	  protein	  with	  reported	   roles	   in	   T	   cell	   activation	   and	   motility,	   phosphorylated	   at	   the	   S5	   site	  following	  IL-­‐2	  and	  TCR	  stimulation	  (Morley,	  2013;	  Zu	  et	  al.,	  1990).	  The	  S5	  site	   is	  required	   for	   actin	   binding,	   and	   has	   been	   reported	   to	   be	   phosphorylated	   by	   PKA	  and	  PKC	  (Janji,	  2006).	  	  	  Lymphocyte	  specific	  protein	  1	  (LSP1)	  is	  an	  F-­‐actin	  binding	  protein	  involved	  in	  the	  regulation	   of	   immune	   cell	   migration	   (Jongstra-­‐Bilen	   &	   Jongstra,	   2006).	   LSP1	  phosphorylation	  at	  T164,	  S166	  and	  S178	  was	  significantly	  increased	  after	  4	  hours	  tofacitinib	   treatment	   (Appendix	   A.3,	   table	   A15).	   LSP1	   is	   expressed	   in	   CD4+	   and	  CD8+	   T	   cells,	   and	   expression	   increases	   after	   TCR	   triggering,	   and	   negatively	  regulates	  T	  cell	  migration	  (Hwang	  et	  al.,	  2015).	  The	  function	  and	  putative	  kinases	  for	   the	   identified	   phosphorylation	   sites	   are	   not	   known,	   although	   LSP1	   has	   been	  reported	  to	  be	  phosphorylated	  by	  MK2	  (Wu	  et	  al.,	  2007)	  and	  PKC	  (Carballo	  et	  al.,	  1996).	  	  	  Phosphorylation	   of	   CLIP1	   at	   T194	   was	   also	   increased	   after	   4	   hours	   tofacitinib	  treatment	  (Appendix	  A.3	  table	  A15).	  CLIP1	  has	  been	  described	  as	  an	  intermediate	  filament	  associated	  protein	  (Bilbe	  et	  al.,	  1992)	  and	  a	  microtubulue	  binding	  protein	  (Pierre	  et	  al.,	  1992)	  with	  various	  functions,	  including	  the	  tethering	  of	  kinetochores	  to	  microtubule	  ends	  during	  chromosome	  assembly	   in	  mitosis	   (Amin	  et	  al.,	  2015)	  	  and	  a	  role	  in	  regulating	  endocytosis	  by	  linking	  endocytic	  vesicles	  to	  microtubules	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(Kedashiro	  et	  al.,	  2015;	  Pierre	  et	  al.,	  1992).	  The	  human	  equivalent	  of	   the	  murine	  S194	  phosphorylation	  site,	  S195,	  has	  been	  reported	  to	  be	  a	  substrate	  of	  Polo-­‐like	  kinase	   1	   (PLK1).	   Phosphorylation	   of	   the	   S195	   site	   seems	   to	   facilitate	   the	  recruitment	  of	  casein	  kinase	  2	  (CK2)	  to	  CLIP-­‐170.	  CK2	  then	  phosphorylates	  CLIP-­‐170	  at	  S1318,	  which	  can	  then	  interact	  with	  dynein/dynactin	  and	  drive	  microtubule	  dependent	  events	   like	  kinetochore	   tethering	  during	  chromosome	  assembly	  (Li	  et	  al.,	  2010).	  	  	  The	   regulation	   of	   these	   sites	   suggest	   that	   JAK	   kinase	   dependent	   signalling	  regulates	   proteins	   involved	   in	   regulation	   of	   the	   actin	   cytoskeleton	   and	  microtubules.	  This	  could	  be	  investigated	  further	  by	  validating	  the	  regulation	  of	  the	  sites	  by	  other	  techniques	  such	  as	  Western	  blotting.	  Functional	  analysis	  of	  actin	  and	  microtubule	   dependent	   processes	   such	   as	   cell	   migration,	   endocytosis	   and	   cell	  division	  in	  tofacitinib	  and	  IL-­‐2	  deprived	  CTL	  could	  also	  be	  performed.	  	  IL-­‐2	  maintained	  CTL	  have	  active	  PKB	  signalling,	  demonstrated	  by	   the	  changes	   in	  gene	   expression	   in	   IL-­‐2	   maintained	   CTL	   treated	   with	   the	   PKB	   inhibitor	   Akti	  (Macintyre	   et	   al.,	   2011).	   IL-­‐2	   has	   been	   thought	   to	   regulate	   PKB	   signalling	   by	  scaffold	   protein	   dependent	   recruitment	   of	   the	   p85	   subunit	   of	   PI3K	   to	   the	   IL-­‐2	  receptor	   (Gesbert	   et	   al.,	   1998b;	   Gesbert	   et	   al.,	   1998a)	   and	   regulating	  PtdIns(3,4,5)P3	   accumulation.	   This	   should	   allow	   recruitment	   of	   the	   PH	   domain	  containing	  PDK1	  and	  PKB	  to	  the	  cell	  membrane	  and	  PDK1	  phosphorylation	  of	  PKB	  at	  the	  activating	  T308	  site	  (Pearce	  et	  al.,	  2010).	  In	  Kit225	  cells,	  IL-­‐2	  stimulation	  has	  been	   reported	   to	   increase	  binding	  of	   the	  p85	   regulatory	  P13K	  α	   and	  β	   subunits,	  and	   to	   a	   less	   extent	   the	   PI3K	   α,	   β	   and	   γ	   catalytic	   subunits,	   to	   the	   IL-­‐2	   receptor	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associated	  scaffold	  protein	  GAB2	  (Osinalde	  et	  al.,	  2016).	  	  	  However,	   in	  CTL	  PKB	  signalling	   is	   JAK	  kinase	   independent.	  Tofacitinib	   treatment	  and	  IL-­‐2	  deprivation	  do	  not	  induce	  relocalisation	  of	  FOXO1	  to	  the	  nucleus	  and	  do	  not	   regulate	   PKB	   phosphorylation	   at	   the	   activating	   PKB	   T308	   site	   or	   the	  phosphorylation	  of	  FOXO1	  and	  FOXO3	  at	  the	  PKB	  target	  sites	  (figure	  4.4	  and	  4.5;,	  Ross	  et	  al.,	  2016).	  Instead,	  PKB	  activity	  in	  CTL	  is	  regulated	  by	  SRC	  kinase	  activity.	  The	  SRC	  kinase	   inhibitor	  PP2	  regulates	  over	  a	   thousand	  phosphorylation	  sites	   in	  IL-­‐2	  maintained	  CTL	  with	  little	  overlap	  with	  JAK	  kinase	  sites,	  suggesting	  that	  SRC	  kinase	  activity	  is	  an	  important	  JAK	  kinase	  independent	  contributor	  to	  regulation	  of	  the	  CTL	  phosphoproteome.	   Inhibition	  of	   SRC	  kinases	  with	  PP2	   also	   inhibits	   PKB	  activity	  and	  the	  abundance	  of	  PtdIns(3,4,5)P3,	  suggesting	  that	  SRC	  kinase	  regulate	  PKB	  activity	  by	  regulating	  PtdIns(3,4,5)P3	  abundance	  at	  the	  cell	  membrane	  (Ross	  et	  al.,	  2016).	  SRC	  family	  kinases	  have	  been	  reported	  to	  regulate	  a	  Y688	  site	  in	  the	  p85	  subunit	  of	  PI3K	  that	  may	  relieve	  p85	  inhibition	  of	  the	  p110	  subunit	  (Cuevas	  et	  al.,	  2001).	  	  A	   major	   limitation	   of	   phosphoproteomic	   analysis	   is	   the	   lack	   of	   information	  concerning	   the	   function	   of	   many	   of	   the	   phosphorylation	   sites	   identified:	   the	  majority	  of	   sites	   identified	  as	  significantly	   regulated	  by	   tofacitinib	   treatment	  had	  no	   known	   function	   and	   in	   many	   cases	   there	   was	   no	   information	   available	   on	  possible	  kinases	  that	  would	  phosphorylate	  these	  sites	  (although	  potential	  kinases	  can	  be	  identified	  by	  looking	  for	  kinase	  motifs).	  This	  should	  improve	  to	  some	  extent	  as	  more	  phosphoproteomic	  datasets	  are	  deposited	  in	  databases.	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Chapter	  5:	  Proteomic	  analysis	  of	  tofacitinib	  treated	  CTL	  
5.1	  Introduction	  Previous	   experiments	   (chapter	   3)	   had	   suggested	   that	   long-­‐term	   tofacitinib	  treatment	   reduces	   the	   size	   of	   IL-­‐2	   maintained	   CTL	   and	   inhibited	   mTORC1	  signalling,	  which	  regulates	  processes	  involved	  in	  protein	  synthesis	  (Hukelmann	  et	  al.,	   2015).	   Tofacitinib	   treatment	   and	   IL-­‐2	   deprivation	   of	   CTL	   also	   reduces	  translation	  (Ross	  et	  al.,	  2016).	  To	  further	  explore	  the	  effect	  of	  tofacitinib	  treatment	  on	   IL-­‐2	   maintained	   CTL	   and	   define	   the	   portion	   of	   the	   proteome	   regulated	  downstream	   of	   the	   JAK	   kinases	   in	   response	   to	   IL-­‐2,	   IL-­‐2	   maintained	   CTL	   were	  treated	   with	   tofacitinib	   for	   24	   hours	   and	   the	   proteome	   analysed	   using	   mass	  spectrometry.	  	  
5.2	  Results	  Cytotoxic	  T	  lymphocytes	  rely	  on	  signalling	  by	  the	  γc	  chain	  cytokines	  IL-­‐2	  or	  IL-­‐15	  to	   retain	   their	   large	  cell	   size	  after	  TCR	  activation,	  with	   IL-­‐2	  supporting	  a	  greater	  cell	  size	  than	  IL-­‐15	  (Cornish	  et	  al.,	  2006).	  When	  IL-­‐2	  maintained	  CTL	  are	  deprived	  of	  IL-­‐2	  signalling,	  they	  lose	  a	  significant	  proportion	  of	  their	  cell	  mass.	  	  The	  protein	  content	  of	  CTL	  deprived	  of	  IL-­‐2	  for	  24	  hours	  is	  reduced	  by	  over	  60%	  compared	  to	  IL-­‐2	  maintained	  CTL.	  CTL	   treated	  with	   tofacitinib	   for	  24	  hours	   lose	  over	  40%	  of	  their	   protein	   content	   (figure	   5.1A).	   Using	   forward	   scatter	   and	   side	   scatter	   as	   an	  estimate	   of	   cell	   size	   during	   flow	   cytometric	   analysis	   of	   CTL,	   CTL	   also	   become	  noticeably	   smaller	   following	   overnight	   IL-­‐2	   deprivation	   or	   tofacitinib	   treatment	  (figure	  5.1B).	  This	  suggests	  that,	  in	  addition	  to	  regulating	  signalling	  events	  in	  CTL,	  IL-­‐2	  signalling	   is	  required	  to	  maintain	  the	  bulk	  proteome	  of	  CTL.	  However,	  while	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this	  shows	  that	  IL-­‐2	  is	  important	  for	  maintaining	  CTL	  mass	  and	  protein	  content,	  it	  does	  not	  indicate	  if	  the	  loss	  of	  cell	  mass	  following	  inhibition	  of	  IL-­‐2	  signalling	  is	  the	  result	  of	  a	  generalized	  arrest	  of	  protein	  synthesis,	  an	  increased	  rate	  of	  degradation	  or	  the	  loss	  of	  a	  selective	  subset	  of	  proteins	  regulated	  by	  IL-­‐2.	  
	  
Figure	  5.1:	   IL-­‐2	   is	  required	  to	  maintain	   the	  protein	  content	  of	  CTL	  A.	  Protein	  content	  of	  IL-­‐2	  maintained	  CTL,	  IL-­‐2	  maintained	  CTL	  treated	  for	  24	  hours	  with	  100nM	  tofacitinib	  or	  CTL	  deprived	  of	  CTL	  for	  24	  hours.	  Significance	  of	  differences	  analysed	  using	  one-­‐way	  ANOVA	  with	  Tukey’s	  post-­‐hoc	  test.	  Asterisks	   indicate	  significance	  of	  difference	  with	  IL-­‐2	  maintained	  CTL.	  Significance:	  *:P	  ≤	  0.05,	   **:	   P	   ≤	   0.01,	   ***:	   P	   ≤	   0.001,	   ****:	   P	   ≤	   0.0001.	   B.	   Flow	   cytometric	   analysis	   of	   CTL	   either	  maintained	   in	   IL-­‐2	   (red)	   or	   treated	   for	   24	   hours	   with	   100nM	   tofacitinib.	   Graph	   shows	   forward	  scatter	   (x-­‐axis)	   and	   side	   scatter	   (y-­‐axis).	   IL-­‐2	  maintained:	   n=3,	   IL-­‐2	   and	   tofacitinib:	   n=3,	   results	  from	  one	  independent	  experiment.	  	  	  Mass	   spectrometry	   was	   used	   to	   determine	   the	   effect	   of	   24	   hours	   of	   tofacitinib	  treatment	   on	   the	   proteome	  of	   IL-­‐2	  maintained	  CTL.	   This	  was	   used	   to	   define	   the	  CTL	  proteome	  regulated	  downstream	  of	  the	  JAK	  kinases	  following	  IL-­‐2	  signalling.	  Mass	   spectrometry	   can	   be	   used	   to	   estimate	   the	   abundance	   of	   thousands	   of	  proteins	   in	   a	   single	   sample	   (Schwanhäusser	   et	   al.,	   2011),	   and	   so	   can	   be	   used	   to	  identify	  broad	  trends	  in	  the	  regulation	  of	  the	  proteome	  of	  a	  cell.	  For	  example,	  the	  regulation	  of	  a	  particular	  subset	  of	  proteins	  after	  treatment	  with	  inhibitors	  such	  as	  tofacitinib	   can	   be	   identified.	   To	   identify	   proteins	   regulated	   on	   inhibition	   of	   IL-­‐2	  signalling,	   three	   biological	   replicates	   of	   IL-­‐2	   maintained	   CTL	   were	   split	   into	  cultures	   maintained	   in	   IL-­‐2	   only	   and	   IL-­‐2	   maintained	   CTL	   treated	   for	   24	   hours	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with	  100nM	  tofacitinib.	  The	  proteomes	  of	  IL-­‐2	  maintained	  and	  tofacitinib	  treated	  CTL	  were	  then	  analysed	  using	  label-­‐free	  mass	  spectrometry.	  	  
	  
5.2.1	  Analysis	  of	  proteomic	  data	  Proteomic	   samples	   were	   generated	   without	   the	   use	   of	   stable	   isotope	   labelling	  methods	  such	  as	  SILAC	  or	  iTRAQ	  or	  spike-­‐in	  standards.	  Label-­‐free	  analysis	  allows	  greater	   flexibility	   in	   experimental	   design,	   as	   the	   number	   of	   conditions	   is	   not	  limited	   by	   the	   number	   of	   isotope	   labels	   available.	   Also,	   in	   contrast	   to	  metabolic	  labels,	   label-­‐free	  analysis	   is	  not	  restricted	  by	  the	  proliferative	  capacity	  of	   the	  cell	  type	  of	   interest:	  while	   this	   is	  not	  a	  direct	   issue	  when	  analyzing	  CTL,	  using	   label-­‐free	   methods	   to	   define	   the	   CTL	   proteome	   does	   allow	   comparison	   of	   the	   CTL	  proteome	   with	   the	   proteomes	   of	   other	   cell	   types	   for	   which	   metabolic	   labelling	  would	   not	   be	   feasible.	  Within	   the	  MaxQuant	   and	   Perseus	   programs,	  which	  were	  used	   to	   analyse	   the	   proteomics	   data,	   there	   are	   multiple	   options	   for	   quantifying	  proteins	   from	   label-­‐free	   analysis,	   including	   MaxLFQ	   (MaxQuant	   label	   free	  quantification)	  and	  copy	  number	  estimation	  using	  a	  proteomic	  ruler	  technique.	  	  	  The	   MaxQuant	   LFQ	   algorithim	   generates	   normalized	   peptide	   intensities	   that	  account	   for	   differences	   between	   samples	   introduced	   by	   separate	   processing	   of	  samples,	  as	  samples	  cannot	  be	  mixed	  for	  label-­‐free	  analysis	  as	  they	  are	  for	  SILAC	  analysis.	  To	  do	  this,	  normalization	  coefficients	  are	  generated	  for	  each	  fraction.	  The	  normalization	   coefficient	   for	   each	   run	   is	   then	   calculated	   as	   the	   value	   that	  minimizes	  the	  fold	  change	  in	  each	  peptide	  between	  samples.	  This	  assumes	  that	  the	  abundance	   of	   the	  majority	   of	   proteins	   identified	   in	   the	   sample	   does	   not	   change	  between	  samples	  (Cox	  et	  al.,	  2014).	  This	  method	  of	  quantification	  is	  generally	  used	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for	   comparing	  protein	   amount	  between	   samples	   rather	   than	   comparing	  how	   the	  abundance	  of	  different	  proteins	  compares	  within	  a	  sample.	  	  	  	  The	   proteomic	   ruler	   method	   described	   by	   Mann	   et	   al.	   (2014)	   exploits	   the	  relationship	  between	  the	  histones	  and	  DNA.	  DNA	  wraps	  around	  histone	  octamers	  at	  regular	  intervals	  of	  ≈	  200bp,	  forming	  nucleosomes	  (McGhee	  &	  Felsenfeld,	  1980),	  and	   diploid	   cells	   have	   a	   consistent	   DNA	   content	   per	   cell	   (Steinert	   et	   al.,	   2015).	  Therefore,	  if	  the	  histone	  content	  of	  a	  sample	  can	  be	  determined,	  an	  approximation	  of	   the	   number	   of	   cells	   present	   in	   a	   sample	   can	   be	   determined.	   As	   the	   signal	  intensity	  obtained	  for	  each	  protein	  during	  mass	  spectrometry	  analysis	  is	  related	  to	  the	  mass	  of	  each	  protein	  in	  each	  sample,	  the	  total	  signal	  intensity	  for	  each	  sample	  is	  related	   to	   the	   total	  mass	  of	  protein	  observed.	  With	   the	  cell	  number	  estimation	  obtained	  from	  the	  histone	  signal,	  the	  mass	  of	  a	  single	  cell	  can	  be	  estimated.	  Using	  this,	   as	   well	   as	   the	   signal	   intensity	   observed	   for	   each	   protein,	   the	  mass	   of	   each	  protein	  per	  cell	  can	  be	  calculated.	  From	  the	  mass	  of	  each	  protein	  an	  estimation	  of	  copy	   number	   per	   cell	   is	   calculated	   (Wiśniewski	   et	   al.,	   2014).	   In	   addition	   to	  comparing	  the	  abundance	  of	  proteins	  between	  different	  treatment	  conditions,	  this	  method	  can	  be	  used	   to	  compare	   the	  abundance	  of	  different	  proteins	   in	   the	  same	  sample.	  	  	  Proteomic	  data	  was	  analysed	  by	  estimating	  copy	  numbers,	  which	  were	  then	  used	  to	  generate	  copy	  number	  ratios.	  Copy	  number	  ratios	  were	  calculated	  as	  the	  copy	  number	   in	   IL-­‐2	  maintained	   CTL	   treated	   for	   24	   hours	  with	   tofacitinib	   versus	   the	  copy	  number	  in	  IL-­‐2	  maintained	  CTL	  for	  each	  biological	  replicate,	  analogous	  to	  the	  SILAC	   ratios	   used	   in	   chapter	   4.	   Copy	   number	   ratios	   were	   used	   to	   identify	  
	   170	  
significantly	  regulated	  proteins	  rather	  than	  comparing	  copy	  numbers,	  as	  estimated	  copy	  numbers	  were	  variable	  between	  replicates.	  Protein	  copy	  numbers	  identified	  for	  individual	  proteins	  was	  similar	  between	  samples,	  with	  0.84	  the	  lowest	  r2	  value	  for	  correlation	  of	  copy	  numbers	  between	  samples.	  The	  distribution	  of	  protein	  copy	  numbers	   within	   each	   sample	   was	   also	   comparable	   between	   replicates	   and	  treatment	  conditions.	  The	  distribution	  of	  protein	  copy	  numbers	   in	  each	  replicate	  could	  be	  fitted	  to	  a	  Gaussian	  curve	  with	  an	  r2	  value	  of	  over	  0.99.	  	  
5.2.2	  Regulation	  of	  the	  proteome	  of	  IL-­‐2	  maintained	  CTL	  following	  tofacitinib	  	  	  
treatment	  Proteomic	  analysis	  of	  IL-­‐2	  maintained	  CTL	  and	  IL-­‐2	  maintained	  CTL	  treated	  for	  24	  hours	  with	  100nM	  tofacitinib	  resulted	   in	  the	   identification	  of	  7021	  proteins	   in	  at	  least	   one	   replicate,	   97.8%	   of	   which	  were	   found	   in	   at	   least	   one	   replicate	   of	   IL-­‐2	  maintained	  CTL	  and	  IL-­‐2	  maintained	  and	  24hr	  tofacitinib	  treated	  CTL	  (figure	  5.2A,	  5.2D).	  In	  total	  6949	  proteins	  were	  identified	  in	  CTL	  maintained	  in	  IL-­‐2	  only,	  with	  6202	   identified	   in	   biological	   replicate	   1	   (BR1),	   6841	   identified	   in	   biological	  replicate	  2	  (BR2)	  and	  6716	  identified	  in	  biological	  replicate	  3	  (BR3).	  In	  CTL	  treated	  for	  24	  hours	  with	  tofacitinib	  6939	  proteins	  were	   identified	   in	  total,	  6181	  in	  BR1,	  6827	   in	  BR2	  and	  6582	   in	  BR3.	  The	  majority	  of	   identified	  proteins	  were	   found	   in	  multiple	   replicates:	   87.8%	   of	   proteins	   identified	   in	   IL-­‐2	   maintained	   CTL	   were	  identified	  in	  all	  three	  replicates	  of	  IL-­‐2	  maintained	  CTL	  (figure	  5.2B),	  while	  87.0%	  of	  proteins	  identified	  in	  IL-­‐2	  maintained	  CTL	  treated	  for	  24	  hours	  with	  tofacitinib	  were	  identified	  in	  all	  three	  replicates	  of	  tofacitinib	  treated	  CTL	  (figure	  5.2C).	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Downregulated	  proteins	  were	  defined	  as	  having	  a	  copy	  number	  ratio	  ≤	  0.67,	  and	  upregulated	  proteins	  as	  having	  a	   copy	  number	   ratio	  ≥	  1.5,	  with	   regulation	  being	  consistent	  across	  replicates.	  More	  proteins	  were	  downregulated	  than	  upregulated	  following	   tofacitinib	   treatment,	   with	   306	   proteins	   downregulated	   and	   135	  proteins	   upregulated.	   In	   total,	   twenty-­‐four	   hours	   tofacitinib	   treatment	   of	   IL-­‐2	  maintained	  CTL	  resulted	  in	  the	  significant	  	  downregulation	  of	  211	  proteins	  and	  the	  significant	  upregulation	  of	  103,	  representing	  3.0%	  and	  1.5%	  of	  the	  total	  identified	  proteome	  respectively	  (figure	  5.2E).	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Figure	   5.2:	   	   Proteomic	   analysis	   of	   IL-­‐2	   maintained	   CTL	   treated	   for	   24	   hours	   with	   100nM	  
tofacitinib	  A.	  Non-­‐proportional	  Venn	  diagram	  showing	  the	  overlap	  between	  the	  proteins	  identified	  in	   all	   biological	   replicates	   of	   IL-­‐2	   maintained	   CTL	   samples	   and	   the	   proteins	   identified	   in	   all	  biological	   replicates	   of	   IL-­‐2	   maintained	   CTL	   treated	   for	   24	   hours	   with	   tofacitinib.	   B.	   Non-­‐proportional	  Venn	  diagram	  showing	  the	  overlap	  between	  proteins	  identified	  in	  biological	  replicates	  of	   IL-­‐2	   maintained	   CTL.	   C.	   Non-­‐proportional	   Venn	   diagram	   showing	   the	   overlap	   of	   proteins	  identified	  in	  biological	  replicates	  of	  IL-­‐2	  maintained	  CTL	  treated	  for	  24	  hours	  with	  tofacitinib.	  Venn	  diagrams	  made	   using	   BioVenn	   (http://www.cmbi.ru.nl/cdd/biovenn/index.php).	   D.	   Table	   shows	  the	   number	   of	   proteins	   identified	   in	   biological	   replicates	   of	   IL-­‐2	  maintained	   CTL	   and	   tofacitinib	  treated	   CTL.	   E.	   Volcano	   plot	   showing	   the	   fold	   change	   in	   the	   abundance	   of	   proteins	   following	  tofacitinib	  treatment.	  





































Biological replicate 1 6202 6181
Biological replicate 2 6841 6827
Biological replicate 3 6716 6532
Total 6949 6939
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5.2.3	  Inhibition	  of	  IL-­‐2	  signalling	  following	  tofacitinib	  treatment	  Reproducibly	   downregulated	   proteins	   included	   known	   targets	   of	   the	   STAT5	  transcription	  factor	  such	  as	  CD25	  and	  Cish.	  Expression	  of	  CD25,	  the	  α	  chain	  of	  the	  IL-­‐2	   receptor,	   is	  maintained	   by	   IL-­‐2	   signalling	   (Kim	   et	   al.,	   2001;	  Nakajima	   et	   al.,	  1997).	   Cytokine-­‐inducible-­‐SH2-­‐containing	   protein	   (Cish),	   a	   cytokine	   induced	  protein	   that	   negatively	   regulates	   STAT5	   dependent	   signalling	   including	   IL-­‐2	  signalling	  by	  limiting	  the	  tyrosine	  phosphorylation	  of	  STAT5,	  is	  also	  a	  STAT5	  target	  (Matsumoto	  et	  al.,	  1997)	  (figure	  5.3A	  and	  5.3B).	  The	  reduced	  abundance	  of	  these	  STAT5	   targets	   suggests	   that	   IL-­‐2	   signalling	   was	   effectively	   inhibited	   in	   the	  tofacitinib	   treated	   samples	   used	   for	   proteomic	   analysis:	   however,	   as	   this	   data	   is	  limited	   to	   protein	   abundance	   it	   is	   not	   possible	   to	   determine	   if	   the	   transcription	  rather	  than	  translation	  of	  these	  targets	  was	  reduced.	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5.2.4	   Pathway	   analysis	   of	   proteins	   regulated	   by	   24	   hours	   tofacitinib	  
treatment	  To	   determine	   what	   pathways	   and	   processes	   were	   affected	   following	   24	   hours	  treatment	  of	  IL-­‐2	  maintained	  CTL	  with	  tofacitinib,	  proteins	  significantly	  regulated	  following	  tofacitinib	  treatment	  were	  submitted	  for	   functional	  annotation	  analysis	  using	  the	  DAVID	  (database	  for	  annotation,	  visualization	  and	  integrated	  discovery)	  analysis	   tool	   (Huang	  et	   al.,	   2008;	  2009).	  Enrichment	  of	   the	   regulated	  proteins	   in	  KEGG	   pathway	   annotations	   and	   enrichment	   in	   GO	   terms	   related	   to	   biological	  processes,	  molecular	  function	  and	  cellular	  compartment	  was	  assessed.	  	  	  The	   set	   of	   downregulated	   proteins	  were	   enriched	   in	  KEGG	  pathway	   annotations	  including	   those	   linked	   to	   steroid	   biosynthesis,	   protein	   processing	   in	   the	  endoplasmic	   reticulum,	   and	   P13K/Akt	   signalling	   pathways	   	   (Appendix	   B.1,	   table	  B1).	  The	  annotations	  linked	  to	  steroid	  biosynthesis	  identified	  proteins	  involved	  in	  cholesterol	   production,	   suggesting	   that	   cholesterol	   metabolism	   is	   affected	   by	  tofacitinib	   treatment.	   Proteins	   identified	   as	   part	   of	   the	   PI3K/PKB	   pathway	  included	  cell	  cycle	  components	  such	  as	  cyclin	  D3,	  cyclin	  E1	  and	  cyclin	  dependent	  kinase	   inhibitor	   1;	   the	   cytokine	   receptors	   IL-­‐2Rα	   and	   IL-­‐2Rβ;	   as	   well	   as	   the	  apoptosis	   inhibitor	   Bcl-­‐2-­‐like	   protein	   1,	   and	   	   lamimin	   subunit	   γ,(Appendix	   B.2,	  table	  B3).	  	  The	   set	   of	   downregulated	   proteins	   were	   also	   enriched	   in	   GO	   term	   biological	  process	   annotations	   linked	   to	   lipid	   metabolism	   and	   cholesterol	   biosynthesis,	  regulation	  of	   ribosome	  biogenesis,	   and	   regulation	  of	   cell	   proliferation	   (Appendix	  B.1,	   table	  B1).	  The	  set	  of	  downregulated	  proteins	  were	  also	  enriched	   in	  GO	   term	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molecular	   function	   annotations	   linked	   to	   transcription	   factor	   activity,	   ATP-­‐dependent	  RNA	  helicase	  activity,	  iron	  binding	  and	  RNA	  binding	  (Appendix	  B,	  table	  B2).	  This	  suggests	   that	   tofacitinib	  treatment	  regulated	  the	  abundance	  of	  proteins	  involved	   in	   regulating	   gene	   expression,	   and	   RNA	   processing.	   Downregulated	  proteins	   were	   also	   significantly	   enriched	   in	   GO	   term	   cellular	   compartment	  annotations	  linked	  to	  the	  nucleolus,	  plasma	  membrane,	  the	  endoplasmic	  reticulum	  and	  the	  ribosome/preribosome	  (Appendix	  B.1,	  table	  B2).	  	  	  The	   set	   of	   proteins	   reproducibly	   detected	   to	   be	   upregulated	   following	   24	   hours	  tofacitinib	  treatment	  of	   IL-­‐2	  maintained	  CTL	  were	  significantly	  enriched	   in	  KEGG	  pathway	  annotations	  linked	  to	  the	  lysosome	  (Appendix	  B.1,	  table	  B3).	  Upregulated	  proteins	  were	   also	   enriched	   in	  GO	   term	  biological	   process	   annotations	   linked	   to	  lysosome	   organization	   and	   intracellular	   signal	   transduction	   (Appendix	   B.1,	   table	  B3).	  Upregulated	  proteins	  were	  also	   significantly	   enriched	   in	  GO	   term	  molecular	  function	   annotations	   linked	   to	  hydrolase	   activity	   and	   acylglycerol	   lipase	   activity;	  and	   GO	   term	   cellular	   compartment	   terms	   linked	   to	   exomes	   and	   the	   lysosome	  (Appendix	  B.1,	  table	  B3).	  	  
5.2.5	  Regulation	  of	  receptor	  protein	  abundance	  by	  tofacitinib	  Tofacitinib	   treatment	  resulted	   in	  reduced	  abundance	  of	   the	  α	  subunit	  of	   the	   IL-­‐2	  receptor	   (figure	   5.3).	   Mass	   spectrometry	   analysis	   identified	   the	   expression	   of	  multiple	  of	   cytokine/hormone	   family	   receptors	  by	  CTL,	   including	  γc	   chain,	   IL-­‐12,	  TNF,	   chemokine,	   TGFβ	   and	   interferon	   family	   receptors	   (Appendix	   B,	   table	   B14).	  Tofacitinib	  treatment	  significantly	  reduced	  the	  abundance	  of	  the	  α	  and	  β	  subunits	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of	  the	  IL-­‐2	  receptor.	  Abundance	  of	  the	  γc	  chain,	  the	  α	  subunit	  of	  the	  IL-­‐7	  receptor	  or	  the	  IL-­‐21	  receptor	  were	  not	  regulated	  by	  tofacitinib	  treatment	  (figure	  5.4).	  	  
	  
Figure	  5.4:	  Regulation	  of	  γc	  chain	  cytokine	  receptors.	  A.	  Volcano	  plot	  showing	  the	  fold	  change	  in	  the	   copy	   number	   ratio	   of	   the	   indicated	   γc	   cytokine	   receptors	   as	   determined	   using	   by	   analysis	   of	  mass	  spectrometry	  data	  using	  the	  proteomic	  ruler	  plug-­‐in	  of	  the	  Perseus	  software.	  B.	  Table	  shows	  the	   copy	   number	   ratios	   of	   common	   γc	   cytokine	   receptors	   in	   tofacitinib	   treated	   versus	   untreated	  CTL,	   and	   mean	   copy	   number	   of	   common	   γc	   cytokine	   receptors	   identified	   in	   IL-­‐2	   maintained,	  untreated	  samples.	  	  Within	   the	   IL-­‐12	   receptor	   family,	   the	   abundance	   of	   the	   IL-­‐12Rβ1	   subunit	   was	  decreased,	  but	  not	  significantly	  following	  tofacitinib	  treatment.	  The	  abundance	  of	  the	  α	  subunit	  of	   the	   IL-­‐27	  receptor	   increased,	  but	   this	  was	  not	  significant	  (figure	  5.5).	  	  




























subunit alpha Il2ra 0.18 0.31 0.21 0.23 + 789,549
P16382
Interleukin-4 receptor 
subunit alpha Il4r 0.18 0.51 0.30 0.33 16,251
P16297
Interleukin-2 receptor 





Il2rg 0.52 1.03 1.44 1.00 193,859
Q9JHX3 Interleukin-21 receptor Il21r 0.62 1.74 0.80 1.05 2,571
P16872 Interleukin-7 receptor 
subunit alpha
Il7r 1.42 0.77 1.23 1.14 7,105
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Figure	   5.5:	   Regulation	   of	   IL-­‐12	   family	   cytokine	   receptors.	   A.	   Volcano	   plot	   showing	   the	   fold	  change	   in	   the	   copy	   number	   ratio	   of	   the	   indicated	   IL-­‐12	   family	   cytokine	   receptors	   as	   determined	  using	   by	   analysis	   of	   mass	   spectrometry	   data	   using	   the	   proteomic	   ruler	   plug-­‐in	   of	   the	   Perseus	  software.	  B.	  Table	   shows	   the	  copy	  number	  ratios	   in	   tofacitinib	   treated	  versus	  untreated	  CTL	  and	  the	  mean	  copy	  number	  of	  IL-­‐12	  family	  receptors	  identified	  in	  IL-­‐2	  maintained,	  untreated	  samples.	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Figure	   5.6:	   Regulation	   of	   TNF	   receptor/receptor	   ligand	   superfamily	   members	   following	  



































O35235-2 Tumor necrosis factor ligand 
superfamily member 11
Tnfsf11 - 0.10 - 0.10 11,151
P20334 Tumor necrosis factor receptor 
superfamily member 9
Tnfrsf9 0.10 0.41 0.15 0.22 378,516
Q60846 Tumor necrosis factor receptor 
superfamily member 8
Tnfrsf8 0.36 0.24 0.20 0.27 + 83,770
Q9QZM4 Tumor necrosis factor receptor 
superfamily member 10B
Tnfrsf10b 0.28 0.39 0.42 0.36 + 9,611
P41274 Tumor necrosis factor ligand 
superfamily member 9
Tnfsf9 - 0.45 - 0.45 3,064
P47741 Tumor necrosis factor receptor 
superfamily member 4
Tnfrsf4 - 0.45 - 0.45 16,556
P25119 Tumor necrosis factor receptor 
superfamily member 1B
Tnfrsf1b 0.67 0.78 0.98 0.81 20,408
O35714 Tumor necrosis factor receptor 
superfamily member 18
Tnfrsf18 0.82 1.04 0.98 0.94 74,044
Q9EPU5 Tumor necrosis factor receptor 
superfamily member 21
Tnfrsf21 - - 1.38 1.38 586
P83626 Tumor necrosis factor receptor 
superfamily member 26
Tnfrsf26 - 2.70 - 2.70 3,516
O08712 Tumor necrosis factor receptor 
superfamily member 11B
Tnfrsf11b - - - - 4,928
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Tofacitinib	   regulated	   the	   abundance	   of	   various	   cytokines	   identified	   by	   mass	  spectrometry.	   The	   abundance	   of	   TGFβ1	   was	   significantly	   reduced	   by	   tofacitinib	  treatment,	   and	   the	   abundance	   of	   osteopontin	  was	   reduced,	   but	   not	   significantly.	  TNF,	  IL-­‐24	  and	  lymphotoxin	  α	  were	  detected	  in	  IL-­‐2	  maintained	  samples	  but	  not	  in	  tofacitinib	  treated	  samples,	  suggesting	  that	  the	  abundance	  of	  these	  cytokines	  may	  have	  been	  reduced	  following	  tofacitinib	  treatment	  (figure	  5.7).	  
	  
	   	  
	  
Figure	   5.7:	   Regulation	   of	   cytokine	   abundance	   following	   tofacitinib	   treatment	   of	   IL-­‐2	  
maintained	  CTL	  Graphs	  show	  estimated	  copy	  number	  of	  indicated	  cytokines	  as	  determined	  using	  by	  analysis	  of	  mass	  spectrometry	  data	  using	  the	  proteomic	  ruler	  plug-­‐in	  of	  the	  Perseus	  software.	  A.	  Volcano	   plot	   showing	   the	   fold	   change	   and	   log10	   transformed	   p-­‐value	   for	   cytokines	   identified	   by	  mass	   spectrometry	   in	   IL-­‐2	  maintained	   and	   IL-­‐2	  maintained	   and	   24	   hr	   tofacitinib	   treated	   CTL	  B.	  Table	   shows	   the	   copy	   number	   ratios	   and	   mean	   copy	   number	   of	   cytokines	   identified	   in	   IL-­‐2	  maintained	  and	  tofacitinib	  treated	  samples.	  	  
A.
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P10923 Osteopontin Spp1 0.22 3 3 527,785 170,754
P04202 Transforming growth factor beta-1 Tgfb1 0.54 + 3 3 195,017 104,493
O54824 Pro-interleukin-16 Il16 1.65 3 3 109,606 180,386
Q925S4 Interleukin-24 Il24 - 3 0 7,455 -
P06804 Tumor necrosis factor Tnf - 2 0 11,206 -
P09225 Lymphotoxin-alpha Lta - 2 0 6,592 -
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5.2.6	  Regulation	  of	  proteins	  involved	  in	  metabolism	  by	  tofacitinib	  Pathway	   analysis	   of	   proteins	   regulated	   following	   tofacitinib	   treatment	   indicated	  significant	   enrichment	   of	   annotations	   linked	   to	   sterol	   metabolism	   in	   proteins	  reproducibly	  detected	  to	  be	  downregulated	  (Appendix	  B,	  table	  B1).	  The	  abundance	  of	  multiple	  enzymes	  involved	  in	  sterol	  biosynthesis	  was	  downregulated	  following	  tofacitinib	   treatment	   (table	   5.1),	   suggesting	   that	   tofacitinib	   treatment	   would	  reduce	  the	  ability	  of	  CTL	  to	  synthesize	  cholesterol.	  Expression	  of	  proteins	  involved	  in	   sterol	   biosynthesis	   has	   been	   reported	   to	   be	   regulated	   by	   the	   SREBP	  transcription	   factors	   SREBP1	   and	   SREBP2	   (Kidani	   et	   al.,	   2013).	   SREBP1	  was	  not	  identified	   by	   mass	   spectrometry,	   but	   SREBP2	   was	   reduced	   following	   tofacitinib	  treatment	   (mean	  copy	  number	  ratio	  of	  0.46,	   table	  5.1),although	  not	   significantly,	  suggesting	   that	   the	   reduced	   abundance	   of	   proteins	   involved	   in	   regulating	   sterol	  biosynthesis	   following	   tofacitinib	   treatment	   may	   be	   the	   result	   of	   the	   reduced	  abundance	  of	  transcription	  factors	  that	  positively	  regulate	  their	  expression.	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Table	   5.1:	   Tofacitinib	   regulates	   the	   abundance	   of	   proteins	   involved	   in	   sterol/cholesterol	  
biosynthesis	   Table	   shows	   the	   copy	   number	   ratio	   of	   proteins	   involved	   in	   sterol	   biosynthesis	   in	  tofacitinib	  treated	  and	  untreated	  CTL,	  and	  the	  and	  mean	  copy	  number	  of	  proteins	  involved	  in	  sterol	  biosynthesis	  in	  IL-­‐2	  maintained,	  untreated	  CTL.	  BR	  –	  biological	  replicate.	  	  













Q01237 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase
Hmgcr 0.36 0.16 0.17 0.23 + 13,002
P35951 Low-density lipoprotein receptor Ldlr 0.31 0.37 0.38 0.35 + 83,595
Q9CRA4 Methylsterol monooxygenase 1 Msmo1 0.42 0.38 0.29 0.36 + 66,449
Q8JZK9
Hydroxymethylglutaryl-CoA synthase, 
cytoplasmic Hmgcs1 0.20 0.46 0.51 0.39 1,823,424
O88822 Lathosterol oxidase Sc5d 0.44 0.40 0.34 0.39 + 6,461
Q3U1N2 Sterol regulatory element-binding protein 2 Srebf2 - 0.38 0.53 0.46 2,425
Q8K0C4 Lanosterol 14-alpha demethylase Cyp51a1 0.40 0.60 0.42 0.47 + 369,106
O88736 3-keto-steroid reductase Hsd17b7 0.48 0.61 0.44 0.51 + 70,495
P53798 Squalene synthase Fdft1 0.50 0.66 0.38 0.51 + 11,943
P52019 Squalene monooxygenase Sqle 0.46 0.75 0.42 0.55 45,374
Q99JF5 Diphosphomevalonate decarboxylase Mvd 0.50 0.53 0.72 0.58 + 153,561
Q8VCH6 Delta(24)-sterol reductase Dhcr24 0.97 0.75 0.36 0.69 49,014
Q920E5 Farnesyl pyrophosphate synthase Fdps 0.50 0.81 0.83 0.71 2,047,546
Q9D1G2 Phosphomevalonate kinase Pmvk 0.32 0.63 1.20 0.72 72,531
Q8BLN5 Lanosterol synthase Lss 0.55 0.73 1.00 0.76 247,939
P70245 3-beta-hydroxysteroid-Delta(8),Delta(7)-
isomerase
Ebp - 0.93 0.60 0.76 20,655
Q9R1J0
Sterol-4-alpha-carboxylate 3-dehydrogenase, 
decarboxylating Nsdhl 0.56 1.01 0.74 0.77 179,973
P58044 Isopentenyl-diphosphate Delta-isomerase 1 Idi1 1.05 0.63 0.74 0.81 2,566,001
Q9WTN0 Geranylgeranyl pyrophosphate synthase Ggps1 0.64 0.89 1.27 0.93 29,279
Q8CAY6 Acetyl-CoA acetyltransferase, cytosolic Acat2 0.92 1.34 0.74 1.00 167,835
Q921H8 3-ketoacyl-CoA thiolase A, peroxisomal Acaa1a 0.86 1.24 1.34 1.14 214,013
O88455 7-dehydrocholesterol reductase Dhcr7 1.06 1.55 0.94 1.18 9,173
Q8QZT1 Acetyl-CoA acetyltransferase, mitochondrial Acat1 0.88 1.25 1.68 1.27 576,421





Fnta 1.32 1.03 2.14 1.49 68,166
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The	  SLC	  (solute	  carrier)	  family	  of	  proteins	  mediate	  the	  transport	  of	  various	  small	  molecules,	   including	  amino	  acids,	  glucose	  and	  metals,	   into	  cells	  (Lin	  et	  al.,	  2015).	  Mass	  spectrometry	  resulted	  in	  the	  identification	  of	  69	  SLC	  proteins	  in	  CTL,	  seven	  of	  which	  were	  significantly	  detected	  to	  be	  regulated	  following	  tofacitinib	  treatment	  of	   IL-­‐2	   maintained	   CTL	   (table	   5.2).	   Of	   the	   reproducibly	   regulated	   SLC	   proteins,	  SLC7A5	   and	   SLC1A4	   are	   amino	   acid	   transporters	   and	   SLC2A1	   is	   a	   glucose	  transporter.	  
	  
Table	   5.2:	   Regulation	   of	   SLC	   proteins	   by	   tofacitinib	   Table	   shows	   the	   copy	   number	   ratio	   in	  tofacitinib	  treated	  and	  untreated	  CTL	  and	  the	  mean	  copy	  number	  in	  IL-­‐2	  maintained,	  untreated	  CTL	  of	  SLC	  proteins	  significantly	  regulated	  by	  tofacitinib	  treatment.	  BR:	  biological	  replicate.	  	  
5.2.7	  Regulation	  of	  effector	  proteins	  by	  tofacitinib	  Proteins	   downregulated	   following	   tofacitinib	   treatment	   were	   significantly	  enriched	   in	   the	   GO	   term	   biological	   process	   annotation	   cytolysis.	   CTL	   express	   a	  number	   of	   effector	   proteins,	   including	   perforin	   and	   the	   granzymes,	   that	   are	  required	   for	   their	   cytotoxic	   function	   (Zhang	   &	   Bevan,	   2011),	   and	   IL-­‐2	   has	  previously	  been	  reported	  to	  regulate	  perforin	  and	  granzyme	  expression	  (Janas	  et	  













O35874 Neutral amino acid 
transporter A
Slc1a4 0.34 0.38 0.45 0.39 + 17,278
Q61609 Sodium-dependent 
phosphate transporter 1
Slc20a1 0.20 0.35 0.33 0.29 + 14,549
P17809
Solute carrier family 2, 
facilitated glucose 
transporter member 1
Slc2a1 0.32 0.44 0.53 0.43 + 258,501
Q78IQ7-2 Zinc transporter ZIP4 Slc39a4 0.67 0.75 0.63 0.68 + 3,363
Q7TML3 Solute carrier family 35 
member F2
Slc35f2 0.53 0.67 0.68 0.63 + 8,825
Q9Z127
Large neutral amino 
acids transporter small 
subunit 1
Slc7a5 0.69 0.68 0.54 0.64 + 306,788
P53986
Monocarboxylate 
transporter 1 Slc16a1 0.61 0.58 0.79 0.66 + 405,560
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al.,	  2005).	  To	  determine	  which	  of	  these	  effector	  proteins	  were	  regulated	  following	  tofacitinib	   treatment,	   the	   abundance	   of	   these	   proteins	   as	   determined	   by	   mass	  spectrometry	  was	  examined.	  This	  showed	  that	  tofacitinib	  treatment	  resulted	  in	  a	  significant	   reduction	   in	   perforin-­‐1	   and	   granzyme	   E,	   but	   not	   other	   granzymes	  including	  A,B,C	  or	  G	  (figure	  5.8).	  This	  suggests	   that	   tofacitinib	   treatment	  reduces	  the	  abundance	  of	  some	  CTL	  effector	  molecules,	  but	  leaves	  the	  expression	  of	  others,	  including	  the	  highly	  expressed	  granzyme	  B	  and	  A,	  intact.	  	  
	   184	  
	  
	  
Figure	  5.8:	  Regulation	  of	   effector	  protein	   abundance	   in	   tofacitinib	   treated	  CTL	   	  A.	  The	  fold	  change	   in	   the	   abundance	   of	   granzymes	   and	   perforin	   in	   CTL	   treated	   for	   24	   hours	   with	   100nM	  tofacitinib	  compared	  to	  IL-­‐2	  maintained	  CTL.	  Fold	  changes	  expressed	  as	  the	  log2	  of	  the	  ratio	  of	  the	  copy	   numbers	   of	   each	   protein	   identified	   in	   tofacitinib	   treated	   CTL	   and	   IL-­‐2	   maintained	   CTL.	  B.	  Table	  showing	  the	  ratio	  of	  effector	  proteins	  in	  tofacitinib	  treated	  versus	  untreated	  CTL	  and	  the	  and	  mean	  copy	  number	  of	  effector	  proteins	  in	  untreated,	  IL-­‐2	  maintained	  CTL.	  BR:	  biological	  replicates.	  	  	  
5.2.8	  Regulation	  of	  transcriptional	  regulators	  by	  tofacitinib	  IL-­‐2	  signalling	  is	  known	  to	  regulate	  various	  transcription	  factors	  including	  STAT5,	  Jun	   family	   transcription	   factors	   and	   c-­‐myc,	   either	   by	   regulating	   post-­‐
A.
B.





























P08883 Granzyme F Gzmf - 0.26 0.16 0.21 34,083
P10820 Perforin-1 Prf1 0.12 0.33 0.31 0.25 + 1,552,834
P11033 Granzyme D Gzmd 0.06 0.53 0.40 0.33 1,661,823
P13366 Granzyme G Gzmg - 0.42 0.32 0.37 447,937
P08884 Granzyme E Gzme 0.34 0.45 0.52 0.44 + 1,620,140
P04187
Granzyme 
B(G,H) Gzmb 0.37 0.91 0.65 0.64 52,800,000
P08882 Granzyme C Gzmc 0.37 0.97 0.85 0.73 2,409,208
P11032-2 Granzyme A Gzma 0.52 1.11 1.06 0.89 39,580,747
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transcriptional	   modifications	   such	   as	   phosphorylation	   or	   by	   regulating	   their	  transcription	   or	   translation.	   To	   identify	   other	   transcription	   factors	   and	  transcriptional	   regulators	   whose	   abundance	   is	   JAK	   kinase	   dependent,	   the	  abundance	   of	   proteins	   as	   determined	   by	   mass	   spectrometry	   with	   the	   GO	   term	  molecular	   function	   annotation	   ‘transcription	   factor	   activity’	   was	   examined.	   In	  addition	   to	   downregulation	   of	   Fos/Jun/AP-­‐1	   family	   transcription	   factors,	   which	  are	   known	   targets	   of	   IL-­‐2	   signalling,	   this	   identified	   regulation	   of	   other	  transcription	   factors	   including	   NFIL3,	   IRF8	   and	   Batf3	   following	   tofacitinib	  treatment	  (table	  5.3).	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Table	   5.3:	   Regulation	   of	   transcription	   factor	   and	   transcriptional	   regulator	   abundance	   in	  
tofacitinib	   treated	   CTL	   Table	   shows	   the	   ratio	   of	   copy	   numbers	   in	   tofacitinib	   treated	   versus	  untreated	  and	   the	  mean	  copy	  number	   in	   IL-­‐2	  maintained,	  untreated	  CTL,	  of	   transcription	   factors	  significantly	  regulated	  following	  tofacitinib	  treatment.	  BR:	  biological	  replicate.	  	  	  	  	  	  	  	  	  	  	  	  	  













O08750 Nuclear factor interleukin-3-
regulated protein
Nfil3 0.06 0.21 0.14 0.14 + 95,028
P23611 Interferon regulatory factor 8 Irf8 0.16 0.22 0.26 0.21 + 33,367
Q9D275 Basic leucine zipper 
transcriptional factor ATF-like 3
Batf3 0.27 0.37 0.12 0.26 + 26,156
P05627 Transcription factor AP-1 Jun 0.27 0.47 0.38 0.37 + 24,644
P42682-2 Tyrosine-protein kinase TXK Txk 0.25 0.46 0.49 0.40 + 5,949
P47930 Fos-related antigen 2 Fosl2 0.36 0.32 0.54 0.41 + 123,833
Q80UV9 Transcription initiation factor 
TFIID subunit 1
Taf1 0.38 0.34 0.51 0.41 + 14,077
P15066 Transcription factor jun-D Jund 0.46 0.47 0.33 0.42 + 126,335
Q8R3L2 Transcription factor 25 Tcf25 0.48 0.44 0.40 0.44 + 52,229
Q8VIG1
RE1-silencing transcription 
factor Rest 0.44 0.49 0.48 0.47 + 2,074
Q8R4Z4 ETS translocation variant 3 Etv3 0.65 0.38 0.49 0.50 + 42,062
Q921D4
Mediator of RNA polymerase II 
transcription subunit 6 Med6 0.54 0.53 0.55 0.54 + 26,019
Q80WC1-2 Ubinuclein-2 Ubn2 0.51 0.46 0.66 0.54 + 1,951
Q61827 Transcription factor MafK Mafk 0.46 0.61 0.67 0.58 + 44,570
Q6PCM1 Lysine-specific demethylase 3A Kdm3a 0.58 0.53 0.66 0.59 + 27,623
Q08639 Transcription factor Dp-1 Tfdp1 0.57 0.71 0.58 0.62 + 45,993
Q9EQN3 TSC22 domain family protein 4 Tsc22d4 2.23 1.46 1.98 1.89 + 29,674
Q8BV49 Pyrin and HIN domain-
containing protein 1
Pyhin1 2.37 3.25 2.99 2.87 + 62,103
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5.2.9	  The	  most	  highly	  regulated	  proteins	  following	  tofacitinib	  treatment	  To	   further	   explore	   the	   effect	   of	   JAK	   kinase	   inhibition	   on	   the	   proteome	   of	   IL-­‐2	  maintained	   CTL,	   information	   was	   found	   on	   the	   functions	   of	   the	   most	   highly	  regulated	  proteins.	   Tables	   5.4	   and	  5.5	   show	   the	  most	   highly	   downregulated	   and	  upregulated	   proteins	   following	   tofacitinib	   treatment	   of	   IL-­‐2	   maintained	   CTL	   as	  determined	   by	   copy	   number	   ratios.	   All	   proteins	   reproducibly	   detected	   to	   be	  downregulated	   by	   24	   hours	   tofacitinib	   treatment	   are	   listed	   in	  Appendix	  B.3	   and	  B.4.	  	  




Table	   5.4:	   Most	   highly	   downregulated	   proteins	   following	   24	   hours	   tofacitinib	   treatment	  Table	  made	  using	  information	  from	  Uniprot	  and	  references	  as	  indicated.	  	  
Uniprot ID Protein names Gene mean ratio mean copy number (IL-2) Protein function
P55041 GTP-binding protein GEM Gem 0.08 72,667
Small GTP binding protein from Ras family. 
Expression induced by T cell activation, involved in 
regulation of the cytoskeleton (Chevalier et al., 2014)
P19182 Interferon-related developmental 
regulator 1
Ifrd1 0.12 7,752
Reported transcriptional regulator function, required 
for NK cell effector function (Vietor et al., 2002; Gu 
et al., 2009)
O08750
Nuclear factor interleukin-3-regulated 
protein Nfil3 0.14 95,028
Transcription factor and circadian protein. Required 
for development of various immune cells including 
ILC (Geiger et al., 2014)
Q8VE91-3 Protein FAM134B Fam134b 0.14 26,427
Involved in autophagy and regulation of the 
endoplasmic reticulum (Khaminets et al. 2015)
Q6EJB6
U3 small nucleolar RNA-associated 
protein 14 homolog B Utp14b 0.15 2,364
In S.cervisae, required for rRNA processing: in 
mammals main role seems to be in spermatogenesis 
(Dragon et al., 2002; Bradley et al., 2004)
P23611 Interferon regulatory factor 8 Irf8 0.21 33,367
Transcription factor with various roles in immune cell 
function including dendritic cell development and 




Hmgcr 0.23 13,002 Required for cholesterol biosynthesis (Kidani et al., 
2013)
P01590 Interleukin-2 receptor subunit alpha Il2ra 0.23 789,549 Part of the high affinity IL-2 receptor (Boyman and 
Sprent, 2012)
O55003
BCL2/adenovirus E1B 19 kDa protein-
interacting protein 3 Bnip3 0.23 46,207
Outer mitochondrial membrane protein involved in 
the induction of autophagy and cell death (Ney, 
2015)
P02468 Laminin subunit gamma-1 Lamc1 0.24 3,548
Binds to proteins including integrins as part of a 
complex with a α and β laminin subunit (Nishiuchi et 
al., 2006)
Q9QZ85 Interferon-inducible GTPase 1 Iigp1 0.24 192,934
Precise function unclear. Involved in the response to 
intracellular pathogens with a potential role in 
autophagy (Maric-Biresev et al., 2016). Required for 
CD4+ T cell survival following IFNγ stimulation (Feng 
et al., 2008).
P10820 Perforin-1 Prf1 0.25 1,552,834 CTL effector protein, forms pores in target cell 
(Voskoboinik et al., 2015)
Q9D275
Basic leucine zipper transcriptional 
factor ATF-like 3 Batf3 0.26 26,156
AP-1 family transcription factor reported to inhibit AP-
1 activity Iacobelli et al., 2000). Involved in dendritic 
cell development Grajales-Reyes et al., 2015).
Q60846 Tumor necrosis factor receptor 
superfamily member 8
Tnfrsf8 0.27 83,770 Also known as CD30, binds CD30L. Possible role in 
T cell memory (Gaspal et al., 2005)
Q5BU09-2 E2F-associated phosphoprotein Eapp 0.27 31,528 Involved in regulating cell cycle arrest. Anti-apoptotic 
(Andofer and Rothender, 2011)
P39689 Cyclin-dependent kinase inhibitor 1 Cdkn1a 0.28 151,465
Binds multiple cyclin dependent kinases, involved in 
various cellular processes including regulation of the 
cell cycle, stress reponses and apoptosis (Kries et 
al., 2013)
Q9QZ82 Cholesterol side-chain cleavage 
enzyme, mitochondrial
Cyp11a1 0.28 9,569 Cleaves cholesterol to form pregnenonlone 
(Yoshimoto et al., 2016)
Q8BYR2 Serine/threonine-protein kinase 
LATS1
Lats1 0.29 1,343
Downstream effector of Hippo (MST1/MST2, Moya 
and Halder, 2016): however, in T cells the role of 
MST1/2 in regulating LATS1 has been questioned 
(Tang et al., 2015). 
Q61609 Sodium-dependent phosphate 
transporter 1
Slc20a1 0.29 14,549 Sodium-phosphate symporter (Beck et al., 2009)
Q8BWW4 La-related protein 4 Larp4 0.30 113,837 Poly(A) binding protein that regulates mRNA stability 
(Yang et al., 2011)




Table	  5.5:	  Most	  highly	  upregulated	  proteins	   following	  24	  hours	   tofacitinib	   treatment	  Table	  made	  using	  information	  from	  Uniprot	  and	  references	  as	  indicated.	  	  	  
Uniprot ID Protein names Gene mean ratio mean copy number (IL-2) Protein function
Q8R1S0 Ubiquinone biosynthesis 
monooxygenase COQ6
Coq6 102.69 2,838
Involved in the synthesis of the redox lipid 
ubiquinone (coenzyme Q), and so involved in 
respiration (Ozeir et al., 2015)
Q64267 DNA repair protein complementing 
XP-A cells homolog
Xpa 10.40 1,171
DNA repair protein whose primary role is the 
recruitment of other DNA damage response proteins 
to the site of DNA damage (Sugitani et al., 2016)
Q3UPP8-3 Centrosomal protein of 63 kDa Cep63 8.21 4,458 Centrosomal protein required for spindle assembly 
(Anderson et al., 2003; E. Smith et al., 2009)
Q61823 Programmed cell death protein 4 Pdcd4 6.66 53,079
Acts as a translationall repressor via its association 
with the translation initatiation factors eIF4GI and 
eIF4GII. Pdcd4 expression induced by IL-12 and 
repressed by IL-2 (Lankat-Buttgereit and Göke, 
2009)
Q8BIJ7 RUN and FYVE domain-containing 
protein 1
Rufy1 6.42 11,496 Endosomal Rab binding protein (Cormont et al. 
2001)
Q00651 Integrin alpha-4 Itga4 5.62 3,022 Collagen binding receptor involved in T cell 
migration (Andreasen et al., 2003)
P45591 Cofilin-2 Cfl2 5.36 1,650 Regulation of actin filament assembly/diassembly 
(Vartiainen et al., 2002)
Q9QZI9 Serine incorporator 3 Serinc3 5.22 7,421
Transmembrane protein, acts as restriction factor for 
HIV (Usami et al., 2015). Putative serine transporter 
(Inuzuka et al., 2005). 
Q8K349 GTPase IMAP family member 6 Gimap6 4.63 6,672 Putative GTPase, function not defined (Uniprot, 
Pascall et al., 2013)
Q3UMW8 Ceroid-lipofuscinosis neuronal protein 
5 homolog
Cln5 4.63 856
Lysosomal glycoprotein, possibly involved in lipid 
metabolism. Mutations associated with lysosomal 
storage disease (Cárcel-Trullols et al., 2015)
Q3V3R4 Integrin alpha-1 Itga1 3.68 1,481
Also known as CD49a. Part of the VLA-1/α1β1 
heterodimer. Binds type IV and I collagen (Ray et al., 
2004).
Q9QZQ8-2 Core histone macro-H2A.1 H2afy 3.55 4,914
Histone subunit involved in transcriptional repression 
(Angelov et al., 2003)
Q923D2 Flavin reductase (NADPH) Blvrb 3.49 29,863 Oxioreductase that reduces flavins (Uniprot)
O35448 Lysosomal thioesterase PPT2 Ppt2 3.26 736
Inhibitory NK cell receptor that interacts with the 
MHC molecule Qa-1b. Known to be expressed on 
CD8+ T cells (Byers et al., 2006)
P97427 Dihydropyrimidinase-related protein 1 Crmp1 3.16 6,175
Member of interferon induced PYHIN family, some 
members of which are involved in DNA sensing and 
the anti-viral response Schatten et al., 2011).
O54707 Natural killer cells antigen CD94 Klrd1 2.98 2,465
Inhibitory NK cell receptor that interacts with the 
MHC molecule Qa-1b. Known to be expressed on 
CD8+ T cells (Byers et al., 2006)
P35276 Ras-related protein Rab-3D Rab3d 2.97 16,440 Reported role in vesicle trafficking in various cell 
types (Pavlos et al., 2005)
Q8BV49 Pyrin and HIN domain-containing 
protein 1
Pyhin1 2.87 62,103
Member of interferon induced PYHIN family, some 
members of which are involved in DNA sensing and 
the anti-viral response Schatten et al., 2011).
P58466
Carboxy-terminal domain RNA 
polymerase II polypeptide A small 
phosphatase 1
Ctdsp1 2.81 4,618
Phosphatase from CTD phosphatase family, which 
dephosphorylase the C-terminal domain of RNA 
polymerase II (Mayfield et al., 2016)
Q3TT38 Uncharacterized protein C6orf106 
homolog
D17Wsu92e 2.75 60,018 Function unknown (Uniprot)
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5.3	  Discussion	  Proteomic	   analysis	   of	   IL-­‐2	  maintained	   CTL	   treated	   for	   24	   hours	  with	   tofacitinib	  resulted	   in	   the	   identification	   of	   6949	   proteins,	   211	   of	   which	   were	   significantly	  downregulated	   and	  103	   significantly	   upregulated.	   Pathway	   analysis	   showed	   that	  proteins	   reproducibly	   detected	   to	   be	   downregulated	   were	   enriched	   in	   proteins	  involved	   in	   lipid/sterol	   metabolism,	   ribosomal	   biogenesis	   and	   the	   cell	   cycle,	   ,	  highlighting	  the	  involvement	  of	  JAK	  kinase	  dependent	  signalling	  in	  regulating	  basic	  processes	   in	   CTL	   such	   as	   metabolism,	   gene	   expression	   and	   cell	   division.	   The	  treatment	   of	   IL-­‐2	   maintained	   CTL	   with	   tofacitinib	   for	   twenty	   four	   hours	   also	  resulted	   in	   the	   identification	   of	   other	   proteins	   including	   transcription	   factors,,	  proteins	   involved	   in	   regulating	   the	   lysosome,	   the	   actin	   cytoskeleton,	   and	   GTP	  binding	   proteins	   and	   proteins	   involved	   in	   regulating	   the	   activity	   of	   GTP	   binding	  proteins	   that	  were	  not	  previously	  known	  to	  be	  regulated	  by	   IL-­‐2.	  These	  proteins	  are	   potential	   effectors	   of	   IL-­‐2	   signalling	   and,	   given	   the	   importance	   of	   IL-­‐2	  signalling	   in	   CTL,	   may	   be	   important	   for	   the	   function	   of	   effector	   CD8+	   T	  lymphocytes.	  	  	  Of	   the	   downregulated	   proteins	   identified	   as	   involved	   in	   lipid/sterol	  metabolism,	  most	  were	  involved	  in	  the	  synthesis	  or	  transport	  of	  cholesterol	  (Appendix	  B	  table	  B1).	   This	   suggests	   that	   JAK	   kinase	   dependent	   signalling	   downstream	   of	   IL-­‐2	   is	  required	  to	  maintain	  cholesterol	  synthesis	  in	  CTL.	  Expression	  of	  components	  of	  the	  cholesterol	   biosynthesis	   pathway	   has	   previously	   been	   shown	   to	   be	   upregulated	  following	  TCR	  treatment,	  and	  upregulation	  of	  cholesterol	  synthesis	  to	  be	  required	  for	   T	   cell	   blasting	   in	   response	   to	   TCR	   stimulation	   (Kidani	   et	   al.,	   2013).	   The	  reduction	   in	   the	   abundance	   of	   cholesterol	   biosynthesis	   components	   following	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tofacitinib	  treatment	  of	  IL-­‐2	  maintained	  CTL	  would	  suggest	  that	  the	  increased	  rate	  of	  cholesterol	  synthesis	  can	  be	  maintained	  after	  TCR	  activation	  by	  IL-­‐2	  signalling.	  While	  it	  has	  not	  been	  tested,	  it	  seems	  likely	  that	  IL-­‐2	  maintained	  CTL	  would	  have	  similar	  requirements	  for	  cholesterol	  synthesis	  as	  a	  T	  cell	  during	  TCR	  stimulation.	  CTL	  maintain	   the	   large	   cell	   size	   reached	   following	  T	   cell	   blasting	   and	  proliferate	  rapidly,	  necessitating	  the	  production	  of	  cell	  components	  such	  as	  the	  cell	  membrane	  that	  contain	  large	  amounts	  of	  cholesterol.	  	  	  Expression	   of	   components	   of	   the	   cholesterol	   biosynthesis	   pathway	   is	   positively	  regulated	  by	   the	   transcription	   factors	   SREBP1	   and	   SREBP2	   (Kidani	   et	   al.,	   2013).	  The	  activity	  of	  the	  SREBP	  transcription	  factors	  is	  regulated	  by	  the	  expression	  of	  the	  transcription	   factors	   and	   proteolytic	   cleavage	   of	   the	   transcription	   factors	   to	   an	  active	  form	  that	  translocates	  to	  the	  nucleus	  and	  regulates	  gene	  expression	  (Lewis	  et	   al.,	   2011).	   Proteomic	   analysis	   showed	   reduced	   abundance	   of	   the	   SREBP2	  transcription	   factor	   following	   tofacitinib	   treatment,	   while	   the	   SREBP1	  transcription	   factor	   was	   not	   identified,	   suggesting	   that	   JAK	   kinase	   dependent	  signalling	  could	  drive	  cholesterol	  biosynthesis	  by	  regulating	  the	  abundance	  of	  the	  SREBP	  transcription	  factors.	  	  	  However,	  proteins	  are	   identified	   in	  bottom-­‐up	  proteomics	  by	  assigning	  identified	  peptides	   to	  proteins,	  and	  so	  differentiating	  between	   isoforms	  of	  a	  protein	  can	  be	  problematic.	  While	  the	  full-­‐length	  protein	  was	  identified	  as	  the	  most	  likely	  source	  of	  the	  SREBP2	  assigned	  peptides,	  the	  shorter	  processed	  isoform	  was	  also	  identified	  as	  a	  potential	  source	  and	  as	  the	  shorter	   isoform	  is	  the	  active	  form	  it	  would	  seem	  likely	  that	  at	   least	  some	  of	   the	   identified	  peptides	  were	  derived	  from	  the	  shorter	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form.	  Therefore,	   it	   is	  difficult	   to	   conclude	   if	   the	  observed	  reduction	   is	  a	   result	  of	  reduced	   abundance	   of	   SREBP2	   or	   a	   reduction	   in	   the	   abundance	   of	   processed	  SREBP2,	   and	   so	   it	   is	   possible	   that	   IL-­‐2	   signalling	   regulates	   abundance	   of	   the	  components	   of	   the	   cholesterol	   biosynthesis	   pathway	   by	   regulating	   processing	   of	  the	  SREBP	  transcription	  factors.	  	  Upregulation	  of	  components	  of	   the	  cholesterol	  biosynthesis	  pathway	   in	  T	  cells	   in	  response	  to	  TCR	  stimulation	  is	  rapamycin	  sensitive	  (Kidani	  et	  al.,	  2013),	  and	  mTOR	  signalling	  has	  been	  reported	   to	  regulate	  expression	  and	  processing	  of	   the	  SREBP	  transcription	   factors	   in	   other	   cells	   (Lewis	   et	   al.,	   2011).	   In	   IL-­‐2	  maintained	   CTL,	  rapamycin	  decreases	  the	  abundance	  of	  components	  of	  the	  cholesterol	  biosynthesis	  pathway	  (Hukelmann	  et	  al.,	  2015),	  suggesting	  that	  the	  reduction	  in	  abundance	  of	  proteins	  in	  the	  cholesterol	  biosynthesis	  pathway	  following	  tofacitinib	  treatment	  is	  dependent	  on	   regulation	  of	  mTORC1	  activity	  downstream	  of	   the	   JAK	  kinases.	  To	  determine	   what	   proteins	   downstream	   of	   mTORC1	   are	   involved	   in	   JAK	   kinase	  dependent	   regulation	   of	   cholesterol	   biosynthesis	   proteins,	   it	   would	   be	   useful	   to	  clarify	  if	  transcription	  of	  SREBP1	  and	  SREBP2	  was	  reduced	  or	  if	  SREBP	  processing	  was	   regulated	   following	   tofacitinib	   treatment.	   Processing	   of	   the	   SREBP	  transcription	   factors	   has	   been	   reported	   to	   be	   dependent	   on	   S6K	   (Owen	   et	   al.,	  2012),	  although	  this	  has	  been	  disputed	  (Lewis	  et	  al.,	  2011).	  	  Proteins	  downregulated	  following	  24	  hours	  tofacitinib	  treatment	  were	  enriched	  in	  ribosomal	  proteins,	  suggesting	  that	  JAK	  kinase	  dependent	  signalling	  is	  required	  for	  ribosome	   biogenesis	   in	   CTL.	   Treatment	   of	   IL-­‐2	  maintained	   CTL	   with	   rapamycin	  also	   reduces	   the	  abundance	  of	   ribosomal	  proteins	   (Hukelmann	  et	   al.,	   2015),	   and	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mTORC1	   has	   previously	   been	   reported	   to	   be	   required	   for	   ribosome	   biogenesis	  (Gentilella	  et	  al.,	  2015;	  Iadevaia	  et	  al.,	  2014),	  suggesting	  that	  JAK	  kinase	  dependent	  regulation	  of	  ribosome	  biogenesis	  is	  upstream	  of	  mTORC1.	  Interestingly,	  following	  TCR	  activation	  of	  T	  cells	  deficient	  in	  the	  SREBP	  chaperone	  SCAP	  (and	  so	  deficient	  in	   SREBP	   mediated	   transcription),	   regulated	   proteins	   are	   enriched	   in	   proteins	  involved	   in	   ribosome	  biogenesis,	   suggesting	   that	   ribosome	  biogenesis	   could	   also	  be	   linked	   to	   cholesterol	   metabolism	   (Kidani	   et	   al.,	   2013).	   The	   reduction	   in	  ribosomal	  proteins	  would	  also	  suggest	  that	  tofacitinib	  treatment	  would	  result	  in	  a	  global	  reduction	  in	  protein	  synthesis	  in	  CTL.	  	  Phosphoproteomic	  analysis	  indicated	  that	  IL-­‐2	  signalling	  and	  tofacitnib	  treatment	  regulated	  the	  phosphorylation	  of	  transcription	  factors	  and	  other	  proteins	  involved	  in	   regulating	   transcription	   (Ross	   et	   al.,	   2016).	   Tofacitinib	   treatment	   of	   IL-­‐2	  maintained	   CTL	   resulted	   in	   the	   reduced	   abundance	   of	   various	   transcription	  factors,	   including	  NFIL3,	   IRF8	   and	   Interferon-­‐related	   developmental	   regulator	   1,	  suggesting	  that	  JAK	  kinase	  dependent	  IL-­‐2	  signalling	  can	  regulate	  gene	  expression	  by	   regulating	   transcription	   factor	   abundance	   as	   well	   as	   regulating	   the	  phosphorylation	  of	  transcriptional	  regulators.	  	  	  NFIL3	  is	  a	  circadian	  protein	  which	  has	  previously	  shown	  to	  play	  an	  important	  role	  in	   the	   immune	   system	   as	   NFIL3	   expression	   is	   required	   for	   the	   development	   of	  various	   ILC	   subsets	   and	   has	   been	   shown	   to	   play	   a	   role	   in	   other	   immune	   cells	  including	   B	   and	   T	   lymphocytes	   (Geiger	   et	   al.,	   2014;	   Kashiwada	   et	   al.,	   2011;	  Kashiwada	  et	  al.,	  2010;	  Seillet	  et	  al.,	  2014),	  but	  its	  function	  in	  CD8+	  T	  lymphocytes	  has	  not	  been	  defined.	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IRF8	  has	  also	  been	  shown	  to	  have	  a	  significant	  role	  in	  the	  immune	  system:	  IRF8-­‐/-­‐	  mice	   have	   altered	   innate	   immune	   compartments,	   with	   a	   lack	   of	   dendritic	   cells,	  monocytes,	   eosinophil	   and	   basophils	   and	   an	   increased	   number	   of	   neutrophils	  (Tamura	  et	  al.,	  2015),	  and	  patients	  with	  various	  mutations	  in	  the	  IRF8	  gene	  have	  a	  spectrum	  of	  immunodeficiency	  syndromes	  (Hambleton	  et	  al.,	  2011).	  	  IRF8	  has	  also	  been	   suggested	   to	   play	   a	   role	   in	   regulating	   B	   cell	   development	   (Wang	  &	  Morse,	  2008)	   	   and	   to	   repress	   Th17	   cell	   development	   via	   interaction	   with	   the	   Th17	  transcription	  factor	  RORγt	  (Ouyang	  et	  al.,	  2011b).	  However,	  despite	  importance	  of	  IRF8	   in	  regulating	  various	  aspects	  of	   immune	  cell	  development	  and	   function,	   the	  role	  of	  IRF8	  in	  CD8+	  T	  lymphocytes	  has	  not	  been	  investigated	  extensively.	  	  	  Interferon-­‐related	  developmental	  regulator	  1	  (Ifrd1),	  also	  known	  as	  Tis7	  and	  PC4	  (Micheli	   et	   al.,	   2011)	   may	   act	   as	   a	   transcriptional	   regulator.	   Regulation	   of	   gene	  expression	  is	  thought	  to	  be	  dependent	  on	  its	  interaction	  with	  the	  HDAC	  containing	  SIN3	  complex	  rather	  than	  direct	  binding	  to	  DNA	  (Vietor	  et	  al.,	  2002).	  Neutrophils	  from	   Ifrd1-­‐/-­‐	   mice	   have	   reduced	   effector	   function,	   including	   a	   reduction	   in	   the	  magnitude	   of	   oxidative	   burst,	   reduced	   bacterial	   killing	   and	   reduced	   cytokine	  production,	  suggesting	  that	  interferon-­‐related	  developmental	  regulator	  1	  has	  some	  role	   in	   the	   immune	  system,	  but	   the	  role	   for	   Ifrd1	   in	  T	   lymphocytes	   is	  not	  known	  (Gu	  et	  al.,	  2009).	  	  	  The	   regulation	  of	   these	   transcription	   factors	   suggests	   that	   JAK	  kinase	  dependent	  IL-­‐2	   signalling	   can	  affect	   transcription	   in	  CTL	  using	  various	  effector	  proteins	  not	  previously	   identified	   as	  participating	   in	   IL-­‐2	   control	   of	   transcription.	  The	   role	   of	  many	   of	   the	   regulated	   transcription	   factors	   in	   CTL	   have	   not	   previously	   been	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described,	  and	  could	  be	  further	  explored	  by	  using	  knockout	  mice	  deficient	  in	  these	  transcription	  factors	  and	  using	  methods	  such	  as	  ChIP	  and	  ChIP-­‐seq	  to	  identify	  the	  IL-­‐2	  regulated	  targets	  of	  these	  transcription	  factors.	  
	  Phosphoproteomic	   analysis	   indicated	   that	   IL-­‐2	   stimulation	   and	   tofacitnib	  treatment	   regulated	   the	   phosphorylation	   of	   various	   GTP	   binding	   protein	  regulators	   (Ross	   et	   al.,	   2016).	   Proteomic	   analysis	   of	   tofacitinib	   treated	   CTL	  demonstrated	   that	   JAK	   kinase	   dependent	   IL-­‐2	   signalling	   also	   regulated	   the	  abundance	  of	  GTP	  binding	  proteins	  or	  proteins	  involved	  in	  regulating	  the	  activity	  of	  GTP	  binding	  proteins.	  This	   included	  downregulation	  of	   the	  abundance	  of	  GEM	  and	  upregulation	  of	  the	  abundance	  of	  Rufy1,	  Rufy3	  and	  Gimap6.	  The	  regulation	  of	  GTPase	   and	   GTPase	   regulating	   protein	   phosphorylation	   and	   abundance	   could	  suggest	   that	   regulation	   of	   GTPase	   activity	   beyond	   the	   relatively	   well-­‐defined	  Ras/MAPK	   pathway	   is	   an	   important	   component	   of	   IL-­‐2	   signalling.	   For	   example,	  RAC1	   has	   been	   reported	   to	   be	   activated	   downstream	   of	   PKCθ	   following	   IL-­‐2	  stimulation	   of	   KIT225	   cells,	   with	   this	   activity	   potentially	   linked	   to	   IL-­‐2	   induced	  proliferation	  (Llavero	  et	  al.,	  2015).	  	  GEM	   is	   a	   GTP	   binding	   protein	   of	   the	   Ras	   family	   expressed	   in	   activated	   T	   cells	  (Maguire	   et	   al.,	   1994).	   GEM	   associates	   with	   both	   actin	   and	   microtubules,	  suggesting	  a	  role	  in	  regulating	  the	  cytoskeleton	  (Piddini	  et	  al.,	  2001).	  Run	  and	  Fyve	  domain	   containing	   protein	   1	   (Rufy1,	   also	   known	   as	   Rabip4	   and	   EEA2)	   was	  originally	   identified	   in	  a	   screen	   for	  Rab4	   interacting	  proteins	   in	  S.cervisae.	  Rufy1	  interacts	   with	   PtdIns3P	   and	   localises	   to	   endosomes,	   particularly	   early	   sorting	  endosomes.	   Rufy1	   expression	   may	   be	   required	   for	   membrane	   protein	   recycling	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(Cormont	  et	  al.,	  2001;	  Fouraux	  et	  al.,	  2004).	  Rabip4	  (in	  association	  with	  AP-­‐3)	  also	  seems	   to	   be	   involved	   in	   the	   positioning	   of	   lysosomes,	   as	   siRNA	   knockdown	   of	  Rabip4	   in	   HEK293T	   cells	   results	   in	   a	   redistribution	   of	   the	   lysosomal	   marker	  proteins	  CD63	  and	  LAMP-­‐1	  to	  membrane	  protrusions	  (Ivan	  et	  al.,	  2012).	  	  The	  GIMAP	  family	  (GTPase	  of	   immunity	  associated	  proteins,	  also	  known	  as	  IANs,	  or	   immune	   associated	   nucleotide	   binding	   proteins)	   have	   been	   reported	   to	   be	  particularly	   highly	   expressed	   in	   the	   immune	   system,	   and	   share	   an	   AIG1	   domain	  involved	  in	  GTP	  binding.	  GTPase	  activity	  has	  been	  demonstrated	  for	  some	  GIMAP	  proteins	  but	  the	  GTPase	  activity	  of	  GIMAP	  6	  does	  not	  appear	  to	  have	  been	  tested.	  Various	  GIMAP	  proteins	  also	  have	  specific	  functions	  within	  the	  immune	  system,	  for	  example	  GIMAP4	  has	  been	  linked	  to	  regulation	  of	  T	  cell	  apoptosis	  and	  GIMAP3	  to	  positive	  selection	  during	  thymocyte	  development	  (Nitta	  &	  Takahama,	  2007).	  	  The	  role	  of	  these	  GTPases	  and	  GTPase	  regulatory	  proteins	  are	  not	  well	  defined	  in	  CTL,	   and	   could	   potentially	   be	   important	   effectors	   of	   IL-­‐2	   signalling.	   Further	  experiments	  could	  focus	  on	  defining	  the	  role	  of	  these	  proteins	  using	  knockout	  mice	  or	  focus	  on	  the	  effect	  of	  tofacitinib	  treatment	  on	  the	  processes	  that	  these	  proteins	  are	   involved	   in,	   including	   regulation	   of	   the	   actin	   cytoskeleton	   or	  endosome/lysosome	  function.	  	  In	   conclusion,	   phosphoproteomic	   and	   proteomic	   analysis	   resulted	   in	   the	  identification	  of	  various	  phosphorylation	  sites	  and	  proteins	  that	  were	  regulated	  by	  tofacitinib	  and	  groups	  of	  regulated	  sites	  or	  proteins	  that	  indicated	  processes	  such	  as	  CTL	  metabolism,	  effector	  function	  and	  progression	  through	  the	  cell	  cycle	  were	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regulated	   following	   tofacitinib	   treatment,	   indicating	   that	   in	   CTL	   these	   processes	  were	   JAK	   kinase	   dependent.	   Phosphoproteomic	   and	   proteomic	   analysis	   also	  indicated	  regulation	  of	   transcription	   factors	  and	  other	   transcriptional	   regulators,	  and	   regulation	   of	   GTPases	   and	   GTPase	   regulating	   proteins.	   Further	   experiments	  focused	  on	  validating	  the	  regulation	  of	  these	  proteins	  and	  processes	  by	  tofacitinib.	  The	  role	  of	  JAK	  kinase	  dependent	  signalling	  in	  regulating	  CTL	  glucose	  metabolism,	  expression	   of	   the	   tumour	   necrosis	   superfamily	   member	   4-­‐1BB,	   CTL	   effector	  function	  and	  the	  regulation	  and	  function	  of	  the	  transcription	  factor	  NFIL3	  will	  be	  discussed	  in	  chapter	  6.	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Chapter	  6:	  Validation	  of	  phosphoproteomics	  and	  proteomics	  
6.1	  Introduction	  Phosphoproteomic	  and	  proteomic	  analysis	   indicated	   that	   tofacitinib	   treatment	  of	  CTL	  resulted	   in	   the	   regulation	  of	  a	   selective	   subset	  of	   the	  phosphoproteome	  and	  proteome	   of	   an	   IL-­‐2	   maintained	   CTL.	   This	   included	   the	   phosphorylation	   of	  proteins	   involved	   in	   the	   regulation	   of	   gene	   transcription,	   regulation	   of	   the	   actin	  cytoskeleton	   and	   proteins	   with	   GTPase	   activity.	   The	   abundance	   of	   proteins	  involved	   in	   sterol	   and	   glucose	   metabolism,	   CTL	   effector	   function,	   the	   cell	   cycle,	  ribosomes	  and	  proteins	  involved	  in	  transcriptional	  regulation	  were	  also	  regulated	  following	   tofacitinib	   treatment.	  This	  suggested	   that	   in	   IL-­‐2	  maintained	  CTL	  these	  processes	  are	  dependent	  on	  signalling	  downstream	  of	  the	  JAK	  kinases.	  	  	  More	   targeted	   in	   vitro	   assays	   were	   performed	   to	   test	   the	   regulation	   of	   some	   of	  these	  processes	  in	  IL-­‐2	  maintained	  CTL	  treated	  with	  tofacitinib,	  and	  to	  determine	  which	  signalling	  pathways	  downstream	  of	  the	  JAK	  kinases	  were	  involved	  in	  their	  regulation.	   Experiments	   focused	   on	   the	   regulation	   of	   CTL	   glycolysis	   by	   IL-­‐2	  signalling,	   validation	   of	   the	   regulation	   of	   the	   TNFR	   superfamily	   member	   4-­‐1BB,	  CTL	  effector	  function	  and	  the	  regulation	  of	  the	  transcription	  factor	  NFIL3	  by	  IL-­‐2	  JAK	  kinase	  dependent	  signalling.	  HIF	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6.2	  Results	  
6.3.1	  Regulation	  of	  glucose	  transport	  and	  glycolysis	  in	  IL-­‐2	  maintained	  CTL	  Proteomic	   analysis	   of	   CTL	   treated	   for	   24	   hours	   with	   tofacitinib	   showed	   a	  reproducible	   reduction	   in	   the	   abundance	   of	   the	   glucose	   transporter	   Glut-­‐1	   and	  hexokinase	  II	  compared	  to	  IL-­‐2	  maintained	  CTL	  (chapter	  5).	  Glut-­‐1	  and	  Glut-­‐3	  are	  the	  most	   abundant	   glucose	   transporters	   in	  differentiated	  CTL	   (Hukelmann	  et	   al.,	  2015)	  and	  so	  loss	  of	  Glut-­‐1	  suggests	  that	  the	  rate	  at	  which	  CTL	  can	  import	  glucose	  would	  be	  reduced	  following	  inhibition	  of	  IL-­‐2	  signalling.	  Given	  the	  highly	  glycolytic	  phenotype	   of	   CTL,	   and	   the	   reduction	   in	   CTL	   glucose	   uptake	   following	   the	  withdrawal	   of	   IL-­‐2	   (Finlay	   et	   al.,	   2012),	   this	   suggests	   that	   IL-­‐2	   can	   sustain	   CTL	  glycolysis	   by	   maintaining	   glucose	   transporter	   expression.	   As	   hexokinase	   is	  required	  for	  the	  phosphorylation	  of	  glucose	  in	  the	  first	  step	  of	  glycolysis	  (Roberts	  &	  Miyamoto,	   2014),	   the	   loss	   of	   hexokinase	   II	   is	   also	   likely	   to	   reduce	   the	   rate	   of	  glycolysis	  in	  CTL.	  
	  To	   determine	   if	   tofacitinib	   treatment	   reduces	   glucose	   uptake	   by	   CTL,	   CTL	  were	  either	  maintained	  in	  IL-­‐2	  only	  or	  treated	  with	  tofacitinib	  or	  the	  mTORC1	  inhibitor	  rapamycin	   overnight	   and	   the	   uptake	   of	   the	   radiolabelled	   glucose	   analogue	   2-­‐deoxyglucose	   was	   measured.	   This	   showed	   that	   tofacitinib	   treated	   CTL	   had	   a	  significantly	   reduced	  uptake	  of	  glucose	  compared	   to	   IL-­‐2	  maintained	  CTL	  (figure	  6.1A).	  	  	  The	  reduction	   in	   the	  abundance	  of	  cell	  membrane	  glucose	   transporters	   implies	  a	  reduction	   in	   flux	   through	   the	   glycolytic	   pathway	   in	   tofacitinib	   treated	   CTL.	  Pyruvate	   generated	   through	   glycolysis	   can	   be	   converted	   into	   lactate	   by	   lactate	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dehydrogenase	  enzymes,	  and	  much	  of	  this	  lactate	  is	  released	  from	  the	  cell	  into	  the	  extracellular	   environment	   (Lunt	   &	   Vander	   Heiden,	   2011).	   To	   determine	   if	  tofacitinib	   affected	   flux	   through	   the	   glycolytic	   pathway,	   CTL	   were	   either	  maintained	  in	  IL-­‐2	  or	  treated	  with	  tofacitinib	  or	  rapamycin	  for	  two	  days,	  and	  the	  amount	  of	  lactate	  released	  into	  the	  media	  measured.	  IL-­‐2	  maintained	  CTL	  treated	  for	   48	   hours	  with	   either	   tofacitinib	   or	   rapamycin	   released	   less	   lactate	   than	   IL-­‐2	  maintained	   CTL	   (figure	   6.1B),	   suggesting	   that	   in	   addition	   to	   reduced	   glucose	  uptake	   following	   tofacitinib	   treatment,	   tofacitinib	   treated	   CTL	   had	   reduced	   flux	  through	  the	  glycolytic	  pathway.	  	  
	  
Figure	  6.1:	  Tofactitinib	  treatment	  of	  IL-­‐2	  maintained	  CTL	  reduces	  glucose	  uptake	  and	  lactate	  
output	  A.	  Graph	  shows	  uptake	  of	  the	  radiolabelled	  glucose	  analogue	  2-­‐deoxyglucose	  in	  polyclonal	  CTL	  treated	  overnight	  with	  100nM	  tofacitinib	  or	  20nM	  rapamycin	  relative	  to	  IL-­‐2	  maintained	  CTL.	  N=3,	  three	  independent	  experiments.	  B.	  Lactate	  outputs	  of	  IL-­‐2	  maintained	  polyclonal	  CTL	  and	  CTL	  treated	   with	   20nM	   rapamycin,	   100nM	   tofacitinib	   or	   deprived	   of	   IL-­‐2	   for	   two	   days.	   N=3,	   one	  independent	   experiment.	   In	   both	   graphs,	   bars	   represent	   the	   mean	   and	   error	   bars	   the	   standard	  deviation.	  Significance:	  *:P	  ≤	  0.05,	  **:	  P	  ≤	  0.01,	  ***:	  P	  ≤	  0.001,	  ****:	  P	  ≤	  0.0001.	  	  
6.3.2	  Tofacitinib	   reduces	   the	  abundance	  of	   the	   transcription	   factor	   subunit	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glycolysis	   via	   the	   transcription	   factor	   complex	   HIF1.	   HIF1	   deficient	   CTL	   express	  reduced	   levels	   of	   various	   components	   of	   the	   glycolytic	   pathway	   including	  hexokinase	   II,	  Glut-­‐1	  and	  Glut-­‐3	  and	  other	  glycolytic	  enzymes	   including	  aldolase,	  enolase,	  pyruvate	  kinase	  and	  others	  (Finlay	  et	  al.,	  2012).	  IL-­‐2	  maintains	  mTORC1	  signalling	   in	   CTL	   (chapter	   3)	   and	   stabilizes	   HIF1α	   protein	   (figure	   6.2).	   This	  suggests	   that	   IL-­‐2	   signalling	   can	   maintain	   CTL	   glycolysis	   in	   part	   by	   stimulating	  mTORC1	  signalling	  and	  so	  maintaining	  expression	  of	  HIF1α.	  	  
	   	  
Figure	   6.2:	   Regulation	   of	   HIF1α	   protein	   by	   JAK	   kinase	   and	  mTOR	   dependent	   signalling	   in	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6.4	  Regulation	  of	  4-­‐1BB	  by	  tofacitinib	  Proteomic	   analysis	   of	   IL-­‐2	   maintained	   CTL	   treated	   for	   24	   hours	   with	   100nM	  tofacitinib	   showed	   that	   multiple	   members	   of	   the	   TNFR	   superfamily	   were	  downregulated	   following	   tofacitinib	   treatment	   (chapter	   5),	   including	   the	   TNF	  superfamily	   receptor	  4-­‐1BB.	   IL-­‐2	  has	  been	   reported	   to	   significantly	   augment	   the	  TCR	   induced	   cell	   surface	   expression	   of	   4-­‐1BB	   by	   activated	   CD8+	   T	   lymphocytes,	  suggesting	   that	   IL-­‐2	   signalling	   can	   positively	   regulate	   CTL	   4-­‐1BB	   expression	  (McNamara	   et	   al.,	   2014).	   To	   determine	   if	   tofacitinib	   treatment	   regulated	   the	  abundance	  of	  4-­‐1BB,	  the	  cell	  surface	  expression	  of	  4-­‐1BB	  was	  measured	  using	  flow	  cytometric	  analysis.	  	  
6.4.1	   Tofacitinib	   treatment	   reduces	   4-­‐1BB	   cell	   surface	   expression	   in	   IL-­‐2	  
maintained	  CTL	  Flow	  cytometric	  analysis	  of	  IL-­‐2	  maintained	  CTL	  showed	  a	  significant	  reduction	  in	  cell	   surface	   expression	   of	   4-­‐1BB	   after	   24	   hours	   100nM	   tofacitinib	   treatment,	  suggesting	  that	  in	  CTL	  4-­‐1BB	  expression	  is	  regulated	  by	  IL-­‐2	  signalling	  (figure	  6.3B	  and	   6.3D).	   Cell	   surface	   staining	   for	   the	   known	   IL-­‐2	   regulated	   protein	   CD25	  was	  included	  as	  a	  positive	  control	  for	  inhibition	  of	  IL-­‐2	  signalling	  by	  tofacitinib	  (figure	  6.3A	  and	  6.3C).	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Figure	  6.3:	  Tofacitinib	  treatment	  of	   IL-­‐2	  maintained	  CTL	  reduces	  cell	  surface	  expression	  of	  
4-­‐1BB	  A.	  Histogram	  shows	  cell	  surface	  expression	  of	  CD25	  on	  IL-­‐2	  maintained	  LCMV	  CTL	  and	  CTL	  treated	  overnight	  with	  100nM	  tofacitinib.	  B.	  Histogram	  shows	  cell	  surface	  expression	  of	  4-­‐1BB	  on	  IL-­‐2	  maintained	  LCMV	  CTL	  and	  CTL	  treated	  overnight	  with	  100nM	  tofacitinib.	  C.	  Graph	  shows	  the	  geometric	   mean	   of	   CD25	   FITC	   stain	   in	   CTL	   treated	   as	   indicated.	  D.	   Graph	   shows	   the	   geometric	  mean	   of	   4-­‐1BB	   staining	   in	   CTL	   treated	   as	   indicated.	   Results	   shown	   from	   one	   independent	  experiments,	   n=4.	   In	   all	   graphs,	   bars	   represent	   the	  mean,	   and	   error	  bars	   the	   standard	  deviation.	  Statistical	  significance	  of	  differences	  determined	  using	  an	  unpaired	  T	  test.	  Significance:	  *:P	  ≤	  0.05,	  **:	  P	  ≤	  0.01,	  ***:	  P	  ≤	  0.001,	  ****:	  P	  ≤	  0.0001.	  	  
6.4.2	  Tofacitinib	  does	  not	  regulate	  TCR	  induced	  upregulation	  of	  4-­‐1BB	  	  4-­‐1BB	   has	   been	   described	   as	   a	   co-­‐stimulatory	   receptor	   and	   therefore	   may	   be	  expected	  to	  exert	  the	  majority	  of	  its	  effects	  during	  TCR	  activation.	  Tofacitinib	  was	  added	  to	  splenocyte	  cultures	  during	  TCR	  activation	  to	  determine	  if	  this	  resulted	  in	  regulation	  of	  4-­‐1BB	  expression.	  As	  previously	  reported	  (Cannons	  et	  al.,	  2001),	  4-­‐1BB	  expression	  was	  upregulated	  on	  CD8+	  T	  lymphocytes	  following	  TCR	  activation:	  however,	   there	   was	   no	   reduction	   in	   4-­‐1BB	   expression	   seen	   after	   24	   hours	  activation	   in	   tofacitinib	   treated	   cells.	   This	   was	   in	   contrast	   to	   the	   STAT5	   target	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CD25,	   whose	   cell	   surface	   expression	   on	   cells	   TCR	   triggered	   in	   the	   presence	   of	  tofacitinib	  was	  decreased	  after	  24	  hours	  TCR	  activation	  (figure	  6.4).	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6.5	  Effector	  function	  of	  CTL	  treated	  with	  tofacitinib	  In	  order	  to	  act	  efficiently	  as	  effector	  cells,	  CTL	  must	  be	  able	  to	  identify	  target	  cells,	  produce	   cytokines	   in	   response	   to	   target	   cells,	   express	   effector	   proteins	   such	   as	  perforin	  and	   the	  granzymes	  and	  mobilise	  cytotoxic	  granules	  and	  release	   them	   in	  response	   to	   target	   cells	   (Zhang	   &	   Bevan,	   2011).	   Tofacitinib	   treated	   CTL	   lose	  expression	   of	   perforin	   (chapter	   5)	   and	   the	   phosphorylation	   of	   various	   proteins	  such	  as	  plastin-­‐2	  and	  DOCK5	  involved	  in	  actin	  and	  microtubule	  dynamics	  (chapter	  4),	  suggesting	  effector	  function	  in	  response	  to	  target	  cells	  could	  be	  compromised.	  In	   particular,	   DOCK5	   is	   an	   atypical	   Rac	   GEF	   with	   a	   reported	   role	   for	   DOCK5	   in	  degranulation	   in	   mast	   cells	   (Ogawa	   et	   al.,	   2014),	   suggesting	   it	   could	   also	   be	  involved	  in	  CTL	  degranulation.	  	  The	  ability	  of	  tofacitinib	  treated	  CTL	  to	  degranulate	  and	  kill	  target	  cells	  in	  response	  to	  TCR	  stimulation	  was	  tested	  using	  a	  LAMP-­‐1	  degranulation	  assay.	  This	  assay	   is	  used	  to	  determine	  the	  capacity	  of	  CTL	  to	  release	  their	  effector	  granules	  in	  response	  to	   stimulation.	   This	   is	   done	   by	   tracking	   the	   appearance	   of	   CD107a	   (LAMP-­‐1),	   a	  lysosomal	  protein	  normally	  restricted	  to	  the	  intracellular	  compartment	  (Liu	  et	  al.,	  2009),	   on	   the	   cell	   surface	   of	   CTL	   following	   exocytosis	   and	   release	   of	   cytotoxic	  granules.	  The	  presence	  of	  LAMP-­‐1	  at	  the	  cell	  surface	  of	  cytotoxic	  cells	  such	  as	  CD8+	  T	   lymphocytes	   and	  NK	  cells	  has	  been	   reported	   to	   correlate	  with	  killing	  of	   target	  cells,	  and	  so	  this	  assay	  can	  be	  used	  as	  an	  alternative	  to	  a	  51Cr	  release	  assay	  (Aktas	  et	  al.,	  2008;	  Alter	  et	  al.,	  2004;	  Betts	  et	  al.,	  2003).	  	  	  CTL	  expressing	  the	  P14	  transgenic	  TCR	  receptor	  were	  used	  as	  the	  effector	  CTL.	  IL-­‐2	  maintained	  CTL,	  IL-­‐2	  maintained	  CTL	  treated	  with	  tofacitinib	  or	  the	  SRC	  kinase	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inhibitor	  PP2	  or	  IL-­‐2	  deprived	  P14	  CTL	  were	  incubated	  with	  target	  B	  cells	  from	  a	  non-­‐TCR	  transgenic	  mouse.	  Prior	  to	   incubation	  with	  P14	  CTL,	  target	  B	  cells	  were	  activated	  with	   LPS	   and	   stained	  with	   Cell	   Tracker	  Orange,	   and	   some	   cells	   loaded	  with	  the	  gp33-­‐41	  peptide.	  All	  cells	  were	  stained	  with	  live/dead	  aqua	  stain	  before	  fixation	   to	   determine	   the	   efficiency	   of	   CTL	   killing	   of	   target	   B	   cells,	   and	   CD25	  expression	   on	   P14	   CTL	  was	   used	   as	   a	   control	   for	   inhibition	   of	   IL-­‐2	   signalling	   in	  tofacitinib	  treated	  CTL	  (figure	  6.5A	  and	  6.5B).	  	  
	  
Figure	   6.5:	   Cell	   surface	   expression	   of	   CD25	   is	   reduced	   by	   tofacitinib	   treatment	   and	   IL-­‐2	  
deprivation	   A.	   Histogram	   shows	   CD25	   PE-­‐Cy7	   staining	   P14	   CD8+	   cells	   incubated	   with	   LPS	  activated,	  gp33-­‐41	  peptide	  loaded	  B	  cells.	  Labels	  indicate	  the	  treatment	  condition	  received	  by	  P14	  CTL.	  B.	   Graph	   shows	  geometric	  mean	   fluorescence	   intensity	   of	   CD25	  Pe-­‐Cy7	   staining	   in	  CMTMR-­‐	  CD8+	  cells	   incubated	  with	  LPS	  activated,	  gp33-­‐41	  peptide	   loaded	  B	  cells.	  Error	  bars	  represent	  the	  standard	   deviation,	   statistical	   significance	   of	   differences	   determined	   using	   one-­‐way	  ANOVA	  with	  Dunn’s	   correction	   for	   multiple	   comparisons.	   Significant	   differences	   compared	   to	   with	   the	   IL-­‐2	  maintainined	  P14	  CTL	   condition	   indicated	  with	   astericks:	   *:P	  ≤	  0.05,	   **:	   P	  ≤	  0.01,	   ***:	   P	  ≤	  0.001,	  ****:	  P	  ≤	  0.0001.	  
	  	  CTL	  incubated	  with	  B	  cells	  treated	  with	  LPS	  only	  showed	  minimal	  LAMP-­‐1	  staining	  above	  the	  LAMP-­‐1	  FMO	  (fluorescence	  minus	  one)	  control	  (the	  purpose	  of	  the	  FMO	  control	   is	   discussed	   in	   the	   method	   section	   describing	   this	   assay),	   while	   CTL	  incubated	  with	  B	  cells	  treated	  with	  LPS	  and	  loaded	  with	  gp33-­‐41	  peptide	  showed	  a	  higher	   LAMP-­‐1	   staining,	   indicating	   that	   CTL	   degranulated	   only	   when	   activated	  with	   the	   gp33-­‐41	   peptide.	   The	   shift	   towards	   higher	   CD107a	   staining	   when	   CTL	  were	  incubated	  with	  peptide	  loaded	  B	  cells	  was	  prevented	  if	  CTL	  were	  pretreated	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overnight	  with	  PP2,	  a	  Src	  inhibitor,	  suggesting	  that	  the	  increase	  in	  CD107a	  staining	  in	  the	  presence	  of	  peptide	  loaded	  B	  cells	  was	  a	  result	  of	  TCR	  activation.	  Tofacitinib	  treatment	  and	  IL-­‐2	  deprivation	  of	  CTL	  did	  not	  prevent	  a	  shift	  to	  higher	  CD107a	  cell	  surface	   expression	   when	   incubated	   with	   peptide	   loaded	   B	   cells	   (figure	   6.6),	  indicating	  that	  inhibition	  of	  IL-­‐2	  signalling	  did	  not	  prevent	  degranulation.	  	  	  
	  
Figure	  6.6:	   Cell	   surface	  LAMP-­‐1	  expression	  on	  CTL	   in	   response	   to	  TCR	   stimulation	  Prior	  to	  degranulation	  assay,	  P14	  CTL	  were	  either	  maintained	  in	  IL-­‐2	  only,	  treated	  with	  100nM	  tofacitinib,	  deprived	   of	   IL-­‐2	   or	   treated	   with	   10μM	   PP2	   overnight.	   N=3,	   one	   independent	   experiment.	  Histograms	  show	  cell	  surface	  staining	  of	  CD107a	  in	  P14	  CD8+	  cells	  (Cell	  Tracker	  Orange	  negative).	  The	  CD107a	  FMO	  (fluorescence	  minus	  one,	  grey)	  condition	  indicates	  P14	  CTL	  incubated	  with	  LPS	  activated	  and	  gp33-­‐41	  peptide	  loaded	  B	  cells,	  and	  stained	  for	  CD8,	  CD25,	  IFNγ	  and	  with	  live/dead	  aqua,	  but	  not	  CD107a;	  LPS	  only	  (blue)	  indicates	  P14	  CTL	  incubated	  with	  B	  cells	  activated	  with	  LPS	  but	   not	   loaded	   with	   gp33-­‐41	   peptide;	   and	   the	   LPS+gp33	   condition	   (red)	   indicated	   P14	   CTL	  incubated	   with	   LPS	   activated	   B	   cells	   loaded	   with	   gp33-­‐41	   peptide.	   Labels	   above	   histograms	  indicate	  which	  treatment	  the	  effector	  P14	  CTL	  received.	  	  	  IL-­‐2	  maintained	  CTL	  efficiently	  killed	  peptide	   loaded	   target	   cells,	  with	  a	  mean	  of	  87.6%	   target	   cells	   dead	   at	   the	   end	   of	   the	   assay.	   Following	   incubation	   with	  tofacitinib	  treated	  CTL,	  a	  mean	  of	  72.3%	  of	  target	  cells	  were	  dead.	  Killing	  efficiency	  dropped	   further	   following	   incubation	   with	   IL-­‐2	   deprived	   CTL,	   with	   a	   mean	   of	  35.4%	  of	  target	  cells	  dead	  at	  the	  end	  of	  the	  assay.	  PP2	  treated	  CTL	  were	  unable	  to	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efficiently	  kill	  peptide	   loaded	  target	  cells,	  with	  a	  mean	  of	  only	  20.6%	  dead	  at	   the	  end	   of	   the	   assay,	   suggesting	   that	   the	   high	   percentage	   of	   dead	   B	   cells	   seen	   in	  samples	   incubated	  with	   IL-­‐2	  maintained	   CTL	  was	   a	   result	   of	   TCR	   stimulation	   of	  CTL	  (figure	  6.7).	  This	  suggests	  that,	  while	  inhibition	  of	  IL-­‐2	  signalling	  reduces	  CTL	  killing	   efficacy	   to	   some	   extent,	   CTL	   are	   still	   able	   to	   degranulate	   and	   respond	   to	  target	  cells	  following	  tofacitinib	  treatment.	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Figure	   6.7:	   Tofacitinib	   treated	   CTL	   can	   kill	   target	   cells	   in	   response	   to	   TCR	   stimulation	   A.	  Scatter	  plots	  show	  live/dead	  aqua	  stain	  and	  forward	  scatter	  of	  CMTMR+	  B220+	  cells.	  Labels	  above	  plots	   indicate	   the	   treatment	   received	  by	  P14	  CTL,	   labels	   to	   the	   left	   indicate	  whether	   the	   target	  B	  cells	  added	  to	  the	  CTL	  were	  LPS	  activated	  but	  not	   loaded	  with	  gp33-­‐41	  peptide	  (top	  row)	  or	  LPS	  activated	  and	  loaded	  with	  gp33-­‐41	  peptide	  (bottom	  row).	  B.	  Graph	  shows	  the	  percentage	  of	  target	  LPS	  activated,	  gp33-­‐41	  peptide	  loaded	  B	  cells	  alive	  after	  incubation	  with	  effector	  P14	  CTL	  treated	  as	  indicated.	  Live	  cells	  defined	  by	  exclusion	  of	  live/dead	  aqua	  dye.	  C.	  Graph	  shows	  the	  percentage	  of	   target	  LPS	  activated,	  gp33-­‐41	  peptide	   loaded	  cells	  dead	   following	   incubation	  with	  effector	  P14	  CTL	   treated	   as	   indicated.	   Dead	   cells	   defined	   by	   uptake	   of	   live/dead	   aqua	   dye.	   In	   all	   graphs,	   bar	  represents	  the	  mean	  and	  error	  bars	  the	  standard	  deviation.	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6.6	  Regulation	  of	  NFIL3	  in	  CD8+	  T	  cells	  Proteomic	  analysis	  suggested	  that	  the	  abundance	  of	  the	  transcription	  factor	  NFIL3	  was	  reduced	  following	  tofacitinib	  treatment	  (chapter	  5).	  NFIL3	  is	  required	  for	  the	  development	  of	  various	  immune	  cells	  such	  as	  various	  subsets	  of	  NK	  cells	  and	  other	  ILC,	  and	  its	  function	  and	  regulation	  has	  been	  characterized	  in	  these	  cells	  (Geiger	  et	  al.,	   2014;	   Seillet	   et	   al.,	   2014).	   NFIL3	   has	   also	   be	   reported	   to	   repress	   Th17	  development	   (Yu	   et	   al.,	   2013),	   Th2	   cell	   cytokine	   production	   (Kashiwada	   et	   al.,	  2011),	  and	  regulate	  IL-­‐10	  and	  TIM3	  expression	  in	  exhausted	  CD4+	  and	  CD8+	  T	  cells	  (Zhu	   et	   al.,	   2015).	   However,	   the	   role	   of	   NFIL3	   in	   CTL	   has	   not	   been	   studied.	   To	  clarify	   the	   role	   of	  NFIL3	   in	  CTL,	   the	   expression	  of	  NFIL3	   in	  CD8+	  T	   lymphocytes	  thoughout	   differentiation	   was	   measured.	   Signalling	   pathways	   involved	   in	   the	  regulation	   of	   NFIL3	   expression	   in	   CTL	   were	   explored	   and	   possible	   functions	   of	  NFIL3	  in	  CTL	  were	  studied	  using	  an	  NFIL3-­‐/-­‐	  mouse	  model.	  
6.6.1	  NFIL3	  abundance	  and	  phosphorylation	  in	  tofacitinib	  treated	  CTL	  Proteomic	   analysis	   of	   IL-­‐2	   maintained	   and	   tofacitinib	   treated	   CTL	   showed	   a	  reduction	   in	   the	   relative	   abundance	   of	   NFIL3	   protein	   following	   tofacitinib	  treatment,	  with	  a	  mean	  ratio	  in	  IL-­‐2	  maintained	  CTL	  and	  tofacitinib	  treated	  CTL	  of	  0.61	  after	  4	  hours	  treatment	  and	  0.24	  after	  24	  hours	  treatment	  (figure	  6.8A).	  Loss	  of	   NFIL3	   protein	   following	   tofacitinib	   treatment	   was	   confirmed	   with	   a	  Western	  blot	  for	  NFIL3	  in	  IL-­‐2	  maintained	  and	  CTL	  treated	  with	  tofacitinib	  for	  30	  minutes,	  4	  hours	   and	   24	   hours	   (figure	   6.8B).	   This	   confirmed	   the	   results	   seen	   by	   proteomic	  analysis,	  with	  some	  loss	  of	  NFIL3	  protein	  by	  four	  hours	  tofacitinib	  treatment	  and	  a	  large	  loss	  of	  NFIL3	  protein	  by	  24	  hours	  treatment.	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Figure	   6.9:	   NFIL3	   phosphorylation	   in	   tofacitinib	   treated	   CTL	   A.	   Table	   showing	   the	   ratio	   of	  NFIL3	   phosphorylation	   sites	   identified	   in	   IL-­‐2	  maintained	   CTL	   and	   IL-­‐2	  maintained	   CTL	   treated	  with	   tofacitinib	   for	   30	  minutes	   or	   4hrs.	   Sites	   identified	   following	   phosphoproteomic	   analysis	   of	  SILAC	   labelled	   cells..	  B.	   Table	   shows	   representation	   of	   reported	   phosphorylation	   sites	   in	   NFIL3	  from	   the	   phosphosite	   database.	   Accessed	   18/10/15,	  http://www.phosphosite.org/proteinAction.do?id=5497&showAllSites=true.	   C.	   	   Figure	   shows	   the	  domains	   and	   regions	   listed	   as	   identified	   in	   the	   Uniprot	   entry	   for	   NFIL3	   with	   the	   NFIL3	  phosphorylation	  sites	   identified	  by	  phosphoproteomic	  analysis	  of	   IL-­‐2	  maintained	  and	   tofacitinib	  treated	   CTL.	   Figure	   made	   using	   information	   from	   Uniprot,	   entry	   accessed	   18/10/2015	  http://www.uniprot.org/uniprot/O08750.	  	  	  
6.6.2	  NFIL3	  expression	  during	  CTL	  differentiation	  To	  determine	   if	  NFIL3	  expression	  varies	  between	  naïve	  CD8+	  T	   lymphocytes	  and	  fully	  differentiated	  CTL	  effectors,	  samples	  of	  CD8+	  T	  lymphocytes	  were	  taken	  from	  naïve	   CD8+	   T	   lymphocytes,	   TCR	   stimulated	   CD8+	   T	   lymphocytes	   and	   CD8+	   T	  lymphocytes	  maintained	   in	   IL-­‐2	   following	   TCR	   stimulation	   and	   analysed	   for	   the	  abundance	  of	  NFIL3	  protein	  and	  NFIL3	  mRNA.	  	  	  NFIL3	  protein	  was	  not	  detected	  in	  naïve	  CD8+	  T	  lymphocytes.	  NFIL3	  protein	  levels	  were	  still	  relatively	  low	  after	  48hrs	  TCR	  stimulation	  with	  the	  gp33-­‐41	  peptide	  but	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                        30 minutes tofacitinib                                4hrs tofacitinib
Gene names Amino acid Position BR1 BR2 BR3 mean ratio 30 mins BR1 BR2 BR3 mean ratio 4 hours
Nfil3 S 352 0.53 - - 0.53 - - - -
Nfil3 S 353 0.53 0.63 0.73 0.63 0.50 0.41 1.03 0.65
Nfil3 S 210 0.87 0.90 0.93 0.90 0.49 0.58 0.42 0.50
Nfil3 S 301 0.91 0.90 1.05 0.95 0.50 0.52 0.48 0.50
Nfil3 S 461 1.17 - - 1.17 0.66 - 0.55 0.61
Nfil3 S 441 2.07 - - 2.07 - - - -
Nfil3 S 275 - - - - 0.50 0.55 - 0.53
Nfil3 S 459 - - - - 0.66 0.69 - 0.68
Nfil3 S 286 - - - - - 0.64 - 0.64
Nfil3 S 285 - - - - - 0.64 - 0.64
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began	   to	   increase	   between	   1-­‐3	   days	   IL-­‐2	   stimulation,	   suggesting	   that	   the	  upregulation	  in	  NFIL3	  abundance	  between	  naïve	  CD8+	  T	  lymphocytes	  and	  mature	  CTL	   was	   not	   triggered	   by	   signalling	   downstream	   of	   the	   T	   cell	   receptor	   (figure	  6.10A).	   The	   increase	   in	   NFIL3	   abundance	   following	   IL-­‐2	   stimulation	   of	  differentiating	   CD8+	   T	   cells	   and	   the	   reduction	   in	  NFIL3	   protein	   levels	   in	  mature	  CTL	  following	  tofacitinib	  treatment	  implicate	  IL-­‐2	  signalling	  as	  the	  main	  driver	  of	  NFIL3	   expression	   in	   in	   vitro	   generated	   CTL.	   Blots	   for	   the	   CTL	   effector	   protein	  granzyme	   B	  were	   included	   as	   a	   control	   for	   the	   effective	   differentiation	   of	   naïve	  CD8+	  T	  cells	  into	  effector	  CTL.	  	  The	   Western	   blot	   shown	   in	   figure	   6.11A	   was	   loaded	   to	   equal	   cell	   number.	  However,	   the	   differentiation	   from	   naïve	   CD8+	   T	   lymphocyte	   to	   mature	   CTL	   is	  accompanied	  by	  a	  large	  increase	  in	  cell	  size.	  To	  eliminate	  the	  possibility	  that	  NFIL3	  protein	  abundance	  appeared	  to	  be	  increasing	  in	  response	  to	  IL-­‐2	  as	  a	  result	  of	  the	  general	   increase	  in	  cell	  mass	  and	  so	  a	  general	   increase	  in	  cell	  protein	  content,	  an	  additional	  Western	  blot	  was	  loaded	  to	  equal	  protein	  (figure	  6.10B).	  This	  Western	  blot	   recapitulated	   the	   results	   seen	   in	   previous	   blots,	   with	   a	   minor	   increase	   in	  NFIL3	  protein	  abundance	  seen	  after	  TCR	  stimulation	  and	  a	  large	  increase	  in	  NFIL3	  protein	  after	   IL-­‐2	   stimulation.	  This	   suggests	   that	   the	  observed	   increase	   in	  NFIL3	  protein	  abundance	  following	  IL-­‐2	  stimulation	  was	  not	  sufficiently	  explained	  by	  the	  increase	   in	   cell	   mass	   and	   a	   general	   increase	   in	   cell	   protein	   content	   during	   CTL	  differentiation.	  	  	  The	  increase	   in	  NFIL3	  protein	   levels	  during	  CTL	  differentiation	  could	  result	   from	  increased	   transcription,	   increased	   translation	   or	   decreased	   protein	   degradation.	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To	   determine	   if	   the	   increase	   in	   NFIL3	   protein	   could	   be	   explained	   by	   increased	  transcription	   from	   the	  nfil3	   locus,	   the	   relative	  NFIL3	  mRNA	   levels	   in	   naïve,	   TCR	  activated	  and	  IL-­‐2	  maintained	  CD8+	  T	  lymphocytes	  was	  measured	  by	  RT-­‐PCR.	  Two	  sets	  of	  NFIL3	  primers	  were	  generated,	  corresponding	  to	  the	  coding	  region	  and	  the	  untranslated	  region.	  The	  nfil3	   locus	  only	  has	  a	  single	  exon	  and	  so	  exon	  spanning	  primers	  cannot	  be	  generated.	  	  Analysis	  with	  primers	  corresponding	  to	  both	  the	  coding	  sequence	  of	  the	  nfil3	  locus	  and	  the	  untranslated	  region	  suggested	  that	  the	  levels	  of	  NFIL3	  mRNA	  was	  low	  in	  naïve	   and	  TCR	   stimulated	  CD8+	  T	   cells	   compared	   to	  mature	  D5	   IL-­‐2	   CTL	   (figure	  6.10C	   and	   6.10D).	   Analysis	   with	   the	   coding	   region	   primers	   suggested	   that	  expression	   of	   NFIL3	   also	   appeared	   to	   increase	   from	   day	   1	   to	   day	   5	   of	   IL-­‐2	  stimulation.	  This	  was	  largely	  recapitulated	  in	  analysis	  with	  the	  untranslated	  region	  primers,	  with	  the	  exception	  of	  one	  value	  on	  day	  3	  IL-­‐2.	  The	  relative	  mRNA	  levels	  of	  CD62L,	  highly	  expressed	  by	  naïve	  CD8+	  T	  cells,	  and	  perforin,	  a	  characteristic	  CTL	  effector	  molecule,	  were	  included	  as	  a	  control	  for	  the	  differentiation	  of	  the	  CD8+	  T	  lymphocytes	   (figure	   6.10E	   and	   figure	   6.10F).	   The	   increase	   in	  NFIL3	  mRNA	   from	  naïve	  CD8+	  T	  cells	  to	  mature	  D5	  CTL	  mirrors	  the	  increase	  in	  NFIL3	  protein	  during	  CTL	   differentiation,	   suggesting	   that	   the	   increase	   in	   NFIL3	   protein	   during	   CTL	  development	  is	  at	  least	  partially	  the	  result	  of	  increased	  transcription	  from	  the	  nfil3	  locus	   following	   IL-­‐2	   stimulation,	   although	   this	   does	   not	   eliminate	   changes	   in	  translation	  of	  NFIL3	  or	  regulation	  of	  its	  degradation.	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Figure	  6.10:	  NFIL3	  protein	  and	  mRNA	  abundance	  during	  CTL	  differentiation	  Splenocytes	  from	  P14	  mice	  were	  peptide	  activated	  and	  samples	  from	  CD8+	  cells	  were	  taken	  for	  Western	  blot	  and	  RT-­‐PCR.	   Samples	   taken	   from	   naïve	   cells,	   TCR	   activated	   cells	   and	   cells	   maintained	   for	   the	   indicated	  number	   of	   days	   in	   IL-­‐2	   after	   TCR	   activation.	   RT-­‐PCR	   data	   normalised	   to	   TBP	   (TATA	   binding	  protein)	   and	   expressed	   relative	   to	   D5	   IL-­‐2	   maintained	   CTL	   or	   naïve	   CD8+	   T	   lymphocytes	   as	  indicated.	  A.	  Western	  blot	  showing	  amount	  of	  NFIL3	  protein.	  Loaded	  equal	  cell	  number,	  n=3,	  three	  independent	  experiments.	  B.	  Western	  blot	  showing	  amount	  of	  NFIL3	  protein.	  Loaded	  equal	  protein,	  n=1.	  C.	  NFIL3	  mRNA	  (coding	  region	  specific	  primers)	  relative	  to	  D5	  IL-­‐2	  maintained	  cells.	  D.	  NFIL3	  mRNA	  (untranslated	  region	  specific	  primers)	  relative	  to	  D5	  IL-­‐2	  maintained	  cells.	  E.	  CD62L	  mRNA	  relative	   to	  naïve	  cells.	  F.	  Perforin	  mRNA	   	  relative	   to	  D5	   IL-­‐2	  maintained	   	  cells.	   In	  all	  graphs,	  bars	  represent	  the	  mean	  and	  error	  bars	  the	  standard	  deviation.	  Expression	  data	  analysed	  with	  matched	  two-­‐way	  ANOVA	  with	  Tukey	  post	  hoc	  test.	  Significance:	  *:P	  ≤	  0.05,	  **:	  P	  ≤	  0.01,	  ***:	  P	  ≤	  0.001,	  ****:	  P	  ≤	  0.0001,	  in	  graphs	  C,	  D	  and	  F	  astericks	  indictate	  significance	  of	  difference	  between	  the	  indicated	  timepoint	   and	   D5	   IL-­‐2	   CTL	   and	   in	   E	   indicate	   significance	   of	   difference	   between	   the	   indicated	  timepoint	  and	  naive	  CD8+	  T	  lymphocytes.	  Molecular	  weights	  of	  blotted	  proteins	  (kDa)	  indicated	  on	  left	  of	  blots.	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6.6.3	   Signalling	   pathways	   regulating	   NFIL3	   expression	   in	   IL-­‐2	   maintained	  
CTL	  As	   discussed	   in	   the	   introduction,	   various	   signalling	   pathways	   are	   activated	  downstream	   of	   the	   IL-­‐2	   receptor,	   including	   activation	   of	   the	   STAT	   transcription	  factors,	  PDK1/mTORC1	  signalling	  and	  RAS/MAPK	  signalling.	  Src	  kinases	  are	  also	  active	   in	   IL-­‐2	   maintained	   CTL	   but	   are	   IL-­‐2	   independent	   (Ross	   et	   al.,	   2016).	   To	  determine	  which	  signalling	  pathways	  are	  involved	  in	  the	  IL-­‐2	  induced	  increase	  in	  NFIL3	   protein,	   IL-­‐2	   maintained	   CTL	   were	   treated	   with	   the	   mTOR	   inhibitors	  rapamycin	  (mTORC1	  selective)	  and	  KU	  (mTORC1	  and	  mTORC2),	  a	  PDK1	  inhibitor,	  a	   Akti	   inhibitor,	   a	   P13K	   inhibitor	   IC87114	   (p110δ	   selective)	   and	   the	   Src	   kinase	  inhibitor	   PP2.	   CTL	   were	   treated	   for	   four	   hours,	   as	   previous	   proteomic	   and	  immunoblot	   experiments	   had	   suggested	   that	   CTL	   had	   lost	   NFIL3	   protein	   in	  response	   to	   tofacitinib	   treatment	   at	   this	   point.	   CTL	   were	   also	   treated	   with	  rapamycin	  at	  longer	  timepoints,	  as	  previous	  experiments	  in	  the	  lab	  had	  suggested	  that	  long	  term	  rapamycin	  treatment	  reduced	  NFIL3	  protein	  levels	  (Hukelmann	  et	  al.,	  2015).	   JAK	  kinase	   inhibitors	   (tofacitinib,	  GSK186	  and	  GSK192)	  were	   included	  as	  a	  control,	  as	  tofacitinib	  had	  been	  shown	  to	  reduce	  NFIL3	  protein	  levels	  (figure	  6.8).	  	  Treatment	  of	  IL-­‐2	  maintained	  CTL	  with	  the	  JAK1/3	  inhibitor	  tofacitinib,	   the	  JAK1	  inhibitor	   GSK186	   and	   the	   JAK3	   inhibitor	   GSK192	   reduced	   NFIL3	   protein	  abundance	   within	   four	   hours,	   as	   had	   been	   found	   for	   tofacitinib	   in	   previous	  experiments.	   None	   of	   the	   other	   inhibitors	   used	   showed	   a	   decrease	   in	   NFIL3	  protein	  abundance	  within	  this	  timepoint,	  suggesting	  that	  the	  immediate	  tofacitinib	  induced	   loss	   of	   NFIL3	   was	   the	   result	   of	   loss	   of	   signalling	   through	   JAK	   kinase	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dependent	  and	  PDK1/mTORC1,	  P13K/Akt	  and	  SRC	  kinase	  independent	  pathways.	  Longer	  term	  treatment	  with	  rapamycin	  (48	  hours)	  reduced	  NFIL3	  proteins	  levels,	  although	  not	   to	   the	  same	  extent	  as	   the	   JAK	  kinase	   inhibitors,	  suggesting	  multiple	  pathways	   can	   contribute	   to	   NFIL3	   protein	   abundance	   in	   IL-­‐2	   maintained	   CTL	  (figure	  6.11).	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  Inhibition	   of	   IL-­‐2	   signalling	   could	   lead	   to	   loss	   of	   NFIL3	   protein	   abundance	   by	  various	  mechanisms	  including	  reducing	  transcription	  and	  translation	  or	  reducing	  protein	   stability.	   To	   determine	   if	   treatment	   of	   CTL	   with	   tofacitinib	   reduced	  transcription	   from	   the	  nfil3	   locus,	   IL-­‐2	  maintained	  CTL	  were	   treated	  with	   either	  tofacitinib	  or	  rapamycin	  and	  relative	  levels	  of	  NFIL3	  mRNA	  were	  measured	  using	  RT-­‐PCR.	   Analysis	   of	   the	   levels	   of	   IFNγ	   mRNA	   was	   included	   as	   a	   control	   for	  tofacitinib	  and	  rapamycin	   treatment.	  Western	  blots	   from	  the	  same	  cultures	  were	  run	   concurrently	   to	   determine	   if	   the	   regulation	   of	   the	   mRNA	   levels	   of	   NFIL3	  corresponded	  with	  that	  of	  the	  protein.	  As	  seen	  in	  previous	  experiments,	  tofacitinib	  reduced	   NFIL3	   protein	   levels,	   with	   a	   large	   reduction	   seen	   after	   four	   hours	  treatment.	   Rapamycin	   reduced	   NFIL3	   protein,	   but	   not	   to	   the	   same	   extent	   as	  tofacitinib	  (figure	  6.12A).	  Tofacitinib	  treatment	  reduced	  levels	  of	  NFIL3	  mRNA.	  In	  contrast	  with	  the	  regulation	  of	  NFIL3	  protein,	  the	  reduction	  in	  NFIL3	  mRNA	  was	  at	  its	  maximum	  after	  one	  hour	  tofacitinib	  treatment	  (figure	  6.12B,	  6.12C	  and	  6.12D).	  This	  demonstrates	   that	   tofacitnib	  regulation	  of	  NFIL3	  mRNA	  precedes	  regulation	  of	   the	   protein,	   suggesting	   that	   inhibition	   of	   IL-­‐2	   signalling	   can	   regulate	   NFIL3	  protein	   through	   a	   transcriptional	   mechanism.	   Rapamycin	   did	   not	   significantly	  affect	   levels	  of	  NFIL3	  mRNA,	  although	  analysis	  using	  NFIL3	  UTR	  specific	  primers	  did	   show	   some	   reduction	   in	   NFIL3	   mRNA	   abundance	   following	   rapamycin	  treatment.	  	  	  	  	  	  	  	  




Figure	  6.12:	  Regulation	  of	  NFIL3	  protein	  and	  mRNA	  by	  tofacitinib	  and	  rapamycin	  A.	  Western	  blot	  showing	  NFIL3	  protein	  levels	  in	  IL-­‐2	  maintained	  CTL	  treated	  with	  100nM	  tofacitinib	  or	  20nM	  rapamycin,	  n=3.	  B.	  Levels	  of	  NFIL3	  mRNA	  in	  tofacitinib	  and	  rapamycin	  treated	  CTL	  relative	  to	  IL-­‐2	  maintained	  CTL	  (NFIL3	  coding	  region	  specific	  primers),	  n=3.	  C.	  Levels	  of	  NFIL3	  mRNA	  in	  tofacitinib	  and	  rapamycin	  treated	  CTL	  relative	  to	  IL-­‐2	  maintained	  CTL	  (NFIL3	  UTR	  specific	  primers),	  n=3.	  D.	  Levels	  of	  IFNγ	  mRNA	  in	  tofacitinib	  and	  rapamycin	  treated	  CTL	  relative	  to	  IL-­‐2	  maintained	  CTL,	  n=3.	  In	   all	   graphs,	   bars	   represent	   the	   mean	   and	   error	   bars	   the	   standard	   deviation.	   RT-­‐PCR	   data	  normalised	  to	  TBP	  and	  expressed	  relative	  to	  IL-­‐2	  maintained	  CTL.	  RNA	  data	  analysed	  using	  a	  two-­‐way	  ANOVA	  with	  Dunnet’s	  correction	  for	  multiple	  comparisons.	  Asterisks	  indicate	  the	  significance	  of	  the	  difference	  between	  the	  labelled	  condition	  and	  IL-­‐2	  maintained	  CTL.	  Significance:	  *:P	  ≤	  0.05,	  **:	  P	  ≤	  0.01,	  ***:	  P	  ≤	  0.001,	  ****:	  P	  ≤	  0.0001.	  Molecular	  weights	  of	  blotted	  proteins	  (kDa)	  indicated	  on	  left	  of	  blot.	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Figure	  6.13:	  NFIL3	  protein	   in	  HIF1α	  deficient	  CTL.	  A.	  Cell	  surface	  expression	  of	  CD62L	  in	  wild	  type	   (Cre-­‐	   fl/fl)	   and	  HIF1α	   knockout	   (Cre+	   fl/fl).	   Graph	   shows	   percentage	   of	   CD62L	   high	   CD8+	   T	  lymphocytes	  after	  4	  days	  IL-­‐2.	  B.	  Western	  blot	  showing	  the	  abundance	  of	  NFIL3	  in	  IL-­‐2	  maintained	  HIF1α	  Cre-­‐	  fl/fl	  and	  Cre+	  fl/fl	  CTL	  cultured	  in	  normoxia	  and	  cultured	  for	  8	  hours	  in	  1%	  O2.	  Cre+	  fl/fl:	  n=4,	   cre-­‐	   fl/fl:	   n=4.	   One	   independent	   experiment.	   Molecular	   weights	   of	   blotted	   proteins	   (kDa)	  indicated	  on	  left	  of	  blots.	  
	  	  To	   test	   if	   regulation	   of	   NFIL3	   by	   the	   HIF1	   transcription	   factor	   complex	   was	  transcriptional,	   P14	   CTL	   were	   switched	   into	   hypoxia	   for	   4	   hours	   and	   the	  abundance	  of	  NFIL3	  mRNA	  compared	  in	  hypoxia	  switched	  CTL	  and	  CTL	  cultured	  in	  normoxia	   only.	   The	   abundance	   of	   NFIL3	   mRNA	   was	   significantly	   higher	   in	   CTL	  switched	   into	   hypoxic	   conditions	   (figure	   6.14A	   and	   6.14B)	   compared	   to	   IL-­‐2	  maintained	  cells	  cultured	  in	  normoxic	  conditions	  only.	  When	  analysed	  using	  NFIL3	  primers	  specific	  to	  the	  coding	  region,	  expression	  of	  NFIL3	  was	  2.7±0.8	  fold	  higher	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Figure	   6.14:	   Regulation	   of	   NFIL3	   expression	   in	   hypoxic	   conditions	   CTL	   generated	   from	   the	  spleens	  of	  P14	  mice	  were	  either	  maintained	  in	  IL-­‐2	  or	  maintained	  in	  IL-­‐2	  and	  kept	  for	  4	  hours	   in	  hypoxic	   conditions	   (1%	  O2).	  Graphs	  show	   levels	  of	  NFIL3	  mRNA	  determined	  using	  coding	   region	  specific	  primers	  (A),	  NFIL3	  mRNA	  determined	  using	  untranslated	  region	  specific	  primers	  (B),	  Glut-­‐1	  mRNA	   	   (C)	   and	   CD25	  mRNA	   (D)	   in	   CTL	  maintained	   in	   IL-­‐2	   or	  maintained	   in	   IL-­‐2	   and	   kept	   in	  hypoxic	  conditions	  for	  4	  hours.	  Expression	  data	  graphs	  show	  the	  mean	  and	  standard	  deviation	  of	  mRNA	   levels	   for	   the	   indicated	  mRNA	  normalised	   to	  TBP	   (TATA	  binding	   protein)	   relative	   to	   IL-­‐2	  maintained	   CTL,	   with	   three	   biological	   replicates	   in	   two	   independent	   experiments.	   Differences	  between	  treatment	  conditions	  analysed	  using	  an	  unpaired	  T-­‐test.	  Asterisks	   indicate	  a	  statistically	  significant	  difference	  from	  IL-­‐2	  maintained	  CTL.	  Significance:	  *:P	  ≤	  0.05,	  **:	  P	  ≤	  0.01,	  ***:	  P	  ≤	  0.001,	  ****:	  P	  ≤	  0.0001.	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suggesting	  that	  NFIL3	  is	  not	  required	  for	  T	  and	  B	  cell	  development.	  	  To	  determine	  in	  CTL	  effector	  cells	  require	  expression	  of	  NFIL3,	  spleens	   from	  NFIL3-­‐/-­‐	  mice	  and	  spleens	   from	   NFIL3+/+	   mice	   were	   activated	   with	   anti-­‐CD3	   (2C11),	   anti-­‐CD28,	  20ng/mL	  IL-­‐2	  and	  2ng/mL	  IL-­‐12	  for	  48	  hours,	  then	  cells	  were	  washed	  out	  of	  TCR	  activation	  and	  maintained	  in	  IL-­‐2	  to	  generate	  CTL	  cultures.	  Loss	  of	  NFIL3	  in	  NFIL3-­‐
/-­‐	  CTL	  was	  checked	  by	  Western	  blotting	  (figure	  6.15).	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Figure	  6.16:	  NFIL3-­‐/-­‐	  mice	  have	  normal	  splenocyte	  cell	  numbers	  and	  lymphocyte	  population	  
distributions	  A.	  Number	  of	  live	  obtained	  from	  the	  spleens	  of	  wild	  type	  and	  NFIL3	  deficient	  mice.	  B.	  Numbers	  of	  B	  cells	  and	  CD4+	  and	  CD8+	  T	  lymphocytes	  obtained	  from	  the	  spleens	  of	  wild	  type	  and	  NFIL3	   deficient	   mice.	   Wild	   type	   n=4;	   NFIL3-­‐/-­‐	   n=3,	   two	   independent	   experiments.	   Statistical	  significance	  analysed	  with	  an	  unpaired	  T-­‐test.	  	  CD8+	   T	   lymphocytes	   also	   upregulated	   the	   activation	   markers	   CD25,	   CD69	   and	  CD71	  normally	  in	  response	  to	  TCR	  stimulation,	  with	  no	  significant	  difference	  in	  the	  upregulation	  of	  these	  markers	  between	  wild	  type	  and	  NFIL3-­‐/-­‐	  CTL	  (figure	  6.17A,	  6.17B	   and	   6.17C).	   NFIL3	   expression	   is	   therefore	   not	   required	   for	   CD8+	   T	  lymphocytes	  to	  respond	  to	  TCR	  stimulation.	  	  
	  
	  
Figure	  6.17:	  NFIL3-­‐/-­‐	  CD8+	  T	  lymphocytes	  activate	  normally	  in	  response	  to	  TCR	  stimulation	  A.	  Histogram	  shows	  cell	  surface	  expression	  of	  CD25	  on	  polyclonal	  CD8+	  T	  lymphocytes,	  graph	  shows	  geometric	   mean	   fluorescence	   of	   CD25	   staining	   relative	   to	   wild	   type.	   B.	   Histogram	   shows	   cell	  surface	  expression	  of	  CD69	  on	  CD8+	  T	  lymphocytes,	  graph	  shows	  geometric	  mean	  fluorescence	  of	  CD69	   staining	   relative	   to	   wild	   type.	   Statistical	   significance	   analysed	   with	   an	   unpaired	   T-­‐test.	   C.	  Histogram	  shows	  cell	  surface	  expression	  of	  CD71	  on	  CD8+	  T	  lymphocytes,	  graph	  shows	  geometric	  mean	  fluorescence	  of	  CD71	  APC	  staining	  relative	  to	  wild	  type.	  Two	  independent	  experiments,	  wild	  type	  n=4,	  NFIL3-­‐/-­‐	  n=3.	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The	   proliferation	   of	   wild	   type	   and	   NFIL3-­‐/-­‐	   cells	   in	   response	   to	   IL-­‐2	   varied	   but	  there	  was	  not	  a	  clear	  defect	  in	  NFIL3-­‐/-­‐	  cell	  proliferation	  in	  response	  to	  IL-­‐2	  (figure	  6.18A).	   After	   5	   days	   of	   culture	   in	   the	   presence	   of	   IL-­‐2,	   there	  was	   no	   significant	  difference	   in	   the	   percentage	   of	   total	   live	   cells	   that	   were	   CD8+	   (figure	   6.18B),	  suggesting	  that	  NFIL3	  is	  not	  essential	  for	  the	  survival	  and	  proliferation	  of	  CD8+	  T	  lymphocytes	   in	   response	   to	   IL-­‐2.	   The	   protein	   content	   of	   D5	   IL-­‐2	   CTL,	   as	  determined	   by	   BCA	   analysis	   for	   total	   protein	   content,	   was	   not	   significantly	  different	   in	  NFIL3-­‐/-­‐	  CTL	  compared	   to	  wild	   type	  CTL,	   suggesting	   that	  NFIL3	  does	  not	  play	  an	  important	  role	  in	  maintaining	  CTL	  size	  (figure	  6.18C).	  	  
	  
	  
Figure	   6.18:	   NFIL3-­‐/-­‐	   CD8+	   T	   lymphocytes	   proliferate	   and	   maintain	   cell	   mass	   normally	   in	  
response	   to	   IL-­‐2	   A.	   Proliferation	   of	   wild	   type	   and	   NFIL3-­‐/-­‐	   polyclonal	   CD8+	   cells	   after	   TCR	  stimulation	  and	  culture	   in	   the	  presence	  of	   IL-­‐2.	  B.	  Percentage	  of	   live	  cells	   that	  were	  CD8+	  after	  5	  days	  culture	   in	   the	  presence	  of	   IL-­‐2.	  Analysed	  with	  unpaired	  T-­‐test.	  C.	  Protein	  content	  of	  D5	   IL-­‐2	  wild	   type,	   IL-­‐2	   wild	   type	   CTL	   treated	   overnight	   with	   100nM	   tofacitinib	   and	   NFIL3-­‐/-­‐	   CTL	   (BCA	  assay).	  Analysed	  using	  one-­‐way	  ANOVA.	  	  	  The	   cell	   surface	   expression	   of	   CD25,	   CD69,	   CD71,	   CD98,	   CD44	   and	   CD62L	  were	  measured	  after	  one	  day,	  three	  days	  and	  five	  days	  culture	  in	  IL-­‐2.	  CD25	  expression	  is	  regulated	  by	  STAT5	  (Lin	  et	  al.,	  2012).	  CD69	  and	  CD71	  expression	  is	  upregulated	  on	  TCR	  activation	  (Caruso	  et	  al.,	  1997).	  CD98	  is	  the	  heavy	  chain	  subunit	  of	  the	  LAT	  amino	   acid	   transporters	   (Cantor	  &	  Ginsberg,	   2012)	   and	  CD44	   is	   a	  T	   lymphocyte	  activation	   marker	   (Graham	   et	   al.,	   2007).	   CD62L	   is	   highly	   expressed	   on	   naïve	   T	  lymphocytes	   and	   is	   shed	   shortly	   after	   TCR	   activation.	   CD62L	   transcription	   is	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downregulated	   in	   an	   mTORC1	   dependent	   manner	   (Finlay	   &	   Cantrell,	   2010).	  Expression	  of	  CD25,	  CD69,	  CD71,	  CD98	  and	  CD44	  were	   similar	   in	  wild	   type	  CTL	  and	   NFIL3-­‐/-­‐	   CTL	   (figure	   6.19A):	   however,	   a	   greater	   percentage	   of	   NFIL3-­‐/-­‐	   CTL	  remained	  CD62L	  high	  during	  culture	  in	  the	  presence	  of	  IL-­‐2	  compared	  to	  wild	  type	  CTL	  .NFIL3-­‐/-­‐	  CTL	  remained	  predominantly	  CD62L	  high	  throughout	  culture	  in	  IL-­‐2,	  with	   an	   increased	  number	   of	   CD62L	  high	  CD8+	  T	   cells	   even	   after	   nine	   days	   IL-­‐2	  treatment	  (figure	  6.19B).	  	  	  As	   previously	   stated,	   CD62L	   cell	   surface	   expression	   can	   be	   regulated	   in	   various	  ways,	  including	  cleavage	  from	  the	  cell	  surface	  by	  cysteine	  proteases	  following	  TCR	  stimulation	   and	   decreased	   transcription	   from	   the	   sell	   locus	   (Finlay	   &	   Cantrell,	  2010).	   After	   five	   days	   culture	   in	   the	   presence	   of	   IL-­‐2,	   NFIL3-­‐/-­‐	   CTL	   expressed	  significantly	  more	  CD62L	  mRNA	  than	  wild	  type	  CTL,	  demonstrating	  that	  a	  lack	  of	  NFIL3	  increases	  transcription	  from	  the	  sell	  locus.	  This	  suggests	  that	  the	  increased	  CD62L	  seen	  in	  NFIL3-­‐/-­‐	  CTL	  is	  due	  to	  increased	  transcription	  rather	  than	  defective	  shedding	  (figure	  6.19C).	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Figure	  6.19:	  NFIL3-­‐/-­‐	  CTL	  have	  increased	  cell	  surface	  CD62L	  and	  increased	  sell	  expression	  A.	  Histograms	  showing	  the	  staining	  of	  D5	  IL-­‐2	  wild	  type	  and	  NFIL3-­‐/-­‐	  polyclonal	  CTL	  for	  CD25,	  CD69,	  CD71,	  CD98,	  CD44	  and	  CD62L.	  Grey	  filled:	  unstained,	  blue:	  wild	  type	  CD8+,	  red:	  NFIL3-­‐/-­‐	  CD8+.	  CD25,	  CD69,	   CD71,	   CD98	   and	   CD62L:	   CD25,	   CD69,	   CD71,	   CD98,	   CD62L:	   two	   independent	   experiments,	  wild	  type	  n=4,	  NFIL3-­‐/-­‐	  n=3,	  CD44:	  one	  experiment,	  wild	  type	  n=2,	  NFIL3-­‐/-­‐	  n=2.	  Graphs	  show	  the	  MFI	  of	  NFIL3	  knockouts	  relative	   to	  wild	   type	  CD8+	  T	  cells,	  data	  analysed	  with	  unpaired	  T-­‐test.	  B.	  Graph	  shows	  the	  percentage	  of	  wild	  type	  and	  NFIL3-­‐/-­‐	  CD8+	  T	  lymphocytes	  expressing	  high	  levels	  of	  CD62L	   on	   day	   5	   and	   day	   9	   IL-­‐2	   treatment.	   Data	   were	   analysed	   with	   a	   two	   way	   ANOVA,	   which	  demonstrated	   that	   genotype	   but	   not	   day	   of	   analysis	   was	   a	   significant	   source	   of	   variation	   in	   the	  percentage	  of	  CD62L	  high	  CD8+	  T	  cells	  (genotype	  83.8%	  of	  the	  variation,	  p=0.0008,	  day	  0.06991%	  of	  the	  variation,	  p=0.6767).	  	  C.	  Graph	  shows	  levels	  of	  CD62L	  mRNA	  in	  D5	  IL-­‐2	  wild	  type	  and	  NFIL3-­‐/-­‐	  CTL	  relative	  to	  wild	  type	  CTL	  treated	  overnight	  with	  tofacitinib.	  Data	  analysed	  with	  unpaired	  two	  tailed	  T-­‐test,	  PCR	  data	  normalized	  to	  HPRT.	  Significance:	  *:P	  ≤	  0.05,	  **:	  P	  ≤	  0.01,	  ***:	  P	  ≤	  0.001,	  ****:	  P	  ≤	  0.0001.	  	  In	   addition	   to	   increased	   CD62L,	   NFIL3-­‐/-­‐	   CTL	   also	   had	   reduced	   protein	   (figure	  6.20A)	   and	  mRNA	  expression	   (figure	  6.20B)	  of	   the	  CTL	   effector	  protein	  perforin	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and	  reduced	  expression	  of	  IFNγ	  (figure	  6.20C),	  indicating	  that	  NFIL3	  may	  regulate	  the	  effector	  function	  of	  CTL.	  	  	  
	  
Figure	  6.20:	  NFIL3	  deficiency	  reduces	  expression	  of	  the	  CTL	  effector	  molecules	  perforin	  and	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NFIL3-­‐/-­‐	  CTL	  (figure	  6.22A	  and	  6.22B).	  There	  was	  also	  no	  difference	  in	  FOXO1	  and	  FOXO3	  phosphorylation	  at	  the	  threonine	  24	  and	  32	  sites	  (figure	  6.22C),	  suggesting	  that	  in	  NFIL3-­‐/-­‐	  CTL	  FOXO1	  is	  phosphorylated	  and	  excluded	  from	  the	  nucleus.	  Lack	  of	   PKB	   signalling	   is	   therefore	   unlikely	   to	   be	   the	   cause	   of	   increased	   CD62L	  expression	  in	  NFIL3-­‐/-­‐	  CTL.	  Expression	  of	  the	  FOXO1	  targets	  IL7Rα	  and	  KLF2	  was	  slightly	  increased	  in	  NFIL3-­‐/-­‐	  CTL	  compared	  to	  wild	  type,	  but	  this	  was	  not	  found	  to	  be	  significant	  (figure	  6.22D	  and	  6.22E).	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6.7	  Discussion	  The	   uptake	   of	   glucose	   and	   output	   of	   lactate	   into	   the	   extracellular	   media	   was	  reduced	   in	   tofacitinib	   treated	   and	   IL-­‐2	   deprived	   CTL,	   confirming	   that	   glucose	  metabolism	   in	   CTL	   requires	   JAK	   kinase	   dependent	   signalling	   pathways.	   Glucose	  uptake	  and	  lactate	  output	  was	   lower	   in	  tofacitinib	  treated	  and	  IL-­‐2	  deprived	  CTL	  compared	  to	  rapamycin	  treated	  CTL,	  suggesting	  that	  other	  pathways	  in	  addition	  to	  mTORC1	  dependent	  signalling	  contribute	  to	  the	  JAK	  kinase	  dependent	  regulation	  of	  glucose	  metabolism	  in	  CTL.	  	  Expression	   of	   4-­‐1BB	   in	   IL-­‐2	   maintained	   CTL	   was	   reduced	   following	   tofacitinib	  treatment,	   which	   is	   consistent	   with	   previous	   reports	   that	   demonstrated	   4-­‐1BB	  expression	   could	   be	   induced	   on	   activated	   T	   lymphocytes	   by	   IL-­‐2	   stimulation	  (McNamara	  et	  al.,	  2014).	  Tofacitinib	  treatment	  had	  little	  effect	  on	  the	  TCR	  induced	  upregulation	   of	   4-­‐1BB.	   Given	   that	   4-­‐1BB	   has	   been	   described	   as	   a	   costimulatory	  molecule,	  the	  function	  of	  4-­‐1BB	  in	  the	  absence	  of	  TCR	  activation	  is	  not	  clear.	  Any	  role	   for	  4-­‐1BB	   in	  an	   IL-­‐2	  maintained	  CTL	  culture	  would	  presumably	  require	  CTL	  expression	   of	   the	   ligand	   4-­‐1BBL.	   In	   OT-­‐II	   T	   cells	   4-­‐1BBL	   expression	   has	   been	  reported	   to	   be	   increased	   following	   TCR,	   but	   then	   downregulated	   in	   cells	  expressing	  high	   levels	  of	  4-­‐1BB	  (Eun	  et	  al.,	  2014).	  Given	  that	  CTL	  express	  4-­‐1BB,	  this	  would	  suggest	  that	  there	  may	  not	  be	  much	  4-­‐1BBL	  available	  in	  a	  CTL	  culture.	  	  	  These	  results	  show	  that	  inhibition	  of	  IL-­‐2	  signalling	  through	  tofacitinib	  treatment	  or	   IL-­‐2	   deprivation	   does	   not	   prevent	   CTL	   degranulation	   in	   response	   to	   a	   TCR	  restimulation	  in	  the	  form	  of	  target	  B	  cells	  loaded	  with	  peptide.	  This	  suggests	  that	  either	   DOCK5	   is	   not	   involved	   in	   this	   response	   and	   so	   the	   regulation	   of	   DOCK5	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phosphorylation	   sites	   by	   tofacitinib	   is	   irrelevant	   or	   that	   these	   phosphorylation	  sites	  are	  not	  important	  in	  this	  response.	  For	  example,	  CTL	  express	  other	  proteins	  involved	   in	   regulation	   of	   the	   actin	   cytoskeleton	   and	   other	   DOCK	   proteins	   that	  could	   be	   involved	   in	   degranulation	   (proteomics	   data).	   Alternatively,	   these	   sites	  may	  be	  re-­‐phosphorylated	  following	  TCR	  activation.	  	  	  Both	   IL-­‐2	   deprivation	   and	   tofacitinib	   treatment	   of	   CTL	   reduced	   the	   protein	  abundance	   of	   perforin	   and	   some	   granzymes	   (chapter	   5).	   However,	   IL-­‐2	  deprivation	  reduced	  the	  efficiency	  of	  CTL	  killing	  whereas	  tofacitinib	  treatment	  did	  not	   (figure	   6.6).	   This	   suggests	   that	   JAK	   kinase	   independent	   IL-­‐2	   signalling	  pathways	   could	   be	   involved	   in	   regulating	   CTL	   cytotoxicity.	   	   This	   result	   also	  suggests	   that	   the	  reduced	  abundance	  of	  perforin	   found	   in	   tofacitinib	   treated	  CTL	  were	  sufficient	  for	  killing	  of	  target	  cells.	  	  It	  would	  be	  interesting	  to	  determine	  if	  tofacitinib	  treatment	  reduced	  the	  efficiency	  of	  CTL	  killing	  in	  vivo.	  In	  the	  in	  vitro	  assay	  described	  above	  TCR	  transgenic	  CTL	  from	  P14	   mice	   were	   used	   and	   the	   target	   cells	   loaded	   exclusively	   with	   the	   cognate	  peptide,	  and	  so	  killing	  efficiency	  would	  be	  expected	  to	  be	  high.	  In	  vivo	  CTL	  killing	  efficiency	  has	  been	  reported	  to	  be	  quite	  low	  (Halle	  et	  al.,	  2016),	  and	  so	  tofacitinib	  treatment	  may	   have	   a	   greater	   effect	   on	   the	   ability	   of	   CTL	   to	  mount	   an	   effective	  response.	  In	  clinical	  trials,	  tofacitinib	  treatment	  has	  been	  reported	  to	  be	  associated	  with	   an	   increased	   incidence	   of	   tuberculosis	   and	   herpes	   zoster	   (Winthrop	   et	   al.,	  2015;	   2014),	   both	   infections	   that	  would	   require	   an	   effective	   CD8+	  T	   lymphocyte	  response.	   	   However,	   this	   could	   also	   be	   attributed	   to	   reduced	   T	   cell	   survival	   or	  other	  factors.	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One	   novel	   finding	   from	   the	   present	   data	   is	   that	   CTL	   express	   the	   transcription	  factor	   NFIL3.	   	   NFIL3	   protein	   abundance	   was	   below	   the	   limit	   of	   detection	   by	  Western	   blotting	   in	   naïve	   CD8+	   T	   lymphocytes	   but	   increased	   during	   CTL	  differentiation	  in	  response	  to	  IL-­‐2.	  Expression	  of	  NFIL3	  was	  found	  to	  be	  induced	  by	  IL-­‐2	   in	   a	   JAK	   kinase	   dependent	  manner.	   Signalling	   downstream	  of	  mTORC1	   also	  contributed	   to	   NFIL3	   proteins	   level.	   Rapamycin	   reduced	   NFIL3	   protein	   in	   IL-­‐2	  maintained	   CTL	   to	   some	   extent,	   and	   CTL	   deficient	   in	   the	   mTORC1	   regulated	  protein	  HIF1α	  did	  not	  have	  detectable	  levels	  of	  NFIL3	  protein.	  	  	  	  However,	  the	  IL-­‐2	  JAK	  kinase	  dependent	  regulation	  of	  NFIL3	  does	  not	  appear	  to	  be	  soley	  dependent	  on	  mTORC1	  signalling,	  as	  the	  reduction	  in	  NFIL3	  protein	  in	  IL-­‐2	  maintained	   CTL	   was	   greater	   following	   JAK	   kinase	   inhibitor	   treatment	   than	  rapamycin	  treatment.	  Previously	  NK	  cell	  expression	  of	  NFIL3	  in	  response	  to	  IL-­‐15	  signalling	   has	   been	   reported	   to	   be	   dependent	   on	   PDK1,	   PKB	   and	  mTOR	   activity	  (Yang	   et	   al.,	   2015);	  while	   ILC	   expression	   of	   NFIL3	   in	   response	   to	   IL-­‐7	   has	   been	  reported	  to	  be	  dependent	  on	  STAT5	  (Xu	  et	  al.,	  2015).	  The	  data	  presented	  here	  on	  the	   IL-­‐2	   dependent	   regulation	   of	   NFIL3	   in	   CTL	   would	   suggest	   that	   a	  PDK1/mTORC1	  pathway	  and	  another	  IL-­‐2	  dependent	  pathway	  are	  contributing	  to	  NFIL3	   abundance.	   Given	   the	   STAT5	   dependent	   regulation	   of	   NFIL3	   reported	   in	  response	   to	   IL-­‐7,	   STAT5	   would	   be	   a	   reasonable	   candidate	   for	   mTORC1	  independent	  regulation	  of	  NFIL3	  in	  response	  to	  IL-­‐2.	  	  	  Unlike	  other	  immune	  cells	  such	  as	  NK	  cells	  and	  ILC	  (Geiger	  et	  al.,	  2014),	  NFIL3	  is	  not	  required	  for	  CD8+	  T	  lymphocyte	  development.	  NFIL3	  was	  also	  not	  required	  for	  activation	  in	  response	  to	  TCR	  triggering	  or	  proliferation	  of	  CTL	  in	  response	  to	  IL-­‐2.	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NFIL3-­‐/-­‐	  CTL	  had	  a	  marked	  reduction	  in	  the	  abundance	  of	  the	  CTL	  effector	  protein	  perforin,	  and	  reduced	  expression	  of	  other	  CTL	  effectors	  such	  as	   IFNγ,	   suggesting	  that	   while	   NFIL3-­‐/-­‐	   CTL	   are	   able	   to	   activate	   and	   proliferate	   they	   may	   be	   less	  efficient	   at	   killing	   target	   cells.	   The	   increased	   cell	   surface	   expression	  of	   CD62L	   in	  NFIL3-­‐/-­‐	   CTL	  may	   also	   affect	   the	   ability	   of	   CTL	   to	   traffic	   appropriately	   during	   an	  immune	  response.	  	  	  NFIL3	  deficient	  CTL	  have	  been	  reported	  to	  mount	  a	  cytotoxic	  response,	  as	  injecting	  NFIL3-­‐/-­‐	  mice	  with	  target	  cells	  pulsed	  with	  influenza	  peptides	  results	  in	  lysis	  of	  the	  target	   cells	   (Gascoyne	  et	   al.,	   2009).	  To	  determine	   if	   lack	  of	  NFIL3	  protein	  affects	  CTL	  effector	  function,	  CTL	  killing	  efficiency	  could	  be	  determined	  by	  either	  LAMP1	  assay	  or	  51Cr	  release	  assay.	  Alternatively	  the	  ability	  of	  NFIL3-­‐/-­‐	  mice	  to	  produce	  a	  CTL	  dependent	  immune	  response	  to	  murine	  cytomegalovirus	  (MCMV)	  or	  influenza	  could	   be	   measured.	   However,	   due	   to	   the	   role	   of	   NFIL3	   in	   other	   immune	   cells,	  including	  in	  NK	  cells,	  production	  of	  a	  targeted	  deletion	  model	  such	  as	  a	  granzyme-­‐cre	  mice	  crossed	  to	  floxed	  NFIL3	  mice	  would	  be	  required	  to	  determine	  the	  effect	  of	  NFIL3	   deficiency	   on	   CD8+	   T	   lymphocyte	   effector	   function.	   The	   effect	   of	   the	  increased	   CD62L	   cell	   surface	   on	   the	   ability	   of	   NFIL3	   deficient	   CTL	   to	   traffic	  normally	   could	   also	   be	   tested	   by	   transferring	   equal	   numbers	   of	   wild	   type	   and	  NFIL3-­‐/-­‐	  CTL	  to	  an	  immunodeficient	  host	  and	  comparing	  the	  number	  of	  wild	  type	  and	  NFIL3-­‐/-­‐	  CTL	  found	  in	  the	  spleen,	  lymph	  nodes	  and	  blood.	  	  Some	   aspects	   of	   the	   phenotype	   seen	   in	   NFIL3-­‐/-­‐	   CTL,	   such	   as	   increased	   CD62L	  staining	   and	   reduced	   IFNγ	   expression,	   resemble	   the	   situation	   in	   a	   naïve	   CD8+	   T	  lymphocyte	  in	  which	  PKB	  is	  not	  active.	  In	  the	  absence	  of	  PKB	  activity,	  FOXO1	  is	  not	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phosphorylated	  and	  excluded	  from	  the	  nucleus	  and	  so	  can	  regulate	  the	  expression	  of	  its	  target	  genes.	  However,	  no	  defect	  in	  PKB	  signalling	  was	  seen	  in	  NFIL3-­‐/-­‐	  CTL	  (figure	   6.23),	   suggesting	   that	   in	   these	   cells	   there	   is	   no	   increase	   in	   FoxO1	  localization	   to	   the	   nucleus	   and	   corresponding	   increase	   in	   DNA	   binding	   and	  transcriptional	   regulation.	   NFIL3	   could	   be	   involved	   in	   PKB	   signalling	   without	  regulating	  PKB	  kinase	  activity.	  In	  the	  HEK	  293	  cell	  line,	  NFIL3	  has	  been	  reported	  to	  prevent	  FOXO1	  from	  regulating	  some	  of	  its	  targets	  by	  recruiting	  HDAC2	  (Keniry	  et	  al.,	  2013).	  This	  effect	  seemed	  to	  be	  sufficient	  to	  reduce	  FOXO1	  regulation	  of	  target	  genes	  even	  when	  the	  proportion	  of	  nuclear	  FoxO	  is	  low.	  Knockdown	  of	  NFIL3	  with	  shRNA	  was	  reported	  to	  cause	  re-­‐expression	  of	  positively	  regulated	  FoxO	  genes	  in	  a	  PTEN	  deficient	  cell	  line,	  in	  which	  increased	  PIP3	  accumulation	  would	  be	  expected	  to	   increase	   PKB	   activity	   and	   so	   FOXO	   exclusion	   from	   the	   nucleus.	   This	   suggests	  that	   loss	   of	   NFIL3	   in	   CTL	   could	   be	   able	   to	   restore	   some	   FOXO	   regulation	   of	  transcription	  despite	  the	  bulk	  of	  FOXO1	  remaining	  sequestered	   in	  the	  cytoplasm.	  Alternatively,	  NFIL3	  could	  independently	  regulate	  the	  transcription	  of	  these	  genes.	  	  To	   determine	   if	   NFIL3	   is	   preventing	   FOXO	   regulation	   of	   target	   genes,	   ChIP-­‐seq	  could	  be	  used	  to	  compare	  FOXO1	  binding	  to	  target	  genes	  in	  wild	  type	  and	  NFIL3-­‐/-­‐	  CTL,	  with	   an	   Akti	   treated	  wild	   type	   positive	   control.	   This	  would	   show	   if	   FOXO1	  binding	  to	  target	  genes	  is	  increased	  in	  the	  absence	  of	  NFIL3.	  ChIP	  could	  be	  used	  to	  determine	  if	  NFIL3	  binds	  directly	  to	  genes	  that	  appeared	  to	  be	  affected	  by	  NFIL3	  deficiency	  such	  as	  CD62L	  and	  perforin.	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Chapter	  7.	  Conclusion	  The	  aims	  of	  this	  project	  were	  to	  compare	  the	  contributions	  of	  JAK1	  and	  JAK3	  to	  γc	  signalling	  using	  selective	  JAK1	  and	  JAK3	  inhibitors,	  and	  to	  assess	  the	  effect	  of	  the	  JAK	   kinase	   inhibitor	   tofacitinib	   on	   the	   phosphoproteome	   and	   proteome	   of	   IL-­‐2	  maintained	  CTL.	  Delineating	  the	  respective	  roles	  of	   JAK1	  and	  JAK3	   in	  γc	  cytokine	  signalling	   is	   of	   interest	   as	   selective	   inhibition	   of	   JAK3	   would	   target	   only	   the	   γc	  family	   of	   cytokines,	  whereas	   JAK1	   inhibitors	   or	   inhibitors	  which	   target	  multiple	  JAKs	  like	  tofacitinib	  would	  inhibit	  signalling	  through	  multiple	  families	  of	  cytokines.	  This	   would	   potentially	   reduce	   the	   number	   of	   side	   effects	   associated	   with	   JAK	  kinase	  inhibitors	  without	  completely	  losing	  efficacy.	  Tofacitinib	  is	  used	  clinically	  to	  treat	  inflammatory	  conditions	  such	  as	  rheumatoid	  arthritis	  and	  so	  information	  on	  its	   effects	   on	   cells	   is	   potentially	   useful.	   Identifying	   the	   effect	   of	   tofacitinib	  treatment	  on	  the	  phosphoproteome	  and	  proteome	  of	  IL-­‐2	  maintained	  CTL	  allows	  the	   identification	  of	  novel	   IL-­‐2	   induced	  JAK	  dependent	  phosphorylation	  sites	  and	  proteins,	  which	  can	  be	  used	  to	  identify	  novel	  IL-­‐2	  induced	  signalling	  and	  effectors	  in	  an	  unbiased	  manner.	  	  The	  pan	   JAK1/3	   inhibitor	  and	   the	   JAK1	  selective	   inhibitor	  GSK186	   inhibited	   IL-­‐2	  signalling	  at	  lower	  doses	  than	  the	  JAK3	  inhibitor	  GSK192,	  which	  could	  suggest	  that	  inhibiting	   JAK1	   inhibits	   signalling	   downstream	   of	   IL-­‐2	   more	   effectively	   than	  inhibition	  of	  JAK3.	  This	  is	  in	  agreement	  with	  the	  conclusions	  reached	  by	  Haan	  et	  al.	  (2011),	  which	  suggested	  that	  JAK1	  kinase	  activity	  was	  absolutely	  required	  for	  IL-­‐2	  signalling	  while	   JAK3	  kinase	   activity	   had	   a	   limited	   role	   in	   initiating	   downstream	  signalling	   events	   (C.	   Haan	   et	   al.,	   2011).	   This	   could	   argue	   that	   JAK1	   is	   dominant	  over	  JAK3	  in	  mediating	  signaling	  through	  γc	  cytokine	  receptors.	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However,	  there	  are	  several	  issues	  to	  be	  considered	  when	  comparing	  a	  single	  JAK1	  inhibitor	   to	   a	   single	   JAK3	   inhibitor.	   	   Firstly,	   while	   in	   vitro	   kinase	   assays	  demonstrate	  that	   the	   JAK	  kinase	   inhibitors	  have	  some	  selectivity	   for	  a	  single	   JAK	  kinase,	   the	  other	   JAK	  kinases	  will	   be	   inhibited	   to	   some	  extent	  by	  a	   selective	   JAK	  kinase	  inhibitor.	  It	  was	  also	  not	  demonstrated	  in	  the	  course	  of	  this	  project	  that	  the	  JAK1	  and	   JAK3	  selective	   inhibitors	  were	   taken	  up	   into	  cells	  equally	  well	  or	  were	  equally	   stable	   in	   cells.	   The	   differences	   in	   the	   efficiency	   of	   the	   JAK1	   and	   JAK3	  inhibitor	   at	   inhibition	   of	   IL-­‐2	   signalling	   could	   therefore	   be	   linked	   to	   a	   lower	  concentration	   of	   the	   JAK3	   inhibitor	   at	   the	   IL-­‐2	   receptor	   compared	   to	   the	   JAK1	  inhibitor.	  	  These	   issues	   could	  be	  overcome	  by	   comparing	  multiple	  different	   JAK1	  and	   JAK3	  selective	  inhibitors	  or	  using	  a	  genetic	  approach.	  Phosphoproteomic	  analysis	  could	  be	  performed	  on	  CTL	  treated	  with	  different	  types	  of	  JAK1	  and	  JAK3	  inhibitors.	  For	  example,	   the	   JAK	   kinase	   inhibitors	   used	   throughout	   this	   project	   were	   ATP	  competitive	  inhibitors,	  but	  JAK3	  inhibitors	  that	  form	  a	  covalent	  bond	  with	  a	  thiol	  group	  in	  a	  cysteine	  residue	   in	   JAK3	  have	  been	  reported	  to	  effectively	   inhibit	   IL-­‐2	  signalling	  (Smith	  et	  al.,	  2016).	  Further	  experiments	  could	  compare	  the	  potency	  of	  JAK3	  inhibitors	  with	  alternative	  modes	  of	  action	  with	  selective	  JAK1	  inhibitors	  and	  the	  pan	  JAK1/JAK3	  inhibitor	  tofacitinib.	  Phosphoproteomic	  analysis	  could	  also	  be	  carried	  out	  on	  CTL/cell	  lines	  expressing	  kinase	  dead	  JAK1	  and	  JAK3.	  	  Approximately	   4.5%	   of	   the	   CTL	   proteome	   and	   less	   than	   1.2%	   of	   the	  phosphoproteome	   identified	   by	   mass	   spectrometry	   was	   regulated	   following	  tofacitinib	   treatment	   of	   IL-­‐2	   maintained	   CTL,	   despite	   the	   requirement	   for	   IL-­‐2	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signalling	   for	   CTL	   survival,	   proliferation	   and	   growth.	   This	   highlights	   that	   JAK	  kinase	   dependent	   signalling	   networks	   involving	   a	   relatively	   small	   proportion	   of	  the	   phosphoproteome	   and	   proteome	   can	   regulate	   important	   processes	   in	   CTL	  including	   proliferation,	   survival	   and	   cell	   metabolism.	   	   Tofacitinib	   treatment	  regulated	   the	  phosphorylation	  of	   various	  proteins	   including	  proteins	   involved	   in	  transcriptional	  regulation	  and	  regulation	  of	  proteins	  involved	  in	  the	  regulation	  of	  GTPase	   protein	   activity.	   Tofacitnib	   treatment	   also	   regulated	   the	   abundance	   of	  cytokine	   receptor	   proteins	   including	   γc	   cytokine	   receptors	   and	   TNF	   superfamily	  receptors,	   proteins	   involved	   in	   sterol	   metabolism,	   CTL	   effector	   proteins	   and	  transcription	  factors	  including	  NFIL3	  and	  IRF8.	  Follow-­‐up	  experiments	  confirmed	  that	   JAK	   kinase	   dependent	   IL-­‐2	   signalling	   is	   required	   for	   expression	   of	   the	   TNF	  superfamily	  receptor	  4-­‐1BB	  and	  the	  transcription	  factor	  NFIL3.	  	  	  The	   regulation	   of	   proteins	   involved	   in	   sterol	   metabolism	   suggests	   that	   IL-­‐2	  signalling	   maintains	   the	   high	   level	   of	   cholesterol	   induced	   by	   TCR	   activation	   of	  naïve	   T	   cells.	   Upregulation	   of	   CTL	   cholesterol	   biosynthesis	   is	   required	   for	   T	   cell	  growth	  (Kidani	  et	  al.,	  2013),	  but	   its	  role	   in	  already	  activated	  T	  cells	  has	  not	  been	  explored.	   The	   role	   of	   cholesterol	   biosynthesis	   in	   IL-­‐2	   maintained	   CTL	   could	   be	  investigated	   by	   measuring	   the	   levels	   of	   cholesterol	   in	   IL-­‐2	   maintained	   and	   IL-­‐2	  deprived	   or	   tofacitinib	   treated	   CTL,	   and	   by	   inhibiting	   cholesterol	   biosynthesis	  using	   a	   HMG	   CoA	   reductase	   inhibitor	   (e.g.	   a	   statin)	   in	   an	   IL-­‐2	   maintained	   CTL	  culture	   and	   determining	   if	   this	   affects	   CTL	   proliferation,	   survival	   or	   effector	  function.	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The	   global	   proteomic	   and	   phosphoproteomic	   analysis	   of	   tofacitinib	   treated	   CTL	  suggested	   that	   JAK	   kinase	   dependent	   IL-­‐2	   signalling	   regulates	   multiple	   GTP	  binding	  proteins	  and	  regulators	  of	  these	  proteins.	  Regulated	  proteins	  included	  the	  GTPases	   GEM,	   GIMAP6	   and	   Rap2a	   and	   the	   Rab4/14	   interacting	   protein	   RUFY1.	  Regulated	  phosphorylation	  sites	  included	  regulation	  of	  RACGAP1	  phosphorylation.	  IL-­‐2	   is	  known	  to	  activate	  Ras	  (Marks	  et	  al.,	  2003),	  resulting	   in	  the	  activation	  of	  a	  MAPK	   cascade.	   Rac	   has	   also	   been	   described	   to	   be	   regulated	   by	   IL-­‐2	   signalling	  (Llavero	  et	  al.,	  2015),	  however,	  the	  roles	  of	  other	  GTPases	  regulated	  by	  tofacitinib	  treatment	  such	  as	  GEM	  have	  not	  been	  described.	  The	  roles	  of	  GTPase	  signalling	  in	  IL-­‐2	   maintained	   CTL	   could	   be	   explored	   using	   knockouts	   of	   specific	   GTPases	   or	  GTPase	  regulatory	  proteins	  or	  using	  inhibitors	  of	  upstream	  activators	  (for	  example	  PKCθ	  inhibitors	  for	  Rac).	  	  Proteins	  involved	  in	  CTL	  motility	  and	  migration	  were	  also	  found	  to	  be	  regulated	  by	  tofacitinib	  treatment.	  For	  example,	  tofacitinib	  treatment	  resulted	  in	  the	  regulation	  of	   phosphorylation	   of	   the	   actin	   binding	   protein	   plastin	   2	   and	   LSP1.	   Tofacitinib	  treatment	   also	   increases	   the	   abundance	   of	   the	   extracellular	   matrix	   interacting	  proteins	  integrin	  α1	  and	  integrin	  α4.	  This	  suggests	  that	  tofacitinib	  treatment	  could	  alter	  CTL	  motility.	  This	  could	  be	  tested	  by	  co-­‐transferring	  CTL	  maintained	  in	  IL-­‐2	  only	  and	  tofacitinib	  treated	  CTL	  into	  an	  immune	  deficient	  host,	  and	  determining	  if	  CTL	  are	  able	  to	  traffic	  in	  vivo.	  	  The	   present	   study	   highlights	   the	   importance	   of	   unbiased	   analysis	   to	   probe	   the	  actions	   of	   kinase	   inhibitors.	   Phosphoproteomic	   and	   proteomic	   studies	   revealed	  JAK	   kinase	   regulation	   of	   a	   number	   of	   transcription	   factors	   not	   previously	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described	   to	   be	   regulated	   by	   IL-­‐2	   e.g.	   NFIL3.	   Follow	   up	   experiments	   then	  demonstrated	   that	   CTL	   express	   NFIL3	   and	   that	   NFIL3	   is	   regulated	   by	   IL-­‐2.	  Important	   functions	   for	  NFIL3	   in	   regulating	   CTL	  perforin	   and	  CD62L	   expression	  were	   also	   identified.	   Following	   the	   identification	   of	   NFIL3	   as	   an	   IL-­‐2	   regulated	  protein,	   information	   from	   other	   datasets	   generated	   using	   unbiased	   approaches	  including	  a	  proteomic	  analysis	  of	  rapamycin	  treated	  CTL	  and	  a	  microarray	  analysis	  of	   HIF1β-­‐/-­‐	   CTL	   suggested	   that	   NFIL3	   was	   regulated	   downstream	   of	   mTORC1	  signalling	  and	  the	  HIF1	  transcriptional	  complex.	  This	  demonstrates	  how	  datasets	  such	   as	   the	   proteome	   and	   transcriptome	   of	   cells	   can	   be	   used	   to	   reconstruct	  signalling	  pathways	  and	  generate	  hypotheses	  for	  further	  testing.	  	  	  There	   are	   some	   limitations	   to	   the	   phosphoproteomic	   and	   proteomic	   analysis	   by	  mass	   spectrometry.	   The	   generation	   of	   peptides	   that	  will	   be	   the	   right	   length	   and	  will	   fly	   in	   the	  mass	   spectrometer	   is	   affected	  by	   the	  protease	  used.	  Generation	  of	  samples	  by	  a	  single	  protease	  limits	  the	  potential	  peptides	  that	  could	  be	  generated	  from	   the	   original	   protein	   sample	   (Giansanti	   et	   al.,	   2015).	   This	   is	   a	   particular	  problem	  with	  phosphoproteomic	  analysis.	  Whereas	  a	  protein	  can	  be	  identified	  by	  peptides	  produced	  from	  anywhere	  along	  the	  length	  of	  the	  protein,	  identification	  of	  a	   phosphosite	   requires	   the	   generation	   of	   a	   peptide	   detectable	   in	   the	   mass	  spectrometer	   from	   a	   very	   localised	   area	   of	   the	   protein.	   Given	   that	   both	  phosphorylation	  of	  a	  site	  by	  a	  particular	  kinase	  and	  cleavage	  of	  a	  site	  by	  a	  protease	  is	   amino	   acid	   sequence	   dependent,	   this	   raises	   the	   possibility	   that	   the	  phosphorylation	  sites	   in	  a	  particular	  signalling	  pathway	  will	  not	  be	  well	  detected	  by	   phosphoproteomic	   analysis.	   For	   example,	   in	   the	   phosphoproteomic	   analysis	  presented	  here,	  PKB	  substrate	  sites	  were	  not	  well	  detected.	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There	  are	  several	  potential	  solutions	  to	  this	  problem.	  	  Protein	  samples	  to	  be	  used	  for	   phosphoproteomic	   analysis	   could	   be	   divided	   and	   different	   proteases	   used	  (Giansanti	  et	  al.,	  2015).	  This	  would	  increase	  the	  number	  of	  samples	  to	  be	  analysed	  by	  mass	  spectrometry,	  increasing	  the	  cost	  of	  the	  experiment.	  There	  may	  have	  to	  be	  some	  trade	  off	  with	  the	  number	  of	   fractions	  each	  sample	   is	  divided	   into,	  but	   this	  should	   increase	   coverage	   of	   the	   phosphoproteome.	   Alternatively,	   if	   a	   particular	  signalling	   pathway	   is	   of	   interest,	   the	   sample	   could	   be	   enriched	   for	   proteins	  involved	  in	  that	  signalling	  pathway.	  	  Neverthless	   the	   current	   protocols	   have	   identified	  many	   phosphorylation	   sites	   in	  CTL	  that	  were	  not	  previously	  known.	  A	  frustration	  is	  the	  lack	  of	  information	  on	  the	  function	   of	   phosphorylation	   sites	   identified	   by	   phosphoproteomic	   mass	  spectrometry.	   Currently	   pathway	   analysis	   conducted	   on	   phosphoproteomic	  datasets	   focuses	   on	   the	   proteins	   on	   which	   the	   regulated	   phosphorylation	   sites	  were	  identified.	  However,	  each	  protein	  has	  multiple	  phosphorylation	  sites	  and	  not	  all	   sites	  may	  affect	   the	   functioning	  of	   the	  protein.	  Given	   the	  number	  of	  potential	  phosphorylation	  sites	  in	  the	  phosphoproteome	  it	  seems	  unlikely	  that	  information	  of	   the	   function	  of	   each	   site	  will	   ever	  be	   available.	  Additionally,	   pathway	  analysis	  does	  not	   incorporate	   information	  on	  the	  cell	   type	  used	  in	  the	  experiment,	  and	  so	  can	  suggest	  the	  regulation	  of	  pathways	  and	  processes	  that	  are	  not	  active	  in	  the	  cell	  type	   used	   on	   the	   basis	   of	   the	   identification	   of	   proteins	   involved	   in	   multiple	  pathways.	  	  	  Potential	   kinases	   involved	   in	   the	   phosphorylation	   of	   individual	   sites	   can	   also	   be	  predicted	   on	   the	   basis	   of	   the	   amino	   acid	   sequence	   surrounding	   the	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phosphorylation	   site	  and	   the	  amino	  acid	  phosphorylated.	  This	   can	  potentially	  be	  used	  to	  identify	  active	  and	  regulated	  signalling	  pathways.	  However,	  many	  kinases	  have	   overlapping	   or	   undetermined	   substrate	   specificities,	   which	   can	   lead	   to	   the	  identification	   of	   multiple	   different	   kinases	   for	   each	   site;	   and	   it	   is	   difficult	   to	  incorporate	  existing	  knowledge	  about	  the	  kinases	  active	  in	  the	  cell	  type	  of	  interest	  and	  the	  localization	  of	  the	  putative	  kinase	  and	  the	  protein	  phosphorylated	  into	  this	  analysis.	  	  Instead,	  more	  useful	  information	  on	  the	  function	  of	  phosphorylation	  sites	  may	  be	  found	   by	   comparing	   multiple	   phosphoproteomics	   datasets	   and	   identifying	  patterns	   of	   regulated	   phosphorylation	   sites,	   and	   identifying	   specific	  phosphorylation	   events	   to	   investigate	   further.	   Once	   generated,	   the	  phosphoproteomic	   databases	   are	   also	   available	   for	   others	   with	   an	   interest	   in	   a	  specific	  phosphorylation	  event	  or	  signalling	  pathway.	  	  HIF	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Appendix	  A:	  Phosphoproteomics	  
A.1	  Phosphoproteomics	  pathway	  analysis	  tables	  	  	  
	  
	  
Table	  A1:	  KEGG	  pathway	  and	  GO	  term	  biological	  process	  (BP),	  molecular	  functions	  (MF)	  and	  
cellular	   compartments	   (CC)	   terms	   significantly	   enriched	   in	   proteins	  with	   phosphorylation	  
sites	  that	  were	  significantly	  downregulated	  following	  30	  minutes	  tofacitinib	  treatment	  of	  IL-­‐
2	  maintained	  CTL	  	  	  	  
	  
	  
Table	  A2:	   GO	  biological	   process	   (BP),	  molecular	   functions	   (MF)	   and	   cellular	   compartment	  	  
(CC)	   terms	   significantly	   enriched	   in	   proteins	   with	   phosphorylation	   sites	   that	   were	  




	  	  	  	  
30 mins down 
Category Term Count P-Value Benjamini
KEGG_PATHWAY Wnt signaling pathway 3 3.60E-02 8.30E-01
KEGG_PATHWAY Jak-STAT signaling pathway 3 4.30E-02 6.50E-01
Category Term Count P-Value Benjamini
GOTERM_BP_DIRECT cytokine-mediated signaling pathway 3 1.50E-02 9.80E-01
GOTERM_BP_DIRECT peptidyl-tyrosine phosphorylation 3 2.50E-02 9.60E-01
GOTERM_BP_DIRECT signal transduction 6 3.20E-02 9.40E-01
GOTERM_BP_DIRECT negative regulation of apoptotic process 5 4.40E-02 9.50E-01
GOTERM_BP_DIRECT positive regulation of transcription from RNA polymerase II promoter 7 4.40E-02 9.10E-01
GOTERM_BP_DIRECT transcription, DNA-templated 11 4.60E-02 8.70E-01
GOTERM_BP_DIRECT intracellular signal transduction 5 4.60E-02 8.30E-01
Category Term Count P-Value Benjamini
GOTERM_MF_DIRECT signal transducer activity 4 2.60E-02 9.30E-01
GOTERM_MF_DIRECT transcription factor activity, sequence-specific DNA binding 6 2.70E-02 7.40E-01
GOTERM_MF_DIRECT sequence-specific DNA binding 5 3.70E-02 7.10E-01
Category Term Count P-Value Benjamini
GOTERM_CC_DIRECT intracellular 8 3.40E-02 9.30E-01
30 mins up
Category Term Count P-Value Benjamini
GOTERM_MF_DIRECT RNA binding 10 2.30E-02 9.60E-01
GOTERM_MF_DIRECT poly(A) RNA binding 13 4.00E-02 9.40E-01
Category Term Count P-Value Benjamini
GOTERM_CC_DIRECT nucleus 29 2.20E-02 9.40E-01
GOTERM_CC_DIRECT nuclear membrane 5 2.30E-02 7.60E-01
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Table	  A3:	  KEGG	  pathway	  terms,	  GO	  term	  biological	  process,	  molecular	  function	  and	  cellular	  
compartment	  terms	  significantly	  enriched	  in	  proteins	  with	  phosphorylation	  sites	  that	  were	  
significantly	  downregulated	  following	  4hrs	  tofacitinib	  treatment	  of	  IL-­‐2	  maintained	  CTL	  	  	  	  
Category Term Count P-Value Benjamini
KEGG_PATHWAY Acute myeloid leukemia 6 2.60E-03 2.70E-01
KEGG_PATHWAY Thyroid cancer 4 5.80E-03 3.00E-01
KEGG_PATHWAY MicroRNAs in cancer 8 8.80E-03 3.00E-01
KEGG_PATHWAY Proteoglycans in cancer 8 9.70E-03 2.60E-01
KEGG_PATHWAY ErbB signaling pathway 6 1.30E-02 2.80E-01
KEGG_PATHWAY Prolactin signaling pathway 5 1.40E-02 2.50E-01
KEGG_PATHWAY Chronic myeloid leukemia 6 1.50E-02 2.30E-01
KEGG_PATHWAY Vascular smooth muscle contraction 5 2.20E-02 2.90E-01
KEGG_PATHWAY Pathways in cancer 9 3.00E-02 3.40E-01
KEGG_PATHWAY Jak-STAT signaling pathway 5 3.60E-02 3.60E-01
KEGG_PATHWAY Hepatitis B 6 4.50E-02 4.00E-01
KEGG_PATHWAY Glycerophospholipid metabolism 3 4.60E-02 3.80E-01
Category Term Count P-Value Benjamini
GOTERM_BP_DIRECT MAPK cascade 7 1.40E-04 1.40E-01
GOTERM_BP_DIRECT response to wounding 5 6.00E-04 2.70E-01
GOTERM_BP_DIRECT cellular response to fibroblast growth factor stimulus 5 6.00E-04 2.70E-01
GOTERM_BP_DIRECT negative regulation of erythrocyte differentiation 4 1.10E-03 3.20E-01
GOTERM_BP_DIRECT cellular response to granulocyte macrophage colony-stimulating factor 
stimulus 
4 1.10E-03 3.20E-01
GOTERM_BP_DIRECT positive regulation of transcription from RNA polymerase II promoter 21 1.20E-03 2.70E-01
GOTERM_BP_DIRECT cellular response to epidermal growth factor stimulus 5 2.80E-03 4.50E-01
GOTERM_BP_DIRECT cellular response to glucocorticoid stimulus 3 4.50E-03 5.50E-01
GOTERM_BP_DIRECT negative regulation of mitotic cell cycle phase transition 3 4.50E-03 5.50E-01
GOTERM_BP_DIRECT cellular response to phorbol 13-acetate 12-myristate 3 8.70E-03 7.30E-01
GOTERM_BP_DIRECT cellular response to insulin stimulus 5 1.70E-02 9.00E-01
GOTERM_BP_DIRECT T cell differentiation in thymus 4 1.90E-02 9.00E-01
GOTERM_BP_DIRECT positive regulation of gene expression 8 2.00E-02 8.80E-01
GOTERM_BP_DIRECT 
nuclear-transcribed mRNA catabolic process, deadenylation-dependent 
decay 3 2.10E-02 8.70E-01
GOTERM_BP_DIRECT positive regulation of B cell differentiation 3 2.10E-02 8.70E-01
GOTERM_BP_DIRECT mRNA catabolic process 3 2.10E-02 8.70E-01
GOTERM_BP_DIRECT positive regulation of transcription, DNA-templated 12 2.20E-02 8.50E-01
GOTERM_BP_DIRECT heart development 7 2.30E-02 8.50E-01
GOTERM_BP_DIRECT negative regulation of transcription from RNA polymerase II promoter 16 2.60E-02 8.70E-01
GOTERM_BP_DIRECT ERK1 and ERK2 cascade 3 2.80E-02 8.70E-01
GOTERM_BP_DIRECT positive regulation of nuclear-transcribed mRNA catabolic process, 
deadenylation-dependent decay 
3 2.80E-02 8.70E-01
GOTERM_BP_DIRECT cellular response to drug 4 3.10E-02 8.80E-01
GOTERM_BP_DIRECT 3'-UTR-mediated mRNA destabilization 3 3.70E-02 9.00E-01
GOTERM_BP_DIRECT cell fate commitment 3 3.70E-02 9.00E-01
GOTERM_BP_DIRECT positive regulation of fat cell differentiation 3 4.60E-02 9.40E-01
GOTERM_BP_DIRECT positive regulation of epithelial cell proliferation 3 4.60E-02 9.40E-01
GOTERM_BP_DIRECT phospholipid biosynthetic process 3 4.60E-02 9.40E-01
GOTERM_BP_DIRECT regulation of transcription from RNA polymerase II promoter 9 4.70E-02 9.30E-01
GOTERM_BP_DIRECT cellular response to tumor necrosis factor 4 4.70E-02 9.20E-01
Category Term Count P-Value Benjamini
GOTERM_MF_DIRECT transcription factor activity, sequence-specific DNA binding 18 8.60E-05 2.00E-02
GOTERM_MF_DIRECT sequence-specific DNA binding 14 3.80E-04 4.40E-02
GOTERM_MF_DIRECT protein binding 55 2.40E-03 1.70E-01
GOTERM_MF_DIRECT 14-3-3 protein binding 4 1.30E-02 5.20E-01
GOTERM_MF_DIRECT AU-rich element binding 3 1.40E-02 4.90E-01
GOTERM_MF_DIRECT 
transcriptional activator activity, RNA polymerase II core promoter proximal 
region sequence-specific binding 7 1.50E-02 4.40E-01
GOTERM_MF_DIRECT mRNA 3'-UTR AU-rich region binding 3 2.10E-02 5.00E-01
GOTERM_MF_DIRECT RNA polymerase II regulatory region sequence-specific DNA binding 6 3.50E-02 6.50E-01
Category Term Count P-Value Benjamini
GOTERM_CC_DIRECT endoplasmic reticulum membrane 9 1.60E-02 9.60E-01
GOTERM_CC_DIRECT integral component of membrane 25 2.50E-02 9.20E-01
GOTERM_CC_DIRECT endoplasmic reticulum 12 3.50E-02 9.10E-01
GOTERM_CC_DIRECT perinuclear region of cytoplasm 13 4.50E-02 9.00E-01
GOTERM_CC_DIRECT membrane 50 4.90E-02 8.60E-01
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Table	  A4:	  GO	  biological	  process	  (BP)	  significantly	  enriched	  in	  proteins	  with	  phosphorylation	  
sites	   that	   were	   significantly	   upregulated	   following	   4hrs	   tofacitinib	   treatment	   of	   IL-­‐2	  










Category Term Count P-Value Benjamini
GOTERM_BP_DIRECT chemotaxis 2 3.70E-02 9.80E-01
GOTERM_BP_DIRECT transcription, DNA-templated 7 5.00E-02 9.40E-01
	   272	  
A.2	  Proteins	  with	  phosphosites	  identified	  as	  part	  of	  significantly	  regulated	  
pathways	  (listed	  by	  gene	  name)	  
	  
Table	  A5:	  Gene	  names	  of	  proteins	   identified	  as	  part	  of	   the	   listed	  KEGG	  pathways,	  GO	   term	  
biological	   processes	   (BP),	   molecular	   functions	   (MF)	   and	   cellular	   compartments	   (CC)	  
significantly	   enriched	   in	   proteins	   with	   phosphorylation	   sites	   significantly	   downregulated	  




Table	   A6:	   Gene	   names	   of	   proteins	   identified	   as	   part	   of	   the	   listed	   GO	   term	   biological	  
processes	   (BP),	   molecular	   functions	   (MF)	   and	   cellular	   compartments	   (CC)	   significantly	  
enriched	   in	   proteins	   with	   phosphorylation	   sites	   significantly	   upregulated	   following	   30	  
minutes	  tofacitinib	  treatment	  	  
30 mins down 
Category Term P-Value Genes
KEGG_PATHWAY Wnt signaling pathway 3.60E-02 Senp2, Chd8, Nfatc2
KEGG_PATHWAY Jak-STAT signaling pathway 4.30E-02 Jak3, Stat4, Stat5a
Category Term P-Value Genes
GOTERM_BP_DIRECT cytokine-mediated signaling pathway 1.50E-02 Jak3, Stat4, Stat5a
GOTERM_BP_DIRECT peptidyl-tyrosine phosphorylation 2.50E-02 Jak3, Pxn, Stat5a
GOTERM_BP_DIRECT signal transduction 3.20E-02 Sh2b1, Cd97, Hmha1, Stat4, Stat5a, Shc1
GOTERM_BP_DIRECT negative regulation of apoptotic process 4.40E-02 Rps6, Ankle2, Chd8, Rps6ka1, Stat5a
GOTERM_BP_DIRECT positive regulation of transcription from RNA polymerase II 
promoter 
4.40E-02 Jak3, Senp2, Chd8, Nfatc2, Rps6ka1, Stat4, Stat5a
GOTERM_BP_DIRECT transcription, DNA-templated 4.60E-02 Senp2, Taf3, Tsc22d4, Cic, Chd8, Foxk1, Nfatc2, 
Nfil3, Stat4, Stat5a, Samd4b
GOTERM_BP_DIRECT intracellular signal transduction 4.60E-02 Jak3, Sh2b1, Hmha1, Rps6ka1, Shc1
Category Term P-Value Genes
GOTERM_MF_DIRECT signal transducer activity 2.60E-02 Sh2b1, Cd97, Stat4, Stat5a
GOTERM_MF_DIRECT transcription factor activity, sequence-specific DNA binding 2.70E-02 Tsc22d4, Foxk1, Nfatc2, Nfil3, Stat4, Stat5a
GOTERM_MF_DIRECT sequence-specific DNA binding 3.70E-02 Foxk1, Nfatc2, Nfil3, Stat4, Stat5a
Category Term P-Value Genes
GOTERM_CC_DIRECT intracellular 3.40E-02 Jak3, Sh2b1, Dock5, Hmha1, Rps6ka1, Shc1, 
Stmn1, Zc3h11a
30 mins up
Category Term P-Value Genes
GOTERM_MF_DIRECT RNA binding 2.30E-02 Dnmt1, Ranbp2, Rbm14, Sltm, Tardbp, Ythdc1, 
Ankrd17, Hnrnpa2b1, Hnrnpm, Tnrc6a
GOTERM_MF_DIRECT poly(A) RNA binding 4.00E-02
Huwe1, Rbm14, Sltm, Samsn1, Tardbp, Ythdc1, 
Ankrd17, Fam208a, Hnrnpa2b1, Hnrnpm, Snd1, 
Ssrp1, Tnrc6a
Category Term P-Value Genes
GOTERM_CC_DIRECT nucleus 2.20E-02
Arl2, Dnmt1, Huwe1, Phf8, Ranbp2, Rbm14, 
Racgap1, Sltm, Samsn1, Senp1, Smarca4, Tardbp, 
Ythdc1, Ankrd17, Paxx, Fam208a, Hcls1, 
Hnrnpa2b1, Hnrnpm, Lsg1, Msn, Pml, Runx3, 
Snd1, Ssrp1, Tmpo, Tgs1, Ubash3a, Usp25 
GOTERM_CC_DIRECT nuclear membrane 2.30E-02 Phf8, Ranbp2, Senp1, Pml, Tmpo
GOTERM_CC_DIRECT perichromatin fibrils 3.90E-02 Smarca4, Tardbp
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Table	   A7:	   Gene	   names	   of	   proteins	   identified	   as	   part	   of	   the	   listed	   KEGG	   pathways	   and	   GO	  
biological	   process	   terms	   significantly	   enriched	   in	   proteins	   with	   phosphorylation	   sites	  
significantly	  downregulated	  following	  4	  hours	  tofacitinib	  treatment	  	  
4hrs down
Category Term P-Value Genes
KEGG_PATHWAY Acute myeloid leukemia 2.60E-03 Araf, Map2k2, Myc, Pim1, Stat5a, Stat5b
KEGG_PATHWAY Thyroid cancer 5.80E-03 Map2k2, Myc, Pparg, Tpr
KEGG_PATHWAY MicroRNAs in cancer 8.80E-03 Cd44, Ccnd2, Map2k2, Myc, Notch1, Pim1, Shc1, 
Stmn1
KEGG_PATHWAY Proteoglycans in cancer 9.70E-03 Araf, Cd44, Arhgef1, Arhgef12, Map2k2, Myc, 
Ppp1r12a, Slc9a1
KEGG_PATHWAY ErbB signaling pathway 1.30E-02 Araf, Map2k2, Myc, Stat5a, Stat5b, Shc1
KEGG_PATHWAY Prolactin signaling pathway 1.40E-02 Ccnd2, Map2k2, Stat5a, Stat5b, Shc1
KEGG_PATHWAY Chronic myeloid leukemia 1.50E-02 Araf, Map2k2, Myc, Stat5a, Stat5b, Shc1
KEGG_PATHWAY Vascular smooth muscle contraction 2.20E-02 Araf, Arhgef1, Arhgef12, Map2k2, Ppp1r12a
KEGG_PATHWAY Pathways in cancer 3.00E-02 Araf, Arhgef1, Arhgef12, Map2k2, Myc, Pparg, 
Stat5a, Stat5b, Tpr
KEGG_PATHWAY Jak-STAT signaling pathway 3.60E-02 Ccnd2, Myc, Pim1, Stat5a, Stat5b
KEGG_PATHWAY Hepatitis B 4.50E-02 Atf4, Map2k2, Myc, Nfatc2, Stat5a, Stat5b
KEGG_PATHWAY Glycerophospholipid metabolism 4.60E-02 Gpat3, Pcyt1a, Ptdss2
Category Term P-Value Genes
GOTERM_BP_DIRECT MAPK cascade 1.40E-04 Dok1, Map2k2, Myc, Shc1, Zfp36, Zfp36l1, Zfp36l2
GOTERM_BP_DIRECT response to wounding 6.00E-04 Lcp1, Myc, Zfp36, Zfp36l1, Zfp36l2
GOTERM_BP_DIRECT cellular response to fibroblast growth factor stimulus 6.00E-04 Cd44, Myc, Zfp36, Zfp36l1, Zfp36l2
GOTERM_BP_DIRECT negative regulation of erythrocyte differentiation 1.10E-03 Stat5a, Stat5b, Zfp36, Zfp36l1
GOTERM_BP_DIRECT cellular response to granulocyte macrophage colony-
stimulating factor stimulus 
1.10E-03 Etv3, Stat5a, Zfp36, Zfp36l2
GOTERM_BP_DIRECT positive regulation of transcription from RNA polymerase II 
promoter 
1.20E-03
Arid4b, Agap2, Atf4, Csrnp1, Eomes, Mcf2l, Myc, 
Notch1, Nfatc2, Pprc1, Pparg, Pelp1, Ppp1r12a, 
Rgcc, Stat5a, Stat5b, Slc9a1, Srebf1, Tcf20, Tsc2, 
Mycn
GOTERM_BP_DIRECT cellular response to epidermal growth factor stimulus 2.80E-03 Myc, Stat5b, Zfp36, Zfp36l1, Zfp36l2
GOTERM_BP_DIRECT cellular response to glucocorticoid stimulus 4.50E-03 Zfp36, Zfp36l1, Zfp36l2
GOTERM_BP_DIRECT negative regulation of mitotic cell cycle phase transition 4.50E-03 Rgcc, Zfp36l1, Zfp36l2
GOTERM_BP_DIRECT cellular response to phorbol 13-acetate 12-myristate 8.70E-03 Myc, Zfp36l1, Zfp36l2
GOTERM_BP_DIRECT cellular response to insulin stimulus 1.70E-02 Myc, Pparg, Slc9a1, Tsc2, Zfp36l1
GOTERM_BP_DIRECT T cell differentiation in thymus 1.90E-02 Stat5a, Stat5b, Zfp36l1, Zfp36l2
GOTERM_BP_DIRECT positive regulation of gene expression 2.00E-02 Cd44, Prdm1, Atf4, Lmna, Nfatc2, Nfil3, Rgcc, Mycn
GOTERM_BP_DIRECT nuclear-transcribed mRNA catabolic process, deadenylation-
dependent decay 
2.10E-02 Zfp36, Zfp36l1, Zfp36l2
GOTERM_BP_DIRECT positive regulation of B cell differentiation 2.10E-02 Prdm1, Stat5a, Stat5b
GOTERM_BP_DIRECT mRNA catabolic process 2.10E-02 Zfp36, Zfp36l1, Zfp36l2
GOTERM_BP_DIRECT positive regulation of transcription, DNA-templated 2.20E-02 Atf4, Eomes, Foxk1, Irf8, Map2k2, Myc, Notch1, 
Nfatc2, Pparg, Pim1, Srebf1, Mycn
GOTERM_BP_DIRECT heart development 2.30E-02 Map2k2, Notch1, Pparg, Shc1, Tp53bp2, Tsc2, 
Zfp36l1
GOTERM_BP_DIRECT 
negative regulation of transcription from RNA polymerase II 
promoter 2.60E-02
N4bp2l2, Prdm1, Eomes, Etv3, Ehmt2, Irf2bp2, Irf8, 
Myc, Nedd4, Notch1, Nfatc2, Nfil3, Pparg, Srebf1, 
Tpr, Zfp36
GOTERM_BP_DIRECT ERK1 and ERK2 cascade 2.80E-02 Map2k2, Zfp36l1, Zfp36l2
GOTERM_BP_DIRECT positive regulation of nuclear-transcribed mRNA catabolic 
process, deadenylation-dependent decay 
2.80E-02 Zfp36, Zfp36l1, Zfp36l2
GOTERM_BP_DIRECT cellular response to drug 3.10E-02 Ehmt2, Myc, Ppp1r12a, Tfrc
GOTERM_BP_DIRECT 3'-UTR-mediated mRNA destabilization 3.70E-02 Zfp36, Zfp36l2, Zfp36l1
GOTERM_BP_DIRECT cell fate commitment 3.70E-02 Prdm1, Notch1, Pparg
GOTERM_BP_DIRECT positive regulation of fat cell differentiation 4.60E-02 Pparg, Zfp36, Zfp36l1
GOTERM_BP_DIRECT positive regulation of epithelial cell proliferation 4.60E-02 Ccnd2, Myc, Notch1
GOTERM_BP_DIRECT phospholipid biosynthetic process 4.60E-02 Gpat3, Pcyt1a, Ptdss2
GOTERM_BP_DIRECT regulation of transcription from RNA polymerase II promoter 4.70E-02 Atf4, Eomes, Ehmt2, Foxk1, Notch1, Pparg, Stat5a, 
Stat5b, Zfp36
GOTERM_BP_DIRECT cellular response to tumor necrosis factor 4.70E-02 Tnfrsf21, Zfp36, Zfp36l1, Zfp36l2
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Table	  A8:	  Gene	  names	  of	  proteins	  identified	  as	  part	  of	  the	  listed	  GO	  molecular	  function	  and	  
cellular	   compartment	   terms	   significantly	   enriched	   in	   proteins	   with	   phosphorylation	   sites	  
significantly	  downregulated	  following	  4	  hours	  tofacitinib	  treatment	  	  	  	  	  	  
	  	  
Table	  A9:	  Gene	  names	  of	  proteins	  identified	  as	  part	  of	  the	  listed	  GO	  term	  biological	  process	  
(BP)	   terms	   significantly	   enriched	   in	   proteins	   with	   phosphorylation	   sites	   reproducibly	  
detected	  to	  be	  upregulated	  following	  4	  hours	  tofacitinib	  treatment	  
	  
	  	  	  
4hrs down
Category Term P-Value Genes
GOTERM_MF_DIRECT transcription factor activity, sequence-specific DNA binding 8.60E-05
Ahctf1, Prdm1, Atf4, Csrnp1, Eomes, Etv3, Foxk1, 
Irf8, Myc, Notch1, Nfatc2, Nfil3, Pparg, Stat5a, 
Stat5b, Srebf1, Tcf20, Mycn
GOTERM_MF_DIRECT sequence-specific DNA binding 3.80E-04 Prdm1, Atf4, Csrnp1, Eomes, Etv3, Foxk1, Myc, 
Notch1, Nfatc2, Nfil3, Pparg, Stat5a, Stat5b, Srebf1
GOTERM_MF_DIRECT protein binding 2.40E-03
Araf, Agap2, Clip1, Cd44, Ctc1, Limd1, Mycbp2, 
N4bp2l2, Prdm1, No66, Arhgef1, Arhgef12, Wdhd1, 
Atf4, Bicd2, Baz1a, Ccnd2, Etv3, Ehmt2, Eef1b, 
Eif3a, Foxk1, Hdgfrp2, Ier3, Irf8, Klc3, Lmna, Lcp1, 
Mcf2l, Map2k2, Map4k1, Myc, Nedd4, Notch1, 
Nfatc2, Nfil3, Pparg, Pcyt1a, Ppp1r12a, Pim1, 
Rgcc, Stat5a, Stat5b, Shc1, Stmn1, Srebf1, Stx4, 
Tcf20, Tfrc, Tpr, Tsc2, Mycn, Vapa, Zfp36, Zfp36l1
GOTERM_MF_DIRECT 14-3-3 protein binding 1.30E-02 Ppp1r12a, Tsc2, Zfp36, Zfp36l1
GOTERM_MF_DIRECT AU-rich element binding 1.40E-02 Zfp36, Zfp36l1, Zfp36l2
GOTERM_MF_DIRECT transcriptional activator activity, RNA polymerase II core 
promoter proximal region sequence-specific binding 
1.50E-02 Atf4, Myc, Nfatc2, Stat5a, Stat5b, Srebf1, Tcf20
GOTERM_MF_DIRECT mRNA 3'-UTR AU-rich region binding 2.10E-02 Zfp36, Zfp36l2, Zfp36l1
GOTERM_MF_DIRECT RNA polymerase II regulatory region sequence-specific DNA 
binding 
3.50E-02 Myc, Nfil3, Stat5a, Stat5b
Category Term P-Value Genes
GOTERM_CC_DIRECT endoplasmic reticulum membrane 1.60E-02 Gpat3, Notch1, Pcyt1a, Ptdss2, Rhbdf2, Slc9a1, 
Srebf1, Use1, Vapa
GOTERM_CC_DIRECT integral component of membrane 2.50E-02
Gpat3, Akap1, Clip1, Cd44, Huwe1, Arhgef12, 
Stard3nl, Acbd5, Eef1b, Ier3, Lrp12, Lrp12, Mfsd8, 
Notch1, Ptdss2, Rhbdf2, Slc7a11, Slc9a1, Srebf1, 
Stx4, Tfrc, Tmem39b, Tnfrsf21, Ubr4, Use1, Vapa
GOTERM_CC_DIRECT endoplasmic reticulum 3.50E-02 Gpat3, Akap1, Eef1b, Map2k2, Notch1, Pcyt1a, 
Ptdss2, Rhbdf2, Slc9a1, Srebf1, Use1, Vapa
GOTERM_CC_DIRECT perinuclear region of cytoplasm 4.50E-02 Arfgef2, Lmna, Map2k2, Myc, Nedd4, Pparg, 
Pacs1, Slc9a1, Stx4, Tfrc, Tp53bp2, Tsc2, Vapa
GOTERM_CC_DIRECT membrane 4.90E-02
Gpat3, Akap1, Arfgef2, Agap2, Clip1, Cd44, 
Ddx19a, Huwe1, Larp1, Larp4b, Mycbp2, Nop56, 
Arhgef1, Arhgef12, Stard3nl, Atf4, Acbd5, Ccnd2, 
Ctps1, Dock2, Dock5, Eif3a, Hspa14, Hmha1, Ier3, 
Lrp12, Lcp1, Mfsd8, Mcf2l, Map2k2, Map4k1, 
Nedd4, Notch1, Pcyt1a, Pik3c2a, Ptdss2, Rhbdf2, 
Slc7a11, Slc9a1, Stmn1, Srebf1, Stx4, Tfrc, Tpr, 
Tmem39b, Tsc2, Tnfrsf21, Ubr4, Use1, Vapa
4hrs up
Category Term P-Value Genes
GOTERM_BP_DIRECT chemotaxis 3.70E-02 Il16, Lsp1
GOTERM_BP_DIRECT transcription, DNA-templated 5.00E-02 Dnmt1, Elk3, Hdgfrp2, Il16, Kdm2b, Med24, 
Tp53bp1
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A.3	  Phosphorylation	  sites	  significantly	  regulated	  following	  30	  minutes	  
tofacitinib	  treatment	  	  	  
	  	  
Table	   A10:	   Phosphorylation	   sites	   significantly	   downregulated	   following	   30	   minutes	  
tofacitinib	  treatment.	  	  	  
	  	  
Table	  A11:	  Phosphorylation	  sites	  significantly	  upregulated	  following	  30	  minutes	  tofacitinib	  
treatment.	  
30 mins down
Site name Mean ratio Site name
Mean 
ratio
Signal transducer and activator of transcription 5A Y694 0.09 Paxillin S83 0.55
Protein capicua homolog S2275 0.32 Ubiquitin carboxyl-terminal hydrolase 25 S136 0.55
Chromodomain-helicase-DNA-binding protein 8 S2040 0.40 ATP-dependent RNA helicase DDX24 S67 0.57
Plastin-2 S5 0.44 Stathmin S25 0.57
Protein DDI1 homolog 2 S194 0.45 Minor histocompatibility protein HA-1 S877 0.58
WASH complex subunit FAM21 S832 0.45 Nuclear factor of activated T-cells, cytoplasmic 2 S761 0.59
Signal transducer and activator of transcription 4 Y694 0.45 CD97 antigen S720 0.59
Chloride channel CLIC-like protein 1 S433 0.46 SH2B adapter protein 1 S96 0.61
SHC-transforming protein 1 Y313 0.46 Transmembrane protein 163 S54 0.61
Dedicator of cytokinesis protein 5 T1793 0.48 Zinc finger CCCH domain-containing protein 11A S289 0.61
40S ribosomal protein S6 S236 0.49 Protein Smaug homolog 2 S585 0.61
TSC22 domain family protein 4 S271 0.51 Sentrin-specific protease 2 S332 0.62
Ribosomal protein S6 kinase alpha-1 S352 0.52 Nuclear factor interleukin-3-regulated protein S353 0.63
Transcription initiation factor TFIID subunit 3 S199 0.53 Forkhead box protein K1 S406 0.63
DENN domain-containing protein 4C S1221 0.53 Tyrosine-protein kinase JAK3 T778 0.64
Protein FAM114A2 S112 0.54 Nuclear factor of activated T-cells, cytoplasmic 2 S757 0.64
Phosphorylase b kinase regulatory subunit alpha, liver isoform 
S735
0.54 Ankyrin repeat and LEM domain-containing protein 2 S819 0.64
Meiosis arrest female protein 1 S65 0.55 Tyrosine-protein kinase JAK3 S19 0.67
30 mins up
Site name Mean ratio Site name
Mean 
ratio
Rac GTPase-activating protein 1 S590 2.74 Heterogeneous nuclear ribonucleoprotein M S597 1.78
Trinucleotide repeat-containing gene 6A protein S1825 2.70 Uncharacterized protein C9orf142 homolog S116 1.77
Trimethylguanosine synthase S92 2.22 Ythdc1 S571 1.76
Kinesin-like protein KIF20A S681 2.19 Runt-related transcription factor 3 S249 1.76
E3 SUMO-protein ligase RanBP2 S1446 2.10 Unconventional myosin-IXb S1302 1.76
TAR DNA-binding protein 43 S292 2.09 Genetic suppressor element 1 S969 1.74
Hematopoietic lineage cell-specific protein S232 2.09 Sentrin-specific protease 1 S229 1.67
Histone lysine demethylase PHF8 S686 2.02 SAFB-like transcription modulator S768 1.66
AMP deaminase 2 S53 2.02 FACT complex subunit SSRP1 S662 1.65
Moesin S407 2.00 Ubiquitin-associated and SH3 domain-containing protein A S345 1.64
RNA-binding protein 14 S620 1.99 Brain-specific angiogenesis inhibitor 1-associated protein 2 S337 1.63
Heterogeneous nuclear ribonucleoproteins A2/B1 S200 1.98 Protein FAM208A S795 1.62
Ankyrin repeat domain-containing protein 17 S152 1.97 ADP-ribosylation factor-like protein 2 S45 1.62
Oxysterol-binding protein-related protein 9 S228 1.96 RNA-binding protein 14 S623 1.58
Protein strawberry notch homolog 1 S804 1.95 Protein PML S609 1.57
Ubiquitin carboxyl-terminal hydrolase 25 S113 1.95 cGMP-inhibited 3',5'-cyclic phosphodiesterase B S533 1.56
Heterogeneous nuclear ribonucleoprotein M S593 1.95 Staphylococcal nuclease domain-containing protein 1 S909 1.55
DNA (cytosine-5)-methyltransferase 1 S15 1.92 Activating molecule in BECN1-regulated autophagy protein 1 S607 1.53
E3 ubiquitin-protein ligase HUWE1 S2593 1.91 PERQ amino acid-rich with GYF domain-containing protein 1 S445 1.53
N-alpha-acetyltransferase 30 S192 1.89 Histamine H2 receptor S321 1.52
Transcription activator BRG1 S1349 1.87 SAM domain-containing protein SAMSN-1 S90 1.52
Probable ubiquitin carboxyl-terminal hydrolase FAF-X S590 1.86 FACT complex subunit SSRP1 S659 1.51
E3 ubiquitin-protein ligase HUWE1 S2595 1.79 Sentrin-specific protease 1 S57 1.51
Large subunit GTPase 1 homolog S97 1.78 Lamina-associated polypeptide 2, isoforms 
beta/delta/epsilon/gamma S264
1.50
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A.4	  Phosphorylation	  sites	  reproducibly	  detected	  to	  be	  regulated	  following	  
four	  hours	  tofacitinib	  treatment	  
	   	  	  
Table	   A12:	   Phosphorylation	   sites	   significantly	   downregulated	   following	   four	   hours	  
tofacitinib	  treatment.	  
4hrs down
Site name Mean ratio Site name
Mean 
ratio
CST complex subunit CTC1 T2 0.12 E3 ubiquitin-protein ligase UBR4 S2603 0.61
Eomesodermin homolog S659 0.15 Arf-GAP with GTPase, ANK repeat and PH domain-containing 
protein 2 S901
0.61
NEDD4-binding protein 2-like 2 S35 0.17 Protein lin-9 homolog S65 0.61
Signal transducer and activator of transcription 5A Y694 0.20 Phosphofurin acidic cluster sorting protein 1 S318 0.61
Signal transducer and activator of transcription 5B Y699 0.21 Mitogen-activated protein kinase kinase kinase kinase 1 S455 0.62
LIM domain-containing protein 1 S308 0.37 Mitogen-activated protein kinase kinase kinase kinase 1 S405 0.62
Peroxisome proliferator-activated receptor gamma coactivator-
related protein 1 S1059
0.40 Phosphatidylserine synthase 2 S12 0.62
Elongation factor 1-beta S90 0.45 MLN64 N-terminal domain homolog S39 0.62
Protein FAM114A2 S112 0.47 Rho guanine nucleotide exchange factor 12 S341 0.62
Prelamin-A/C S12 0.48 Stathmin S25 0.62
Zinc finger protein 36, C3H1 type-like 1 S92 0.48 Hepatoma-derived growth factor-related protein 2 S450 0.63
Interferon regulatory factor 8 S162 0.48 La-related protein 1 T1050 0.63
Interferon regulatory factor 8 S164 0.48 Bifunctional lysine-specific demethylase and histidyl-hydroxylase 
NO66 S107
0.63
Cysteine/serine-rich nuclear protein 1 S535 0.49 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing 
subunit alpha S1525
0.63
Minor histocompatibility protein HA-1 S875 0.49 Proline-, glutamic acid- and leucine-rich protein 1 S483 0.63
Nuclear factor interleukin-3-regulated protein S210 0.50 Dual specificity mitogen-activated protein kinase kinase 2 S23 0.63
Radiation-inducible immediate-early gene IEX-1 S31 0.50 Cordon-bleu protein-like 1 T956 0.63
Nuclear factor interleukin-3-regulated protein S301 0.50 Protein RRP5 homolog S1468 0.63
La-related protein 1 S743 0.51 PR domain zinc finger protein 1 S237 0.63
Eukaryotic translation initiation factor 3 subunit A S584 0.51 Neurogenic locus notch homolog protein 1 S1807 0.63
Serine/threonine-protein kinase pim-1 S32 0.51 Signal transducer and activator of transcription 5A S127 0.64
Myc proto-oncogene protein S62 0.51 Nucleoprotein TPR T2184 0.64
Dedicator of cytokinesis protein 5 S1788 0.52 Apoptosis-stimulating of p53 protein 2 S328 0.64
Dedicator of cytokinesis protein 5 T1793 0.52 WD repeat and HMG-box DNA-binding protein 1 S851 0.64
N-myc proto-oncogene protein T58 0.52 La-related protein 4B S570 0.64
Myc proto-oncogene protein T58 0.52 E3 ubiquitin-protein ligase NEDD4 S309 0.64
Nuclear factor interleukin-3-regulated protein S275 0.53 Nucleolar protein 56 S554 0.64
Acyl-CoA-binding domain-containing protein 5 S359 0.54 Dedicator of cytokinesis protein 2 T1674 0.64
SHC-transforming protein 1 Y313 0.54 E3 ubiquitin-protein ligase HUWE1 S3753 0.64
Tristetraprolin S178 0.54 Putative RNA-binding protein 3 S133 0.64
Glycerol-3-phosphate acyltransferase 3 S68 0.55 Docking protein 1 S290 0.65
Minor histocompatibility protein HA-1 S877 0.55 Tumor necrosis factor receptor superfamily member 21 S541 0.65
Rho guanine nucleotide exchange factor 1 S785 0.55 Major facilitator superfamily domain-containing protein 8 S18 0.65
Myc proto-oncogene protein S164 0.55 Transferrin receptor protein 1 Y20 0.65
Phostensin S224 0.55 Choline-phosphate cytidylyltransferase A S319 0.65
Heat shock 70 kDa protein 14 S61 0.55 Forkhead box protein K1 S427 0.65
Cyclic AMP-dependent transcription factor ATF-4 S247 0.56 Cystine/glutamate transporter S26 0.65
Peroxisome proliferator-activated receptor gamma S82 0.56 Signal transducer and activator of transcription 5A S128 0.65
CD44 antigen S318 0.56 Kinesin light chain 3 S506 0.65
Brefeldin A-inhibited guanine nucleotide-exchange protein 2 S1022 0.56 Rho guanine nucleotide exchange factor 1 S905 0.65
Syntaxin-4 S36 0.57 Eomesodermin homolog S52 0.65
RNA-binding protein 7 S203 0.57 ETS translocation variant 3 S139 0.65
Rho GTPase-activating protein 25 S274 0.57 Vesicle transport protein USE1 S165 0.66
ATP-dependent RNA helicase DDX19A S85 0.57 Plastin-2 S5 0.66
Ubiquitin-associated protein 1 S146 0.58 Sterol regulatory element-binding protein 1 S72 0.66
Regulator of cell cycle RGCC T99 0.58 Transcription factor 20 S1395 0.66
Uridine-cytidine kinase 2 S254 0.58 A-kinase anchor protein 1, mitochondrial S104 0.66
Nuclear factor of activated T-cells, cytoplasmic 2 S738 0.58 Transmembrane protein 39B S47 0.66
Bromodomain adjacent to zinc finger domain protein 1A S1416 0.59 Probable E3 ubiquitin-protein ligase MYCBP2 S1583 0.66
Inactive rhomboid protein 2 S279 0.59 Interferon regulatory factor 2-binding protein 2 S226 0.66
G1/S-specific cyclin-D2 T280 0.59 Nuclear factor of activated T-cells, cytoplasmic 2 S757 0.66
Protein ELYS S1930 0.60 Serine/threonine-protein kinase A-Raf T181 0.67
Treslin S1778 0.60 Sodium/hydrogen exchanger 1 S727 0.67
Protein phosphatase 1 regulatory subunit 12A S507 0.60 Zinc finger protein 36, C3H1 type-like 2 S127 0.67
WD repeat-containing protein 46 S91 0.60 AT-rich interactive domain-containing protein 4B S743 0.67
Vesicle-associated membrane protein-associated protein A S214 0.60 Lysine-specific demethylase 4B S988 0.67
CTP synthase 1 S575 0.60 Guanine nucleotide exchange factor DBS S621 0.67
Probable ATP-dependent RNA helicase DDX10 S522 0.60 Low-density lipoprotein receptor-related protein 12 S700 0.67
CAP-Gly domain-containing linker protein 1 S347 0.60 182 kDa tankyrase-1-binding protein S1022 0.67
Myc proto-oncogene protein S71 0.60 RING finger protein 219 S522 0.67
Protein bicaudal D homolog 2 S411 0.61 Tuberin S1301 0.67
Histone-lysine N-methyltransferase EHMT2 S228 0.61 Tuberin S1300 0.67
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Table	  A13:	  Phosphorylation	  sites	  significantly	  upregulated	   following	   four	  hours	   tofacitinib	  
treatment.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4hrs up
Site name Mean ratio Site name
Mean 
ratio
Melanoma inhibitory activity protein 3 S1566 4.03 ETS domain-containing protein Elk-3 S398 1.65
CAP-Gly domain-containing linker protein 1 S194 2.65 Pro-interleukin-16 S296 1.61
Lymphocyte-specific protein 1 T164 2.01 Tumor suppressor p53-binding protein 1 S1663 1.61
Lymphocyte-specific protein 1 S166 1.88 Hepatoma-derived growth factor-related protein 2 S640 1.60
Microprocessor complex subunit DGCR8 S373 1.76 Pre-mRNA-processing factor 40 homolog A S884 1.59
Prothymosin alpha S9 1.73 Lymphocyte-specific protein 1 S178 1.56
Lysine-specific demethylase 2B S447 1.73 Mediator of RNA polymerase II transcription subunit 24 S840 1.53
DNA (cytosine-5)-methyltransferase 1 S15 1.67 Transmembrane channel-like protein 8 S663 1.50
Eukaryotic translation initiation factor 4 gamma 1 S1081 1.67
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Appendix	  B:	  proteomics	  
B.1	   Pathway	   analysis:	   24	   hour	   100nM	   tofacitinib	   treatment	   of	   IL-­‐2	  
maintained	  CTL	  
	  	  	  	  
Table	   B1:	   KEGG	   pathways	   and	   GO	   biological	   processes	   (BP),	  molecular	   function	   (MF)	   and	  
cellular	   compartment	   (CC)	   significantly	   enriched	   in	   proteins	   significantly	   downregulated	  
after	  24	  hours	  tofacitinib	  treatment	  of	  IL-­‐2	  maintained	  CTL	  	  
Downregulated
Category Term Count P-Value Benjamini
KEGG_PATHWAY Steroid biosynthesis 5 2.50E-04 3.70E-02
KEGG_PATHWAY Steroid hormone biosynthesis 3 1.30E-02 6.20E-01
KEGG_PATHWAY p53 signaling pathway 5 1.50E-02 5.10E-01
KEGG_PATHWAY Biosynthesis of antibiotics 10 1.50E-02 4.30E-01
KEGG_PATHWAY Ovarian steroidogenesis 3 2.60E-02 5.40E-01
KEGG_PATHWAY HTLV-I infection 9 3.20E-02 5.50E-01
KEGG_PATHWAY Protein processing in endoplasmic reticulum 8 3.50E-02 5.30E-01
KEGG_PATHWAY PI3K-Akt signaling pathway 8 4.90E-02 6.00E-01
Category Term Count P-Value Benjamini
GOTERM_BP_DIRECT ribosome biogenesis 16 1.10E-08 1.10E-05
GOTERM_BP_DIRECT steroid biosynthetic process 9 9.80E-07 5.20E-04
GOTERM_BP_DIRECT steroid metabolic process 8 5.30E-05 1.80E-02
GOTERM_BP_DIRECT sterol biosynthetic process 6 1.70E-04 4.30E-02
GOTERM_BP_DIRECT rRNA processing 12 6.40E-04 1.30E-01
GOTERM_BP_DIRECT regulation of cell cycle 9 1.20E-03 1.90E-01
GOTERM_BP_DIRECT cholesterol biosynthetic process 5 1.50E-03 2.10E-01
GOTERM_BP_DIRECT cholesterol metabolic process 6 2.80E-03 3.10E-01
GOTERM_BP_DIRECT lipid metabolic process 15 2.80E-03 2.80E-01
GOTERM_BP_DIRECT response to radiation 4 4.00E-03 3.50E-01
GOTERM_BP_DIRECT ribosomal large subunit biogenesis 5 4.20E-03 3.30E-01
GOTERM_BP_DIRECT fatty acid biosynthetic process 5 1.60E-02 7.60E-01
GOTERM_BP_DIRECT positive regulation of apoptotic process 11 2.20E-02 8.40E-01
GOTERM_BP_DIRECT response to ischemia 4 2.60E-02 8.60E-01
GOTERM_BP_DIRECT immune response 6 2.90E-02 8.70E-01
GOTERM_BP_DIRECT 
maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-
rRNA) 3 3.00E-02 8.60E-01
GOTERM_BP_DIRECT isoprenoid biosynthetic process 3 3.00E-02 8.60E-01
Category Term Count P-Value Benjamini
GOTERM_MF_DIRECT poly(A) RNA binding 45 4.50E-04 1.50E-01
GOTERM_MF_DIRECT iron ion binding 7 1.80E-03 2.80E-01
GOTERM_MF_DIRECT ATP-dependent RNA helicase activity 6 9.50E-03 6.90E-01
GOTERM_MF_DIRECT 
transcription factor activity, RNA polymerase II core promoter proximal region sequence-
specific binding 3 1.60E-02 7.80E-01
GOTERM_MF_DIRECT oxidoreductase activity 16 2.30E-02 8.20E-01
GOTERM_MF_DIRECT RNA binding 26 2.40E-02 7.80E-01
GOTERM_MF_DIRECT nucleic acid binding 20 3.00E-02 8.00E-01
GOTERM_MF_DIRECT helicase activity 8 3.30E-02 7.90E-01
GOTERM_MF_DIRECT transcription factor activity, sequence-specific DNA binding 12 4.70E-02 8.60E-01
Category Term Count P-Value Benjamini
GOTERM_CC_DIRECT nucleolus 40 5.30E-06 1.20E-03
GOTERM_CC_DIRECT integral component of membrane 62 9.40E-05 1.10E-02
GOTERM_CC_DIRECT endoplasmic reticulum 36 1.10E-04 8.40E-03
GOTERM_CC_DIRECT endoplasmic reticulum membrane 22 2.80E-04 1.60E-02
GOTERM_CC_DIRECT cytosolic large ribosomal subunit 7 4.90E-03 2.00E-01
GOTERM_CC_DIRECT preribosome, large subunit precursor 5 6.60E-03 2.20E-01
GOTERM_CC_DIRECT integral component of plasma membrane 12 6.90E-03 2.00E-01
GOTERM_CC_DIRECT membrane 96 2.50E-02 5.00E-01
GOTERM_CC_DIRECT external side of plasma membrane 8 2.60E-02 4.90E-01
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Table	   B2:	   KEGG	   pathway	   and	   GO	   biological	   process	   (BP),	   molecular	   functions	   (MF)	   and	  
cellular	  compartment	  (CC)	  terms	  significantly	  enriched	  in	  proteins	  significantly	  upregulated	  
after	  24	  hours	  tofacitinib	  treatment	  of	  IL-­‐2	  maintained	  CTL	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Upregulated
Category Term Count P-Value Benjamini
KEGG_PATHWAY Lysosome 8 9.40E-05 6.80E-03
Category Term Count P-Value Benjamini
GOTERM_BP_DIRECT intracellular signal transduction 8 1.10E-02 1.00E+00
GOTERM_BP_DIRECT lysosome organization 3 4.40E-02 1.00E+00
Category Term Count P-Value Benjamini
GOTERM_MF_DIRECT hydrolase activity 24 9.10E-04 1.70E-01
GOTERM_MF_DIRECT hydrolase activity, acting on ester bonds 3 2.10E-02 9.00E-01
GOTERM_MF_DIRECT protein homodimerization activity 11 4.50E-02 9.60E-01
GOTERM_MF_DIRECT thiolester hydrolase activity 2 4.50E-02 9.10E-01
Category Term Count P-Value Benjamini
GOTERM_CC_DIRECT extracellular exosome 38 1.30E-04 2.00E-02
GOTERM_CC_DIRECT lysosome 10 8.80E-04 6.50E-02
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B.2	  Proteins	  identified	  as	  part	  of	  significantly	  regulated	  pathways	  (listed	  by	  
gene	  name)	  
	  	  
Table	  B3:	  Gene	  names	  of	  proteins	  listed	  in	  KEGG	  pathways	  significantly	  enriched	  in	  proteins	  
reproducibly	   detected	   to	   be	   downregulated	   after	   24	   hours	   tofacitinib	   treatment	   of	   IL-­‐2	  
maintained	  CTL	  	  	  	  	  
Downregulated
Category Term P-Value Genes
KEGG_PATHWAY Steroid biosynthesis 2.50E-04 Cyp51a1, Fdft1, Hsd17b7, Msmo1, Sc5d
KEGG_PATHWAY Steroid hormone biosynthesis 1.30E-02 Cyp11a1, Hsd17b12, Hsd17b7
KEGG_PATHWAY p53 signaling pathway 1.50E-02 Cd82, Ccnd3, Ccne1, Cdkn1a, Sesn2
KEGG_PATHWAY Biosynthesis of antibiotics 1.50E-02 Hmgcr, Bcat1, Cyp51a1, Fdft1, Hk2, Hsd17b7, 
Msmo1, Mvd, Rpia, Sc5d
KEGG_PATHWAY Ovarian steroidogenesis 2.60E-02 Cyp11a1, Hsd17b7, Ldlr
KEGG_PATHWAY HTLV-I infection 3.20E-02
Bcl2l1, Canx, Ccnd3, Cdkn1a, Il2ra, Il2rb, Jun, 
Slc2a1, Tgfb1
KEGG_PATHWAY Protein processing in endoplasmic reticulum 3.50E-02
Sec63, Stt3a, Vimp, Canx, Dad1, Hyou1, Ssr3, 
Ube2j1
KEGG_PATHWAY PI3K-Akt signaling pathway 4.90E-02 Bcl2l1, Ccnd3, Ccne1, Cdkn1a, Eif4b, Il2ra, 
Il2rb, Lamc1
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Table	  B4:	  Gene	  names	  of	  proteins	   listed	   in	  GO	   term	  biological	  processes	   (BP)	  significantly	  
enriched	   in	  proteins	   significantly	  downregulated	  after	  24	  hrs	   tofacitinib	   treatment	  of	   IL-­‐2	  
maintained	  CTL	  
Downregulated
Category Term P-Value Genes
GOTERM_BP_DIRECT ribosome biogenesis 1.10E-08
Ddx56, Dhx30, Ftsj3, Gtpbp4, Nip7, Rrn3, 
Sdad1, Tsr3, Utp14b, Gnl2, Ipo4, Pes1, Rpl34, 
Rpf1, Surf6, Znhit6
GOTERM_BP_DIRECT steroid biosynthetic process 9.80E-07 Hmgcr, Cyp11a1, Cyp51a1, Fdft1, Hsd17b12, 
Hsd17b7, Msmo1, Mvd, Sc5d
GOTERM_BP_DIRECT steroid metabolic process 5.30E-05 Hmgcr, Cyp11a1, Cyp51a1, Fdft1, Ldlr, Msmo1, 
Mvd, Sc5d
GOTERM_BP_DIRECT sterol biosynthetic process 1.70E-04 Hmgcr, Cyp51a1, Fdft1, Msmo1, Mvd, Sc5d
GOTERM_BP_DIRECT rRNA processing 6.40E-04 Ddx21, Ddx56, Dimt1, Ftsj3, Tsr3, Utp14b, 
Chd7, Isg20, Nol11, Pes1, Rpl35a, Rpf1
GOTERM_BP_DIRECT regulation of cell cycle 1.20E-03 Son, Ccndbp1, Ccnd3, Ccne1, Cdkn1a, Jund, 
Jun, Pes1, Rgcc
GOTERM_BP_DIRECT cholesterol biosynthetic process 1.50E-03 Hmgcr, Cyp51a1, Fdft1, Hsd17b7, Mvd
GOTERM_BP_DIRECT cholesterol metabolic process 2.80E-03 Hmgcr, Cyp51a1, Fdft1, Hsd17b7, Mvd
GOTERM_BP_DIRECT lipid metabolic process 2.80E-03
Agpat3, Hmgcr, Cyp11a1, Cyp51a1, Degs1, 
Fdft1, Fads2, Hsd17b12, Hsd17b7, Ldlr, Lpcat4, 
Msmo1, Mvd, Slc16a1, Sc5d
GOTERM_BP_DIRECT response to radiation 4.00E-03 Bcl2l1, Dcun1d3, Jund, Jun
GOTERM_BP_DIRECT ribosomal large subunit biogenesis 4.20E-03 Heatr3, Nip7, Sdad1, Rpl35a, Surf6
GOTERM_BP_DIRECT fatty acid biosynthetic process 1.60E-02 Degs1, Fads2, Hsd17b12, Msmo1, Sc5d
GOTERM_BP_DIRECT positive regulation of apoptotic process 2.20E-02 Bcl2l1, Bnip3, Dcun1d3, Rest, Degs1, Jun, 
Lats1, Rps29, Stk3, Tgfb1, Tnfrsf8
GOTERM_BP_DIRECT response to ischemia 2.60E-02 Bcl2l1, Cpeb4, Hk2, Hyou1
GOTERM_BP_DIRECT immune response 2.90E-02 Gzme, Irf8, Il2ra, Nfil3, Tnfrsf10b, Tnfrsf8
GOTERM_BP_DIRECT 
maturation of LSU-rRNA from tricistronic rRNA 
transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) 3.00E-02 Ftsj3, Gtpbp4, Pes1
GOTERM_BP_DIRECT isoprenoid biosynthetic process 3.00E-02 Hmgcr, Fdft1, Mvd
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Table	  B5:	  Gene	  names	  of	  proteins	   listed	   in	  GO	   term	  molecular	   functions	   (MF)	  significantly	  
enriched	   in	  proteins	   significantly	  downregulated	  after	  24	  hrs	   tofacitinib	   treatment	  of	   IL-­‐2	  
maintained	  CTL.	  
Downregulated
Category Term P-Value Genes
GOTERM_MF_DIRECT poly(A) RNA binding 4.50E-04
Ddx21, Ddx24, Ddx55, Ddx56, Dhx30, Dhx33, 
Dimt1, Ftsj3, Gpatch4, Gtpbp4, Larp4, Lyar, 
Mak16, Nkrf, Nip7, Noc3l, Sec63, Son, Canx, 
Cpeb4, Diexf, Eif4b, Gnl2, Jun, Metap2, Mrps24, 
Nol11, Nifk, Pes1, Prrc2a, Pum3, Rpl19, Rpl24, 
Rpl35a, Rps12, Rps19bp1, Rpf1, Serbp1, 
Spats2, Surf6, Trmt6, Tbl2, Tfrc, Uchl5, Usp36
GOTERM_MF_DIRECT iron ion binding 1.80E-03 Alkbh8, Cyp11a1, Cyp51a1, Jmjd6, Kdm3a, 
Msmo1, Sc5d
GOTERM_MF_DIRECT ATP-dependent RNA helicase activity 9.50E-03 Ddx21, Ddx24, Ddx55, Ddx56, Dhx30, Dhx33
GOTERM_MF_DIRECT 
transcription factor activity, RNA polymerase II 
core promoter proximal region sequence-specific 
binding 
1.60E-02 Batf3, Fosl2, Jun
GOTERM_MF_DIRECT oxidoreductase activity 2.30E-02
Hmgcr, Alkbh6, Alkbh8, Cyp11a1, Cyp51a1, 
Degs1, Dus2, Fdft1, Fads2, Hsd17b12, 
Hsd17b7, Jmjd6, Kdm3a, Msmo1, Sesn2, Sc5d
GOTERM_MF_DIRECT RNA binding 2.40E-02
Ddx21, Ddx24, Ddx55, Ddx56, Dhx30, Dimt1, 
Larp4, Nip7, Son, Alkbh8, Cluh, Cpeb4, Dus2, 
Eif4b, Isg20, Ireb2, Jmjd6, Marf1, Nifk, Pes1, 
Rpl34
GOTERM_MF_DIRECT nucleic acid binding 3.00E-02
Ddx21, Ddx24, Ddx55, Ddx56, Dhx30, Dhx33, 
Gpatch4, Mak16, Nkrf, Rest, Son, Alkbh8, 
Cpeb4, Eif4b, Isg20, Marf1, Nifk, Polr3k, Tut1, 
Znf593
GOTERM_MF_DIRECT helicase activity 3.30E-02
Ddx21, Ddx24, Ddx55, Ddx56, Dhx30, Dhx33, 
Chd7, Chd8
GOTERM_MF_DIRECT 
transcription factor activity, sequence-specific 
DNA binding 4.70E-02
Rest, Batf3, Etv3, Fosl2, Irf8, Jund, Jun, Kdm3a, 
Nfil3, Tcf25, Tfdp1, Mafk
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Table	  B6:	  Gene	  names	  of	  proteins	  listed	  in	  GO	  term	  cellular	  compartments	  (CC)	  significantly	  
enriched	  in	  proteins	  sigmificantly	  downregulated	  after	  24	  hours	  tofacitinib	  treatment	  of	  IL-­‐






Category Term P-Value Genes
GOTERM_CC_DIRECT nucleolus 5.30E-06
Ddx21, Ddx24, Ddx56, Dhx33, Dimt1, Ftsj3, 
Gtpbp4, Lyar, Mak16, Nkrf, Nip7, Noc3l, 
Pak1ip1, Rrn3, Sdad1, Senp5, Taf1, Utp14b, 
Cdkn1a, Diexf, Gnl2, Isg20, Jmjd6, Morf4l2, 
Nol11, Nifk, Pes1, Polr1b, Polr3k, Rpl34, Pum3, 
Rpl19, Rps19bp1, Rpf1, Surf6, Tut1, Tma16, 
Usp36, Znf330, Znf593
GOTERM_CC_DIRECT integral component of membrane 9.40E-05
Agpat3, Hmgcr, Atad3, Bcap29, Bcl2l1, Bnip3, 
C2cd2l, Cd69, Cd82, Dnajc16, Sec63, Slamf7, 
Stt3a, Vimp, Atl2, Odr4, Canx, Cldnd1, 
Cyp51a1, Dad1, Degs1, Entpd7, Ece2, 
Fam134b, Fdft1, Fads2, Hsd17b12, Hsd17b7, 
Icos, Il2ra, Il2rb, Lrrc8d, Ldlr, Lpcat4, Marf1, 
Ctage5, Msmo1, Mrpl48, Prf1, Pecam1, Kcnn4, 
Sec61g, Rer1, Rttn, Ssr3, Slc1a4, Slc16a1, 
Slc2a1, Slc20a1, Slc35f2, Slc7a5, Spag9, Sc5d, 
Tex2, Tmx2, Tfrc, Tmem135, Tmem147, 
Tnfrsf10b, Tnfrsf8, Ube2j1, Vapa
GOTERM_CC_DIRECT endoplasmic reticulum 1.10E-04
Agpat3, Hmgcr, Bcap29, Bnip3, Nkrf, Sec63, 
Slamf7, Stt3a, Vimp, Atl2, Canx, Cyp51a1, 
Cpeb4, Dad1, Degs1, Dus2, Fam134b, Fdft1, 
Fads2, Hsd17b12, Hsd17b7, Hyou1, Iigp1, 
Ireb2, Lrrc8d, Lpcat4, Ctage5, Msmo1, Pum3, 
Ssr3, Sc5d, Tex2, Tbl2, Tmem147, Ube2j1, 
Vapa
GOTERM_CC_DIRECT endoplasmic reticulum membrane 2.80E-04
Agpat3, Hmgcr, Bcap29, Sec63, Atl2, Canx, 
Cyp51a1, Degs1, Fdft1, Fads2, Hsd17b12, 
Iigp1, Lrrc8d, Lpcat4, Ctage5, Msmo1, Sec61g, 
Ssr3, Sc5d, Tmem147, Ube2j1, Vapa
GOTERM_CC_DIRECT cytosolic large ribosomal subunit 4.90E-03 Rpl34, Rpl19, Rpl24, Rpl35a, Rpl36a, Rps12, 
Surf6
GOTERM_CC_DIRECT preribosome, large subunit precursor 6.60E-03 Ftsj3, Mak16, Nip7, Pes1, Rpf1
GOTERM_CC_DIRECT integral component of plasma membrane 6.90E-03
Bcap29, Cd82, Icos, Lrrc8d, Kcnn4, Slc16a1, 
Slc2a1, Slc20a1, Slc7a5, Tfrc, Tnfrsf10b, Tnfrsf8
GOTERM_CC_DIRECT membrane 2.50E-02
Agpat3, Hmgcr, Arl8a, Atad3, Bcap29, Bcl2l1, 
Bnip3, C2cd2l, Cd69, Cd82, Dcun1d3, Ddx21, 
Ddx24, Ddx55, Ddx56, Dnajc16, Gem, Gtpbp4, 
Larp4, Mark3, Sec63, Slamf7, Stt3a, Txk, Vimp, 
Appbp2, Atl2, Odr4, Canx, Cldnd1, Cul3, Ccnd3, 
Cyp11a1, Cyp51a1, Dad1, Degs1, Drg2, Eea1, 
Entpd7, Ece2, Fam134b, Fdft1, Fads2, Gzme, 
Gnl2, Hk2, Hsd17b12, Hsd17b7, Hyou1, Ipo4, 
Icos, Iigp1, Il2ra, Il2rb, Lrrc8d, Ldlr, Kdm3a, 
Lpcat4, Med6, Marf1, Ctage5, Msmo1, Map7, 
Ncdn, Prf1, Pes1, Pecam1, Kcnn4, Sec61g, 
Prrc2a, Rer1, Rpl19, Rpl24, Rpl35a, Rps12, 
Serbp1, Ssr3, Slc1a4, Slc16a1, Slc2a1, 
Slc20a1, Slc35f2, Slc7a5, Spry2, Sc5d, Sdf4, 
Tex2, Tmx2, Tfrc, Tmem135, Tmem147, 
Tnfrsf10b, Tnfrsf8, Ube2j1, Vapa, Zfyve16
GOTERM_CC_DIRECT external side of plasma membrane 2.60E-02 Cd69, Slamf7, Icos, Il2ra, Il2rb, Ldlr, Pecam1, 
Tfrc
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Table	  B7:	  Gene	  names	  of	  proteins	  listed	  in	  KEGG	  pathway	  and	  GO	  term	  biological	  processes	  
(BP),	   molecular	   functions	   (MF)	   and	   cellular	   compartments	   (CC)	   significantly	   enriched	   in	  










Category Term P-Value Genes
KEGG_PATHWAY Lysosome 9.40E-05 Npc2, Ctsa, Cln5, Hexb, Lipa, Mfsd8, Man2b1, 
Ppt2
Category Term P-Value Genes
GOTERM_BP_DIRECT intracellular signal transduction 1.10E-02 Rasa3, Rassf5, Tnik, Dapk2, Dgka, Hmha1, 
Stk17b, Spata13
GOTERM_BP_DIRECT lysosome organization 4.40E-02 Cln5, Hexb, Mfsd8
Category Term P-Value Genes
GOTERM_MF_DIRECT hydrolase activity 9.10E-04
Ctdsp1, Pan2, Samhd1, Wdyhv1, Abhd6, Acot2, 
Ctsa, Crmp1, Dxo, Dpp4, Faah, Gnpda1, Hexb, 
Lipa, Man2b1, Nudt14, Ppt2, Pon2, Padi2, 
Pafah1b3, Hrsp12, Usp38, Ublcp1
GOTERM_MF_DIRECT hydrolase activity, acting on ester bonds 2.10E-02 Faah, Lipa, Ester hydrolase C11orf54 homolog
GOTERM_MF_DIRECT protein homodimerization activity 4.50E-02 Gabpb2, S100a10, Anxa1, Dpp4, Faah, Hexb, 
Pygl, Hrsp12, Suds3, Tesc, Xpa, 
GOTERM_MF_DIRECT thiolester hydrolase activity 4.50E-02 Acot2, Ppt2
Category Term P-Value Genes
GOTERM_CC_DIRECT extracellular exosome 1.30E-04
Ctdsp1, H2afy, Ndufb9, Npc2, Rab3d, S100a10, 
S100a11, Tnik, Ubxn6, Abhd6, Acot2, Anxa1, 
Blvrb, Ctsa, Cln5, Cotl1, Cfl2, Dpp4, Fam129b, 
Fam213a, Gnpda1, Gstt2, Gpx4, Hexb, Itga1, 
Itga4, Pygl, Lipa, Man2b1, Nudt14, Ppt2, Padi2, 
Pafah1b3, Kctd12, Hrsp12, Arhgef18, Sntb2
GOTERM_CC_DIRECT lysosome 8.80E-04 Npc2, Ctsa, Cln5, Hexb, Lipa, Mfsd8, Man2b1, 
Ppt2, Pon2
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B.3	  Proteins	  reproducibly	  detected	  to	  be	  downregulated	  by	  24	  hours	  
tofacitinib	  treatment	  	  	  
	  
Table	   B8:	   Proteins	   significantly	   downregulated	   following	   24	   hrs	   treatment	   of	   IL-­‐2	  
maintained	  CTL	  with	  tofacitinib	  	  	  
Protein Mean ratio Protein 
Mean 
ratio
GTP-binding protein GEM 0.08 Transcription initiation factor TFIID subunit 1 0.41
Interferon-related developmental regulator 1 0.12 B-cell receptor-associated protein 29 0.41
Nuclear factor interleukin-3-regulated protein 0.14 Interleukin-2 receptor subunit beta 0.41
Protein FAM134B 0.14 Spermatogenesis-associated serine-rich protein 2 0.42
U3 small nucleolar RNA-associated protein 14 homolog B 0.15 Transcription factor jun-D 0.42
Interferon regulatory factor 8 0.21 Protein SDA1 homolog 0.42
3-hydroxy-3-methylglutaryl-coenzyme A reductase 0.23 Cytoplasmic polyadenylation element-binding protein 4 0.42
Interleukin-2 receptor subunit alpha 0.23 Methionine aminopeptidase 2 0.43
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 0.23 Ubiquitin carboxyl-terminal hydrolase 36 0.43
Laminin subunit gamma-1 0.24 Solute carrier family 2, facilitated glucose transporter member 1 0.43
Interferon-inducible GTPase 1 0.24 Regulator of cell cycle RGCC 0.43
Perforin-1 0.25 Claudin domain-containing protein 1 0.44
Basic leucine zipper transcriptional factor ATF-like 3 0.26 Intermediate conductance calcium-activated potassium channel protein 4 0.44
Tumor necrosis factor receptor superfamily member 8 0.27 Granzyme E 0.44
E2F-associated phosphoprotein 0.27 Pumilio domain-containing protein KIAA0020 0.44
Cyclin-dependent kinase inhibitor 1 0.28 Transcription factor 25 0.44
Cholesterol side-chain cleavage enzyme, mitochondrial 0.28 Protein SON 0.45
Serine/threonine-protein kinase LATS1 0.29 Sentrin-specific protease 5 0.45
Sodium-dependent phosphate transporter 1 0.29 Iron-responsive element-binding protein 2 0.46
La-related protein 4 0.30 Sphingolipid delta(4)-desaturase DES1 0.46
Early activation antigen CD69 0.30 Ectonucleoside triphosphate diphosphohydrolase 7 0.47
Nucleolar protein 11 0.30 Transferrin receptor protein 1 0.47
Sestrin-2 0.30 1-acyl-sn-glycerol-3-phosphate acyltransferase gamma 0.47
Mortality factor 4-like protein 2 0.31 Protein LTV1 homolog 0.47
Translation machinery-associated protein 16 0.33 RE1-silencing transcription factor 0.47
Ensconsin 0.33 Histone acetyltransferase KAT8 0.47
G1/S-specific cyclin-D3 0.34 Lanosterol 14-alpha demethylase 0.47
Testis-expressed sequence 2 protein 0.35 40S ribosomal protein S29 0.48
Low-density lipoprotein receptor 0.35 Protein sprouty homolog 2 0.48
Tumor necrosis factor receptor superfamily member 10B 0.36 Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6 0.48
Methylsterol monooxygenase 1 0.36 Serine/threonine-protein kinase 3 0.48
DCN1-like protein 3 0.36 Protein odr-4 homolog 0.49
Transcriptional protein SWT1 0.36 Nucleolar GTP-binding protein 2 0.49
Fatty acid desaturase 2 0.37 Hexokinase-2 0.50
Transcription factor AP-1 0.37 Calponin-3 0.50
G1/S-specific cyclin-E1 0.37 Protein FAM60A 0.50
RNA polymerase I-specific transcription initiation factor RRN3 0.38 ETS translocation variant 3 0.50
Zinc finger protein 593 0.38 Ubiquitin carboxyl-terminal hydrolase isozyme L5 0.51
Endothelin-converting enzyme 2 0.38 Clustered mitochondria protein homolog 0.51
Amyloid protein-binding protein 2 0.38 Cytoskeleton-associated protein 2 0.51
Neutral amino acid transporter A 0.39 Putative ATP-dependent RNA helicase DHX33 0.51
Lathosterol oxidase 0.39 3-keto-steroid reductase 0.51
60S ribosomal protein L34 0.39 Squalene synthase 0.51
ADP-ribosylation factor-like protein 8A 0.39 Nuclear distribution protein nudE-like 1 0.51
Inducible T-cell costimulator 0.39 Nucleolar complex protein 3 homolog 0.51
Serine/threonine-protein kinase Nek6 0.39 Cell growth-regulating nucleolar protein 0.52
1110004E09Rik 0.40 Probable ATP-dependent RNA helicase DDX56 0.52
Tyrosine-protein kinase TXK 0.40 ATP-dependent RNA helicase DDX24 0.52
Branched-chain-amino-acid aminotransferase, cytosolic 0.40 Zinc finger FYVE domain-containing protein 16 0.52
Fos-related antigen 2 0.41 Probable dimethyladenosine transferase 0.53
Lysophospholipid acyltransferase LPCAT4 0.41 Box C/D snoRNA protein 1 0.53
	   286	  
	  
	  
Table	   B9:	   Proteins	   significantly	   downregulated	   following	   24	   hours	   treatment	   of	   IL-­‐2	  
maintained	  CTL	  with	  tofacitinib	  (cont.)	  
Protein Mean ratio Protein 
Mean 
ratio
Translocation protein SEC63 homolog 0.53 Protein MAK16 homolog 0.60
Importin-4 0.54 Hypoxia up-regulated protein 1 0.60
Ribosome biogenesis protein TSR3 homolog 0.54 Meiosis arrest female protein 1 0.60
DNA-directed RNA polymerase III subunit RPC4 0.54 Neurochondrin 0.60
Ankyrin repeat and SOCS box protein 6 0.54 NK-tumor recognition protein 0.60
Mediator of RNA polymerase II transcription subunit 6 0.54 Protein PRRC2A 0.60
Transforming growth factor beta-1 0.54 GrpE protein homolog 2, mitochondrial 0.60
NF-kappa-B-repressing factor 0.54 39S ribosomal protein L48, mitochondrial 0.61
Ubinuclein-2 0.54 Protein LCHN 0.61
Transmembrane protein 147 0.54 Developmentally-regulated GTP-binding protein 2 0.61
Bcl-2-like protein 1 0.54 Coiled-coil domain-containing protein 174 0.61
Ribosome production factor 1 0.55 Speckle targeted PIP5K1A-regulated poly(A) polymerase 0.61
Tubulin alpha chain-like 3 0.55 40S ribosomal protein S12 0.61
Rotatin 0.55 p21-activated protein kinase-interacting protein 1 0.61
Ribose-5-phosphate isomerase 0.55 C-Jun-amino-terminal kinase-interacting protein 4 0.61
Protein RER1 0.55 DnaJ homolog subfamily C member 16 0.61
CD82 antigen 0.55 Vesicle-associated membrane protein-associated protein A 0.61
Digestive organ expansion factor homolog 0.55 60S ribosomal protein L36a 0.62
C2 domain-containing protein 2-like 0.56 Cell division cycle protein 123 homolog 0.62
45 kDa calcium-binding protein 0.56 Transcription factor Dp-1 0.62
Selenoprotein S 0.56 Zinc finger protein 330 0.62
Nuclear export mediator factor Nemf 0.56 Transmembrane protein 135 0.62
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit DAD1
0.56 Solute carrier family 35 member F2 0.63
Transducin beta-like protein 2 0.56 60S ribosomal protein L24 0.63
Ubiquitin-conjugating enzyme E2 J1 0.56 ATPase family AAA domain-containing protein 3 0.63
Active regulator of SIRT1 0.56 Interferon-stimulated gene 20 kDa protein 0.63
ATP-dependent RNA helicase DDX55 0.56 Protein FAM195A 0.63
Translocon-associated protein subunit gamma 0.56 Bromodomain adjacent to zinc finger domain protein 1A 0.64
tRNA-dihydrouridine(20) synthase [NAD(P)+]-like 0.57 Coiled-coil domain-containing protein 102A 0.64
Plasminogen activator inhibitor 1 RNA-binding protein 0.57 Large neutral amino acids transporter small subunit 1 0.64
Leucine-rich repeat-containing protein 8D 0.57 Cyclin-D1-binding protein 1 0.64
Cyclin-dependent kinase 2-interacting protein 0.57 60S ribosomal protein L35a 0.64
SLAM family member 7 0.57 Unconventional myosin-Ie 0.64
Putative ATP-dependent RNA helicase DHX30 0.57 Chromodomain-helicase-DNA-binding protein 8 0.64
60S ribosome subunit biogenesis protein NIP7 homolog 0.58 Early endosome antigen 1 0.64
Estradiol 17-beta-dehydrogenase 12 0.58 tRNA (adenine(58)-N(1))-methyltransferase non-catalytic subunit TRM6 0.64
Transcription factor MafK 0.58 Calnexin 0.65
Chromodomain-helicase-DNA-binding protein 7 0.58 60S ribosomal protein L19 0.65
Eukaryotic translation initiation factor 4B 0.58 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 
STT3A
0.65
DNA-directed RNA polymerase I subunit RPA2 0.58 Alkylated DNA repair protein alkB homolog 8 0.65
Cullin-3 0.58 Nucleolar RNA helicase 2 0.65
Platelet endothelial cell adhesion molecule 0.58 cTAGE family member 5 0.65
Alpha-ketoglutarate-dependent dioxygenase alkB homolog 6 0.58 N-terminal Xaa-Pro-Lys N-methyltransferase 1 0.65
Diphosphomevalonate decarboxylase 0.58 pre-rRNA processing protein FTSJ3 0.65
General transcription factor IIH subunit 1 0.59 Protein FAM177A1 0.66
Thioredoxin-related transmembrane protein 2 0.59 Surfeit locus protein 6 0.66
Protein FAM203A 0.59 28S ribosomal protein S24, mitochondrial 0.66
E3 ubiquitin-protein ligase listerin 0.59 Monocarboxylate transporter 1 0.66
Lysine-specific demethylase 3A 0.59 Pescadillo homolog 0.66
Tetratricopeptide repeat protein 32 0.59 Nuclear factor related to kappa-B-binding protein 0.67
G patch domain-containing protein 4 0.60 Protein transport protein Sec61 subunit gamma 0.67
MAP/microtubule affinity-regulating kinase 3 0.60 MKI67 FHA domain-interacting nucleolar phosphoprotein 0.67
Tripeptidyl-peptidase 2 0.60 Nucleolar GTP-binding protein 1 0.67
Atlastin-2 0.60 DNA-directed RNA polymerase III subunit RPC10 0.67
HEAT repeat-containing protein 3 0.60
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B.4	  Proteins	  reproducibly	  detected	  to	  be	  upregulated	  by	  24	  hours	  tofacitinib	  
treatment	  	  
	  
Table	   B10:	   Proteins	   significantly	   upregulated	   following	   24	   hours	   treatment	   of	   IL-­‐2	  




Protein Mean ratio Protein 
Mean 
ratio
Ubiquinone biosynthesis monooxygenase COQ6 102.69 Ras GTPase-activating protein 3 1.90
DNA repair protein complementing XP-A cells homolog 10.40 TSC22 domain family protein 4 1.89
Centrosomal protein of 63 kDa 8.21 Tetratricopeptide repeat protein 7A 1.88
Programmed cell death protein 4 6.66 High mobility group protein 20A 1.85
RUN and FYVE domain-containing protein 1 6.42 Platelet-activating factor acetylhydrolase IB subunit gamma 1.84
Integrin alpha-4 5.62 Coactosin-like protein 1.84
Cofilin-2 5.36 Protein S100-A11 1.83
Serine incorporator 3 5.22 Zinc finger protein 687 1.82
GTPase IMAP family member 6 4.63 Redox-regulatory protein FAM213A 1.81
Ceroid-lipofuscinosis neuronal protein 5 homolog 4.63 GA-binding protein subunit beta-2 1.80
Integrin alpha-1 3.68 Ribonuclease UK114 1.80
Core histone macro-H2A.1 3.55 Regulator of G-protein signaling 3 1.79
Flavin reductase (NADPH) 3.49 Ester hydrolase C11orf54 homolog 1.78
Lysosomal thioesterase PPT2 3.26 Protein-arginine deiminase type-2 1.77
Dihydropyrimidinase-related protein 1 3.16 Ubiquitin-conjugating enzyme E2 H 1.76
Natural killer cells antigen CD94 2.98 Trafficking protein particle complex subunit 10 1.76
Ras-related protein Rab-3D 2.97 Decapping and exoribonuclease protein 1.75
Pyrin and HIN domain-containing protein 1 2.87 BTB/POZ domain-containing protein KCTD12 1.72
Carboxy-terminal domain RNA polymerase II polypeptide A 
small phosphatase 1
2.81 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 1.71
Uncharacterized protein C6orf106 homolog 2.75 Minor histocompatibility protein HA-1 1.71
Beta-2-syntrophin 2.74 Putative RNA-binding protein 3 1.70
Inhibitor of growth protein 1 2.72 Centromere protein T 1.70
SH2 domain-containing protein 1A 2.71 Lysosomal protective protein 1.69
Protein zer-1 homolog 2.67 Traf2 and NCK-interacting protein kinase 1.69
Diacylglycerol kinase alpha 2.61 UBX domain-containing protein 6 1.69
Rho guanine nucleotide exchange factor 18 2.59 Sin3 histone deacetylase corepressor complex component SDS3 1.66
Bcl-2-binding component 3 2.59 Sel1 repeat-containing protein 1 1.66
Cytohesin-interacting protein 2.50 Calcineurin B homologous protein 3 1.64
Protein RUFY3 2.49 Serine/threonine-protein kinase 17B 1.63
Aspartyl/asparaginyl beta-hydroxylase 2.48 Malcavernin 1.62
Death-associated protein 1 2.40 Epididymal secretory protein E1 1.62
Cytochrome c oxidase assembly protein COX11, mitochondrial 2.38 Acyl-coenzyme A thioesterase 2, mitochondrial 1.61
Death-associated protein kinase 2 2.33 Glucosamine-6-phosphate isomerase 1 1.61
Oxidation resistance protein 1 2.26 Protein N-terminal glutamine amidohydrolase 1.59
Beta-hexosaminidase subunit beta 2.21 Major facilitator superfamily domain-containing protein 8 1.59
Ubiquitin-like domain-containing CTD phosphatase 1 2.20 Lysine-specific demethylase 2B 1.59
PAB-dependent poly(A)-specific ribonuclease subunit 2 2.20 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 1.59
Annexin A1 2.19 Fatty-acid amide hydrolase 1 1.58
Uridine diphosphate glucose pyrophosphatase 2.18 Factor VIII intron 22 protein 1.57
PHD finger protein 21A 2.17 BRCA1-A complex subunit RAP80 1.57
Dipeptidyl peptidase 4 2.12 Lysosomal alpha-mannosidase 1.56
Rho GTPase-activating protein 25 2.11 Sideroflexin-3 1.56
Nurim 2.11 Monoacylglycerol lipase ABHD6 1.56
Non-syndromic hearing impairment protein 5 homolog 2.08 Sorbin and SH3 domain-containing protein 1 1.55
Putative transferase CAF17 homolog, mitochondrial 2.06 Ras association domain-containing protein 5 1.55
Spermatogenesis-associated protein 13 2.01 Glutathione S-transferase theta-2 1.55
Membrane-spanning 4-domains subfamily A member 6B 1.99 UMP-CMP kinase 2, mitochondrial 1.53
LIM domain kinase 2 1.95 Lysosomal acid lipase/cholesteryl ester hydrolase 1.53
Serum paraoxonase/arylesterase 2 1.95 WD repeat-containing protein 91 1.51
Niban-like protein 1 1.94 Phospholipid hydroperoxide glutathione peroxidase, mitochondrial 1.51
Protein S100-A10 1.94 Ubiquitin carboxyl-terminal hydrolase 38 1.51
Glycogen phosphorylase, liver form 1.93
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B5	  Cytokine	  receptors	  in	  CTL	  identified	  by	  proteomics	  
	  
Table	  B11:	  Cytokine/hormone	  receptor	  expression	  in	  CTL	  BR	  –	  biological	  replicate	  	  











P01590 Interleukin-2 receptor subunit alpha Il2ra 789549 8 0.18 0.31 0.21 0.23
P20334 Tumor necrosis factor receptor superfamily member 9 Tnfrsf9 378516 8 0.10 0.41 0.15 0.22
P34902 Cytokine receptor common subunit gamma Il2rg 193859 11 0.52 1.03 1.44 1.00
P16297 Interleukin-2 receptor subunit beta Il2rb 84099 9 0.33 0.51 0.40 0.41
Q60846 Tumor necrosis factor receptor superfamily member 8 Tnfrsf8 83770 10 0.36 0.24 0.20 0.27
P15261 Interferon gamma receptor 1 Ifngr1 77162 7 0.29 1.58 1.71 1.20
P51682 C-C chemokine receptor type 5 Ccr5 59614 4 1.58 1.33 1.40 1.44
Q62312-2 TGF-beta receptor type-2 Tgfbr2 40682 11 1.18 0.90 1.17 1.08
Q60837 Interleukin-12 receptor subunit beta-1 Il12rb1 26738 12 0.12 0.60 0.57 0.43
P25119 Tumor necrosis factor receptor superfamily member 1B Tnfrsf1b 20408 4 0.67 0.78 0.98 0.81
P47741 Tumor necrosis factor receptor superfamily member 4 Tnfrsf4 16556 3 - 0.45 - 0.45
Q9QZM4 Tumor necrosis factor receptor superfamily member 10B Tnfrsf10b 9611 6 0.28 0.39 0.42 0.36
P16872 Interleukin-7 receptor subunit alpha Il7r 7105 1 1.42 0.77 1.23 1.14
Q8BX43 Tumor necrosis factor receptor superfamily member 19L Relt 3612 3 0.39 0.78 1.29 0.82
P83626 Tumor necrosis factor receptor superfamily member 26 Tnfrsf26 3516 1 - 2.70 - 2.70
P47774 C-C chemokine receptor type 7 Ccr7 3044 1 1.10 - 5.63 3.37
Q9EQ16 C-X-C chemokine receptor type 6 Cxcr6 2938 1 - 6.30 - 6.30
Q64729-2 TGF-beta receptor type-1 Tgfbr1 2893 2 0.54 1.42 1.52 1.16
Q9JHX3 Interleukin-21 receptor Il21r 2571 3 0.62 1.74 0.80 1.05
O70394 Interleukin-27 receptor subunit alpha Il27ra 2037 5 - 2.89 1.47 2.18
Q60943 Interleukin-17 receptor A Il17ra 2024 3 0.59 1.34 2.58 1.50
P26618-2 Platelet-derived growth factor receptor alpha Pdgfra 1914 1 - 1.25 1.60 1.42
P16056 Hepatocyte growth factor receptor Met 1839 2 0.50 - 1.75 1.13
P15208 Insulin receptor Insr 1505 5 2.24 0.41 1.43 1.36
Q03145 Ephrin type-A receptor 2 Epha2 1336 4 1.21 0.95 0.87 1.01
Q91VH1 Adiponectin receptor protein 1 Adipor1 1167 1 - 0.42 1.13 0.77
Q61190 Interleukin-10 receptor subunit beta Il10rb 984 2 - 1.58 1.21 1.40
P33896 Interferon alpha/beta receptor 1 Ifnar1 681 2 0.53 4.07 4.46 3.02
Q9EPU5 Tumor necrosis factor receptor superfamily member 21 Tnfrsf21 586 1 - - 1.38 1.38
P97378 Interleukin-12 receptor subunit beta-2 Il12rb2 538 1 - 0.91 1.40 1.16
